



HU000030591T2

(19) **HU**(11) Lajstromszám: **E 030 591**(13) **T2****MAGYARORSZÁG****Szellemi Tulajdon Nemzeti Hivatala**

EURÓPAI SZABADALOM SZÖVEGÉNEK FORDÍTÁSA

(21) Magyar ügyszám: **E 11 161716**(22) A bejelentés napja: **2003. 02. 20.**(51) Int. Cl.: **C07K 14/47** (2006.01)**A61K 393/95** (2006.01)**C07K 16/18** (2006.01)**G01N 33/68** (2006.01)

(96) Az európai bejelentés bejelentési száma:

EP 20030161716

(97) Az európai bejelentés közzétételi adatai:

EP 2368907 A2 **2011. 09. 28.**

(97) Az európai szabadalom megadásának meghirdetési adatai:

EP 2368907 B1 **2016. 07. 06.**

(30) Elsőbbségi adatok:

02003844**2002. 02. 20.****EP**

(72) Feltalálók(k):

BARDROFF, Michael, 81375 München (DE)**Bohrmann, Bernd, 79100 Freiburg (DE)****Brockhaus, Manfred, 4126 Bettingen (CH)****Huber, Walter, 4303 Kaiseraugst (CH)****Kretzschmar, Titus, 86857 Hurlach (DE)****Löhning, Corinna, 82131 Stockdorf (DE)****Loetscher, Hansruedi, 4313 Möhlin (CH)****Nordstedt, Christer, 151 85 Sodertalje (SE)****Rothe, Christine, 85221 Dachau (DE)**

(73) Jogosult(ak):

F. Hoffmann-La Roche AG, 4070 Basel (CH)**MorphoSys AG, 82152 Martinsried/München****(DE)**

(74) Képviselő:

dr. Miskolczi Mária, Budapest

(54)

Anti-Abeta antitestek és alkalmazásuk

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.

(19)



(11)

EP 2 368 907 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
06.07.2016 Bulletin 2016/27

(51) Int Cl.:
C07K 14/47 (2006.01) **C07K 16/18** (2006.01)
A61K 39/395 (2006.01) **G01N 33/68** (2006.01)

(21) Application number: **11161716.3**

(22) Date of filing: **20.02.2003**

(54) Anti-Abeta antibodies and their use

Anti-Abeta-Antikörper und ihre Verwendung

Anticorps anti-Abeta et leur utilisation

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT SE SI SK TR**
Designated Extension States:
AL LT LV MK RO

(30) Priority: **20.02.2002 EP 02003844**

(43) Date of publication of application:
28.09.2011 Bulletin 2011/39

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
03714751.9 / 1 481 008

(73) Proprietors:
• **F. Hoffmann-La Roche AG**
4070 Basel (CH)
• **MorphoSys AG**
82152 Martinsried/München (DE)

(72) Inventors:
• **Bardroff, Michael**
81375 München (DE)
• **Bohrmann, Bernd**
79100 Freiburg (DE)
• **Brockhaus, Manfred**
4126 Bettingen (CH)
• **Huber, Walter**
4303 Kaiseraugst (CH)
• **Kretzschmar, Titus**
86857 Hurlach (DE)
• **Löhning, Corinna**
82131 Stockdorf (DE)
• **Loetscher, Hansruedi**
4313 Möhlin (CH)

• **Nordstedt, Christer**
151 85 Sodertalje (SE)
• **Rothe, Christine**
85221 Dachau (DE)

(74) Representative: **Vossius & Partner**
Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München (DE)

(56) References cited:
EP-A- 0 683 234 EP-A- 1 125 905
WO-A-01/15655 WO-A-01/39796
WO-A-02/10354 WO-A-96/20218
WO-A-97/08320 WO-A-02/064734
WO-A-02/096937

• **O'NUALLAIN BRIAN ET AL: "Conformational Abs
recognizing a generic amyloid fibril epitope",
PROCEEDINGS OF THE NATIONAL ACADEMY
OF SCIENCES OF USA, NATIONAL ACADEMY OF
SCIENCE. WASHINGTON, US, vol. 99, no. 3, 5
February 2002 (2002-02-05), pages 1485-1490,
XP002211263, ISSN: 0027-8424**
• **GHOSHAL NUPUR ET AL: "Tau-66: Evidence for
a novel tau conformation in Alzheimer's
disease.", JOURNAL OF NEUROCHEMISTRY,
vol. 77, no. 5, June 2001 (2001-06), pages
1372-1385, XP002249110, ISSN: 0022-3042**
• **KNAPPIK A ET AL: "Fully synthesis human
combinatorial antibody libraries (HuCAL) based
on modular consensus frameworks and cdrs
randomized with trinucleotides", JOURNAL OF
MOLECULAR BIOLOGY, LONDON, GB, vol. 296,
no. 1, 2000, pages 57-86, XP000939143, ISSN:
0022-2836**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 368 907 B1

- SOLOMON B ET AL: "VACCINATION FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE", DRUGS OF TODAY / MEDICAMENTOS DE ACTUALIDAD, J.R. PROUS SS.A. INTERNATIONAL PUBLISHERS, ES, vol. 36, no. 9, September 2000 (2000-09), pages 655-663, XP001030591, ISSN: 0025-7656
- SOLOMON B ET AL: "DISAGGREGATION OF ALZHEIMER BETA-AMYLOID BY SITE-DIRECTED MAB", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC; US, vol. 94, 1 April 1997 (1997-04-01), pages 4109-4112, XP002942849, ISSN: 0027-8424, DOI: 10.1073/PNAS.94.8.4109
- FRENKEL DAN ET AL: "Modulation of Alzheimer's beta-amyloid neurotoxicity by site-directed single-chain antibody", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 106, no. 1-2, 1 July 2000 (2000-07-01), pages 23-31, XP002300150, ISSN: 0165-5728, DOI: 10.1016/S0165-5728(99)00232-5
- CRIBBS D H ET AL: "Adjuvant-dependent modulation of TH1 and TH2 responses to immunization with beta-amyloid", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 15, no. 4, April 2003 (2003-04), pages 505-514, XP009013327, ISSN: 0953-8178

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

Description

[0001] The present disclosure relates to an antibody molecule capable of specifically recognizing two regions of the β -A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the antibody molecule and vectors and hosts comprising said nucleic acid molecule are disclosed. In addition, the present disclosure provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the disclosure as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the disclosure.

[0002] Several documents are cited throughout the text of this specification. Each of the documents cited herein (including any manufacturers specifications, instructions, etc.) are hereby incorporated by reference.

[0003] About 70% of all cases of dementia are due to Alzheimer's disease which is associated with selective damage of brain regions and neural circuits critical for cognition. Alzheimer's disease is characterized by neurofibrillary tangles in particular in pyramidal neurons of the hippocampus and numerous amyloid plaques containing mostly a dense core of amyloid deposits and defused halos.

[0004] The extracellular neuritic plaques contain large amounts of a pre-dominantly fibrillar peptide termed "amyloid β ", "A-beta", "A β 4", " β -A4" or "A β "; see Selkoe (1994), Ann. Rev. Cell Biol. 10, 373-403, Koo (1999), PNAS Vol. 96, pp. 9989-9990, US 4,666,829 or Glenner (1984), BBRC 12, 1131. This amyloid β is derived from "Alzheimer precursor protein/ β -amyloid precursor protein" (APP). APPs are integral membrane glycoproteins (see Sisodia (1992), PNAS Vol. 89, pp. 6075) and are endoproteolytically cleaved within the A β sequence by a plasma membrane protease, α -secretase (see Sisodia (1992), loc. cit.). Furthermore, further secretase activity, in particular β -secretase and γ -secretase activity leads to the extracellular release of amyloid- β (A β) comprising either 39 amino acids (A β 39), 40 amino acids (A β 40), 42 amino acids (A β 42) or 43 amino acids (A β 43); see Sinha (1999), PNAS 96, 11094-1053; Price (1998), Science 282, 1078 to 1083; WO 00/72880 or Hardy (1997), TINS 20, 154.

[0005] It is of note that A β has several naturally occurring forms, whereby the human forms are referred to as the above mentioned A β 39, A β 40, A β 41, A β 42 and A β 43. The most prominent form, A β 42, has the amino acid sequence (starting from the N-terminus): DAEFRHDSGYEVHHQKLFFAEDVGSNKGAIIGLMVGGVVIA (SEQ ID NO: 27). In A β 41, A β 40, A β 39, the C-terminal amino acids A, IA and VIA are missing, respectively. In the A β 43-form an additional threonine residue is comprised at the C-terminus of the above depicted sequence (SEQ ID NO: 27).

[0006] The time required to nucleate A β 40 fibrils was shown to be significantly longer than that to nucleate A β 42 fibrils; see Koo, loc. cit. and Harper (1997), Ann. Rev. Biochem. 66, 385-407. As reviewed in Wagner (1999), J. Clin. Invest. 104, 1239-1332, the A β 42 is more frequently found associated with neuritic plaques and is considered to be more fibrillogenic in vitro. It was also suggested that A β 42 serves as a "seed" in the nucleation-dependent polymerization of ordered non-crystalline A β peptides; Jarrett (1993), Cell 93, 1055-1058.

[0007] It has to be stressed that modified APP processing and/or the generation of extracellular plaques containing proteinaceous depositions are not only known from Alzheimer's pathology but also from subjects suffering from other neurological and/or neurodegenerative disorders. These disorders comprise, inter alia, Down's syndrome, Hereditary cerebral hemorrhage with amyloidosis Dutch type, Parkinson's disease, ALS (amyotrophic lateral sclerosis), Creutzfeldt Jacob disease, HIV-related dementia and motor neuropathy.

[0008] In order to prevent, treat and/or ameliorate disorders and/or diseases related to the pathological deposition of amyloid plaques, means and methods have to be developed which either interfere with β -amyloid plaque formation, which are capable of preventing A β aggregation and/or are useful in de-polymerization of already formed amyloid deposits or amyloid- β aggregates.

[0009] Accordingly, and considering the severe defects of modified and/or pathological amyloid biology, means and methods for treating amyloid related disorders are highly desirable. In particular, efficient drugs which either interfere with pathological amyloid aggregation or which are capable of de-polymerization of aggregated A β are desired. Furthermore, diagnostic means are desirable to detect, inter alia, amyloid plaques.

[0010] Thus, the technical problem of the present invention is to comply with the needs described herein above.

[0011] Accordingly, the present disclosure relates to an antibody molecule capable of specifically recognizing two regions of the β -A4/A β 4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY (SEQ ID NO: 1) or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLFFAEDVG (SEQ ID NO: 2) or a fragment thereof. In particular, the present invention relates to an antibody molecule comprising

(a) a variable VL-Region comprising complementary determining regions, L-CDR1, L-CDR2 and L-CDR3, wherein:

- (1) L-CDR1 comprises SEQ ID No: 143: Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala;
- (2) L-CDR2 comprises SEQ ID No: 144: Gly Ala Ser Ser Arg Ala Thr; and
- (3) L-CDR3 comprises SEQ ID No: 95: Leu Gln Ile Tyr Asn Met Pro Ile; and

(b) a variable VH-Region comprising complementary determining regions, H-CDR1, H-CDR2 and H-CDR3, wherein:

- (1) H-CDR1 comprises SEQ ID No: 146: Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser;
- (2) H-CDR2 comprises SEQ ID Nos.: 192: Ala Ile Asn Ala Ser Gly Thr Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly; and
- (3) H-CDR3 comprises SEQ ID Nos.: 93: Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp Val.

[0012] In context of the present invention, the term "antibody molecule" relates to full immunoglobulin molecules, preferably IgMs, IgDs, IgEs, IgAs or IgGs, more preferably IgG1, IgG2a, IgG2b, IgG3 or IgG4 as well as to parts of such immunoglobulin molecules, like Fab-fragments or V_L -, V_H - or CDR-regions. Furthermore, the term relates to modified and/or altered antibody molecules, like chimeric and humanized antibodies. The term also relates to modified or altered monoclonal or polyclonal antibodies as well as to recombinantly or synthetically generated/synthesized antibodies. The term also relates to intact antibodies as well as to antibody fragments/parts thereof, like, separated light and heavy chains, Fab, Fab/c, Fv, Fab', F(ab')₂. The term "antibody molecule" also comprises antibody derivatives, the bifunctional antibodies and antibody constructs, like single chain Fvs (scFv), bispecific scFvs or antibody-fusion proteins. Further details on the term "antibody molecule" of the invention are provided herein below.

[0013] The term "specifically recognizing" means in accordance with this invention that the antibody molecule is capable of specifically interacting with and/or binding to at least two amino acids of each of the two regions of β -A4 as defined herein. Said term relates to the specificity of the antibody molecule, i.e. to its ability to discriminate between the specific regions of the β -A4 peptide as defined herein and another, not related region of the β -A4 peptide or another, not APP-related protein/peptide/(unrelated) tests-peptide. Accordingly, specificity can be determined experimentally by methods known in the art and methods as disclosed and described herein. Such methods comprise, but are not limited to Western blots, ELISA-, RIA-, ECL-, IRMA-tests and peptide scans. Such methods also comprise the determination of K_D -values as, inter alia, illustrated in the appended examples. The peptide scan (pepspot assay) is routinely employed to map linear epitopes in a polypeptide antigen. The primary sequence of the polypeptide is synthesized successively on activated cellulose with peptides overlapping one another. The recognition of certain peptides by the antibody to be tested for its ability to detect or recognize a specific antigen/epitope is scored by routine colour development (secondary antibody with horseradish peroxidase and 4-chloronaphthol and hydrogenperoxide), by a chemoluminescence reaction or similar means known in the art. In the case of, inter alia, chemoluminescence reactions, the reaction can be quantified. If the antibody reacts with a certain set of overlapping peptides one can deduce the minimum sequence of amino acids that are necessary for reaction; see illustrative Example 6 and appended Table 2.

The same assay can reveal two distant clusters of reactive peptides, which indicate the recognition of a discontinuous, i. e. conformational epitope in the antigenic polypeptide (Geysen (1986), Mol. Immunol. 23, 709-715).

[0014] In addition to the pepsot assay, standard ELISA assay can be carried out. As demonstrated in the appended examples small hexapeptides may be coupled to a protein and coated to an immunoplate and reacted with antibodies to be tested. The scoring may be carried out by standard colour development (e.g. secondary antibody with horseradish peroxidase and tetramethyl benzidine with hydrogenperoxide). The reaction in certain wells is scored by the optical density, for example at 450 nm. Typical background (=negative reaction) may be 0.1 OD, typical positive reaction may be 1 OD. This means the difference (ratio) positive/negative can be more than 10 fold. Further details are given in the appended examples. Additional, quantitative methods for determining the specificity and the ability of "specifically recognizing" the herein defined two regions of the β -A4 peptide are given herein below.

[0015] The term "two regions of the β -A4 peptide" relates to two regions as defined by their amino acid sequences shown in SEQ ID NOs: 1 and 2, relating to the N-terminal amino acids 2 to 10 and to the central amino acids 12 to 25 of β -A4 peptide. The term " β -A4 peptide" in context of this invention relates to the herein above described A β 39, A β 41, A β 43, preferably to A β 40 and A β 42. A β 42 is also depicted in appended SEQ ID NO: 27. It is of note that the term "two regions of the β -A4 peptide" also relates to an "epitope" and/or an "antigenic determinant" which comprises the herein defined two regions of the β -A4 peptide or parts thereof. In accordance with this disclosure, said two regions of the β -A4 peptide are separated (on the level of the amino acid sequence) in the primary structure of the β -A4 peptide by at least one amino acid, preferably by at least two amino acids, more preferably by at least three amino acids, more preferably by at least four amino acids, more preferably by at least five amino acids, more preferably at least six amino acids, more preferably at least nine amino acids and most preferably at least twelve amino acids. As shown herein and as documented in the appended examples, the antibodies/antibody molecules as described herein detect/interact with and/or bind to two regions of the β -A4 peptide as defined herein, whereby said two regions are separated (on the primary structure level of the amino acid sequence) by at least one amino acid and wherein the sequence separating said two regions/"epitope" may comprise more than ten amino acids, preferably 14 amino acids, more preferably 15 amino acids or 16 amino acids. For example, MSR-3 Fab (as an antibody molecule described herein) recognizes detects/interacts with two regions on the β -A4 peptide, wherein said first region comprises amino acids 3 and 4 (EF) and said second regions comprises amino acids 18 to 23 (VFFAED). Accordingly, the separating sequence between the region/epitopes to be detected/recognized has a length of 13 amino acids on the primary amino acid sequence structure. Similarly, MSR

#3.4H7 IgG1, an optimized and matured antibody molecules derived from MSR-3 and comprised in an IgG1-framework, detects/interacts with/binds to two epitopes/regions of β -A4 which comprise in the first region positions 1 to 4 (DAEF) and in the second region positions 19 to 24 (FFAEDV) of β -A4 as defined herein. Accordingly, MSR #3.4H7 IgG1 recognizes/detects/interacts with/binds to two epitopes/regions which are, on the primary amino acid sequence level, separated by 14 amino acids. As detailed in the appended examples, affinity maturation and conversion of monovalent Fab fragments to full-length IgG1 antibodies may result in a certain broadening of the epitopes/regions detected in pepspot, ELISA assays and the like. Therefore, the antibody molecules of the disclosure are capable of simultaneously and independently recognizing two regions of the β -A4 peptide/A β 4 wherein said regions comprise the amino acid sequence as shown in SEQ ID NO: 1 (or parts thereof) and the amino acid sequence as shown in SEQ ID NO: 2 (or (a) part(s) thereof). Due to the potential broadening of epitopes as detailed herein it is, however, also envisaged that amino acids in close proximity to the sequences of SEQ ID NO: 1 and 2 are detected/recognized, i.e. that additional amino acids are part of the two regions to be detected/recognized. Accordingly, it is also envisaged that, e.g. the first amino acid of A β (1-42) as defined herein, namely D (Aspartic acid) in part of one epitope to be detected/recognized or that amino acids located after the region of A β (1-42) as defined in SEQ ID NO: 2 are detected/recognized. Said additional amino acid may, e.g., be the amino acid on position 26 of SEQ ID NO: 27 (β A4/A β (1-42)), namely S (Serine).

[0016] The term may also relate to a conformational epitope, a structural epitope or a discontinuous epitope consisting of said two regions or parts thereof; see also Geysen (1986), loc. cit. In context of this invention, a conformational epitope is defined by two or more discrete amino acid sequences separated in the primary sequence which come together on the surface when the polypeptide folds to the native protein (Sela, (1969) Science 166, 1365 and Laver, (1990) Cell 61, 553-6). The antibody molecules of the present invention are envisaged to specifically bind to/interact with a conformational/structural epitope(s) composed of and/or comprising the two regions of β -A4 described herein or parts thereof as disclosed herein below. The "antibody molecules" of the present invention are thought to comprise a simultaneous and independent dual specificity to (a) an amino acid stretch comprising amino acids 2 to 10 (or (a) part(s) thereof) of β -A4 and (b) an amino acid stretch comprising amino acids 12 to 25 (or (a) part(s) thereof) of β -A4 (SEQ ID NO. 27). Fragments or parts of these stretches comprise at least two, more preferably at least three amino acids. Preferred fragments or parts are in the first region/stretch of SEQ ID NO: 27 the amino acid sequences AEFRHD, EF, EFR, FR, EFRHDSG, EFRHD or HDSG and in the second region/stretch of SEQ ID NO: 27 the amino acid sequences HHQKL, LV, LVFFAE, VFFAED VFFA, or FFAEDV. As mentioned above, said fragments may also comprise additional amino acids or may be parts of the fragments defined herein. Specific examples are DAE, DAEF, FRH or RHDSG.

[0017] A number of antibodies specifically recognizing A β peptides have been described in the art. These antibodies have mainly been obtained by immunizing animals with A β 1-40 or A β 1-42 or fragments thereof using standard technologies. According to published data monoclonal antibodies that were generated by immunization with the complete As peptide (1-40 or 1-42) recognize exclusively an epitope close to the N-terminus of A β . Further, examples are the antibodies BAP-1 and BAP-2 (Brockhaus, unpublished) which were generated by immunization of mice with A β 1-40 and which recognize the amino acids 4-6 in the context of larger A β peptides; see appended Example 7, Table 2 and Example 12, Table 7. Antibodies that recognize the middle part of A β derive from immunizations with smaller peptides. For example, the antibody 4G8 was generated by immunization with the A β peptide 1-24 and recognizes exclusively the sequence 17-24 (Kim, (1988) Neuroscience Research Communications 2, 121-130). Many other monoclonal antibodies have been generated by immunizing mice with A β -derived fragments, and antibodies recognizing the C-terminal end of A β 1-40 and A β 1-42 are widely used to distinguish and quantitate the corresponding A β peptides in biological fluids and tissues by ELISA, Western blot and immunohistochemistry analysis (Ida et al, (1996) J. Biol. Chem. 271, 22908-22914; Johnson-Wood et al., (1997), Proc. Natl. Acad. Sci. USA (1994), 1550-1555; Suzuki et al., (1994), Science 264, 1336-1340; Brockhaus (1998), Neuro Rep. 9, 1481-1486). BAP-17 is a mouse monoclonal antibody which has been generated by immunizing mice with A β fragment 35-40. It specifically recognizes the C-terminal end of A β 1-40 (Brockhaus (1998) Neuroreport 9, 1481-1486).

It is believed that the immunization with T-cell dependent antigens (often poor immunogens) requires a proteolytic cleavage of the antigen in the endosomes of antigen presenting cells. The in vivo selection of high affinity antibodies after immunization is driven by the contact of helper T cells to antigen presenting cells. The antigen presenting cells only present short peptides and not polypeptides of large size. Accordingly, these cells have a complicated (but well known) machinery to endocytose antigen(s), degrade the antigen(s) in endosomes, combine selected peptides with suitable MHC class II molecules, and to export the peptide-MHC complex to the cell surface. This is where the antigen specific recognition by T cells occurs, with the aim to provide help to maturing B cells. The B cells which receive most T cell help have the best chance to develop into antibody secreting cells and to proliferate. This shows that antigen processing by proteolysis is an important step for the generation of an high affinity antibody response in vivo and may explain the dominance of the N-terminal A β epitope in prior art monoclonal and polyclonal antibodies derived by immunization.

In contrast, the selection of antibodies/antibody molecules of the present invention is driven by the physical adherence of Fab expressing phages to the antigen. There is no degradation of the antigen involved in this in vitro selection process. The phages which express the Fab with the highest affinity towards the antigen are selected and propagated. A synthetic

library as employed in the appended examples to select for specific antibody molecules according to this invention is particularly suited for avoiding any bias for single, continuous epitopes that is often found in libraries derived from immunized B cells.

[0018] It is of note that the prior art has not described antibody molecules recognizing two, independent regions of A β 4 which specifically recognizes (a) discontinuous/structural/conformational epitope(s) and/or which are capable of simultaneously and independently recognizing two regions/epitopes of A β 4.

Vaccination of transgenic mice overexpressing mutant human APP V717F (PDAPP mice) with A β 1-42 resulted in an almost complete prevention of amyloid deposition in the brain when treatment was initiated in young animals, i. e. before the onset of neuropathologies, whereas in older animals a reduction of already formed plaques was observed suggesting antibody-mediated clearance of plaques (Schenk et al., (1999), Nature 400,173-177). The antibodies generated by this immunization procedure were reactive against the N-terminus of A β 4 covering an epitope around amino acids 3-7 (Schenk et al., (1999), loc. cit.; WO 00/72880). Active immunization with A β 1-42 also reduced behavioural impairment and memory loss in different transgenic models for Alzheimer's Disease (Janus et al., (2000) Nature 408, 979-982; Morgan et al., (2000) Nature 408, 982-985). Subsequent studies with peripherally administered antibodies, i. e. passive immunization, have confirmed that antibodies can enter the central nervous system, decorate plaques and induce clearance of preexisting amyloid plaques in APP transgenic mice (PDAPP mice) (Bard et al., (2000) Nat. Med. 6, 916-919; WO 00/72880). In these studies, the monoclonal antibodies with the most potent *in vivo* and *ex vivo* efficacy (triggering of phagocytosis in exogenous microglial cells) were those which recognized A β 4 N-terminal epitopes 1-5 (mab 3D6, IgG2b) or 3-6 (mab 10D5, IgG1). Likewise, polyclonal antibodies isolated from mice, rabbits or monkeys after immunization with A β 1-42 displayed a similar N-terminal epitope specificity and were also efficacious in triggering phagocytosis and *in vivo* plaque clearing. In contrast, C-terminal specific antibodies binding to A β 1-40 or A β 1-42 with high affinity did not induce phagocytosis in the *ex vivo* assay and were not efficacious *in vivo* (WO 00/72880). Monoclonal antibody m266 (WO 00/72880) was raised against A β 13-28 (central domain of A β) and epitope mapping confirmed the antibody specificity to cover amino acids 16-24 in the A β sequence. This antibody does not bind well to aggregated A β and amyloid deposits and merely reacts with soluble (monomeric) A β , i. e. properties which are similar to another well-known and commercially available monoclonal antibody (4G8; Kim, (1988) Neuroscience Research Communications 2, 121-130; commercially available from Signet Laboratories Inc. Dedham, MA USA) which recognizes the same epitope.

[0019] *In vivo*, the m266 antibody was recently found to markedly reduce A β deposition in PDAPP mice after peripheral administration (DeMattos, (2001) Proc. Natl. Acad. Sci. USA 98, 8850-8855). However, and in contrast to N-terminal specific antibodies, m266 did not decorate amyloid plaques *in vivo*, and it was therefore hypothesized that the brain A β burden was reduced by an antibody-induced shift in equilibrium between CNS and plasma A β resulting in the accumulation of brain-derived A β in the periphery, firmly complexed to m266 (DeMattos, (2001) loc. cit.).

[0020] The antibody/antibody molecule of the present disclosure, by simultaneously (for example in a structural/conformational epitope formed by the N-terminal and central region of A β 4 as described herein) and independently (for example in pepspot assays as documented in the appended experimental part) binding to the N-terminal and central epitopes, combine the properties of an N-terminal-specific antibody and a central epitope-specific antibody in a single molecule. Antibodies with the dual epitope specificity, as described in the present invention, are considered to be more efficacious *in vivo*, in particular in medical and diagnostic settings for, e.g., reducing amyloid plaque burden or amyloidogenesis or for the detection of amyloid deposits and plaques. It is well known that in the process of A β 4 aggregation and amyloid deposition conformational changes occur, and while the central epitope is easily accessible in soluble A β 4 it appears to be hidden and less reactive in aggregated or fibrillar A β 4. The fact that the central/middle epitope-specific antibody m266 is efficacious *in vivo* indicates that neutralization of soluble A β 4 may also be a critical parameter. The antibodies/antibody molecules of the present disclosure, due to the dual epitope specificity, can bind to both fibrillar and soluble A β 4 with similar efficacy, thus allowing interaction with amyloid plaques as well as neutralization of soluble A β 4. The term "simultaneously and independently binding to the N-terminal and central/middle epitopes of A β -A4" as employed herein in context of the antibody molecules as described herein relates to the fact that the antibodies/antibody molecules described herein may detect and/or bind to both epitopes simultaneously, i.e. at the same time (for example on conformational/structural epitopes formed by the N-terminal epitope (or (a) part(s) thereof) and central epitopes (or (a) part(s) thereof) of A β 4 as defined herein) and that the same antibody molecules, however, are also capable of detecting/binding to each of the defined epitopes in an independent fashion, as inter alia, demonstrated in the pepspot analysis shown in the examples.

[0021] Clearance of amyloid plaques *in vivo* in PDAPP mice after direct application of the antibodies to the brain is not dependent on the IgG subtype and may also involve a mechanism which is not Fc-mediated, i. e. no involvement of activated microglia in plaque clearance (Bacskaï, (2001), Abstract Society for Neuroscience 31st Annual Meeting, November 10-15, 2001, San Diego). This observation is in contrast to what has been postulated in an earlier study by Bard (2000), loc. cit.

[0022] In another study antibodies raised against A β 1-28 and A β 1-16 peptides were found to be effective in disaggregating A β fibrils *in vitro*, whereas an antibody specific for A β 13-28 was much less active in this assay (Solomon, (1997)

Proc. Natl. Acad. Sci. USA 94, 4109-4112). Prevention of A β aggregation by an anti-A β 1-28 antibody (AMY-33) has also been reported (Solomon, (1996) Proc. Natl. Acad. Sci. USA 93, 452-455). In the same study, antibody 6F/3D which has been raised against A β fragment 8-17 slightly interfered with Zn²⁺-induced A β aggregation but had no effect on the self aggregation induced by other aggregation-inducing agents.

The efficacy of the various antibodies in these in vitro assays correlates with the accessibility of their epitopes in A β 4 aggregates. The N-terminus is exposed and N-terminal specific antibodies clearly induce de-polymerization, whereas the central region and the C-terminus are hidden and not easily accessible and thus antibodies against these epitope are much less effective.

Investigations with respect to epitope accessibility for antibodies have shown that in aggregated A β the N-terminal epitope is exposed and reacts with the BAP-1 antibody, whereas the middle or central epitope indeed remains cryptic, i. e. no binding of the 4G8 antibody was observed. However, in monomeric A β both epitopes are overt and are equally recognized by both prior art antibodies.

[0023] In contrast, in the present invention, it was surprisingly found that the herein described antibody molecules recognize two discontinuous amino acid sequences, e.g. a conformational/structural epitope on the A β peptide. Two "discontinuous amino acid sequences" in accordance with this invention means that said two amino acid sequences forming the N-terminal and central/middle epitopes, respectively, are separated on β -A4 in its primary structure by at least two amino acids which are not part of either epitope.

[0024] The binding area of an antibody Fab (=paratope) occupies a molecular surface of approximately 30 x 30 Å in size (Laver, Cell 61 (1990), 553-556). This is enough to contact 15 to 22 amino acid residues which may be present on several surface loops. The discontinuous epitope recognized by the antibody molecules as described herein resembles a conformation in which the N-terminal (residues 2 to 10 or parts thereof) and middle A β peptide sequences (residues 12 to 25 or parts thereof) are in close proximity. Only within this conformation, the maximum number of antigen-antibody contacts and the lowest free energy state are obtained.

Based on energetic calculations it has been suggested that a smaller subset of 5-6 residues, which are not arranged in a linear sequence but are scattered over the epitope surface, contributes most of the binding energy while surrounding residues may merely constitute a complementary array (Laver (1990) loc. cit.).

[0025] The antibodies/antibody molecules as described herein are capable of binding to aggregated A β and strongly react with amyloid plaques in the brain of AD patients (as documented in the appended examples). In addition, they are capable of depolymerizing/disintegrating amyloid aggregates.

[0026] Without being bound by theory, the conformational/structural epitope (composed by the two regions of A β 4 or (a) part(s) of said regions as described herein) is believed to be partially exposed in aggregated A β . However, it is known that major part of the middle/second epitope/region alone is not freely accessible in these A β aggregates (based on the poor reactivities of middle epitope-specific antibodies 4G8 and m266). On the other hand, and in view of the considerations mentioned above, it is likely that one or several residues of the middle region are components of the conformational epitope and, in conjunction with the residues from the N-terminal region, are accessible to the antibodies of the present disclosure, thereby significantly contributing to the binding energy of the antibody-A β 4 interaction. The reactivity of the antibody molecule as described herein with the conformational epitope in aggregated AD is therefore unique and clearly distinct from α A β 4 antibodies described in the prior art. Yet, as pointed out herein above, a further unique feature of the antibodies/antibody molecules as described herein is their capacity to simultaneously and independently binding to/recognizing two separate epitopes on β -A4, as defined herein and in the appended examples.

[0027] In a preferred aspect of the disclosure, the antibody molecule as described herein is an antibody molecule wherein the least two regions of the β -A4 to be specifically recognized by said antibody form a conformational/structural epitope or a discontinuous epitope; see Geysen (1986), loc. cit.; Ghoshal (2001), J. Neurochem. 77, 1372-1385; Hochleitner (2000), J. Imm. 164, 4156-4161; Laver (1990), loc. cit.. The term "discontinuous epitope" means in context of the invention non-linear epitopes that are assembled from residues from distant portions of the polypeptide chain. These residues come together on the surface when the polypeptide chain folds into a three-dimensional structure to constitute a conformational/structural epitope. The present disclosure provides for preferred, unexpected epitopes within β -A4, which result in the generation of specific antibody molecules described herein, capable of specifically interacting with these epitopes. These antibodies/antibody molecules described herein provide the basis for increased efficacy, and a reduced potential for side effects. As pointed out above, the antibodies described herein, however, were also capable of independently interacting with each of the defined two regions/epitopes of β -A4, for example in Pepspot assays as documented in the appended examples.

[0028] The present invention, accordingly, provides for unique tools which may be employed to de-polymerize aggregated A β -fibrils in vivo and in vitro and/or which are capable of stabilizing and/or neutralizing a conformational epitope of monomeric A β and thereby capable of preventing the pathological A β aggregation.

It is furthermore envisaged that the inventive antibodies bind to A β deposits at the rim of amyloid plaques in, inter alia, Alzheimer's brain and efficiently dissolve the pathological protofibrils and fibrils.

[0029] The antibody molecule of the disclosure recognizes at least two consecutive amino acids within the two regions

of A β 4 defined herein, more preferably said antibody molecule recognizes in the first region an amino acid sequence comprising the amino acids: AEFRHD, EF, EFR, FR, EFRHDSG, EFRHD or HDSG and in the second region an amino acid sequence comprising the amino acids: HHQKL, LV, LVFFAE, VFFAED, VFFA or FFAEDV. Further fragments or broadened parts comprise: DAE, DAEF, FRH or RHD SG.

[0030] It is particularly preferred that the antibody molecule of the disclosure comprises a variable V_H-region as encoded by a nucleic acid molecule as shown in SEQ ID NO: 3, 5 or 7 or a variable V_H-region as shown in the amino acid sequences depicted in SEQ ID NOs: 4, 6 or 8. The sequences as shown in SEQ ID NOs: 3 and 4 depict the coding region and the amino acid sequence, respectively, of the V_H-region of the parental antibody MSR-3 (MS-Roche 3), the sequences in SEQ ID NOs: 5 and 6 depict the coding region and the amino acid sequence, respectively, of the V_H-region of the parental antibody MSR-7 (MS-Roche 7) and SEQ ID NOs: 7 and 8 depict the coding region and the amino acid sequence, respectively, of the V_H-region of the parental antibody MSR-8 (MS-Roche 8). Accordingly, the disclosure also provides for antibody molecules which comprise a variable V_L-region as encoded by a nucleic acid molecule as shown in a SEQ ID NO selected from the group consisting of SEQ ID NO: 9, 11 or 13 or a variable V_L-region as shown in the amino acid sequences depicted in SEQ ID NOs: 10, 12 or 14. SEQ ID NOs: 9 and 10 correspond to the V_L-region of MSR-3, SEQ ID NOs: 11 and 12 correspond to the V_L-region of MSR-7 and SEQ ID NOs: 13 and 14 correspond to the V_L-region of MSR-8. As illustrated in the appended examples, the parental antibodies MSR-3, -7 and -8, are employed to further generate optimized antibody molecules with even better properties and/or binding affinities. Some of the corresponding and possible strategies are exemplified and shown in the appended examples.

The optimization strategy as illustrated in the appended examples lead to a plurality of optimized antibodies. These optimized antibodies share with their parental antibodies the CDR-3 domain of the V_H-region. Whereas the original framework region (as shown in appended Figure 1) remains the same, in the matured/optimized antibody molecules, CDR1, CDR2 and/or V_L CDR3-regions are changed. Illustrative, modified sequence motives for optimized antibody molecules are shown in appended table 1. Accordingly, within the scope of the present disclosure are also optimized antibody molecules which are derived from the herein disclosed MSR-3, -7 and -8 and which are capable of specifically reacting with/specifically recognizing the two regions of the β -A4 peptide as defined herein. In particular, CDR-regions, preferably CDR1s, more preferably CDR1s and CDR2s, most preferably CDR1s, CDR2s and CDR3s as defined herein may be employed to generate further antibodies/antibody molecules, inter alia, by CDR-grafting methods known in the art; see Jones (1986), Nature 321, 522-515 or Riechmann (1988), Nature 332, 323-327. The antibodies/antibody molecules as described herein as well as antibody fragments or derivatives are derived from the parental antibodies as disclosed herein and share, as disclosed above, the CDR-3 domain of the V_H-region with at least one of said parental antibodies. As illustrated below, it is also envisaged that cross-cloned antibodies are generated which are to be considered as optimized/matured antibodies/antibody molecules of the present disclosure. Antibody molecules as described herein may also comprise or may also be derived from antibodies/antibody molecules which are characterized by V_H-regions as shown in any of SEQ ID NOs: 32 to 45 or V_L-regions as shown in SEQ ID NOs: 46 to 59 or which may comprise a CDR-3 region as defined in any of SEQ ID NOs: 60 to 87. The optimized antibody molecule of the present invention comprises V_H-regions and V_L-regions as depicted in SEQ ID NOs: 90/91, respectively, or parts thereof. A part thereof may be (a) CDR-region(s), preferably (a) CDR3-region(s). The antibody molecule of the optimized type comprises a H-CDR3 as characterized in SEQ ID NO: 93 and/or a L-CDR3 as characterized in SEQ ID NO: 95.

It is preferred that the antibodies/antibody molecules of the invention are characterized by their specific reactivity with β -A4 and/or peptides derived from said β -A4. For example, optical densities in ELISA-tests, as illustrated in the appended examples, may be established and the ratio of optical densities may be employed to define the specific reactivity of the parental or the optimized antibodies. Accordingly, a preferred antibody of the invention is an antibody which reacts in an ELISA-test with β -A4 to arrive at an optical density measured at 450 nm that is 10 times higher than the optical density measured without β -A4, i. e. 10 times over background. Preferably the measurement of the optical density is performed a few minutes (e.g. 1, 2, 3, 4, 5, 6, or 7 minutes) after initiation of the color developing reaction in order to optimize signal to background ratio.

[0031] Herein described antibody molecules comprise at least one CDR3 of an V_L-region as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 15, 17 or 19 or at least one CDR3 amino acid sequence of an V_L-region as shown in SEQ ID NOs: 16, 18 or 20 and/or said antibody molecule comprises at least one CDR3 of an V_H-region as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 21, 23 or 25 or at least one CDR3 amino acid sequence of an V_H-region as shown in SEQ ID NOs: 22, 24 or 26. Most preferred are antibodies comprising at least one CDR3 of an V_H-region as defined herein. The CDR-3 domains mentioned herein above relate to the illustrative parental antibody molecules MSR-3, -7, or -8. However, as illustrated in the appended tables 1, 8 or 10, matured and/or optimized antibody molecules obtainable by the methods disclosed in the appended examples may comprise modified V_H-, V_L-, CDR1, CDR2 and CDR3 regions. Accordingly, the antibody molecule may be selected from the group consisting of MSR-3, -7 and -8 or an affinity-matured version of MSR-3, -7 or -8. Affinity-matured as well as cross-cloned versions of MSR-3, -7 and -8 comprise, inter alia, antibody molecules comprising CDR1, CDR2 and/or CDR3 regions as shown in table 1 or 8 or characterized in any of SEQ ID NOs: 15 to 20, 21 to 26, 60 to 74, 75 to 87, 92 and 93 or 94 and 95 as well as in

SEQ ID NOs: 354 to 413. The antibody as described herein comprises at least one CDR, preferably a CDR1, more preferably a CDR2, most preferably a CDR3 as shown in the appended table 1, 8 or as documented in appended table 10.

[0032] It is of note that affinity-maturation techniques are known in the art, described in the appended examples and, inter alia, in Knappik (2000), J. Mol. Biol. 296, 55; Krebs (2000), J. Imm. Meth. 254, 67-84; WO 01/87337; WO 01/87338; US 6,300,064; EP 96 92 92 78.8 and further references cited herein below.

[0033] In a more preferred embodiment of the invention, the antibody molecule is a full antibody (immunoglobulin, like an IgG1, an IgG2, an IgG2b, an IgG3, an IgG4, an IgA, an IgM, an IgD or an IgE), an F(ab)-, Fab-, Fv-, Fab'-, F(ab')₂-fragment, a single-chain antibody, a chimeric antibody, a CDR-grafted antibody, a bivalent antibody-construct, an antibody-fusion protein, a cross-cloned antibody or a synthetic antibody. Also envisaged are genetic variants of immunoglobulin genes. Genetic variants of, e.g., immunoglobulin heavy G chain subclass 1 (IgG1) may comprise the G1m(17) or G1m(3) allotypic markers in the CH1 domain, or the G1m(1) or the G1m(non-1) allotypic marker in the CH3 domain. The antibody molecule of the invention also comprises modified or mutant antibodies, like mutant IgG with enhanced or attenuated Fc-receptor binding or complement activation. It is also envisaged that the antibodies of the invention are produced by conventional means, e.g. the production of specific monoclonal antibodies generated by immunization of mammals, preferably mice, with peptides comprising the two regions of β A4 as defined herein, e.g. the N-terminal and central region/epitope comprising (a) amino acids 2 to 10 (or (a) part(s) thereof) of β -A4 and (b) an amino acid stretch comprising amino acids 12 to 25 (or (a) part(s) thereof) of β -A4 (SEQ ID NO. 27). Accordingly, the person skilled in the art may generate monoclonal antibodies against such a peptide and may screen the obtained antibodies for the capacity to simultaneously and independently binding to/reacting with the N-terminal and central region/epitope of β A4 as defined herein. Corresponding screening methods are disclosed in the appended examples.

[0034] As illustrated in the appended examples, the inventive antibodies/antibody molecules can readily and preferably be recombinantly constructed and expressed. Preferably, the antibody molecule of the disclosure comprises at least one, more preferably at least two, preferably at least three, more preferably at least four, more preferably at least five and most preferably six CDRs of the herein defined MSR-3, MSR-7 or MSR-8 parental antibodies or of affinity-matured/optimized antibodies derived from said parental antibodies. It is of note that also more than six CDRs may be comprised in recombinantly produced antibodies of the invention. The person skilled in the art can readily employ the information given in the appended examples to deduce corresponding CDRs of the parental as well as the affinity optimized antibodies. Examples of optimized antibodies which have been obtained by maturation/optimization of the parental antibodies are, inter alia, shown in appended table 1. An matured/optimized antibody molecule of the invention is, e.g. MSR 7.9H7 which is also characterized by sequences appended herein, which comprise SEQ ID NOs: 88 to 95 and which depict the V_H-region of MSR 7.9H7 (SEQ ID NOs: 88 and 89), the V_L-region of MSR 7.9H7 (SEQ ID NOs: 90 and 91), the H-CDR3 of MSR 7.9H7 (SEQ ID NOs: 92 and 93) as well as the L-CDR3 of MSR 7.9H7 (SEQ ID NOs: 94 and 95). Illustrative antibody molecule 7.9H7 is derived from parental antibody MSR7 and is a particular preferred inventive example of an optimized/matured antibody molecule of the present invention. This antibody molecule may be further modified in accordance with this invention, for example in form of cross-cloning, see herein below and appended examples.

[0035] As documented in the appended examples, the antibodies of the invention also comprise cross-cloned antibodies, i.e. antibodies comprising different antibody regions (e.g. CDR-regions) from one or more parental or affinity-optimized antibody(ies) as described herein. These cross-cloned antibodies may be antibodies in several, different frameworks, whereby the most preferred framework is an IgG-framework, even more preferred in an IgG1-, IgG2a or an IgG2b-framework. It is particularly preferred that said antibody framework is a mammalian, most preferably a human framework. The domains on the light and heavy chains have the same general structure and each domain comprises four framework regions, whose sequences are relatively conserved, joined by three hypervariable domains known as complementarity determining regions (CDR1-3).

[0036] As used herein, a "human framework region" relates to a framework region that is substantially identical (about 85% or more, usually 90-95% or more) to the framework region of a naturally occurring human immunoglobulin. The framework region of an antibody, that is the combined framework regions of the constituent light and heavy chains, serves to position and align the CDR's. The CDR's are primarily responsible for binding to an epitope of an antigen. It is of note that not only cross-cloned antibodies described herein may be presented in a preferred (human) antibody framework, but also antibody molecules comprising CDRs from, inter alia, the parental antibodies MSR-3, -7 or -8 as described herein or of matured antibodies derived from said parental antibodies, may be introduced in an immunoglobulin framework. Preferred frameworks are IgG1, IgG2a and IgG2b. Most preferred are human frameworks and human IgG1 frameworks.

[0037] As shown in the appended examples, it is, inter alia possible, to transfer, by genetic engineering known in the art whole light chains from an optimized donor clone to an optimized recipient clone. Example for an optimized donor clone is, e.g. L-CDR1 (L1) and an example for an optimized recipient clone is H-CDR2 (H2). Epitope specificity may be conserved by combining clones which possess the same H-CDR-3 regions. Further details are given in illustrative Example 13.

Cross-cloned antibody molecules may be selected from the group consisting of MS-R #3.3H1x3.4L9, MS-R #3.4H1x3.4L9, MS-R #3.4H3x3.4L7, MS-R #3.4H3x3.4L9, MS-R #3.4H7x3.4L9, MS-R #3.4H7x3.4L7, MS-R #3.6H5x3.6L1, MS-R #3.6H5x3.6L2, MS-R #3.6H8x3.6L2, MS-R #7.2H2x7.2L1, MS-R #7.4H2x7.2L1, MS-R #7.4H2x7.12L2, MS-R #7.9H2x7.2L1(L1), MS-R #7.9H2x7.12L1, MS-R #7.9H2x7.12L2, MS-R #7.9H2x7.12L2(L1+2), MS-R #7.9H4x7.12L2, MS-R #7.11H1x7.2L1, MS-R #7.11H1x7.11L1, MS-R #7.11H2x7.2L1(L1), MS-R #7.11H2x7.9L1 (L1), MS-R #7.11H2x7.12L or MS-R #8.1H1x8.2L1.

[0038] The generation of cross-cloned antibodies is also illustrated in the appended examples. The above mentioned preferred cross-cloned antibodies/antibody molecules are optimized/matured antibody molecules derived from parental antibodies disclosed herein, in particular from MSR-3 and MSR-7. In addition, further characterizing CDR-sequences and V-regions of the cross-cloned antibody molecules/antibodies are given in appended SEQ ID NOs: 32, 33, 46 and 47 (MSR 3.6H5x3.6L2; V_H-, V_L-region); 34, 35, 48 and 49 (MSR 3.6H8x3.6L2; V_H-, V_L-regions); 36, 37, 50 and 51 (MSR 7.4H2x7.2L1; V_H-, V_L-regions); 38, 39, 52 and 53 (MSR 7.9H2x7.12L2; V_H-, V_L-regions); 40, 41, 54 and 55 (MSR # 7.9H4x7.12L2; V_H-, V_L-regions); 42, 43, 56 and 57 (MSR #7.11H1x7.11L1; V_H-, V_L-regions); and 44, 45, 58 and 59 (MSR # 7.11H1x7.2L1; V_H-, V_L-regions). Corresponding CDR3 regions of these particular preferred cross-cloned antibody molecules are depicted in SEQ ID NOs: 60 to 87. For further MSR antibody molecules, V_H-, V_L-, CDR-regions can be deduced from appended Tables 8 or 10 and from the appended sequence listing, in particular SEQ ID NOS: 32 to 95 for MS-R antibodies/antibody molecules #3.6H5 x 3.6L2, #3.6H8 x 3.6L2, #7.4H2 x 7.2L1, #7.9H2 x 7.12L2, #7.9H4 x 7.12L2, #7.11H1 x 7.11L1, #7.11H1 x 7.2L1 and #7.9H7 or SEQ ID NOS: 294 to 413 for MSR-R antibodies/antibody molecules MS-R #3.3H1x3.4L9, #3.4H1 x 3.4L9, #3.4H3 x 3.4L7, #3.4H3 x 3.4L9, #3.4H7 x 3.4L9, #3.4H7 x 3.4L7, #3.6H5 x 3.6L1, #7.2H2 x 7.2L1, #7.4H2 x 7.12L2, #7.9H2 x 7.2L1, #7.9H2 x 7.12L1, #7.11H2 x 7.2L1, #7.11H2 x 7.9L1, #7.11H2 x 7.12L1 or #8.1H1 x 8.2L1. Accordingly, besides V_H-regions defined above, preferred antibody molecules of the disclosure may comprise V_H-regions as defined in any one of SEQ ID NOs: 294 to 323. Similarly, SEQ ID NOs: 324 to 353 depict preferred V_L-regions which, besides to V_L-regions defined above which may be comprised in the antibody molecule as described herein. Corresponding CDR-3 regions are defined above, as well as in additional sequences shown in SEQ ID NOs: 354 to 413.

[0039] Inventive antibody molecule can easily be produced in sufficient quantities, inter alia, by recombinant methods known in the art, see, e.g. Bentley, Hybridoma 17 (1998), 559-567; Racher, Appl. Microbiol. Biotechnol. 40 (1994), 851-856; Samuelsson, Eur. J. Immunol. 26 (1996), 3029-3034.

[0040] Theoretically, in soluble β -A4 (monomeric/oligomeric) both the N-terminal and the middle epitopes are accessible for antibody interaction and antibody molecules of the present invention may either bind to the N-terminal or middle epitope separately, but under these conditions maximum affinity will not be obtained. However, it is more likely that an optimal contact to the antibody paratope will be attained by simultaneous binding to both epitopes, i.e. similar to the interaction with aggregated β -A4. Thus, antibodies of the present invention are unique anti-A β antibodies in that they bind to aggregated β -A4 (via interaction with the N-terminal and middle epitope), and at the same time are also able to stabilize and neutralize the conformational epitope in soluble β -A4. These antibodies are distinct to prior art antibodies.

[0041] Most preferred are antibody molecules of the invention which have an affinity to A β or defined fragments thereof with a K_D value lower than 2000 nM, preferably lower than 100 nM, more preferably lower than 10 nM, most preferably lower than 1 nM. The measurement of such affinity/affinities may be carried out by methods illustrated in the examples and known in the art. Such methods comprise, but are not limited to BIACORE™-assays (www.biacore.com; Malmquist (1999), Biochem.Soc. Trans 27, 335-340) and solid phase assays using labeled antibodies or labeled A β .

[0042] Preferably, the antibody molecule of the invention is capable of decorating/reacting with/binding to amyloid plaques in in vitro (post-mortem) brain sections from patients suffering from amyloid-related disorders, like Alzheimer's disease. Yet, it is also preferred that the inventive antibody/antibody molecules prevent A β -aggregation in vivo as well as in in vitro assays, as illustrated in the appended examples. Similarly, the antibody molecules of the present invention are preferred to de-polymerize A β -aggregate in vivo and/or in in vitro assays shown in the examples. This capacity of the inventive antibodies/antibody molecules is, inter alia, to be employed in medical settings, in particular in pharmaceutical compositions described herein below.

[0043] The invention also provides for a nucleic acid molecule encoding an inventive antibody molecule as defined herein.

[0044] Said nucleic acid molecule may be a naturally nucleic acid molecule as well as a recombinant nucleic acid molecule. The nucleic acid molecule of the invention may, therefore, be of natural origin, synthetic or semi-synthetic. It may comprise DNA, RNA as well as PNA and it may be a hybrid thereof.

[0045] It is evident to the person skilled in the art that regulatory sequences may be added to the nucleic acid molecule of the invention. For example, promoters, transcriptional enhancers and/or sequences which allow for induced expression of the polynucleotide of the invention may be employed. A suitable inducible system is for example tetracycline-regulated gene expression as described, e.g., by Gossen and Bujard (Proc. Natl. Acad. Sci. USA 89 (1992), 5547-5551) and Gossen et al. (Trends Biotech. 12 (1994), 58-62), or a dexamethasone-inducible gene expression system as described, e.g. by Crook (1989) EMBO J. 8, 513-519.

[0046] Furthermore, it is envisaged for further purposes that nucleic acid molecule may contain, for example, thioester bonds and/or nucleotide analogues. Said modifications may be useful for the stabilization of the nucleic acid molecule against endo- and/or exonucleases in the cell. Said nucleic acid molecules may be transcribed by an appropriate vector containing a chimeric gene which allows for the transcription of said nucleic acid molecule in the cell. In this respect, it is also to be understood that the polynucleotide of the invention can be used for "gene targeting" or "gene therapeutic" approaches. In another embodiment said nucleic acid molecules are labeled. Methods for the detection of nucleic acids are well known in the art, e.g., Southern and Northern blotting, PCR or primer extension. This embodiment may be useful for screening methods for verifying successful introduction of the inventive nucleic acid molecules during gene therapy approaches.

[0047] The nucleic acid molecule(s) of the invention may be a recombinantly produced chimeric nucleic acid molecule comprising any of the aforementioned nucleic acid molecules either alone or in combination. Preferably, the nucleic acid molecule of the invention is part of a vector.

[0048] The present invention therefore also relates to a vector comprising the nucleic acid molecule of the present invention.

The vector of the present invention may be, e.g., a plasmid, cosmid, virus, bacteriophage or another vector used e.g. conventionally in genetic engineering, and may comprise further genes such as marker genes which allow for the selection of said vector in a suitable host cell and under suitable conditions.

Furthermore, the vector of the present invention may, in addition to the nucleic acid sequences of the invention, comprise expression control elements, allowing proper expression of the coding regions in suitable hosts. Such control elements are known to the artisan and may include a promoter, a splice cassette, translation initiation codon, translation and insertion site for introducing an insert into the vector. Preferably, the nucleic acid molecule of the invention is operatively linked to said expression control sequences allowing expression in eukaryotic or prokaryotic cells.

[0049] Control elements ensuring expression in eukaryotic and prokaryotic cells are well known to those skilled in the art. As mentioned herein above, they usually comprise regulatory sequences ensuring initiation of transcription and optionally poly-A signals ensuring termination of transcription and stabilization of the transcript. Additional regulatory elements may include transcriptional as well as translational enhancers, and/or naturally-associated or heterologous promoter regions. Possible regulatory elements permitting expression in for example mammalian host cells comprise the CMV- HSV thymidine kinase promoter, SV40, RSV-promoter (Rous Sarcoma Virus), human elongation factor 1 α -promoter, the glucocorticoid-inducible MMTV-promoter (Moloney Mouse Tumor Virus), metallothionein- or tetracyclin-inducible promoters, or enhancers, like CMV enhancer or SV40-enhancer. For expression in neural cells, it is envisaged that neurofilament-, PGDF-, NSE-, PrP-, or thy-1-promoters can be employed. Said promoters are known in the art and, inter alia, described in Charron (1995), J. Biol. Chem. 270, 25739-25745. For the expression in prokaryotic cells, a multitude of promoters including, for example, the tac-lac-promoter or the trp promoter, has been described. Besides elements which are responsible for the initiation of transcription such regulatory elements may also comprise transcription termination signals, such as SV40-poly-A site or the tk-poly-A site, downstream of the polynucleotide. In this context, suitable expression vectors are known in the art such as Okayama-Berg cDNA expression vector pcDV1 (Pharmacia), pRc/CMV, pcDNA1, pcDNA3 (In-vitro gene), pSPORT1 (GIBCO BRL), pX (Pagano (1992) Science 255, 1144-1147), yeast two-hybrid vectors, such as pEG202 and dpJG4-5 (Gyuris (1995) Cell 75, 791-803), or prokaryotic expression vectors, such as lambda gt11 or pGEX (Amersham-Pharmacia). Beside the nucleic acid molecules of the present invention, the vector may further comprise nucleic acid sequences encoding for secretion signals. Such sequences are well known to the person skilled in the art. Furthermore, depending on the expression system used leader sequences capable of directing the peptides of the invention to a cellular compartment may be added to the coding sequence of the nucleic acid molecules of the invention and are well known in the art. The leader sequence(s) is (are) assembled in appropriate phase with translation, initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein, or a protein thereof, into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusionprotein including an C- or N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product. Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences, and, as desired, the collection and purification of the antibody molecules or fragments thereof of the invention may follow. The invention also relates, accordingly, to hosts/host cells which comprise a vector as defined herein. Such hosts may be useful for in processes for obtaining antibodies/antibody molecules of the invention as well as in medical/pharmaceutical settings. Said host cells may also comprise transduced or transfected neuronal cells, like neuronal stem cells, preferably adult neuronal stem cells. Such host cells may be useful in transplantation therapies.

[0050] Furthermore, the vector of the present invention may also be an expression, a gene transfer or gene targeting vector. Gene therapy, which is based on introducing therapeutic genes into cells by ex-vivo or in-vivo techniques is one of the most important applications of gene transfer. Transgenic mice expressing a neutralizing antibody directed against nerve growth factor have been generated using the "neuroantibody" technique; Capsoni, Proc. Natl. Acad. Sci. USA 97

(2000), 6826-6831 and Biocca, *Embo J.* 9 (1990), 101-108. Suitable vectors, methods or gene-delivering systems for in-vitro or in-vivo gene therapy are described in the literature and are known to the person skilled in the art; see, e.g., Giordano, *Nature Medicine* 2 (1996), 534-539; Schaper, *Circ. Res.* 79 (1996), 911-919; Anderson, *Science* 256 (1992), 808-813; Isner, *Lancet* 348 (1996), 370-374; Muhlhauser, *Circ. Res.* 77 (1995), 1077-1086; Onodua, *Blood* 91 (1998), 30-36; Verzeletti, *Hum. Gene Ther.* 9 (1998), 2243-2251; Verma, *Nature* 389 (1997), 239-242; Anderson, *Nature* 392 (Supp. 1998), 25-30; Wang, *Gene Therapy* 4 (1997), 393-400; Wang, *Nature Medicine* 2 (1996), 714-716; WO 94/29469; WO 97/00957; US 5,580,859; US 5,589,466; US 4,394,448 or Schaper, *Current Opinion in Biotechnology* 7 (1996), 635-640, and references cited therein. In particular, said vectors and/or gene delivery systems are also described in gene therapy approaches in neurological tissue/cells (see, inter alia Blömer, *J. Virology* 71 (1997) 6641-6649) or in the hypothalamus (see, inter alia, Geddes, *Front Neuroendocrinol.* 20 (1999), 296-316 or Geddes, *Nat. Med.* 3 (1997), 1402-1404). Further suitable gene therapy constructs for use in neurological cells/tissues are known in the art, for example in Meier (1999), *J. Neuropathol. Exp. Neurol.* 58, 1099-1110. The nucleic acid molecules and vectors of the invention may be designed for direct introduction or for introduction via liposomes, viral vectors (e.g. adenoviral, retroviral), electroporation, ballistic (e.g. gene gun) or other delivery systems into the cell. Additionally, a baculoviral system can be used as eukaryotic expression system for the nucleic acid molecules of the invention. The introduction and gene therapeutic approach should, preferably, lead to the expression of a functional antibody molecule of the invention, whereby said expressed antibody molecule is particularly useful in the treatment, amelioration and/or prevention of neurological disorders related to abnormal amyloid synthesis, assembly and/or aggregation, like, Alzheimer's disease and the like.

[0051] Accordingly, the nucleic acid molecule of the present invention and/or the above described vectors/hosts of the present invention may be particularly useful as pharmaceutical compositions. Said pharmaceutical compositions may be employed in gene therapy approaches. In this context, it is envisaged that the nucleic acid molecules and/or vectors of the present invention may be employed to modulate, alter and/or modify the (cellular) expression and/or concentration of the antibody molecules of the invention or of (a) fragment(s) thereof.

[0052] For gene therapy applications, nucleic acids encoding the peptide(s) of the invention or fragments thereof may be cloned into a gene delivering system, such as a virus and the virus used for infection and conferring disease ameliorating or curing effects in the infected cells or organism.

[0053] The present invention also relates to a host cell transfected or transformed with the vector of the invention or a non-human host carrying the vector of the present invention, i.e. to a host cell or host which is genetically modified with a nucleic acid molecule according to the invention or with a vector comprising such a nucleic acid molecule. The term "genetically modified" means that the host cell or host comprises in addition to its natural genome a nucleic acid molecule or vector according to the invention which was introduced into the cell or host or into one of its predecessors/parents. The nucleic acid molecule or vector may be present in the genetically modified host cell or host either as an independent molecule outside the genome, preferably as a molecule which is capable of replication, or it may be stably integrated into the genome of the host cell or host.

[0054] The host cell of the present invention may be any prokaryotic or eukaryotic cell. Suitable prokaryotic cells are those generally used for cloning like *E. coli* or *Bacillus subtilis*. Furthermore, eukaryotic cells comprise, for example, fungal or animal cells. Examples for suitable fungal cells are yeast cells, preferably those of the genus *Saccharomyces* and most preferably those of the species *Saccharomyces cerevisiae*. Suitable animal cells are, for instance, insect cells, vertebrate cells, preferably mammalian cells, such as e.g. HEK293, NSO, CHO, MDCK, U2-OS, NIH3T3, MOLT-4, Jurkat, PC-12, PC-3, IMR, NT2N, Sk-n-sh, CaSki, C33A. These host cells, e.g. CHO-cells, may provide post-translational modifications to the antibody molecules of the invention, including leader peptide removal, folding and assembly of H (heavy) and L (light) chains, glycosylation of the molecule at correct sides and secretion of the functional molecule. Further suitable cell lines known in the art are obtainable from cell line depositories, like the American Type Culture Collection (ATCC). In accordance with the present invention, it is furthermore envisaged that primary cells/cell cultures may function as host cells. Said cells are in particular derived from insects (like insects of the species *Drosophila* or *Blatta*) or mammals (like human, swine, mouse or rat). Said host cells may also comprise cells from and/or derived from cell lines like neuroblastoma cell lines. The above mentioned primary cells are well known in the art and comprise, inter alia, primary astrocytes, (mixed) spinal cultures or hippocampal cultures.

[0055] In a more preferred embodiment the host cell which is transformed with the vector of the invention is a neuronal cell, a neuronal stem cell (e.g. an adult neuronal stem cell), a brain cell or a cell (line) derived therefrom. However, also a CHO-cell comprising the nucleic acid molecule of the present invention may be particularly useful as host. Such cells may provide for correct secondary modifications on the expressed molecules, i.e. the antibody molecules of the present invention. These modifications comprise, inter alia, glycosylations and phosphorylations.

[0056] Hosts may be non-human mammals, most preferably mice, rats, sheep, calves, dogs, monkeys or apes. Said mammals may be indispensable for developing a cure, preferably a cure for neurological and/or neurodegenerative disorders mentioned herein. Furthermore, the hosts of the present invention may be particularly useful in producing the antibody molecules (or fragments thereof) of the invention. It is envisaged that said antibody molecules (or fragments

thereof) be isolated from said host. It is, inter alia, envisaged that the nucleic acid molecules and or vectors described herein are incorporated in sequences for transgenic expression. The introduction of the inventive nucleic acid molecules as transgenes into non-human hosts and their subsequent expression may be employed for the production of the inventive antibodies. For example, the expression of such (a) transgene(s) in the milk of the transgenic animal provide for means of obtaining the inventive antibody molecule in quantitative amounts; see inter alia, US 5,741,957, US 5,304,489 or US 5,849,992. Useful transgenes in this respect comprise the nucleic acid molecules of the invention, for example, coding sequences for the light and heavy chains of the antibody molecules described herein, operatively linked to promotor and/or enhancer structures from a mammary gland specific gene, like casein or beta-lactoglobulin.

[0057] The invention also provides for a method for the preparation of an antibody molecule of the invention comprising culturing the host cell described herein above under conditions that allow synthesis of said antibody molecule and recovering said antibody molecule from said culture.

[0058] The invention also relates to a composition comprising an antibody molecule of the invention or produced by the method described herein above, a nucleic acid molecule encoding the antibody molecule of the invention, a vector comprising said nucleic acid molecule or a host-cell as defined herein above and optionally, further molecules, either alone or in combination, like e.g. molecules which are capable of interfering with the formation of amyloid plaques or which are capable of depolymerizing already formed amyloid-plaques. The term "composition" as employed herein comprises at least one compound of the invention. Preferably, such a composition is a pharmaceutical or a diagnostic composition.

[0059] The composition may be in solid or liquid form and may be, inter alia, in a form of (a) powder(s), (a) tablet(s), (a) solution(s) or (an) aerosol(s). Said composition may comprise on or more antibodies/antibody molecules of the invention or nucleic acid molecules, vector or hosts of the invention. It is also envisaged that said composition comprises at least two, preferably three, more preferably four, most preferably five antibody molecules of the invention or nucleic acid molecule(s) encoding said antibody molecule(s). Said composition may also comprise optimized, inventive antibodies/antibody molecules obtainable by the methods described herein below and in the appended examples.

[0060] It is preferred that said pharmaceutical composition, optionally comprises a pharmaceutically acceptable carrier and/or diluent. The herein disclosed pharmaceutical composition may be particularly useful for the treatment of neurological and/or neurodegenerative disorders. Said disorders comprise, but are not limited to Alzheimer's disease, amyotrophic lateral sclerosis (ALS), hereditary cerebral hemorrhage with amyloidosis Dutch type, Down's syndrome, HIV-dementia, Parkinson's disease and neuronal disorders related to aging. The pharmaceutical composition of the invention is, inter alia, envisaged as potent inhibitors of amyloid plaque formation or as a potent stimulator for the de-polymerization of amyloid plaques. Therefore, the present invention provides for pharmaceutical compositions comprising the compounds of the invention to be used for the treatment of diseases/disorders associated with pathological APP proteolysis and/or amyloid plaque formation.

[0061] Examples of suitable pharmaceutical carriers, excipients and/or diluents are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Compositions comprising such carriers can be formulated by well known conventional methods. These pharmaceutical compositions can be administered to the subject at a suitable dose. Administration of the suitable compositions may be effected by different ways, e.g., by intravenous, intraperitoneal, subcutaneous, intramuscular, topical, intradermal, intranasal or intrabronchial administration. It is particularly preferred that said administration is carried out by injection and/or delivery, e.g., to a site in a brain artery or directly into brain tissue. The compositions of the invention may also be administered directly to the target site, e.g., by biolistic delivery to an external or internal target site, like the brain. The dosage regimen will be determined by the attending physician and clinical factors. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. Proteinaceous pharmaceutically active matter may be present in amounts between 1 ng and 10 mg/kg body weight per dose; however, doses below or above this exemplary range are envisioned, especially considering the aforementioned factors. If the regimen is a continuous infusion, it should also be in the range of 1 µg to 10 mg units per kilogram of body weight per minute. Progress can be monitored by periodic assessment. The compositions of the invention may be administered locally or systemically. It is of note that peripherally administered antibodies can enter the central nervous system, see, inter alia, Bard (2000), Nature Med. 6, 916-919. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like. Furthermore, the pharmaceutical composition of the invention may comprise further agents depending on the

intended use of the pharmaceutical composition. Said agents may be drugs acting on the central nervous system, like, neuroprotective factors, cholinesterase inhibitors, agonists of M1 muscarinic receptor, hormones, antioxidants, inhibitors of inflammation etc. It is particularly preferred that said pharmaceutical composition comprises further agents like, e.g. neurotransmitters and/or substitution molecules for neurotransmitters, vitamin E, or alpha-lipoic acid.

[0062] The pharmaceutical compositions, as well as the methods of the invention or the uses of the invention described infra can be used for the treatment of all kinds of diseases hitherto unknown or being related to or dependent on pathological APP aggregation or pathological APP processing. They may be particularly useful for the treatment of Alzheimer's disease and other diseases where extracellular deposits of amyloid- β , appear to play a role. They may be desirably employed in humans, although animal treatment is also encompassed by the methods, uses and compositions described herein.

[0063] In a preferred embodiment of the invention, the composition of the present invention as disclosed herein above is a diagnostic composition further comprising, optionally, suitable means for detection. The diagnostic composition comprises at least one of the aforementioned compounds of the invention.

Said diagnostic composition may comprise the compounds of the invention, in particular and preferably the antibody molecules of the present invention, in soluble form/liquid phase but it is also envisaged that said compounds are bound to/attached to and/or linked to a solid support.

[0064] Solid supports may be used in combination with the diagnostic composition as defined herein or the compounds of the present invention may be directly bound to said solid supports. Such supports are well known in the art and comprise, inter alia, commercially available column materials, polystyrene beads, latex beads, magnetic beads, colloid metal particles, glass and/or silicon chips and surfaces, nitrocellulose strips, membranes, sheets, duracytes, wells and walls of reaction trays, plastic tubes etc. The compound(s) of the invention, in particular the antibodies of the present invention, may be bound to many different carriers. Examples of well-known carriers include glass, polystyrene, polyvinyl chloride, polypropylene, polyethylene, polycarbonate, dextran, nylon, amyloses, natural and modified celluloses, polyacrylamides, agaroses, and magnetite. The nature of the carrier can be either soluble or insoluble for the purposes of the invention. Appropriate labels and methods for labeling have been identified above and are furthermore mentioned herein below. Suitable methods for fixing/immobilizing said compound(s) of the invention are well known and include, but are not limited to ionic, hydrophobic, covalent interactions and the like.

[0065] It is particularly preferred that the diagnostic composition of the invention is employed for the detection and/or quantification of APP and/or APP-processing products, like amyloid- β or for the detection and/or quantification of pathological and/or (genetically) modified APP-cleavage sides.

[0066] As illustrated in the appended examples, the compounds of the present invention, in particular the inventive antibody molecule is particularly useful as diagnostic reagents in the detection of genuine human amyloid plaques in brain sections of Alzheimer's Disease patients by indirect immunofluorescence.

[0067] It is preferred that said compounds of the present invention to be employed in a diagnostic composition are detectably labeled. A variety of techniques are available for labeling biomolecules, are well known to the person skilled in the art and are considered to be within the scope of the present invention. Such techniques are, e.g., described in Tijssen, "Practice and theory of enzyme immuno assays", Burden, RH and von Knippenburg (Eds), Volume 15 (1985), "Basic methods in molecular biology"; Davis LG, Diber MD; Battey Elsevier (1990), Mayer et al., (Eds) "Immunochemical methods in cell and molecular biology" Academic Press, London (1987), or in the series "Methods in Enzymology", Academic Press, Inc.

[0068] There are many different labels and methods of labeling known to those of ordinary skill in the art. Examples of the types of labels which can be used in the present invention include enzymes, radioisotopes, colloidal metals, fluorescent compounds, chemiluminescent compounds, and bioluminescent compounds.

[0069] Commonly used labels comprise, inter alia, fluorochromes (like fluorescein, rhodamine, Texas Red, etc.), enzymes (like horse radish peroxidase, β -galactosidase, alkaline phosphatase), radioactive isotopes (like ^{32}P or ^{125}I), biotin, digoxigenin, colloidal metals, chemi- or bioluminescent compounds (like dioxetanes, luminol or acridiniums). Labeling procedures, like covalent coupling of enzymes or biotinyl groups, iodinations, phosphorylations, biotinylations, etc. are well known in the art.

Detection methods comprise, but are not limited to, autoradiography, fluorescence microscopy, direct and indirect enzymatic reactions, etc. Commonly used detection assays comprise radioisotopic or non-radioisotopic methods. These comprise, inter alia, Western blotting, overlay-assays, RIA (Radioimmuno Assay) and IRMA (Immune Radioimmunometric Assay), EIA (Enzyme immune Assay), ELISA (Enzyme Linked immune Sorbent Assay), FIA (Fluorescent Immuno Assay), and CLIA (Chemiluminescent Immune Assay).

[0070] Furthermore, the present invention provides for the use of an antibody molecule of invention, or an antibody molecule produced by the method of the invention, of a nucleic acid molecule, vector of or a host of the invention for the preparation of a pharmaceutical or a diagnostic composition for the prevention, treatment and/or diagnosis of a disease associated with amyloidogenesis and/or amyloid-plaque formation. It is further preferred that the compounds described herein, in particular the antibody molecules of the invention, be employed in the prevention and/or treatment of neu-

ropathologies associated with modified or abnormal APP-processing and/or amyloidogenesis. The antibody molecules, e.g. in format of (engineered) immunoglobulins, like antibodies in a IgG framework, in particular in an IgG1-framework, or in the format of chimeric antibodies, bispecific antibodies, single chain Fvs (scFvs) or bispecific scFvs and the like are to be employed in the preparation of the pharmaceutical compositions provided herein. Yet, the antibody molecules are also useful in diagnostic settings as documented in the appended examples, since the antibody molecules of the invention specifically interact with/detect A β 4 and/or amyloid deposits/plaques.

[0071] Therefore an inventive use of the compounds of the present invention is the use for the preparation of a pharmaceutical composition for a neurological disorder which calls for amelioration, for example by disintegration of β -amyloid plaques, by amyloid (plaque) clearance or by passive immunization against β -amyloid plaque formation. As illustrated in the appended examples, the inventive antibody molecules are particularly useful in preventing A β aggregation and in de-polymerization of already formed amyloid aggregates. Accordingly, the inventive antibodies are to be employed in the reduction of pathological amyloid deposits/plaques, in the clearance of amyloid plaques/plaque precursors as well as in neuronal protection. It is in particular envisaged that the antibody molecules of the invention be employed in the in vivo prevention of amyloid plaques as well as in in vivo clearance of pre-existing amyloid plaques/deposits. Furthermore, the antibody molecules of the invention may be employed in passive immunization approaches against A β 4. Clearance of A β 4/A β 4 deposits may, inter alia, be achieved by the medical use of antibodies of the present invention which comprise an Fc-part. Said Fc-part of an antibody may be particularly useful in Fc-receptor mediated immune responses, e.g. the attraction of macrophages (phagocytic cells and/or microglia) and/or helper cells. For the mediation of Fc-part-related immunoresponses, the antibody molecule of the invention is preferably in an (human) IgG1-framework. As discussed herein, the preferred subject to be treated with the inventive antibody molecule, the nucleic acid molecules encoding the same or parts thereof, the vectors of the invention or the host cells of this invention is a human subject. Other frameworks, like IgG2a- or IgG2b-frameworks for the inventive antibody molecule are also envisaged. Immunoglobulin frameworks in IgG2a und IgG2b format are particular envisaged in mouse settings, for example in scientific uses of the inventive antibody molecule, e.g. in tests on transgenic mice expressing (human) wildtype or mutated APP, APP-fragments and/or A β 4.

[0072] The above recited diseases associated with amyloidogenesis and/or amyloid-plaque formation comprise, but are not limited to dementia, Alzheimer's disease, motor neuropathy, Parkinson's disease, ALS (amyotrophic lateral sclerosis), scrapie, HIV-related dementia as well as Creutzfeld-Jakob disease, hereditary cerebral hemorrhage, with amyloidis Dutch type, Down's syndrome and neuronal disorders related to aging. The antibody molecules of the invention and the compositions provided herein may also be useful in the amelioration and or prevention of inflammatory processes relating to amyloidogenesis and/or amyloid plaque formation.

[0073] Accordingly, herein described is also a method for treating, preventing and/or delaying neurological and/or neurodegenerative disorders comprising the step of administering to a subject suffering from said neurological and/or neurodegenerative disorder and/or to a subject susceptible to said neurological and/or neurodegenerative disorder an effective amount of the antibody molecule of the invention, the nucleic acid molecule of invention and/or a composition as defined herein above.

[0074] Also described herein is a kit comprising at least one antibody molecule, at least one nucleic acid molecule, at least one vector or at least one host cell of the invention. Advantageously, the kit comprises, optionally (a) buffer(s), storage solutions and/or remaining reagents or materials required for the conduct of medical, scientific or diagnostic assays and purposes. Furthermore, parts of the kit can be packaged individually in vials or bottles or in combination in containers or multicontainer units.

[0075] The kit may be advantageously used, inter alia, for carrying out the method of the invention and could be employed in a variety of applications referred herein, e.g., as diagnostic kits, as research tools or medical tools. Additionally, the kit of the invention may contain means for detection suitable for scientific, medical and/or diagnostic purposes. The manufacture of the kits follows preferably standard procedures which are known to the person skilled in the art.

[0076] Herein described is also a method for the optimization of an antibody molecule as defined herein above comprising the steps of

- (a) constructing a library of diversified Fab antibody fragments derived from an antibody comprising at least one CDR3 of an V_H-region as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 21, 23 or 25 or at least one CDR3 amino acid sequence of an V_H-region as shown in SEQ ID NOs: 22, 24 or 26;
- (b) testing the resulting Fab optimization library by panning against A β /A β 4;
- (c) identifying optimized clones; and
- (d) expressing of selected, optimized clones.

Optimization of the antibodies/antibody molecules as described herein is also documented in the appended examples and may comprise the selection for, e.g. higher affinity for one or both regions/epitopes of β -A4 as defined herein or selection for improved expression and the like. In one embodiment, said selection for to higher affinity for one or both

regions/epitopes of β -A4 comprises the selection for high affinity to (a) an amino acid stretch comprising amino acids 2 to 10 (or (a) part(s) thereof) of β -A4 and/or (b) an amino acid stretch comprising amino acids 12 to 25 (or (a) part(s) thereof) of β -A4 (SEQ ID NO. 27).

[0077] The person skilled in the art can readily carry out the method employing the teachings of the present invention. Optimization protocols for antibodies are known in the art. These optimization protocols comprise, inter alia, CDR walking mutagenesis as disclosed and illustrated herein and described in Yang (1995), J. Mol. Biol. 25, 392-403; Schier (1996), J. Mol. Biol. 263, 551-567; Barbas (1996), Trends. Biotech 14, 230-34 or Wu (1998), PNAS 95, 6037-6042; Schier (1996), Human Antibodies Hybridomas 7, 97; Moore (1997), J. Mol. Biol. 272, 336.

[0078] "Panning"-techniques are also known in the art, see, e.g. Kay (1993), Gene 128, 59-65. Furthermore, publications like Borrebaeck (1995), "Antibody Engineering", Oxford University, 229-266; McCafferty (1996), "Antibody Engineering", Oxford University Press; Kay (1996), A Laboratory Manual, Academic Press provide for optimization protocols which may be modified in accordance with this invention.

[0079] The optimization method may further comprise a step (ca), whereby the optimized clones are further optimized by cassette mutagenesis, as illustrated in the appended examples.

[0080] The method for the optimization of an antibody molecule described herein is further illustrated in the appended examples as affinity maturation of parental antibodies /antibody molecules capable of specifically recognizing two regions of the beta -A4 peptide/ Abeta4/ A β /A β 4/ β A4.

Preferably, said A β /A β 4 (also designated as β A4 in context of this invention) in step (b) of the method described herein above is aggregated A β /A β 4. Said panning may be carried out (as described in the appended examples) with increased stringency of binding. Stringency may be increased, inter alia, by reducing the A β /A β 4 concentration or by elevating the (assay) temperature. The testing of the optimized library by panning is known to the skilled artisan and described in Kay (1993), loc. cit. Preferably, the identification in step (c) is carried out by ranking according to the lowest K_D -values.

[0081] Most preferably said identification in step (c) is carried out by koff-ranking. Koff-ranking is known to the skilled artisan and described in Schier (1996), loc. cit.; Schier (1996), J. Mol. Biol. 255, 28-43 or Duenas (1996), Mol. Immunol. 33, 279-286. Furthermore, koff-ranking is illustrated in the appended examples. The off-rate constant may be measured as described in the appended examples.

[0082] As mentioned herein above, the identified clones may, for further evaluation, be expressed. The expression may be carried out by known methods, inter alia, illustrated in the appended examples. The expression may, inter alia, lead to expressed Fab-fragments, scFvs, bispecific immunoglobulins, bispecific antibody molecules, Fab- and/or Fv fusion proteins, or full antibodies, like IgGs, in particular IgG1.

[0083] Optimized antibodies, in particular optimized Fabs or optimized IgGs, preferably IgG1s, may be tested by methods as illustrated in the appended examples. Such methods comprise, but are not limited to, the testing of binding affinities, the determination of K_D values, pepspot analysis, ELISA-assays, RIA-assays, CLIA-assays, (immuno-) histological studies (for example staining of amyloid plaques), de-polymerization assays or antibody-dependent β -A4 phagocytoses.

[0084] A method is described herein wherein optimized antibodies are generated by cross-cloning. This method is also illustrated in the appended examples and comprises the step of combining independently optimized CDR-regions, for example, by combining independently optimized H-CDR2 and L-CDR2 from matured clones with H-CDR3, preferably the same H-CDR3.

[0085] Also described is a method for the preparation of a pharmaceutical composition comprising the steps of

(a) optimization of an antibody according to the method described herein and illustrated in the appended examples; and

(b) formulating the optimized antibody/antibody molecule with an physiologically acceptable carrier, as described herein above.

Accordingly, the invention also provides for a pharmaceutical composition prepared by the method disclosed herein and comprising further optimized antibody molecules capable of specifically recognizing two regions of the beta-A4 peptide/Abeta4/A β /A4/ β A4, as described herein above.

Exemplified Sequences as recited herein:

[0086]

SEQ ID NO: 1

AEFRHDSGY

First region of β -A4 peptide, "N-terminal region/epitope"

SEQ ID NO: 2
VHHQKLFFAEDVG
Second region of β -A4 peptide, "Central/middle region/epitope"

5 SEQ ID NO: 3
VH-region of MS-Roche#3 (nucleic acid sequence)

10 CAGGTGCAATTGGTGGAAAGCGGCGGCGGCCTGGTGCACCGGGCGGCAGC
CTGCGTCTGAGCTGCGCGGCCTCCGGATTTACCTTTAGCAGCTATGCGATGAG
CTGGGTGCGCCAAGCCCCCTGGGAAGGGTCTCGAGTGGGTGAGCGCGATTAGC
GGTAGCGGCGGCAGCACCTATTATGCGGATAGCGTGAAAGGCCGTTTTACCAT
TTCACGTGATAATTCGAAAAACACCCTGTATCTGCAAATGAACAGCCTGCGTGC
15 GGAAGATACGGCCGTGTATTATTGCGCGCGTCTTACTCATTATGCTCGTTATTA
TCGTTATTTTGTATGTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCAGC
(SEQ ID NO : 3)

20 SEQ ID NO: 4
VH-region of MS-Roche#3 (amino acid sequence)

25 QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGS
GGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARLTHYARYYRYF
DVWGQGTLVTVSS (SEQ ID NO : 4)

SEQ ID NO: 5
VH-region of MS-Roche#7 (nucleic acid sequence)

30 CAGGTGCAATTGGTGGAAAGCGGCGGCGGCCTGGTGCACCGGGCGGCAGC
CTGCGTCTGAGCTGCGCGGCCTCCGGATTTACCTTTAGCAGCTATGCGATGAG
CTGGGTGCGCCAAGCCCCCTGGGAAGGGTCTCGAGTGGGTGAGCGCGATTAGC
GGTAGCGGCGGCAGCACCTATTATGCGGATAGCGTGAAAGGCCGTTTTACCAT
35 TCACGTGATAATTCGAAAAACACCCTGTATCTGCAAATGAACAGCCTGCGTGC
GAAGATACGGCCGTGTATTATTGCGCGCGTGGTAAGGGTAATACTCATAAGCCT
TATGGTTATGTTTCGTTATTTTGTATGTTTGGGGCCAAGGCACCCTGGTGACGGTT
AGCTCAGC (SEQ ID NO: 5)

40 SEQ ID NO: 6
VH-region of MS-Roche#7 (amino acid sequence)

45 QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGS
GGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGY
VRYFDVWGQGTLVTVSS (SEQ ID NO: 6)

50 SEQ ID NO: 7
VH-region of MS-Roche#8 (nucleic acid sequence)

55

CAGGTGCAATTGGTGGAAAGCGGCGGCGGCCTGGTGGCAACCGGGCGGCAGC
CTGCGTCTGAGCTGCGCGGCCTCCGGATTTACCTTTAGCAGCTATGCGATGAG
CTGGGTGCGCCAAGCCCCTGGGAAGGGTCTCGAGTGGGTGAGCGCGATTAGC
GGTAGCGGCGGCAGCACCTATTATGCGGATAGCGTGAAAGGCCGTTTTACCAT
TTCACGTGATAATTCGAAAAACACCCTGTATCTGCAAATGAACAGCCTGCGTGC
GGAAGATACGGCCGTGTATTATTGCGCGCGTCTTCTTTCTCGTGGTTATAATGG
TTATTATCATAAGTTTGATGTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTC
AGC (SEQ ID NO: 7)

SEQ ID NO: 8
VH-region of MS-Roche#8 (amino acid sequence)

QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGS
GGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARLLSRGYNGYYH
KFDVWGQGT LVT VSS (SEQ ID NO: 8)

SEQ ID NO: 9
VL-region of MS-Roche#3 (nucleic acid sequence)

GATATCGTGCTGACCCAGAGCCCGGCGACCCTGAGCCTGTCTCCGGGCGAAC
GTGCGACCCTGAGCTGCAGAGCGAGCCAGAGCGTGAGCAGCAGCTATCTGGC
GTGGTACCAGCAGAAACCAGGTCAAGCACCGCGTCTATTAATTTATGGCGCGA
GCAGCCGTGCAACTGGGGTCCCGGCGCGTTTTAGCGGCTCTGGATCCGGCAC
GGATTTTACCCTGACCATTAGCAGCCTGGAACCTGAAGACTTTGCGGTTTATTA
TTGCCAGCAGGTTTATAATCCTCCTGTTACCTTTGGCCAGGGTACGAAAGTTGA
AATTAAACGTACG (SEQ ID NO: 9)

SEQ ID NO: 10
VL-region of MS-Roche #3 (amino acid sequence)

DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRA
TGVPARFSGSGSGTDFTLTISSELPEDFAVYYCQQVYNPPVTFGQGTKVEIKRT
(SEQ ID NO: 10)

SEQ ID NO: 11
VL-region of MS-Roche#7 (nucleic acid sequence)

GATATCGTGCTGACCCAGAGCCCGGCGACCCTGAGCCTGTCTCCGGGCGAAC
GTGCGACCCTGAGCTGCAGAGCGAGCCAGAGCGTGAGCAGCAGCTATCTGGC
GTGGTACCAGCAGAAACCAGGTCAAGCACCGCGTCTATTAATTTATGGCGCGA
GCAGCCGTGCAACTGGGGTCCCGGCGCGTTTTAGCGGCTCTGGATCCGGCAC
GGATTTTACCCTGACCATTAGCAGCCTGGAACCTGAAGACTTTGCGACTTATTA
TTGCTTTCAGCTTTATTCTGATCCTTTTACCTTTGGCCAGGGTACGAAAGTTGAA
ATTAAACGTACG (SEQ ID NO. 11)

SEQ ID NO: 12
VL-region of MS-Roche#7 (amino acid sequence)

DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRA
TGVPARFSGSGSGTDFTLTISSELPEDFATYYCFQLYSDPFTFGQGTKVEIKRT
(SEQ ID NO : 12)

5

SEQ ID NO: 13
VL-region of MS-Roche#8 (nucleic acid sequence)

10

GATATCGTGCTGACCCAGAGCCCGGCGACCCTGAGCCTGTCTCCGGGCGAAC
GTGCGACCCTGAGCTGCAGAGCGAGCCAGAGCGTGAGCAGCAGCTATCTGGC
GTGGTACCAGCAGAAACCAGGTCAAGCACCGCGTCTATTAATTTATGGCGCGA
GCAGCCGTGCAACTGGGGTCCCGGCGCGTTTTAGCGGCTCTGGATCCGGCAC
GGATTTTACCCTGACCATTAGCAGCCTGGAACCTGAAGACTTTGCGACTTATTA
TTGCCAGCAGCTTTCTTCTTTTCCTCCTACCTTTGGCCAGGGTACGAAAGTTGA
AATTAAACGTACG (SEQ ID NO: 13)

15

SEQ ID NO: 14
VL-region of MS-Roche#8 (amino acid sequence)

20

DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRA
TGVPARFSGSGSGTDFTLTISSELPEDFATYYCQQLSSFPTFGQGTKVEIKRT
(SEQ ID NO : 14)

25

SEQ ID NO: 15
CDR3 of V_L-region of MSR-3 (nucleic acid sequence)
CAGCAGGTTTATAATCCTCCTGTT
(SEQ ID NO : 15)

30

SEQ ID NO: 16
CDR3 of V_L-region of MSR-3 (amino acid sequence)
QQVYNPPV (SEQ ID NO: 16)

35

SEQ ID NO: 17
CDR3 of V_L-region of MSR-7 (nucleic acid sequence)
TTTCAGCTTTATTCTGATCCTTTT
(SEQ ID NO : 17)

40

SEQ ID NO: 18
CDR3 of V_L-region of MSR-7 (amino acid sequence)
FQLYSDPF (SEQ ID NO. 18)

45

SEQ ID NO: 19
CDR3 of V_L-region of MSR-8 (nucleic acid sequence)
CAG CAG CTT TCT TCT TTT CCT CCT
(SEQ ID NO. 19)

50

SEQ ID NO: 20
CDR3 of V_L-region of MSR-8 (amino acid sequence)
QQLSSFPP (SEQ ID NO: 20)

55

SEQ ID NO: 21
CDR of V_H-region of MSR-3 (nucleic acid sequence)
CTTACT CATTAT GCTCGTTATTAT CGTTATTTT GAT GTT
(SEQ ID NO: 21)

EP 2 368 907 B1

SEQ ID NO: 22
CDR of V_H-region of MSR-3 (amino acid sequence)
LTHYARYYRYFDV (SEQ ID NO: 22)

5 SEQ ID NO: 23
CDR of V_H-region of MSR-7 (nucleic acid sequence)
GGT AAG GGT AAT ACT CAT AAG CCT TAT GGT TAT GTT CGT TAT TTT GAT GTT (SEQ ID NO: 23)

10 SEQ ID NO: 24
CDR of V_H-region of MSR-7 (amino acid sequence)
GKGNTHKPYGYVRYFDV (SEQ ID NO: 24)

15 SEQ ID NO: 25
CDR of V_H-region of MSR-8 (nucleic acid sequence)
CTT CTT TCT CGT GGT TAT AAT GGT TAT TAT CAT AAG TTT GAT GTT (SEQ ID NO: 25)

20 SEQ ID NO: 26
CDR of V_H-region of MSR-8 (amino acid sequence)
LLSRGYNGYYHKFDV (SEQ ID NO: 26)

SEQ ID NO: 27 Aβ4 (amino acids 1 to 42)
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA (SEQ ID NO: 27)

25 SEQ ID NO: 28 primer
5'-GTGGTGGTTCCGATATC-3' (SEQ ID NO: 28)

SEQ ID NO: 29 primer
5'-AGCGTCACACTCGGTGCGGCTTTCGGCTGGCCAAGAACGGTTA-3' (SEQ ID NO: 29)

30 SEQ ID NO: 30 primer
5'-CAGGAAACAGCTATGAC-3' (SEQ ID NO: 30)

35 SEQ ID NO: 31 primer
5'-TACCGTTGCTCTTCACCCC-3' (SEQ ID NO: 31)

SEQ ID NO: 32 VH of MS-Roche#3.6H5 x 3.6L2; DNA; artificial sequence

40 CAATTGGTGGAAAGCGGCGGCGGCCTGGTGCAACCGGGCGGCAGCCTGCGTC
TGAGCTGCGCGGCCTCCGGATTTACCTTTAGCAGCTATGCGATGAGCTGGGTG
CGCCAAGCCCCTGGGAAGGGTCTCGAGTGGGTGAGCGCTATTTCTGAGTCTG
45 GTAAGACTAAGTATTATGCTGATTCTGTAAAGGGTCGTTTTACCATTTACGTGA
TAATTCGAAAAACACCCTGTATCTGCAAATGAACAGCCTGCGTGCGGAAGATAC
GGCCGTGTATTATTGCGCGCGTCTTACTCATTATGCTCGTTATTATCGTTATTTT
50 GATGTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA (SEQ ID NO: 32)

SEQ ID NO: 33: prot VH region of MS-Roche#3.6H5 x 3.6L2; protein/1; artificial sequence

55 QLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISESGK
TKYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARLTHYARYYRYFDV
WGQGT LVT VSS (SEQ ID NO: 33)

EP 2 368 907 B1

SEQ ID NO: 34 VH region of MS-Roche#3.6H8 x 3.6L2; DNA; artificial sequence

5 CAATTGGTGGAAAGCGGCGGCCTGGTGCAACCGGGCGGCAGCCTGCGTC
TGAGCTGCGCGGCCTCCGGATTTACCTTTAGCAGCTATGCGATGAGCTGGGTG
CGCCAAGCCCCTGGGAAGGGTCTCGAGTGGGTGAGCGCTATTTCTGAGTATTC
10 TAAGTTTAAGTATTATGCTGATTCTGTAAAGGGTCGTTTTACCATTTACGTGAT
AATTCGAAAAACACCCTGTATCTGCAAATGAACAGCCTGCGTGCGGAAGATACG
GCCGTGTATTATTGCGCGCGTCTTACTCATTATGCTCGTTATTATCGTTATTTTG
15 ATGTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA (SEQ ID NO: 34)

SEQ ID NO: 35 prot VH region of MS-Roche#3,6H8 x 3.6L2; protein/1; artificial sequence

20 QLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISEYSK
FKYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARLTHYARYYRYFDV
WGQGT LVT VSS (SEQ ID NO: 35)

25 SEQ ID NO: 36 VH region of MS-Roche#7.4H2 x 7.2L1; DNA; artificial sequence

30 CAATTGGTGGAAAGCGGCGGCCTGGTGCAACCGGGCGGCAGCCTGCGTC
TGAGCTGCGCGGCCTCCGGATTTACCTTTAGCAGCTATGCGATGAGCTGGGTG
CGCCAAGCCCCTGGGAAGGGTCTCGAGTGGGTGAGCGCTATTAATTATAATGG
TGCTCGTATTTATTATGCTGATTCTGTAAAGGGTCGTTTTACCATTTACGTGAT
35 AATTCGAAAAACACCCTGTATCTGCAAATGAACAGCCTGCGTGCGGAAGATACG
GCCGTGTATTATTGCGCGCGTGGTAAGGGTAATACTCATAAGCCTTATGGTTAT
GTTCGTTATTTTGATGTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA
40 (SEQ ID NO: 36)

SEQ ID NO: 37 prot VH region of MS-Roche#7.4H2 x 7.2L1; protein/1; artificial sequence

45 QLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINYNGA
RIYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVRY
FDVWGQGT LVT VSS (SEQ ID NO: 37)

50 SEQ ID NO: 38 VH region of MS-Roche#7.9H2 x 7.12 L2; DNA; artificial sequence

55

CAATTGGTGGAAAGCGGCGGCGGCCTGGTGCAACCGGGCGGCAGCCTGCGTC
 TGAGCTGCGCGGCCTCCGGATTTACCTTTAGCAGCTATGCGATGAGCTGGGTG
 5 CGCCAAGCCCCTGGGAAGGGTCTCGAGTGGGTGAGCGCTATTAATGCTGATG
 GTAATCGTAAGTATTATGCTGATTCTGTAAAGGGTCGTTTTACCATTTACGTGA
 TAATTCGAAAAACACCCTGTATCTGCAAATGAACAGCCTGCGTGCGGAAGATAC
 10 GGCCGTGTATTATTGCGCGCGTGGTAAGGGTAATACTCATAAGCCTTATGGTTA
 TGTTCTGTTATTTTGATGTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA
 (SEQ ID NO: 38)

15 SEQ ID NO: 39 prot VH region of MS-Roche#7.9H2 x 7.12 L2; protein/1; artificial sequence

QLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINADGN
 20 RKYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVR
 YFDVWGQGTLVTVSS (SEQ ID NO: 39)

25 SEQ ID NO: 40 VH region of MS-Roche#7.9H4 x 7.12L2; DNA; artificial sequence

CAATTGGTGGAAAGCGGCGGCGGCCTGGTGCAACCGGGCGGCAGCCTGCGTC
 TGAGCTGCGCGGCCTCCGGATTTACCTTTAGCAGCTATGCGATGAGCTGGGTG
 30 CGCCAAGCCCCTGGGAAGGGTCTCGAGTGGGTGAGCGCTATTAATGCTGTTGG
 TATGAAGAAGTTTTATGCTGATTCTGTAAAGGGTCGTTTTACCATTTACGTGAT
 AATTCGAAAAACACCCTGTATCTGCAAATGAACAGCCTGCGTGCGGAAGATACG
 35 GCCGTGTATTATTGCGCGCGTGGTAAGGGTAATACTCATAAGCCTTATGGTTAT
 GTTCGTTATTTTGATGTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA
 (SEQ ID NO: 40)

40 SEQ ID NO: 41 prot VH region of MS-Roche#7.9H4 x 7.12L2; protein/1; artificial sequence

QLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINAVGM
 45 KKFYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVR
 YFDVWGQGTLVTVSS (SEQ ID NO: 41)

50 SEQ ID NO: 42 VH region of MS-Roche#7.11H1 x 7.11L1; DNA; artificial sequence

CAATTGGTGGAAAGCGGCGGCCTGGTGCAACCGGGCGGCAGCCTGCGTC
 TGAGCTGCGCGGCCTCCGGATTTACCTTTAGCAGCTATGCGATGAGCTGGGTG
 5 CGCCAAGCCCCTGGGAAGGGTCTCGAGTGGGTGAGCGGTATTAATGCTGCTG
 GTTTTCGTACTTATTATGCTGATTCTGTAAAGGGTCGTTTTACCATTTACGTGA
 TAATTCGAAAAACACCCTGTATCTGCAAATGAACAGCCTGCGTGCGGAAGATAC
 10 GGCCGTGTATTATTGCGCGCGTGGTAAGGGTAATACTCATAAGCCTTATGGTTA
 TGTTTCGTTATTTTGATGTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA
 (SEQ ID NO: 42)

15 SEQ ID NO. 43 prot VH region of MS-Roche#7.11H1 x 7.11L1; protein/1; artificial sequence

QLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGINAAGF
 20 RTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVR
 YFDVWGQGT LVT VSS (SEQ ID NO: 43)

25 SEQ ID NO: 44 VH region of MS-Roche#7.11H1 x 7.2L1; DNA; artificial sequence

CAATTGGTGGAAAGCGGCGGCCTGGTGCAACCGGGCGGCAGCCTGCGTC
 TGAGCTGCGCGGCCTCCGGATTTACCTTTAGCAGCTATGCGATGAGCTGGGTG
 30 CGCCAAGCCCCTGGGAAGGGTCTCGAGTGGGTGAGCGGTATTAATGCTGCTG
 GTTTTCGTACTTATTATGCTGATTCTGTAAAGGGTCGTTTTACCATTTACGTGA
 TAATTCGAAAAACACCCTGTATCTGCAAATGAACAGCCTGCGTGCGGAAGATAC
 35 GGCCGTGTATTATTGCGCGCGTGGTAAGGGTAATACTCATAAGCCTTATGGTTA
 TGTTTCGTTATTTTGATGTTTGGGGCCAAGGCACCCTGGTGACGGTTAGCTCA
 (SEQ ID NO: 44)

40 SEQ ID NO: 45 prot VH region of MS-Roche#7.11H1 x 7.2L1; protein/1; artificial sequence

QLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGINAAGF
 45 RTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGYVR
 YFDVWGQGT LVT VSS (SEQ ID NO: 45)

50 SEQ ID NO: 46 VL region of MS-Roche#3.6H5 x 3.6L2; DNA; artificial sequence

GATATCGTGCTGACCCAGAGCCCGGCGACCCTGAGCCTGTCTCCGGGCGAAC
 GTGCGACCCTGAGCTGCAGAGCGAGCCAGTTTCTTTCTCGTTATTATCTGGCGT
 5 GGTACCAGCAGAAACCAGGTCAAGCACCGCGTCTATTAATTTATGGCGCGAGC
 AGCCGTGCAACTGGGGTCCCGGCGCGTTTTAGCGGCTCTGGATCCGGCACGG
 ATTTTACCCTGACCATTAGCAGCCTGGAACCTGAAGACTTTGCGGTTTATTATTG
 10 CCAGCAGACTTATAATTATCCTCCTACCTTTGGCCAGGGTACGAAAGTTGAAAT
 TAAACGTACG (SEQ ID NO: 46)

15 SEQ ID NO:47 prot VL region of MS-Roche#3.6H5 x 3.6L2; protein/1; artificial sequence

DIVLTQSPATLSLSPGERATLSCRASQFLSRYYLAWYQQKPGQAPRLLIYGASSRA
 20 TGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQTYNYPPTFGQGTKVEIKRT
 (SEQ ID NO: 47)

SEX ID NO: 48 VL region of MS-Roche#3.6H8 x 3.6L2; DNA,; artificial sequence

25 GATATCGTGCTGACCCAGAGCCCGGCGACCCTGAGCCTGTCTCCGGGCGAAC
 GTGCGACCCTGAGCTGCAGAGCGAGCCAGTTTCTTTCTCGTTATTATCTGGCGT
 30 GGTACCAGCAGAAACCAGGTCAAGCACCGCGTCTATTAATTTATGGCGCGAGC
 AGCCGTGCAACTGGGGTCCCGGCGCGTTTTAGCGGCTCTGGATCCGGCACGG
 ATTTTACCCTGACCATTAGCAGCCTGGAACCTGAAGACTTTGCGGTTTATTATTG
 35 CCAGCAGACTTATAATTATCCTCCTACCTTTGGCCAGGGTACGAAAGTTGAAAT
 TAAACGTACG (SEQ ID NO: 48)

40 SEQ ID NO: 49 prot VL region of MS-Roche#3.6H8 x 3.6L2; protein/1; artificial sequence

DIVLTQSPATLSLSPGERATLSCRASQFLSRYYLAWYQQKPGQAPRLLIYGASSRA
 45 TGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQTYNYPPTFGQGTKVEIKRT
 (SEQ ID NO: 49)

SEQ ID NO: 50 VL region of MS-Roche#7.4H2 x 7.2L1; DNA; artificial sequence

GATATCGTGCTGACCCAGAGCCCGGCGACCCTGAGCCTGTCTCCGGGCGAAC
 GTGCGACCCTGAGCTGCAGAGCGAGCCAGTATGTTGATCGTACTTATCTGGCG
 5 TGGTACCAGCAGAAACCAGGTCAAGCACCGCGTCTATTAATTTATGGCGCGAG
 CAGCCGTGCAACTGGGGTCCCGGCGCGTTTTAGCGGCTCTGGATCCGGGCACG
 GATTTTACCCTGACCATTAGCAGCCTGGAACCTGAAGACTTTGCGACTTATTATT
 10 GCCAGCAGATTTATTCTTTTCCTCATACCTTTGGCCAGGGTACGAAAGTTGAAAT
 TAAACGTACG (SEQ ID NO: 50)

15 SEQ ID NO: 51 prot VL region of MS-Roche#7.4H2 x 7.2L1; protein/1; artificial sequence

DIVLTQSPATLSLSPGERATLSCRASQYVDRTYLAWYQQKPGQAPRLLIYGASSRA
 TGVPARFSGSGSGTDFTLTISSLEPEDFATYYCQQIYSFPHTFGQGTKVEIKRT
 20 (SEQ ID NO: 51)

SEQ ID NO: 52 VL region of MS-Roche#7.9H2 x 7.12 L2; DNA; artificial sequence

25 GATATCGTGCTGACCCAGAGCCCGGCGACCCTGAGCCTGTCTCCGGGCGAAC
 GTGCGACCCTGAGCTGCAGAGCGAGCCAGCGTTTTTTTTTATAAGTATCTGGCGT
 GGTACCAGCAGAAACCAGGTCAAGCACCGCGTCTATTAATTTCTGGTTCTTCTA
 30 ACCGTGCAACTGGGGTCCCGGCGCGTTTTAGCGGCTCTGGATCCGGGCACGGA
 TTTTACCCTGACCATTAGCAGCCTGGAACCTGAAGACTTTGCGGTTTATTATTGC
 CTTTCAGCTTTATAATATTCCTAATACCTTTGGCCAGGGTACGAAAGTTGAAATTA
 35 AACGTACG (SEQ ID NO: 52)

40 SEQ ID NO: 53 prot VL region of MS-Roche#7.9H2 x 7.12 L2; protein/1; artificial sequence

DIVLTQSPATLSLSPGERATLSCRASQRFFYKYLAWYQQKPGQAPRLLISGSSNRA
 TGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCLQLYNIPNTFGQGTKVEIKRT
 45 (SEQ ID NO: 53)

SEQ ID NO: 54 VL region of MS-Roche#7.9H4 x 7.12L2; DNA; artificial sequence

GATATCGTGCTGACCCAGAGCCCGGCGACCCTGAGCCTGTCTCCGGGGCGAAC
 GTGCGACCCTGAGCTGCAGAGCGAGCCAGCGTTTTTTTTTATAAGTATCTGGCGT
 5 GGTACCAGCAGAAACCAGGTCAAGCACCGCGTCTATTAATTTCTGGTTCTTCTA
 ACCGTGCAACTGGGGTCCCGGCGCGTTTTAGCGGCTCTGGATCCGGGCACGGA
 TTTTACCCTGACCATTAGCAGCCTGGAACCTGAAGACTTTGCGGTTTATTATTGC
 10 CTTCAGCTTTATAATATTCCTAATACCTTTGGCCAGGGTACGAAAGTTGAAATTA
 AACGTACG (SEQ ID NO: 54)

15 SEQ ID NO: 55 prot VL region of MS-Roche#7.9H4 x 7.12L2; protein/1; artificial sequence

DIVLTQSPATLSLSPGERATLSCRASQRFFYKYLAWYQQKPGQAPRLLISGSSNRA
 TGVPARFSGSGSGTDFTLTISSELPEDFAVYYCLQLYNIPNTFGQGTKVEIKRT
 20 (SEQ ID NO: 55)

SEQ ID NO: 56 VL region of MS-Roche#7.11 H1 x 7.11L1; DNA; artificial sequence

25 GATATCGTGCTGACCCAGAGCCCGGCGACCCTGAGCCTGTCTCCGGGGCGAAC
 GTGCGACCCTGAGCTGCAGAGCGAGCCAGCGTATTCTTCGTATTTATCTGGCG
 TGGTACCAGCAGAAACCAGGTCAAGCACCGCGTCTATTAATTTATGGCGCGAG
 30 CAGCCGTGCAACTGGGGTCCCGGCGCGTTTTAGCGGCTCTGGATCCGGGCACG
 GATTTTACCCTGACCATTAGCAGCCTGGAACCTGAAGACTTTGCGACTTATTATT
 GCCAGCAGGTTTATTCTCCTCCTCATACCTTTGGCCAGGGTACGAAAGTTGAAA
 35 TTAAACGTACG (SEQ ID NO: 56)

40 SEQ ID NO: 57 prot VL region of MS-Roche#7.11H1 x 7.11L1; protein/1; artificial sequence

DIVLTQSPATLSLSPGERATLSCRASQRILRIYLAWYQQKPGQAPRLLIYGASSRAT
 GVPARFSGSGSGTDFTLTISSELPEDFATYYCQVYSPPHFTFGQGTKVEIKRT
 45 (SEQ ID NO: 57)

SEQ ID NO: 58 VL region of MS-Roche#7.11H1 x 7.2L1; DNA; artificial sequence

50 GATATCGTGCTGACCCAGAGCCCGGCGACCCTGAGCCTGTCTCCGGGGCGAAC
 GTGCGACCCTGAGCTGCAGAGCGAGCCAGTATGTTGATCGTACTTATCTGGCG
 TGGTACCAGCAGAAACCAGGTCAAGCACCGCGTCTATTAATTTATGGCGCGAG
 55

CAGCCGTGCAACTGGGGTCCCGGCGCGTTTTAGCGGCTCTGGATCCGGCACC
 GATTTTACCCTGACCATTAGCAGCCTGGAACCTGAAGACTTTGCGACTTATTATT
 5 GCCAGCAGATTTATTCTTTTCCTCATACCTTTGGCCAGGGTACGAAAGTTGAAAT
 TAAACGTACG (SEQ ID NO: 58)

SEQ ID NO: 59 prot VL region of MS-Roche#7.11H1 x 7.2L1; protein/1; artificial sequence

DIVLTQSPATLSLSPGERATLSCRASQYVDRTYLAWYQQKPGQAPRLLIYGASSRA
 TGVPARFSGSGSGTDFTLTISSELPEDFATYYCQQIYSFPHTFGQGTKVEIKRT
 15 (SEQ ID NO: 59)

SEQ ID NO: 60 HCDR3 region of MS-Roche#3.6H5 x 3.6L2; DNA; artificial sequence
 CTTACTCATTATGCTCGTTATTATCGTTATTTTGATGTT (SEQ ID NO: 60)

SEQ ID NO: 61 prot HCDR3 region of MS-Roche#3.6H5 x 3.6L2; protein/1; artificial sequence
 LTHYARYRYFDV (SEQ ID NO: 61)

SEQ ID NO: 62 HCDR3 region of MS-Roche#3.6H8 x 3.6L2; DNA; artificial sequence
 CTTACTCATTATGCTCGTTATTATCGTTATTTTGATGTT (SEQ ID NO: 62)

SEQ ID NO: 63 prot HCDR3 region of MS-Roche#3.6H8 x 3.6L2; protein/1; artificial sequence
 LTHYARYRYFDV (SEQ ID NO: 63)

SEQ ID NO: 64 HCDR3 region of MS-Roche#7.4H2 x 7.2L1; DNA; artificial sequence
 GGTAAGGGTAATACTCATAAGCCTTATGGTTATGTTCGTTATTTTGATGTT (SEQ ID NO: 64)

SEQ ID NO: 65 prot HCDR3 region of MS-Roche#7.4H2 x 7.2L1; protein/1; artificial sequence
 GKGNTKPYGYVRYFDV (SEQ ID NO: 65)

SEQ ID NO: 66 HCDR3 region of MS-Roche#7.9H2 x 7.12 L2; DNA; artificial sequence
 GGTAAGGGTAATACTCATAAGCCTTATGGTTATGTTCGTTATTTTGATGTT (SEQ ID NO: 66)

SEQ ID NO: 67 prot HCDR3 region of MS-Roche 7.9H2 x 7.12 L2; protein/1; artificial sequence
 GKGNTKPYGYVRYFDV (SEQ ID NO: 67)

SEQ ID NO: 68 HCDR3 region of MS-Roche#7.9H4 x 7.12L2; DNA; artificial sequence
 GGTAAGGGTAATACTCATAAGCCTTATGGTTATGTTCGTTATTTTGATGTT (SEQ ID NO: 68)

SEQ ID NO: 69 prot HCDR3 region of MS-Roche#7.9H4 x 7.12L2; protein/1; artificial sequence
 GKGNTKPYGYVRYFDV (SEQ ID NO: 69)

SEQ ID NO: 70 HCDR3 region of MS-Roche#7.11H1 x 7.11L1; DNA; artificial sequence
 GGTAAGGGTAATACTCATAAGCCTTATGGTTATGTTCGTTATTTTGATGTT (SEQ ID NO: 70)

SEQ ID NO: 71 prot HCDR3 region of MS-Roche#7.11H1 x 7.11L1; protein/1; artificial sequence
 GKGNTKPYGYVRYFDV (SEQ ID NO: 71)

SEQ ID NO: 72 HCDR3 region of MS-Roche#7.11H1 x 7.2L1; DNA; artificial sequence
 GGTAAGGGTAATACTCATAAGCCTTATGGTTATGTTCGTTATTTTGATGTT (SEQ ID NO: 72)

SEQ ID NO: 73 prot HCDR3 region of MS-Roche#7.11H1x 7.2L1; protein/1; artificial sequence
 GKGNTKPYGYVRYFDV (SEQ ID NO: 73)

EP 2 368 907 B1

SEQ ID NO: 74 LCDR3 region of MS-Roche#3.6H5 x 3.6L2; DNA; artificial sequence
CAGCAGACTTATAATTATCCTCCT (SEQ ID NO: 74)

5 SEQ ID NO: 75 prot LCDR3 region of MS-Roche#3.6H5 x 3.6L2; protein/1; artificial sequence
QQTYNYP (SEQ ID NO: 75)

SEQ ID NO: 76 LCDR3 region of MS-Roche#3.6H8 x 3.6L2; DNA; artificial sequence
CAGCAGACTTATAATTATCCTCCT (SEQ ID NO: 76)

10 SEQ ID NO: 77 prot LCDR3 region of MS-Roche#3.6H8 x 3.6L2; protein/1; artificial sequence
QQTYNYP (SEQ ID NO: 77)

SEQ ID NO: 78 LCDR3 region of MS-Roche#7.4H2 x 7.2L1; DNA; artificial sequence
CAGCAGATTTATTCTTTTCCTCAT (SEQ ID NO: 78)

15 SEQ ID NO: 79 prot LCDR3 region of MS-Roche#7.4H2 x 7.2L1; protein/1; artificial sequence
QQIYSFPH (SEQ ID NO: 79)

SEQ ID NO: 80 LCDR3 region of MS-Roche#7.9H2 x 7.12 L2; DNA; artificial sequence
CTTCAGCTTTATAATATTCCTAAT (SEQ ID NO: 80)

20 SEQ ID NO: 81 prot LCDR3 region of MS-Roche#7.9H2 x 7.12 L2; protein/1; artificial sequence
LQLYNIPN (SEQ ID NO: 81)

25 SEQ ID NO: 82 LCDR3 region of MS-Roche#7.9H4 x 7.12L2; DNA; artificial sequence
CTTCAGCTTTATAATATTCCTAAT (SEQ ID NO: 82)

SEQ ID NO: 83 prot LCDR3 region of MS-Roche#7.9H4 x 7.12L2; protein/1; artificial sequence
LQLYNIPN (SEQ ID NO: 83)

30 SEQ ID NO: 84 LCDR3 region of MS-Roche#7.11H1 x 7.11L1; DNA; artificial sequence
CAGCAGGTTTATTCTCCTCCTCAT (SEQ ID NO: 84)

35 SEQ ID NO: 85 prot LCDR3 region of MS-Roche#7.11H1 x 7.11L1; protein/1; artificial sequence
QQVYSPPH (SEQ ID NO: 85)

SEQ ID NO: 86 LCDR3 region of MS-Roche#7.11H1 x 7.2L1; DNA; artificial sequence
CAGCAGATTTATTCTTTTCCTCAT (SEQ ID NO: 86)

40 SEQ ID NO: 87 prot LCDR3 region of MS-Roche#7.11H1 x 7.2L1; protein/1; artificial sequence
QQIYSFPH (SEQ ID NO: 87)

SEQ ID NO: 88 VH region of MS-Roche#7.9H7; DNA; artificial sequence

45 Caggtgcaattggtggaaagcggcgggcggcctggtgcaaccgggaggcagcctgcgtctgagctgcgcggcctc
cggatttaccttagcagctatgcgatgagctgggtgcgccaagcccctgggaagggctcgagtgaggtagcgctat
50 taatgcttctggtactcgacttattatgctgattctgtaagggctggtttaccatttcacgtgataattcgaaaaacaccctg
tatctgcaaatgaacagcctgcgtgcggaagatacggccgtgtattattgcgcgctggtaagggtaatactcataag
ccttatgggtatgttcgttattttgatgtttggggccaaggcaccctggtgacggtagctca (SEQ ID NO: 88)

55 SEQ ID NO: 89 prot VH region of MS-Roche#7.9H7; protein/1; artificial sequence

QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAINAS
 GTRTYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARGKGNTHKPYGY
 5 VRYFDVWGQGTLVTVSS (SEQ ID NO: 89)

SEQ ID NO: 90 VL region of MS-Roche#7.9H7; DNA; artificial sequence

10 Gatatcgtgctgaccagagcccgccgacccctgagcctgtctccggcggaacgtgcgaccctgagctgcagagcg
 agccagagcgtgagcagcagctatctggcgtggtaccagcagaaaccagggtcaagcaccgcgtctattaattatg
 gcgcgagcagccgtgcaactgggggtcccgccgcttttagcggctctggatccggcacggattttaccctgaccatta
 15 gcagcctggaacctgaagactttgcgacttattatgccttcagatttataatatgcctattacctttggccagggtacgaa
 agttgaaattaaacgtacg (SEQ ID NO: 90)

SEQ ID NO: 91 prot VL region of MS-Roche#7.9H7; protein/1; artificial sequence

20 DIVLTQSPATLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRA
 TGVPARFSGSGSGTDFTLTISSELPEDFATYYCLQIYNMPITFGQGTKVEIKRT
 25 (SEQ ID NO: 91)

SEQ ID NO: 92 HCDR3 region of MS-Roche#7.9H7; DNA; artificial sequence Ggtaagggtataactcataagccttatggtat-
 gtcgttattttgatgtt (SEQ ID NO: 92)

30 SEQ ID NO: 93 prot HCDR3 region of MS-Roche#7.9H7; protein/1; artificial sequence
 KKGNT HKPYGYVRYFDV (SEQ ID NO: 93)

SEQ ID NO: 94 LCDR3 region of MS-Roche#7.9H7; DNA; artificial sequence Cttcagattataatatgcctatt (SEQ ID NO:
 94)

35 SEQ ID NO: 95 prot LCDR3 region of MS-Roche#7.9H7; protein/1; artificial sequence
 LQIYNMPI (SEQ ID NO: 95)

40 **[0087]** Further illustrative sequences are depicted in the appended sequence listing and are also shown in the appended
 tables, in particular tables 1, 8 and 10.

[0088] The Figures show:

45 **Figure 1** **Sequence summary of HuCAL[®]-Fab1 Library** The numbering is according to VBASE except the gap
 in VL λ position 9. In VBASE the gap is set at position 10 (*Chothia et al.*, 1992). In the sequence summary
 all CDR3 residues which were kept constant are indicated. Corresponding sequences employed for the
 HuCAL-Fab1 library can be found in the appended sequence listing.

A: amino acid sequence

B: DNA sequence

50 **Figure 2** **Fab display vector pMORPH[®]18_Fab** Vector map and DNA sequence including restriction sites

Figure 3 **Fab expression vector pMORPH[®]x9_Fab** Vector map and DNA sequence including restriction sites

55 **Figure 4** **Sequences of the parental Fab fragments MS-Roche-3, MS-Roche-7 and MS-Roche 8**

A: amino acid sequence

B: DNA sequence

Figure 5: indirect immunofluorescence of amyloid-plaques from a cryostat section of human temporal cortex. The plaques were labeled with MS-R # 3.2 Fab (upper panels) and MS-R # 7.4 Fab (lower panels) at 20 $\mu\text{g/ml}$ (left panels) and 5 $\mu\text{g/ml}$ (right panels) under stringent blocking conditions. Bound MS-R Fab was revealed by goat anti-human-Cy3.

Figure 6: Indirect immunofluorescence of amyloid-plaques from a cryostat section of human temporal cortex. The plaques were labeled with MS-R # 3.3 IgG1 (upper panels) and MS-R # 7.12 IgG1 (lower panels) at 0.05 $\mu\text{g/ml}$ (left panels) and 0.01 $\mu\text{g/ml}$ (right panels) under stringent blocking conditions. Bound MS-R IgG1 antibody was revealed by goat anti-human (H+L)-Cy3.

Figure 7: Indirect immunofluorescence of amyloid-plaques from a cryostat section of human temporal cortex using antibodies after final affinity maturation. The plaques were labeled with MS-R # 7.9.H7 IgG1 (MAB 31, top panel), MS-R # 7.11.H1x7.2.L1 IgG1 (MAB 11, middle panel) and MS-R # 3.4.H7, bottom panel). Antibodies were used at 0.05 $\mu\text{g/ml}$ (left panels) and 0.01 $\mu\text{g/ml}$ (right panels) under stringent blocking conditions. Bound MS-R IgG1 antibody was revealed by goat anti-human (H+L)-Cy3. Scale: 8,5 mm = 150 μm .

Figure 8: Polymerization Assay. Anti-A β antibodies prevent incorporation of biotinylated A β into preformed A β aggregates.

Figure 9: De-polymerization Assay. Anti-A β antibodies induce release of biotinylated A β from aggregated A β .

Figure 10: *In vivo* decoration of amyloid plaques in an APP/PS2 double transgenic mouse after intravenous injection of 1 mg MS-Roche IgG #7.9.H2 x 7.12.L2. After three days the mouse was perfused with phosphate-buffered saline and sacrificed. The presence of human IgG bound to amyloid plaques was revealed by confocal microscopy after labelling cryostat sections from the frontal cortex with a goat anti-human IgG-Cy3 conjugate (panel B). The same section was counterstained with an anti-Abeta mouse monoclonal antibody (BAP-2-Alexa488 conjugate, panel A) to visualize the position of amyloid plaques. Individual red (panel B) and green (panel A) channels, merged image (panel D) and colocalized (panel C) signals are shown. Scale: 1 cm = 50 μm

Figure 11: *In vivo* decoration of amyloid plaques in an APP/PS2 double transgenic mouse after intravenous injection of 1mg MS-Roche IgG #7.9.H4 x 7.12.L2. Experimental conditions and staining procedure were identical to those described in the legend of figure 10. Scale: 1.6 cm = 50 μm

Figure 12: *In vivo* decoration of amyloid plaques in an APP/PS2 double transgenic mouse after intravenous injection of 1mg MS-Roche IgG #7.11.H1 x 7.2.L1 (MAB 11). Experimental conditions and staining procedure were identical to those described in the legend of figure 10. Scale: 1.4 cm = 70 μm

Figure 13: *In vivo* decoration of amyloid plaques in an APP/PS2 double transgenic mouse after intravenous injection of 2 mg MS-Roche IgG #7.9.H7 (MAB 31) at day 0, 3, and 6. After nine days the mouse was perfused with phosphate-buffered saline and sacrificed. The presence of human IgG bound to amyloid plaques was revealed by confocal microscopy after labelling cryostat sections from the frontal cortex with a goat anti-human IgG-Cy3 conjugate (panel B). The same section was counterstained with an anti-Abeta mouse monoclonal antibody (BAP-2-Alexa488 conjugate, panel A) to visualize the position of amyloid plaques. Individual red (panel B) and green (panel A) channels, merged image (panel D) and colocalized (panel C) signals and are shown. Scale: 1.6 cm = 80 μm (panels A, B, C); 1.0 cm = 50 μm (panel D)

Figure 14: *In vivo* decoration of amyloid plaques in an APP/PS2 double transgenic mouse after intravenous injection of 2 mg MS-Roche IgG #7.11.H1 x 7.2.L1 (MAB 11) at day 0, 3 and 6. Experimental conditions and staining procedure were identical to those described in the legend of figure 13. Scale: 1.6 cm = 80 μm

Figure 15: Binding analysis of anti-A β antibodies to cell surface APP. Antibody binding to human APP-transfected HEK293 cells and non-transfected control cells was analyzed by flow cytometry.

[0089] The examples illustrate the invention.

Example 1: Construction and Screening of a Human Combinatorial Antibody Library (HuCAL®-Fab1)*Cloning of HuCAL®-Fab 1*

- 5 **[0090]** HuCAL®-Fab 1 is a fully synthetic, modular human antibody library in the Fab antibody fragment format. HuCAL®-Fab 1 was assembled starting from an antibody library in the single-chain format (HuCAL®-scFv; Knappik, (2000), J. Mol. Biol. 296, 57-86).
- [0091]** *VL positions 1 and 2.* The original HuCAL® master genes were constructed with their authentic N-termini: VL λ 1: QS (CAGAGC), VL λ 2: QS (CAGAGC), and VL λ 3: SY (AGCTAT). Sequences containing these amino acids are shown in WO 97/08320. During HuCAL® library construction, the first two amino acids were changed to DI to facilitate library cloning (*EcoRI* site). All HuCAL® libraries contain VL λ genes with the *EcoRV* site GATATC (DI) at the 5'-end. All HuCAL® kappa genes (master genes and all genes in the library) contain DI at the 5'-end (figure 1A and B).
- 10 **[0092]** *VH position 1.* The original HuCAL® master genes were constructed with their authentic N-termini: VH1A, VH1B, VH2, VH4, and VH6 with Q (=CAG) as the first amino acid and VH3 and VH5 with E (=GAA) as the first amino acid. Sequences containing these amino acids are shown in WO 97/08320. During cloning of the HuCAL®-Fab1 library, amino acid at position 1 of VH was changed to Q (CAG) in all VH genes (figure 1A and B).

Design of the CDR libraries

- 20 **[0093]** *V κ 1/V κ 3 position 85.* Because of the cassette mutagenesis procedure used to introduce the CDR3 library (Knappik, (2000), *loc. cit.*), position 85 of V κ 1 and V κ 3 can be either T or V. Thus, during HuCAL®-scFv1 library construction, position 85 of V κ 1 and V κ 3 was varied as follows: V κ 1 original, 85T (codon ACC); V κ 1 library, 85T or 85V (TRIM codons ACT or GTT); V κ 3 original, 85V (codon GTG); V κ 3 library, 85T or 85V (TRIM codons ACT or GTT); the same applies to HuCAL®-Fab1.
- 25 *CDR3 design.* All CDR3 residues, which were kept constant, are indicated in figure 1 A and B.
- CDR3 length.* The designed CDR3 length distribution is as follows. Residues, which were varied are shown in brackets (x) in figure 1. V kappa CDR3, 8 amino acid residues (position 89 to 96) (occasionally 7-10 residues), with Q89, S90, and D92 fixed; and VH CDR3, 5 to 28 amino acid residues (position 95 to 102) (occasionally 4-28), with D101 fixed.
- 30 **[0094]** HuCAL®-Fab 1 was cloned into a phagemid expression vector pMORPH®18_Fab1 (figure 2). This vector comprises the Fd fragment with a phoA signal sequence fused at the C-terminus to a truncated gene III protein of filamentous phage, and further comprises the light chain VL-CL with an ompA signal sequence. Both chains are under the control of the lac operon. The constant domains C λ C κ and CH1 are synthetic genes fully compatible with the modular system of HuCAL® (Knappik, (2000), *loc. cit.*).
- 35 The whole VH-chain (*MunII*/*StyI*-fragment) was replaced by a 1205 bp dummy fragment containing the β -lactamase transcription unit (*bla*), thereby facilitating subsequent steps for vector fragment preparation and allowing for selection of complete VH removal.
- After VH-replacement, VL λ was removed by *EcoRI*/*DraIII* and VL κ by *EcoRI*/*BsiWI* and replaced with bacterial alkaline phosphatase (*bap*) gene fragment (1420 bp).
- As the variability of the light chains is lower than that of the heavy chains, cloning was started with the light chain libraries.
- 40 The VL λ and VL κ light chain libraries diversified in L-CDR3, which were generated for the HuCAL®-scFv library (Knappik, (2000), *loc. cit.*) were also used for cloning of HuCAL®-Fab1. In case of λ , they consisted of the λ 1-, λ 2- and λ 3-HuCAL®-framework and had a total variability of 5.7×10^6 . VL λ fragments were amplified by 15 PCR cycles (Pwo-polymerase) with primers 5'-GTGGTGGTTCGATATC-3' (SEQ ID NO: 28) and 5'-AGCGTCACACTCGGTGCGGCTTTCGGCTGGCCAAGAACGGTTA-3' (SEQ ID NO: 29). PCR-products were digested with *EcoRV*/*DraIII* and gel-purified. In case of the VL λ -library, the *bap*-dummy was removed by *EcoRV*/*DraIII* from the library vector. 2 μ g of gelpurified vector were ligated with a 3-fold molar excess of VL λ -chains for 16 h at 16°C, and the ligation mixtures were electroporated in 800 μ l *E. coli* TOP10F cells (Invitrogen), yielding altogether 4.1×10^8 independent colonies. The transformants were amplified about 2000-fold in 2 x YT/1% glucose/34 μ g/ml chloramphenicol/100 μ g/ml ampicillin, harvested and stored in 20% (w/v) glycerol at -80°C.
- 45 The κ libraries comprise the κ 1-, κ 2-, κ 3- and κ 4-HuCAL® master genes with a total variability of 5.7×10^6 . VL κ -chains were obtained by restriction digest with *EcoRV*/*BsiWI* and gel-purified. In case of the VL κ -library, the *bap*-dummy was removed by *EcoRV*/*BsiWI* from the library vector. 2 μ g of gel-purified vector were mixed with a 5-fold molar excess of VL κ -chains. Ligation and transformation into *E. coli* TOP10F cells (Invitrogen) was performed as described for VL λ -chains, yielding altogether 1.6×10^8 independent colonies.
- 50 DNA of the two light chain libraries was prepared and the *bla*-dummy was removed by *MunII*/*StyI*, thereby generating the two vectors for insertion of the VH sub-libraries. The VH libraries of HuCAL®-scFv were used for the generation of HuCAL®-Fab1. The VH libraries of HuCAL®-scFv consist of the master genes VH1A/B-6 diversified with two VH-CDR3 trinucleotide library cassettes differing in CDR3 length separately, and each VH-library combined with the VL κ - and with

the VL_κ-library. For the generation of the HuCAL®-Fab1 DNA from these VH-libraries was prepared preserving the original variability. The DNA was digested with *MunII*/*StyI* and gel-purified. A 5-fold molar excess of the VH-chains was ligated with 3 μg of the VL_κ-library vector and with 3 μg of the VL_κ-library vector for 4 h at 22°C. The ligation mixtures were electroporated for each vector in 1200 μl *E. coli* TOP10F cells (Invitrogen), yielding altogether 2.1 x 10¹⁰ independent colonies. The transformants were amplified about 4000-fold in 2 x YT/1% glucose/34 μg/ml chloramphenicol/10 μg/ml tetracycline, harvested and stored in 20% (w/v) glycerol at -80°C.

[0095] As quality control the light chain and heavy chain of single clones was sequenced with 5'-CAGGAAACAGCTAT-GAC-3' (SEQ ID NO: 30) and 5'-TACCGTTGCTCTTCACCCC-3' (SEQ ID NO: 31), respectively.

Phagemid rescue, phage amplification and purification

[0096] HuCAL®-Fab 1 was amplified in 2 x TY medium containing 34 μg/ml chloramphenicol, 10 μg/ml tetracycline and 1 % glucose (2 x TY-CG). After helper phage infection (VCSM13) at 37°C at an OD₆₀₀ of about 0.5, centrifugation and resuspension in 2 x TY / 34 μg/ml chloramphenicol / 50 μg/ml kanamycin cells were grown overnight at 30°C. Phage were PEG-precipitated from the supernatant (Ausubel, (1998), Current protocols in molecular biology. John Wiley & Sons, Inc., New York, USA), resuspended in PBS/20% glycerol and stored at -80°C. Phage amplification between two panning rounds was conducted as follows: mid-log phase TG1-cells were infected with eluted phage and plated onto LB-agar supplemented with 1% of glucose and 34 μg/ml of chloramphenicol. After overnight incubation at 30°C colonies were scraped off, adjusted to an OD₆₀₀ of 0.5 and helper phage added as described above.

Example 2: Solid phase panning

[0097] Wells of MaxiSorp™ microtiterplates F96 (Nunc) were coated with 100 μl 2.5 μM human Aβ (1-40) peptide (Bachem) dissolved in TBS containing NaN₃ (0.05% v/v) and the sealed plate was incubated for 3 days at 37°C where the peptide is prone to aggregate on the plate. After blocking with 5% non-fat dried milk in TBS, 1-5 x 10¹² HuCAL®-Fab phage purified as above were added for 1 h at 20°C. After several washing steps, bound phages were eluted by pH-elution with 500 mM NaCl, 100 mM glycine pH 2.2 and subsequent neutralisation with 1 M TRIS-Cl pH 7. Three rounds of panning were performed with phage amplification conducted between each round as described above, the washing stringency was increased from round to round.

Example 3: Subcloning of selected Fab fragments for expression

[0098] The Fab-encoding inserts of the selected HuCAL®-Fab fragments were subcloned into the expression vector pMORPH®x7_FS to facilitate rapid expression of soluble Fab. The DNA preparation of the selected HuCAL®-Fab clones was digested with *XbaI*/*EcoRI*, thus cutting out the Fab encoding insert (ompA-VL and phoA-Fd). Subcloning of the purified inserts into the *XbaI*/*EcoRI* cut vector pMORPH®x7, previously carrying a scFv insert, leads to a Fab expression vector designated pMORPH®x9_Fab1 (figure 3). Fabs expressed in this vector carry two C-terminal tags (FLAG and Strep) for detection and purification.

Example 4: Identification of Aβ-binding Fab fragments by ELISA

[0099] Wells of Maxisorp™ microtiterplates F384 (Nunc) were coated with 20 μl 2.5 μM human Aβ (1-40) peptide (Bachem) dissolved in TBS containing NaN₃ (0.05% v/v) and the sealed plate was incubated for 3 days at 37°C, where the peptide is prone to aggregate on the plate. Expression of individual Fab was induced with 1 mM IPTG for 16 h at 22°C. Soluble Fab was extracted from *E. coli* by BEL lysis (boric acid, NaCl, EDTA and lysozyme containing buffer pH 8) and used in an ELISA. The Fab fragment was detected with an alkaline phosphatase-conjugated goat anti-Fab antibody (Dianova/Jackson Immuno Research). After excitation at 340 nm the emission at 535 nm was read out after addition of AttoPhos fluorescence substrate (Roche Diagnostics).

Example 5: Optimization of antibody fragments

[0100] In order to optimize the binding affinity of the selected Aβ binding antibody fragments, some of the Fab fragments, MS-Roche-3 (MSR-3), MS-Roche-7 (MSR-7) and MS-Roche-8 (MSR-8) (figure 4), were used to construct a library of Fab antibody fragments by replacing the parental VL κ3 chain by the pool of all kappa chains κ1-3 diversified in CDR3 from the HuCAL® library (Knappik et al., 2000).

The Fab fragments MS-Roche-3, 7 and 8 were cloned via *XbaI*/*EcoRI* from pMORPH®x9_FS into pMORPH®18, a phagemid-based vector for phage display of Fab fragments, to generate pMORPH®18_Fab1 (figure 2). A kappa chain pool was cloned into pMORPH®18_Fab1 via *XbaI*/*SphI* restriction sites.

[0101] The resulting Fab optimization library was screened by panning against aggregated human A β (1-40) peptide coated to a solid support as described in example 2.

Optimized clones were identified by koff-ranking in a Biacore assay as described in Example 8. The optimized clones MS-Roche-3.2, 3.3, 3.4, 3.6, 7.2, 7.3, 7.4, 7.9, 7.11, 7.12, 8.1, 8.2, were further characterized and showed improved affinity and biological activity compared to the starting fragment MS-Roche-3, MS-Roche-7 and MS-Roche-8 (figure 4). The CDRs listed refer to the HuCAL[®] consensus-based antibody gene VH3kappa3. The Fab fragment MS-Roche-7.12 was obtained by cloning the HCDR3 of parental clone MS-R 7 into a HuCAL[®]-Fab library, carrying diversity in all 6 CDR regions using a design procedure identical with that for CDR3 cassettes described in Knappik *et al.*, 2000. The library cassettes were designed strongly biased for the known natural distribution of amino acids and following the concept of canonical CDR conformations established by Allazikani (Allazikani *et al.*, 1997). However in contrast to the HuCAL[®] master genes, the clone MS-Roche 7.12 contains amino acid S at position 49 of the VL chain (see appended table 1).

[0102] The optimized Fabs after the first affinity maturation round showed improved characteristics over the starting MS-Roche-3, MS-Roche-7 and MS-Roche-8 clones (Figure 4). The binding affinities of the matured Fabs to A β 1-40 and A β 1-42 were significantly increased yielding K_D values in the range of 22 - 240 nM in comparison to 850 - 1714 nM of the parental clones (Table 3). Immunohistochemistry analysis of amyloid plaques in human AD brain sections also showed a significantly increased staining profile of the matured clones, i. e. better signal to background ratios were obtained and positive plaque staining was detected at relatively low concentrations of the matured Fabs (Figure 5).

[0103] For further optimization, the VH CDR2 regions and the VL CDR1 regions of a set of antibody fragments derived from L-CDR3 optimized MS-Roche-3, -7 and -8 (table 1; figure 4) were optimized by cassette mutagenesis using trinucleotide-directed mutagenesis (Virnekäs *et al.*, 1994). Therefore, a trinucleotide-based HCDR2 cassette and a trinucleotide-based LCDR1 cassette were constructed using a design procedure identical with that for CDR3 cassettes described in Knappik *et al.*, 2000. The library cassettes were designed strongly biased for the known natural distribution of amino acids and following the concept of canonical CDR conformations established by Allazikani (Allazikani *et al.*, 1997). The protocol used for the optimization of the initial selected antibody fragments would mimic the process of affinity maturation by somatic hypermutation observed during the natural immune response.

[0104] The resulting libraries were screened separately as described above leading to optimized clones either in the H-CDR2 or in the L-CDR1 region. All clones were identified as above by an improved koff towards A β 1-40-fibers after a koff-ranking in the Biacore and showed improved affinity either to A β 1-40 or A β -42 or both when compared to the corresponding parent clone (Table 3). Table 1 contains the sequence characteristics of the parental as well as sequences of the optimized clones. The CDRs listed refer to the HuCAL[®] consensus-based antibody gene VH3kappa3.

For example, the affinity of the MS-Roche-7 parental Fab towards Ab1-40 was improved over 35-fold from 1100 nM to 31 nM after L-CDR3 optimization (MS-Roche-7.9) and further improved to 5 nM after H-CDR2 optimization (MS-Roche-7.9H2) as illustrated in Table 3.

The H-CDR2 and L-CDR1 optimization procedure not only increased the affinity but also resulted for some of the clones in a significantly improved staining of amyloid plaques in AD brain section, as particularly seen with MS-Roche 7.9H2 and 7.9H3.

Table 1

Binder name	L-CDR1	pos.49	L-CDR2	pos. 85	L-CDR3	H-CDR1	pos.47	H-CDR2	H-CDR3
MS-Roche #3	RASQSVSSSYLA	Y	GASSRAT	V	QQVYNPPV	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.1	RASQSVSSSYLA	Y	GASSRAT	T	QQVYSVPP	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.2	RASQSVSSSYLA	Y	GASSRAT	V	QQIYSYPP	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.3	RASQSVSSSYLA	Y	GASSRAT	V	HQMSSYPP	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4	RASQSVSSSYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.5	RASQSVSSSYLA	Y	GASSRAT	T	QQIYDYPP	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.6	RASQSVSSSYLA	Y	GASSRAT	V	QQTYNYPV	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.2.H1	RASQSVSSSYLA	Y	GASSRAT	V	QQIYSYPP	GFTFSSYAMS	W	AISEHGLNIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.2.H2	RASQSVSSSYLA	Y	GASSRAT	V	QQIYSYPP	GFTFSSYAMS	W	AISQRGQFTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.3.H1	RASQSVSSSYLA	Y	GASSRAT	V	HQMSSYPP	GFTFSSYAMS	W	WISEKRFIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.3.H2	RASQSVSSSYLA	Y	GASSRAT	V	HQMSSYPP	GFTFSSYAMS	W	VISQESQYKYYADSVKG	LTHYARYRYFDV
MS-Roche #3.3.H3	RASQSVSSSYLA	Y	GASSRAT	V	HQMSSYPP	GFTFSSYAMS	W	AISQNGFHIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4.H1	RASQSVSSSYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	AISETSIRKYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4.H2	RASQSVSSSYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	VIDMVGHTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4.H3	RASQSVSSSYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	VISQTGRKIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4.H4	RASQSVSSSYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	AISQETGMHIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4.H5	RASQSVSSSYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	VISQVGAHIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4.H6	RASQSVSSSYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	AISESGWSTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4.H7	RASQSVSSSYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	VISETGKNIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4.H8	RASQSVSSSYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	AISEHGRFKYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4.H9	RASQSVSSSYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	AISESSKNKYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4.H10	RASQSVSSSYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	AISESGRGKYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4.H11	RASQSVSSSYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	AISEFGKNIYYADSVKG	LTHYARYRYFDV
MS-Roche#3.4.H12	RASQSVSSSYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	VISQTGQNIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4.H13	RASQSVSSSYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	AISEQGRNIYYADSVKG	LTHYARYRYFDV

(continued)

Binder name	L-CDR1	pos.49	L-CDR2	pos. 85	L-CDR3	H-CDR1	pos.47	H-CDR2	H-CDR3
MS-Roche #3.4.H14	RASQSVSSSYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	AISESGQYKYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4.H16	RASQSVSSSYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	AISESGVNIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4.H17	RASQSVSSSYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	AISEFGQFIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4.H18	RASQSVSSSYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	AISQQSNFIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4.L7	RASQRLGRLYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4.L8	RASQWITKSYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4.L9	RASRRIHVYYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4.L11	RASQLVGRAYLA	Y	GASSRAT	T	QQTVDYPP	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.6.H1	RASQSVSSSYLA	Y	GASSRAT	V	QQTYNYP	GFTFSSYAMS	W	VISESGQYKYYADSVKG	LTHYARYRYFDV
MS-Roche #3.6.H2	RASQSVSSSYLA	Y	GASSRAT	V	QQTYNYP	GFTFSSYAMS	W	VISERGINTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.6.H3	RASQSVSSSYLA	Y	GASSRAT	V	QQTYNYP	GFTFSSYAMS	W	VISETGFIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.6.H4	RASQSVSSSYLA	Y	GASSRAT	V	QQTYNYP	GFTFSSYAMS	W	AISERGRHIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.6.H5	RASQSVSSSYLA	Y	GASSRAT	V	QQTYNYP	GFTFSSYAMS	W	AISESGTKYYADSVKG	LTHYARYRYFDV
MS-Roche #3.6.H6	RASQSVSSSYLA	Y	GASSRAT	V	QQTYNYP	GFTFSSYAMS	W	AISEHGTNIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.6.H8	RASQSVSSSYLA	Y	GASSRAT	V	QQTYNYP	GFTFSSYAMS	W	AISEYSKFKYYADSVKG	LTHYARYRYFDV
MS-Roche #3.6.L1	RASQFIQRFYLA	Y	GASSRAT	V	QQTYNYP	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.6.L2	RASQFLSRYYLA	Y	GASSRAT	V	QQTYNYP	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	LTHYARYRYFDV
MS-Roche #7	RASQSVSSSYLA	Y	GASSRAT	T	FQLYSDPF	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.1	RASQSVSSSYLA	Y	GASSRAT	V	HQLYSSPY	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.2	RASQSVSSSYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.3	RASQSVSSSYLA	Y	GASSRAT	V	HQVYSHPF	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYF DV

(continued)

Binder name	L-CDR1	pos.49	L-CDR2	pos. 85	L-CDR3	H-CDR1	pos.47	H-CDR2	H-CDR3
MS-Roche #7.4	RASQSVSSSYLA	Y	GASSRAT	V	QQIYNFPH	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYP DV
MS-Roche #7.5	RASQSVSSSYLA	Y	GASSRAT	T	HQVYSSPF	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYP DV
MS-Roche #7.6	RASQSVSSSYLA	Y	GASSRAT	V	HQLYSPPY	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYP DV
MS-Roche #7.7	RASQSVSSSYLA	Y	GASSRAT	T	HQVYSAPF	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYP DV
MS-Roche #7.8	RASQSVSSSYLA	Y	GASSRAT	V	HQVYSFPI	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYP DV
MS-Roche #7.9	RASQSVSSSYLA	Y	GASSRAT	T	LQIYNMPI	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYP DV
MS-Roche #7.10	RASQSVSS.SYLA	Y	GASSRAT	T	QQVYNPPH	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYP DV
MS-Roche #7.11	RASQSVSSSYLA	Y	GASSRAT	T	QQVYSPPH	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYP DV
MS-Roche #7.12	RASQYVSSPYLA	S	GSSNRAT	V	LQLYNIPN	GFTFSSYGMS	W	NISGSGSSTYYADSVKG	GKGNTHKPYGYVRYP DV
MS-Roche #7.13	RASQSVSSSYLA	Y	GASSRAT	V	HQVYSPPF	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYP DV
MS-Roche #7.2.H1	RASQSVSSSYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AINANGLKYYADSVKG	GKGNTHKPYGYVRYP DV
MS-Roche #7.2.H2	RASQSVSSSYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AINGTGMKKYYADSVKG	GKGNTHKPYGYVRYP DV
MS-Roche #7.2.H3	RASQSVSSSYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AINANGYKTYADSVKG	GKGNTHKPYGYVRYP DV
MS-Roche #7.2.H4	RASQSVSSSYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AINSKGSRIYYADSVKG	GKGNTHKPYGYVRYP DV

(continued)

Binder name	L-CDR1	pos.49	L-CDR2	pos. 85	L-CDR3	H-CDR1	pos.47	H-CDR2	H-CDR3
MS-Roche #7.2.H5	RASQSVSSSYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AINATGRSKYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.2.H6	RASQSVSSSYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AINARGNRTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.2.H7	RASQSVSSSYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AINSRGSDTHYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.2.H8	RASQSVSSSYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AINASGHKTYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.2.L1	RASQYVDRITYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.2.L2	RASQYISFRYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.2.L4	RASQFIRRSYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.3.H1	RASQSVSSSYLA	Y	GASSRAT	V	HQVYSHPF	GFTFSSYAMS	W	AISAINKNTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.3.L1	RASQYLHYGYLA	Y	GASSRAT	V	HQVYSHPF	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.4.H1	RASQSVSSSYLA	Y	GASSRAT	V	QQIYNFPH	GFTFSSYAMS	W	AINATGYRTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.4.H2	RASQSVSSSYLA	Y	GASSRAT	V	QQIYNFPH	GFTFSSYAMS	W	AINYNGARIYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.9.H1	RASQSVSSSYLA	Y	GASSRAT	T	LQIYNMPI	GFTFSSYAMS	W	AINANGQRKFYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.9.H2	RASQSVSSSYLA	Y	GASSRAT	T	LQIYNMPI	GFTFSSYAMS	W	AINADGNRKYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.9.H3	RASQSVSSSYLA	Y	GASSRAT	T	LQIYNMPI	GFTFSSYAMS	W	AINYQGNRKYYADSVKG	GKGNTHKPYGYVRYF DV

(continued)

Binder name	L-CDR1	pos.49	L-CDR2	pos. 85	L-CDR3	H-CDR1	pos.47	H-CDR2	H-CDR3
MS-Roche #7.9.H4	RASQSVSSSYLA	Y	GASSRAT	T	LQIYNMPI	GFTFSSYAMS	W	AINAVGMKKFYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.9.H5	RASQSVSSSYLA	Y	GASSRAT	T	LQIYNMPI	GFTFSSYAMS	W	AINHAGNKKYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.9.L1	RASQRLSPRYLA	Y	GASSRAT	T	LQIYNMPI	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.9.L 2	RASQYLHKRYLA	Y	GASSRAT	T	LQIYNMPI	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.9.H6	RASQSVSSSYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AINARGNRTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.9.H7	RASQSVSSSYLA	Y	GASSRAT	T	LQIYNMPI	GFTFSSYAMS	W	AINASGTRTYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.9.H8	RASQSVSSSYLA	Y	GASSRAT	T	LQIYNMPI	GFTFSSYAMS	W	AINASGSKIYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.9.H9	RASQSVSSSYLA	Y	GASSRAT	T	LQIYNMPI	GFTFSSYAMS	W	AINKGNGKKYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.11.H1	RASQSVSSSYLA	Y	GASSRAT	T	QQVYSPPH	GFTFSSYAMS	W	GINAAGFRTYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.11.H2	RASQSVSSSYLA	Y	GASSRAT	T	QQVYSPPH	GFTFSSYAMS	W	AINANGYKKYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.11.H3	RASQSVSSSYLA	Y	GASSRAT	T	QQVYSPPH	GFTFSSYAMS	W	GINANGNRTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.11.H4	RASQSVSSSYLA	Y	GASSRAT	T	QQVYSPPH	GFTFSSYAMS	W	AINANGYKTYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.11.H5	RASQSVSSSYLA	Y	GASSRAT	T	QQVYSPPH	GFTFSSYAMS	W	AINAHGQRTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche # 7.11.1_1	RASQRILRIYLA	Y	GASSRAT	T	QQVYSPPH	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	GKGNTHKPYGYVRYF DV

(continued)

Binder name	L-CDR1	pos.49	L-CDR2	pos. 85	L-CDR3	H-CDR1	pos.47	H-CDR2	H-CDR3
MS-Roche #7.12.H1	RASQYVFRRYLA	S	GSSNRAT	V	LQLYNIPN	GFTFSSYGMS	W	NINGNGNRKYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.12.L1	RASQYVFRRYLA	S	GSSNRAT	V	LQLYNIPN	GFTFSSYGMS	W	NISGSGSSTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.12.L2	RASQRFFYKYLA	S	GSSNRAT	V	LQLYNIPN	GFTFSSYGMS	W	NISGSGSSTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche#7.12.L3	RASQFVRRGFLA	S	GSSNRAT	V	LQLYNIPN	GFTFSSYGMS	W	NISGSGSSTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.12.L4	RASQRLKRSYLA	S	GSSNRAT	V	LQLYNIPN	GFTFSSYGMS	W	NISGSGSSTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.12.L5	RASQRLKRSYLA	S	GSSNRAT	V	LQLYNIPN	GFTFSSYGMS	W	NISGSGSSTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.12.L6	RASQYLWYRYLA	S	GSSNRAT	V	LQLYNIPN	GFTFSSYGMS	W	NISGSGSSTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #7.12.L7	RASQWIRKTYLA	S	GSSNRAT	V	LQLYNIPN	GFTFSSYGMS	W	NISGSGSSTYYADSVKG	GKGNTHKPYGYVRYF DV
MS-Roche #8	RASQSVSSSYLA	Y	GASSRAT	T	QQLSSFPF	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	LLSRGYNGYYHKFDV
MS-Roche #8.1	RASQSVSSSYLA	Y	GASSRAT	T	QQLSNYPP	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	LLSRGYNGYYHKFDV
MS-Roche #8.2	RASQSVSSSYLA	Y	GASSRAT	T	QQLSSYPP	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	LLSRGYNGYYHKFDV
MS-Roche #8.1.H1	RASQSVSSSYLA	Y	GASSRAT	T	QQLSNYPP	GFTFSSYAMS	W	AISRSGSNIYYADSVKG	LLSRGYNGYYHKFDV
MS-Roche #8.2.H1	RASQSVSSSYLA	Y	GASSRAT	T	QQLSSYPP	GFTFSSYAMS	W	AISITGRRKYYADSVKG	LLSRGYNGYYHKFDV
MS-Roche#8.2.H2	RASQSVSSSYLA	Y	GASSRAT	T	QQLSSYPP	GFTFSSYAMS	W	AISRTGSKTYADSVKG	LLSRGYNGYYHKFDV
MS-Roche #8.2.H4	RASQSVSSSYLA	Y	GASSRAT	T	QQLSSYPP	GFTFSSYAMS	W	ATSVKGKTYADSVKG	LLSRGYNGYYHKFDV
MS-Roche #8.2.L1	RASQRVSGRYLA	Y	GASSRAT	T	QQLSSYPP	GFTFSSYAMS	W	AISGSGGSTYYADSVKG	LLSRGYNGYYHKFDV
Sequences belonging to V _H 3 and V _K 3 HuCAL consensus sequences see Figure 1 A									

Example 6

Construction of HuCAL[®] immunoglobulin expression vectors

[0105] *Heavy chain cloning.* The multiple cloning site of pcDNA3.1+ (Invitrogen) was removed (*NheI/ApaI*), and a stuffer compatible with the restriction sites used for HuCAL[®] design was inserted for the ligation of the leader sequences (*NheI/EcoRI*), VH-domains (*MunI*), and the immunoglobulin constant regions (*BlpI/ApaI*). The leader sequence (EMBL 83133) was equipped with a Kozak sequence (Kozak, 1987). The constant regions of human IgG (PIR A02146), IgG4 (EMBL K01316), and serum IgA1 (EMBL J00220) were dissected into overlapping oligonucleotides with length of about 70 bases. Silent mutations were introduced to remove restriction sites non-compatible with the HuCAL[®] design. The oligonucleotides were spliced by overlap extension-PCR.

[0106] During sub-cloning from Fab into IgG, the VH DNA sequence of the Fab is cut out via Mfe I / Blp I and ligated into the IgG vector opened via EcoR I / bop I. Eco I (*g/aattc*) and Mfe I (*claatg*) share compatible cohesive ends (*aatt*) and the DNA sequence of the original Mfe I site in the Fab changes from: *claatg* to: *g/aattg* after ligation into the IgG expression vector, thereby destroying both Mfe I and EcoR I site, and thus also leading to an amino acid change from Q (codon: caa) to E (codon: gaa).

[0107] *Light chain cloning.* The multiple cloning site of pcDNA3.1/Zeo+ (Invitrogen) was replaced by two different stuffers. The κ -stuffer provided restriction sites for insertion of a κ -leader (*NheI/EcoRV*), HuCAL[®]-scFv V κ -domains (*EcoRV/BsiWI*), and the κ -chain constant region (*BsiWI/ApaI*). The corresponding restriction sites in the λ -stuffer were *NheI/EcoRV* (λ -leader), *EcoRV/HpaI* (V λ -domains), and *HpaI/ApaI* (λ -chain constant region). The κ -leader (EMBL Z00022) as well as the λ -leader (EMBL J00241) were both equipped with Kozak sequences. The constant regions of the human κ - (EMBL L00241) and λ -chain (EMBL M18645) were assembled by overlap extension-PCR as described above.

[0108] *Generation of IgG-expressing CHO-cells.* CHO-K1 cells were co-transfected with an equimolar mixture of IgG heavy and light chain expression vectors. Double-resistant transfectants were selected with 600 μ g/ml G418 and 300 μ g/ml Zeocin (Invitrogen) followed by limiting dilution. The supernatant of single clones was assessed for IgG expression by capture-ELISA. Positive clones were expanded in RPMI-1640 medium supplemented with 10% ultra-low IgG-FCS (Life Technologies). After adjusting the pH of the supernatant to 8.0 and sterile filtration, the solution was subjected to standard protein A column chromatography (Poros 20 A, PE Biosystems).

Example 7: Pepspot analysis with decapeptides

[0109] The following aminoacid sequence encompassing A β (1-42) was divided into 43 overlapping decapeptides with a frameshift of 1 aminoacid. ISEVKM¹DAEF RHDSGYEVHH QKLVFFAEDV GSNKGAIIGL MVGGVVI⁴²ATV IV (SEQ ID NO: 414). Accordingly, DAEF RHDSGYEVHH QKLVFFAEDV GSNKGAIIGL MVGGVVIA (SEQ ID NO: 27) as enclosed represents amino acids 1 to 42 of A β 4/ β -A4 peptide.

The 43 decapeptides were synthesized with N-terminal acetylation and C-terminal covalent attachment to a cellulose sheet ("pepspot") by a commercial supplier (Jerini BioTools, Berlin). The cellulose sheet is incubated for 2 hours on a rocking platform with monoclonal antibody (2 μ g/ml) in blocking buffer (50 mM Tris·HCl, 140 mM NaCl, 5 mM NaEDTA, 0.05% NP40 (Fluka), 0.25% gelatine (Sigma), 1% bovine serum albumine fraction V (Sigma), pH 7.4). The sheet is washed 3 times 3 minutes on a rocking platform with TBS (10 mM Tris·HCl, 150 mM NaCl, pH 7.5). It is then wetted with cathode buffer (25 mM Tris base, 40 mM 6-Aminohexane acid, 0.01% SDS, 20% methanol) and transferred to a semi-dry blotting stack with the peptide side facing a PVDF membrane (Biorad) of equal size.

The semi-dry blotting stack consists out of freshly wetted filter papers (Whatman No.3) slightly larger than the peptide sheet:

- 3 papers wetted with Cathode buffer
- the peptide sheet
- a sheet of PVDF membrane wetted with methanol
- 3 papers wetted with Anode buffer 1 (30mM Tris base, 20% methanol)
- 3 papers wetted with Anode buffer 2 (0.3 mM Tris base, 20% methanol)

[0110] The transfer is conducted at a current density between Cathode and Anode of 0.8 mA/cm² for 40 minutes which is sufficient to elute most of the antibody from the cellulose sheet and deposit it on the PVDF membrane. The PVDF membrane is then exchanged for a 2nd PVDF membrane and transferred for another 40 minutes to ensure complete elution from the cellulose sheet.

The PVDF membrane is immersed in blocking buffer for 10 minutes. Then HRP-labeled anti-human Ig H+L (Pierce) is added at 1:1000 dilution and the membrane is incubated on a rocking platform for 1 hour. It is washed 3x10 minutes

with TBST (TBS with 0.005% Tween20). Color is developed by immersing the membrane into a solution made of 3 mg 4-chloronaphthol dissolved in 9 ml methanol with 41 ml PBS (20 mM Na-phosphate, 150 mM NaCl, pH 7.2) and 10 μ l 30% hydrogen peroxide (Merck). After the development of blue-black spots the membrane is washed extensively with water and dried.

The assignment of antibody-reactive pepspots is made by visual inspection through a transparent spot matrix. The epitopes of the antibody in question is defined as the minimal amino acid sequence in reactive peptides. For comparison mouse monoclonal antibodies (BAP-2, BAP-1, BAP-17 BAP-21, BAP-24, and 4G8) are analyzed in the same way, except using HRP-labeled anti-mouse Ig instead of anti-human Ig.

[0111] It is of note that affinity maturation and conversion of the monovalent Fab fragments into full-length IgG1 antibodies results usually in some broadening of the epitope recognition sequence as indicated by pepspot and ELISA analyses. This may be related to the recruitment of more contact points in the antibody-antigen interaction area as a consequence of the affinity maturation or to a stronger binding to the minimal epitope such that also weak interactions with adjacent amino acid can be detected. The latter may be the case when A β -derived peptides are probed with full-length IgG antibodies. As illustrated in Table 2 for the pepspot analysis, the recognition sequences of the N-terminal and middle epitopes are extended by up to three amino acids when parent Fabs and corresponding fully matured IgG antibodies are compared. However, it has to be kept in mind that the decapeptides are modified for covalent attachment at the C-terminal amino acid and this amino acid may therefore not easily be accessible to the full-length antibody due to steric hindrance. If this is the case the last C-terminal amino acid does not significantly contribute to the epitope recognition sequence and a potential reduction of the minimal recognition sequence by one amino acid at the C-terminal end has to be considered in the pepspot analysis as used in the present invention.

Table 2: Pepspot analysis of binding Fabs and full-length IgG antibodies to decapeptides on a cellulose sheet. The numbers refer to the essential amino acids from the A β 1-40 sequence which have to be present in the decapeptide for optimal binding of antibody. A weak peptide reactivity, and hence a weak contribution to the epitope, is indicated by brackets.

antibody	position	position
MSR-3 Fab	3-4	18-23
MSR-7 Fab	3-5	19-24
MSR-8 Fab	4-5	18-21
MSR-9 Fab	(1)3-9	18-24
MSR-10 Fab	(4-10)	19-20
MSR-11 Fab	3-7	(18-20)
MSR-26 Fab	3-5	(16)-19-23
MSR-27 Fab	(3)6-9	13-18(20)
MSR-29 Fab		14-16(20)
MSR-37 Fab	(4-6)	(19-24)
MSR-41 Fab	3-7	(17-21)
MSR-42 Fab	(4-9)	(18-24)
MSR 3.4.H7 IgG1	1-3	19-26
MSR 7.9.H2 IgG1	1-4	19-24
MSR 7.9.H7 IgG1	4-6	19-26
MSR 7.2.H2x7.2.L IgG1	(1-4) 5-9	18-26
MSR 7.11.H1x7.2.L1 IgG1	4-6	19-26
BAP-2	4-6	
4G8		19-20(23)
BAP-21		32-34

(continued)

antibody	position	position
BAP-24		38-40
BAP-1	4-6	
BAP-17		38-40

Example 8: Determination of K_D values for MS-R Fab and MS-R IgG1 antibody binding to A β 1-40 and A β 1-42 fibers *in vitro* by surface plasmon resonance (SPR)

[0112] Binding of anti-A β antibodies (Fabs and IgG1) to fibrillar A β was measured online by surface plasmon resonance (SPR), and the affinities of the molecular interactions were determined as described by Johnson, Anal. Biochem. 1991, 198, 268 - 277, and Richalet-Sécordel, Anal. Biochem. 1997, 249, 165 - 173. Biacore2000 and Biacore3000 instruments were used for these measurements. A β 1-40 and A β 1-42 fibers were generated *in vitro* by incubation of synthetic peptides at a concentration of 200 μ g/ml in 10 mM Na-acetat buffer (pH 4.0) for three days at 37°C. Electron microscopic analysis confirmed a fibrillar structure for both peptides, A β 1-40 showing predominantly shorter (< 1 micron) and A β 1-42 predominantly longer (> 1 micron) fibers. These fibers are assumed to represent aggregated A β peptides in human AD brain more closely than ill-defined mixtures of amorphous aggregates and unstructured precipitates. The fibers were diluted 1:10 and directly coupled to a "Pioneer Sensor Chip F1" as described in the Instruction Manual of the manufacturer (BIAApplication Handbook, version AB, Biacore AB, Uppsala, 1998). In initial experiments it was found that selected MS-Roche Fabs differed substantially in their reaction kinetics and therefore the mode of data analysis had to be chosen accordingly. For binders with slow kinetics K_D values were calculated by curve fitting of the time-dependent sensor responses, i. e. from the ratio of k_{off}/k_{on} . Binders with fast kinetics were analyzed by fitting the concentration-dependent sensor responses at equilibrium (adsorption-isotherms). K_D values were calculated from the Biacore sensograms based on the total Fab concentration as determined by a protein assay. For the clones derived from the 1st and 2nd affinity maturation cycle the content of active Fab in each preparation was determined in the Biacore according to a method described by Christensen, Analytical Biochemistry (1997) 249, 153 -164. Briefly, time-dependent protein binding to A β 1-40 fibers immobilized on the Biacore chip was measured during the association phase under mass-limited conditions at different flow rates of the analyte solution. The conditions of mass limitation were realized by immobilizing high amounts of A β fibers (2300 response units) on the chip surface of a measuring channel and by working at relatively low analyte concentrations, i. e. 160 nM (based on the total Fab protein concentration).

A summary of the K_D values of selected MS-Roche clones identified in the primary screen of the HuCAL library and their corresponding matured derivatives after the 1st and 2nd affinity maturation cycle is shown in Table 3. In the 1st affinity maturation cycle the heavy chain CDR3 (VH-CDR3) was kept constant and optimization was focussed on diversification of the light chain CDR3 (VL-CDR3). In the 2nd affinity cycle diversification of VL-CDR1 and VH-CDR2 was performed. Some of the binders from the 1st maturation cycle were converted to full-length human IgG1 antibodies according to the technology developed by MorphoSys as described in Example 6 and K_D values determined in the Biacore as described above. The K_D values for full-length IgG1 binding to A β 1-40 and A β 1-42 fibers are shown in Table 4.

[0113] Matured derivatives from both the L-CDR1 as well as H-CDR2 library after the 2nd maturation cycle were identified and allowed combination of light and heavy chains. The cross-cloning strategy is described in Example 13. Either whole light chains, LCDR1 or L-CDR1+2 were exchanged. K_D values of selected cross-cloned Fabs are shown in Table 8.

Some of the Fabs from the 1st and 2nd maturation cycles and from the cross-cloned binders were converted to full-length human IgG1 antibodies according to the technology developed by MorphoSys as described in Example 6. K_D values of IgG binding to A β 1-40 and A β 1-42 fibers were determined in the Biacore. Briefly, a kinetic model for the stepwise formation of a bivalent complex was used, and K_D values were calculated by Scatchard type analysis of equilibrium binding. Due to the very slow association process at low antibody concentration (several hours to reach equilibrium) equilibrium binding data were obtained by extrapolation of the association curves to long time intervals. The on- and off rates for the formation of the monovalent and bivalent complex were determined via the curve fit procedure and used for the extrapolation. Based on these R_{eq} values a Scatchard analysis was performed and K_D values for the formation of the monovalent and the bivalent complex were determined. The data are summarized in Table 5. From the curvilinear Scatchard plot a higher (bivalent) and lower (monovalent) affinity interaction was derived for the MS-R IgGs derived from the 2nd affinity maturation cycle and cross-clones. These two affinities represent the lower and upper K_D values of the range indicated in Table 5. **Table 3**

Table 3: K_D values for MS-R Fab binding to A β 1-40 and A β 1-42 fibers as determined in the Biacore. For the clones derived from the 1st and 2nd affinity maturation cycle the values are corrected for the content of active Fab present in each sample as described in the text. ^a, values were calculated from the concentration-dependent sensor responses at equilibrium; n.d., not determined.

Secreted clones from	M S-R #	K_D A β 1-40 nM	K_D A β 1-42 nM	M S-R #	K_D A β 1-40 nM	K_D A β 1-42 nM	M S-R #	K_D A β 1-40 nM	K_D A β 1-42 nM
primary screen	3	930	1300	7	1100	1714	8	850	1000
1 st affinity maturation	3.2	52	240	7.2	22	58	8.1	24	42
	3.3	38	104	7.3	23	88	8.2	24	64
	3.4	32	103	7.4	28	103			
	3.6	40	68	7.9	31	93			
				7.11	22	74			
				7.12	28	60			
2 nd affinity maturation	3.2H1	4.4	3.3	7.2H1	9.3	10.2	8.1H1	13.6	9.2
	3.2H2	5.2	1.1	7.2H2	8.2	8.2	8.2H1	1.6 ^a	2.1 ^a
	3.3H1	17.1	19.4	7.2H3	45.4	5.3	8.2H3	n.d.	3.1
	3.3H2	10.6	22.8	7.2H4	5.9	5.0	8.2H4	12.1	11.9
	3.3H3	1.4	3.3	7.2H5	8.0	10.1	8.2L1	4.8	3.7
	3.4H1	13.5	14.0	7.2H6	1.0	n.d.			
	3.4H3	6.7	8.4	7.2H7	15.5	8.1			
	3.4H4	33.0	43.0	7.2H8	1.5	2.1			
	3.4H5	26.5	36.0	7.2L1	13.3	12.7			
	3.4H6	49.0	60.0	7.2L2	5.6	4.0			
	3.4H7	19.2	31.7	7.2L4	1.1	1.1			
	3.4H8	10.7	26.5	7.3H1	8.0	11.2			
	3.4H9	21.7	18.6	7.3L1	4.5	6.0			
	3.4H10	8.1	10.1	7.4H1	8.0	6.6			
	3.4H11	19.5	8.3	7.4H2	9.9	6.2			
	3.4H12	25.5	27.0	7.9H1	4.9	5.4			
	3.4H13	32.3	18.8	7.9H2	5.0	5.7			
	3.4H14	13.3	16.8	7.9H3	4.2	2.8			
	3.4H16	25.5	15.6	7.9H4	4.8	4.2			
	3.4H17	2.0	4.3	7.9H5	1.7	1.8			
	3.4H18	17.1	10.0	7.9H6	1.2	1.2			
	3.4L7	9.3	9.3	7.9H7	1.0	0.9			
	3.4L8	6.2	13.0	7.9H8	0.8	0.7			
	3.4L9	16.3	9.1	7.9H9	0.9	0.9			
	3.4L11	5.3	2.6	7.9L1	1.0	1.1			
	3.6H1	18.9	23.1	7.9L2	1.0	0.5			
	3.6H2	19.8	54.0	7.11H1	12.7	6.7			
	3.6H3	5.4	7.5	7.11 H2	0.3	0.3			
	3.6H4	13.0	7.8	7.11H3	6.6	4.4			
	3.6H5	8.2	6.0	7.11H4	1.0	1.7			
	3.6H6	36.0	11.8	7.11 H5	3.4	1.7			
	3.6H8	2.5	2.5	7.11L1	1.1	1.2			

(continued)

Secreted clones from	M S-R #	K_D A β ₁₋₄₀ nM	K_D A β ₁₋₄₂ nM	M S-R #	K_D A β ₁₋₄₀ nM	K_D A β ₁₋₄₂ nM	M S-R #	K_D A β ₁₋₄₀ nM	K_D A β ₁₋₄₂ nM
	3.6L1	15.6	11.1	7.12H1	0.6	0.8			
	3.6L2	13.7	13.1	7.12L1	n.d.	3.8			
				7.12L2	4.0	5.4			
				7.12L3	0.8	0.9			
				7.12L4	2.0	0.6			
				7.12L5	0.8	0.6			
				7.12L6	n.d.	n.d.			
				7.12L7	n.d.	n.d.			

Table 4:

Table 4: K_D values for MS-R IgG1 binding to A β ₁₋₄₀ and A β ₁₋₄₂ fibers as determined in the Biacore. The IgGs were derived from MS-R Fabs selected after the 1st affinity maturation cycle. The values are corrected for the content of active MS-R IgGs present in each sample as described in the text.

MS-R #	K_D A β ₁₋₄₀ nM	K_D A β ₁₋₄₂ nM
3.3 IgG1	3.7	6.6
7.11 IgG1	2.3	5.7
7.12 IgG1	3.1	13.7
8.1 IgG1	6.6	12.3

Table 5: K_D values for MS-R IgG1 binding to A β ₁₋₄₀ and A β ₁₋₄₂ fibers as determined in the Biacore. The IgGs were derived from MS-R Fabs selected after the 1st and 2nd affinity maturation cycle and from crosscloned Fabs. The values are corrected for the content of active MS-R IgGs present in each sample as described in the text. The two K_D values given for MS-R IgGs derived from the 2nd affinity maturation step and cross-cloned binders represent higher and lower affinity interaction as calculated from the curvilinear Scatchard plots. With a number of additional MS-R IgGs (for example MS-R IgG 7.9.H2x7.12.L2 and MS-R IgG 7.9.H4x7.12.L2), complex curvilinear Scatchard blots were obtained and determination of K_D -values was therefore not possible.

Selected clones from	MS-R IgG1	K_D A β ₁₋₄₀ nM	K_D A β ₁₋₄₂ nM
1 st affinity maturation	3.3	3.7	6.6
	7.11	2.3	5.7
	7.12	3.1	13.7
	8.1	6.6	12.3
2 nd affinity maturation	3.4.H7	0.10-0.30	0.10-0.30
	7.2.H4	0.09-0.30	0.10-0.66
	7.9.H2	0.12-0.42	0.11-0.38
	7.9.H3	0.10-0.50	0.10-0.40
	7.9.H7	0.25-0.69	0.24-0.70
	7.12.L1	1.20-3.50	0.74-2.90
	8.2.H2	0.16-1.00	0.12-0.92
cross-cloned Fabs	3.6.H5x3.6.L2	0.20-1.03	0.20-0.95
	3.6.H8x3.6.L2	0.22-0.95	0.22-0.82
	7.4.H2x7.2.L1	0.12-0.63	0.12-0.56
	7.11.H1x7.2.L1	0.14-0.66	0.15-0.67
	7.11.H1x7.11.L1	0.11-0.70	0.13-0.70

Example 9: Staining of genuine human amyloid plaques in brain sections of an Alzheimer's Disease patient by indirect immunofluorescence

[0114] Selected MS-Roche Fabs and full-length IgG1 were tested for binding to β -amyloid plaques by immunohistochemistry analysis. Cryostat sections of unfixed tissue from human temporal cortex (obtained postmortem from a patient that was positively diagnosed for Alzheimer's disease) were labeled by indirect immunofluorescence using MS-Roche Fabs or full-length human IgG1 antibodies at various concentrations. Fabs and IgG1 antibodies were revealed by goat anti-human affinity-purified F(ab')₂ fragment conjugated to Cy3 and goat anti-human (H+L) conjugated to Cy3, respectively. Both secondary reagents were obtained from Jackson Immuno Research. Controls included an unrelated Fab and the secondary antibodies alone, which all gave negative results. Typical examples of plaque stainings with selected MS-Roche Fabs and MS-Roche IgG1 antibodies are shown in Figures 5 to 7.

Example 10: Polymerization Assay: Prevention of A β aggregation

[0115] Synthetic A β when incubated in aqueous buffer over several days spontaneously aggregates and forms fibrillar structures which are similar to those seen in amyloid deposits in the brains of Alzheimer's Disease patients. We have developed an *in vitro* assay to measure incorporation of biotinylated A β into preformed A β aggregates in order to analyze the A β -neutralizing potential of anti-A β antibodies and other A β -binding proteins such as albumin (Bohrmann et al., 1999, J. Biol. Chem. 274, 15990-15995). The effect of small molecules on A β aggregation can also be analyzed in this assay.

Experimental procedure:

[0116] NUNC Maxisorb microtiter plates (MTP) are coated with a 1:1 mixture of A β 1-40 and A β 1-42 (2 μ M each, 100 μ l per well) at 37°C for three days. Under these conditions highly aggregated, fibrillar A β is adsorbed and immobilized on the surface of the well. The coating solution is then removed and the plates are dried at room temperature for 2-4 hours. (The dried plates can be stored at -20°C). Residual binding sites are blocked by adding 300 μ l/well phosphate-buffered saline containing 0.05 % Tween 20 (T-PBS) and 1 % bovine serum albumin (BSA). After 1-2 hours incubation at room temperature the plates are washed 1 x with 300 μ l T-PBS. A solution of 20 nM biotinylated A β 1-40 in 20 mM Tris-HCl, 150 mM NaCl pH 7.2 (TBS) containing 0.05 % NaN₃ and serially diluted antibody is added (100 μ l/well) and the plate incubated at 37°C overnight. After washing 3 x with 300 μ l T-PBS a streptavidin-POD conjugate (Roche Molecular Biochemicals), diluted 1:1000 in T-PBS containing 1% BSA, is added (100 μ l/well) and incubated at room temperature for 2 hours. The wells are washed 3 x with T-PBS and 100 μ l/well of a freshly prepared tetramethyl-benzidine (TMB) solution are added. [Preparation of the TMB solution: 10 ml 30 mM citric acid pH 4.1 (adjusted with KOH) + 0.5 ml TMB (12 mg TMB in 1 ml acetone + 9 ml methanol) + 0.01 ml 35 % H₂O₂]. The reaction is stopped by adding 100 μ l/well 1 N H₂SO₄ and absorbance is read at 450 nm in a microtiter plate reader.

Result:

[0117] Figure 8 shows that MS-Roche IgG1 antibodies prevented incorporation of biotinylated A β 1-40 into preformed A β 1-40/A β 1-42 aggregates. The A β -neutralizing capacity of these full-length human IgGs was similar to that of the mouse monoclonal antibody BAP-1 which had been generated by a standard immunization procedure and specifically recognizes amino acid residues 4-6 of the A β peptide when analyzed by the Pepspot technique as described in example 7. Mouse monoclonal antibody BAP-2 which also reacts exclusively with amino acids 4-6 (Brockhaus, unpublished) was significantly less active in this assay. An even lower activity was found with the A β 1-40 C-terminal specific antibody BAP-17 (Brockhaus, Neuroreport 9 (1998), 1481-1486) and the monoclonal antibody 4G8 which recognizes an epitope between position 17 and 24 in the A β sequence (Kim, 1988, Neuroscience Research Communication Vol. 2, 121-130). BSA at a concentration of up to 10 μ g/ml did not affect incorporation of biotinylated A β and served as a negative control. However, at higher concentrations, i. e. > 100 μ g/ml, BSA has been reported to inhibit binding of biotinylated A β into preformed A β fibers (Bohrmann, (1999) J Biol Chem 274 (23), 15990-5) indicating that the interaction of BSA with A β is not of high affinity.

Example 11: De-polymerization Assay: Release of biotinylated A β from aggregated A β

[0118] In a similar experimental setup we have tested the potential of MS-Roche IgG antibodies to induce depolymerization of aggregated A β . Biotinylated A β 1-40 was first incorporated into preformed A β 1-40/A β 1-42 fibers before treatment with various anti-A β antibodies. Liberation of biotinylated A β was measured using the same assay as described in the polymerization assay.

Experimental procedure:

[0119] NUNC Maxisorb microtiter plates (MTP) are coated with a 1:1 mixture of A β 1-40 and A β 1-42 as described in the polymerization assay. For incorporation of biotinylated A β the coated plates are incubated with 200 μ l/well 20 nM biotinylated A β 1-40 in TBS containing 0.05 % NaN₃ at 37°C overnight. After washing the plate with 3 x 300 μ l/well T-PBS, antibodies serially diluted in TBS containing 0.05 % NaN₃ were added and incubated at 37°C for 3 hours. The plate was washed and analyzed for the presence of biotinylated A β 1-40 as described above.

Result:

[0120] Figures 9A to D shows that the inventive antibodies induced de-polymerization of aggregated A β as measured by the release of incorporated biotinylated A β 1-40. The MS-R antibodies and the mouse monoclonal antibody BAP-1 were similarly active whereas the BAP-2, BAP-17 and 4G8 antibodies were clearly less efficient in liberating biotinylated A β from the bulk of immobilized A β aggregates. BAP-1 can clearly be differentiated from the MS-R antibodies by its reactivity with cell surface full-length APP (see Figure 15), and antibodies like BAP-1 with such properties are not useful for therapeutic applications as potential autoimmunological reactions may be induced. It is interesting to note that BAP-2, despite its specificity for amino acid residue 4-6 which is exposed in aggregated A β has a clearly lower activity in this assay indicating that not all N-terminus specific antibodies a priori are equally efficient in releasing A β from preformed aggregates. The MS-Roche IgGs are clearly superior to BAP-2 with respect to the depolymerizing activity. The relatively low efficiency of BAP-17 (C-terminus-specific) and 4G8 (amino acid residues 16-24-specific) in this assay is due to the cryptic nature of these two epitopes in aggregated A β . As already noted in the polymerization assay, BSA at the concentrations used here had no effect on aggregated A β .

[0121] The MS-R antibodies derived from the 2nd affinity maturation cycle and from the cross-cloned binders show in general a higher efficacy in the de-polymerization assay (comparison of figure 9A with figures 9B and C), which is consistent with the increased binding affinity of these antibodies (see tables 3-5). The monoclonal antibodies AMY-33 and 6F/3D have been reported to prevent A β aggregation in vitro under certain experimental conditions (Solomon, (1996) Proc. Natl. Acad. Sci. USA 93, 452-455; AMY-33 and 6F/3D antibodies were obtained from Zymed Laboratories Inc., San Francisco (Order No. 13-0100) and Dako Diagnostics AG, Zug, Switzerland (Order No. M087201), respectively). As demonstrated in figure 9D both of these antibodies were completely inactive in the de-polymerization assay.

EXAMPLE 12: Epitope analysis by ELISA on peptide conjugates.

[0122] The following heptapeptides (single letter code) were obtained by solid-phase synthesis and purified by liquid chromatography using the techniques known in the art.

AEFRHDC
EFRHDSC
FRHDSGC
RHDSGYC
HDSGYEC
DSGYEVC
SGYEVHC
YEVHHQC
EVHHQKC
VHHQKLC
HHQKLVC
HQLVFC
QKLVFFC
KLVFFAC
LVFFAEC
VFFAEDC

FFAEDVC
 FAEDVGC
 AEDVGSC
 EDVGSNC
 DVGSNKC
 VGSNKGK
 GSNKGAC
 CSNKGAI
 CNKGAI
 CKGAIIG
 CGLMVGG
 CMVGGVV
 CGGVVIA

[0123] The peptides were dissolved in DMSO to arrive at 10 mM concentration.

[0124] Bovine Albumin (essentially fatty acid free BSA, Sigma Lot 112F-9390) was dissolved to 10 mg/ml in 0.1 M sodium bicarbonate and activated by addition per ml of 50 μ l of a 26 mg/ml solution of N-succinimidyl-maleimido propionate (NSMP, Pierce) in DMSO. After 15 minutes reaction at room temperature the activated BSA was purified by gel filtration (NAP-10, Pharmacia) in PBS with 0.1% sodium azide as solvent. 50 μ l of NSMP activated BSA (6.7 mg/ml) was diluted with 50 μ l of PBS, 0.1% sodium azide and 10 μ l of peptide solution (1 mM in DMSO) was added. As negative control activated BSA was mock-treated without peptide addition. After 4 hrs at room temperature the reaction was stopped by addition of 10 μ l of 10mM Cystein. An aliquot of the conjugate reaction mixture was diluted 1:100 with 0.1 M sodium bicarbonate buffer and immediately filled into the wells (100 μ l) of ELISA plates (Nunc Immuno-Plate). After standing 16 hrs at 4°C 100 μ l blocking buffer (as above) was added to each well and incubated for another 30 minutes. The plates were washed with 2x300 μ l/well TBST (as above) and filled with 100 μ l antibody at 10 μ g/ml or 2 μ g/ml in blocking buffer. The plates were kept 16 hours at 4°C and washed with 2x300 μ l TBST. 100 μ l/well HRP-conjugated anti-human Ig H+L (Pierce, dilution 1:1000 with blocking buffer) was added and incubated for 1 hour at ambient temperature. The plates were washed with 3x300 μ l/well TBST. Colour development was started by addition of 100 μ l tetramethyl benzidine/hydrogen peroxide reagent. The reaction was stopped after 5 minutes by addition of 100 μ l/well 1M sulfuric acid and the optical density is measured by an optical reader (Microplate Reader 3550, BioRad) at 450 nm. For comparison mouse monoclonal antibodies were analysed in the same way, except using as revealing agent HRP-labelled anti-mouse Ig instead of anti-human Ig.

[0125] Employing specific of the above described heptapeptides derived from A β , specific ELISA-tests as described herein above were carried out. Preferably, inventive antibodies comprise antibodies which show, as measured by of optical densities, a signal to background ratio above "10" when their reactivity with an A-beta derived peptide (AEFRHD; amino acid 2 to 7 of A-beta) is compared to an non-related protein/peptide like BSA. Most preferably, the ratio of optical densities is above "5" for a corresponding reaction with at least one of the following three A β derived peptides: (VFFAED; amino acid 18 to 23 of A β) or (FFAEDV; amino acid 19 to 24 of A β) or (LVFFAE; amino acid 17 to 22 of A β). Corresponding results for the inventive parental and/or maturated antibodies are shown in the following two tables:

Table 6: Reactivity of MS-R Fabs with BSA-conjugated Abeta heptapeptides 2-7 (AEFRHD), 17-22 (LVFFAE), 18-23 (VFFAED) and 19-24 (FFAEDV). The ratios of the ELISA read-out (optical density) obtained with peptide-conjugated and non-conjugated BSA are given. The signal intensities obtained with the 17-22, 18-23 and 19-24 peptides in relation to the 2-7 peptide are also indicated.

MS-R #	Peptide2-7	Peptide 17-22	Peptide 18-23	Peptide 19-24	Peptide- ratio	Peptide- ratio	Peptide- ratio
	2-7/BSA	17-22/BSA	18-23/BSA	19-24/BSA	17-22/2-7	18-23/2-7	19-24/2-7
7	24	4	7	4	0.17	0.29	0.17
8	28	10	29	25	0.36	1.04	0.89
7.2	34	12	16	9	0.35	0.47	0.26
7.3	34	11	15	9	0.32	0.44	0.26

EP 2 368 907 B1

(continued)

	MS-R #	Peptide2-7	Peptide 17-22	Peptide 18-23	Peptide 19-24	Peptide- ratio	Peptide- ratio	Peptide- ratio
		2-7/BSA	17-22/BSA	18-23/BSA	19-24BSA	17-22/2-7	18-23/2-7	19-24/2-7
5	7.4	36	10	13	6	0.28	0.36	0.17
	7.9	28	9	13	8	0.32	0.46	0.29
	7.11	37	11	15	9	0.30	0.41	0.24
10	7.12	38	6	8	7	0.16	0.21	0.18
	8.1	30	1	11	8	0.03	0.37	0.27
	8.2	32	4	28	23	0.13	0.88	0.72
15	3.2H2	26	12	23	20	0.46	0.88	0.77
	3.3H1	23	4	12	8	0.17	0.52	0.35
	3.3H3	31	2	5	2	0.06	0.16	0.06
	3.4H1	27	2	8	2	0.07	0.30	0.07
	3.4H2	16	11	1	1	0.69	0.06	0.06
20	3.4H3	22	9	17	11	0.41	0.77	0.50
	3.4H5	28	5	13	4	0.18	0.46	0.14
	3.4H7	24	2	6	5	0.08	0.25	0.21
	3.4H17	28	5	12	11	0.18	0.43	0.39
	3.4L11	31	6	20	5	0.19	0.65	0.16
25	3.6H6	25	1	4	7	0.04	0.16	0.28
	3.6H1	23	3	13	5	0.13	0.57	0.22
30	3.6H2	19	2	8	3	0.11	0.42	0.16
	7.2H1	38	8	11	9	0.21	0.29	0.24
	7.2H2	16	10	10	10	0.63	0.63	0.63
	7.2H3	33	17	20	18	0.52	0.61	0.55
	7.2H4	23	12	13	12	0.52	0.57	0.52
	7.2H5	30	13	18	15	0.43	0.60	0.50
	7.2L1	24	14	16	11	0.57	0.68	0.45
35	7.4H1	31	16	20	16	0.52	0.65	0.51
	7.4H2	36	17	20	16	0.47	0.56	0.46
	7.9H1	32	7	12	6	0.23	0.36	0.19
	7.9H2	35	3	6	8	0.08	0.16	0.23
40	7.9H3	35	11	20	9	0.31	0.57	0.27
	7.9H4	30	10	15	7	0.32	0.49	0.22
	7.11H1	31	8	9	8	0.25	0.29	0.25
	7.11H2	34	10	12	14	0.29	0.36	0.41
	7.12L1	16	10	12	10	0.60	0.70	0.59
45	8.1H1	29	22	25	25	0.77	0.88	0.86
	8.2H1	22	7	23	20	0.34	1.05	0.94
	8.2L1	26	15	32	31	0.60	1.26	1.22

50

55

Table 7: Reactivity of MS-R IgGs and mouse monoclonal antibodies BAP-1, BAP-2, 4G8, 6E10 Amy-33 and 6F/3D with BSA-conjugated A β heptapeptides 2-7 (AEFRHD), 17-22 (LVFFAE), 18-23 (VFFAED) and 19-24 (FFAEDV). The ratios of the ELISA read-out (optical density) obtained with peptide-conjugated and non-conjugated BSA are given. The signal intensities obtained with the 17-22, 18-23 and 19-24 peptides in relation to the 2-7 peptide are also indicated. * this antibody is specific for sequence 8-17 and does not recognize N-terminal or middle epitope sequences.

MS-R IgG	AEFRHD	LVFFAE	VFFAED	FFAEDV	Peptide-ratio	Peptide-ratio	Peptide-ratio
#	2-7/BSA	17-22/BSA	18-23/BSA	19-24/BSA	17-22/2-7	18-23/2-7	19-24/2-7
3.3	17	11	16	11	0.65	0.94	0.65
7.12	19	11	13	11	0.58	0.68	0.58
8.1	16	7	16	14	0.44	1.00	0.88
3.4H7	22	3	16	15	0.14	0.73	0.68
7.9H2	13	5	8	6	0.38	0.62	0.46
7.9H3	13	6	8	6	0.46	0.62	0.46
7.9.H7	30	5	16	10	0.17	0.53	0.33
7.11H2	10	6	7	6	0.60	0.70	0.60
8.2.H2	18	10	15	14	0.56	0.83	0.78
3.6.H5x3.6.L2	11	7	9	8	0.64	0.82	0.73
7.11.H2x7.9.L	14	8	10	9	0.57	0.71	0.64
1 (L1)							
8.2.H2x8.2.L1	13	20	25	25	1.54	1.92	1.92
<i>Mouse mab</i>							
BAP-1	21	1	1	1	0.05	0.05	0.05
BAP-2	21	1	1	1	0.05	0.05	0.05
4G8	1	23	20	1	23	20	1
6E10	18	1	1	1	0.06	0.06	0.06
6F/3D*	1	1	1	1	1	1	1
Amy 33	16	2	1	3	0.13	0.06	0.19

EXAMPLE 13: Combination of optimized H-CDR2 and L-CDR1 by cross-cloning

[0126] The modular design of the HuCAL library allows exchange of complementarity determining regions (CDRs) of two different Fab encoding genes in a simple cloning step. For a further improvement of affinity the independently optimized H-CDR2 and L-CDR1 from matured clones with the same H-CDR3 were combined, because there was a high probability that this combination would lead to a further gain of affinity (Yang et al., 1995, J.Mol.Biol. 254, 392-403; Schier et al., 1996b, J.Mol.Biol. 263, 551-567; Chen et al., 1999, J.Mol.Biol. 293, 865-881). Whole light chains, or fragments thereof, were transferred from an L-CDR1 optimized donor clone to a H-CDR2 optimized recipient clone. Donor and recipient clones were only combined, if both carried identical H-CDR3 sequences. All donor and recipient clones carried the VH3-V κ 3 framework.

[0127] This was accomplished by transferring whole light chains from the L-CDR1-optimized donor clone to the H-CDR2-optimized recipient clone. Epitope specificity was conserved by only combining clones with the same H-CDR3. By light chain exchange a H-CDR2-optimized clone obtained only an optimized L-CDR1, if the exchange occurred between clones with the same L-CDR3. If the L-CDR3 of the clones to be combined was different, the H-CDR2-optimized clone acquired in addition to the optimized L-CDR1 another L-CDR3 (L-CDR2 remained the HuCAL consensus sequence (Knappik et al., 2000)) and when derivatives of MS-Roche #7.12 were used as donors of the light chain L-CDR1, 2 and 3 were exchanged in the H-CDR2-optimized acceptor clone. Three different cloning strategies were employed:

- 1) Using restriction endonucleases XbaI and SphI the whole antibody light chain fragment was excised from plasmid 1 (e.g. pMx9_Fab_MS-Roche#7.11.H1_FS) and the thereby obtained vector backbone was then ligated to the light chain fragment of plasmid 2 (e.g. pMx9_Fab_MS-Roche#7.2.L1_FS) generated by XbaI and SphI digest. Thereby a new plasmid (nomenclature: pMx9_Fab_MS-Roche#7.11.H1x7.2.L1_FS) was created encoding L-CDR1,2,3 of parental clone #7.2.L1 and H-CDR1,2,3 of parental clone #7.11.H1.

2) Using restriction endonucleases XbaI and Acc651 an L-CDR1 coding fragment was excised from plasmid 1 (e.g. pMx9_Fab_MS-Roche#7.11.H2_FS) and the thereby obtained vector backbone was then ligated to the L-CDR1 fragment of plasmid 2 (e.g. pMx9_Fab_MS-Roche#7.12.L1_FS) generated by XbaI and Acc65I. Thereby a new plasmid (nomenclature: pMx9_Fab_MS-Roche#7.11.H2x7.12.L1 (L-CDR1)_FS) was created encoding L-CDR1 of parental clone #7.12.L1 while L-CDR2,3 and H-CDR1,2,3 are derived from parental clone #7.11.H2.

3) Using restriction endonucleases XbaI and BamHI an L-CDR1 and L-CDR2 coding fragment was excised from plasmid 1 (e.g. pMx9_Fab_MS-Roche#7.11.H2_FS) and the thereby obtained vector backbone was then ligated to the L-CDR1 and L-CDR2 fragment of plasmid 2 (e.g. pMx9_Fab_MS-Roche#7.12.L1_FS) generated by XbaI and BamHI digest. Thereby a new plasmid (nomenclature: pMx9_Fab_MS-Roche#7.11.H2x7.12.L1 (L-CDR1+2)_FS) was created encoding L-CDR1 and L-CDR2 of parental clone #7.12.L1 while L-CDR3 and H-CDR1,2,3 are derived from parental clone #7.11.H2.

[0128] Illustrative examples for the different cloning strategies as well as for sequences donor and recipient clones are given in table 8.

[0129] After large scale expression and purification their affinities were determined on A β (1-40) fibers. Furthermore, K_D values for selected cross-cloned MS-R Fab/antibodies are given in appended Table 9.

Binder name	L-CDR1	pos. 49	L-CDR2	pos. 85	L-CDR3	H-CDR1	pos. 47	H-CDR2	H-CDR3
-------------	--------	---------	--------	---------	--------	--------	---------	--------	--------

↓
cloning strategy 1)

↓

MS-Roche #7.11.H1	RASQSVSSSYLA	Y	GASSRAT	T	QQVYSPPH	GTFSSYAMS	W	GINAAGFRTYYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #7.2.L1	RASQVVDRTYLA	Y	GASSRAT	T	QQIYSEPH	GTFSSYAMS	W	AISGSGSTYYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #7.11.H1x7.2.L1	RASQVVDRTYLA	Y	GASSRAT	T	QQIYSEPH	GTFSSYAMS	W	GINAAGFRTYYADSVKG	GKGNTHKPYGYVRYFDV

↓
cloning strategy 2)

↓

MS-Roche #7.11.H2	RASQSVSSSYLA	Y	GASSRAT	T	QQVYSPPH	GTFSSYAMS	W	AINANGYKKYYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #7.12.L1	RASQVVFRRYLA	S	GSSNRAT	V	LQLYNIPN	GTFSSYAMS	W	NISGSGSTYYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #7.11.H2x7.12.L1(LCDR1)	RASQVVFRRYLA	Y	GASSRAT	T	QQVYSPPH	GTFSSYAMS	W	AINANGYKKYYADSVKG	GKGNTHKPYGYVRYFDV

↓
cloning strategy 3)

↓

MS-Roche #7.11.H2	RASQSVSSSYLA	Y	GASSRAT	T	QQVYSPPH	GTFSSYAMS	W	AINANGYKKYYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #7.12.L1	RASQVVFRRYLA	S	GSSNRAT	V	LQLYNIPN	GTFSSYAMS	W	NISGSGSTYYADSVKG	GKGNTHKPYGYVRYFDV

MS-Roche #7.11.H2x7.12.L1(LCDR1+2)	RASQVVFRRYLA	S	GSSNRAT	T	QQWSPPH	GFTFSSYAMS	W	AINANGYKKYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #3.6H5x3.6L2	RASQSVSSSYLA	Y	GASSRAT	V	QQTYNYP	GFTFSSYAMS	W	AISESGTKRYADSVKG	LTHYARYRYFDV
	RASQFLSRYYLA	Y	GASSRAT	V	QQTYNYP	GFTFSSYAMS	W	AISSGSGSTYYADSVKG	LTHYARYRYFDV
	RASQFLSRYYLA	Y	GASSRAT	V	QQTYNYP	GFTFSSYAMS	W	AISESGTKRYADSVKG	LTHYARYRYFDV
MS-Roche #3.6H8	RASQSVSSSYLA	Y	GASSRAT	V	QQTYNYP	GFTFSSYAMS	W	AISEYSKFKYADSVKG	LTHYARYRYFDV
	RASQFLSRYYLA	Y	GASSRAT	V	QQTYNYP	GFTFSSYAMS	W	AISSGSGSTYYADSVKG	LTHYARYRYFDV
	RASQFLSRYYLA	Y	GASSRAT	V	QQTYNYP	GFTFSSYAMS	W	AISEYSKFKYADSVKG	LTHYARYRYFDV
MS-Roche #3.6H8x3.6L2									
MS-Roche #7.4.H2	RASQSVSSSYLA	Y	GASSRAT	V	QQIYNFPH	GFTFSSYAMS	W	AINYNGARIYYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #7.2.L1	RASQYVDRTYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AISSGSGSTYYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #7.4.H2x7.2.L1	RASQYVDRTYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AINYNGARIYYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #7.9H2	RASQSVSSSYLA	Y	GASSRAT	T	LQIYNMPI	GFTFSSYAMS	W	AINADGNRKYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #7.12L2	RASQRFFYKYLA	S	GSSNRAT	V	LQLYNIPN	GFTFSSYAMS	W	NISSGSGSTYYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #7.9H2x7.12L2	RASQRFFYKYLA	S	GSSNRAT	V	LQLYNIPN	GFTFSSYAMS	W	AINADGNRKYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #7.9H4	RASQSVSSSYLA	Y	GASSRAT	T	LQIYNMPI	GFTFSSYAMS	W	AINAVGMKKFYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #7.12.L2	RASQRFFYKYLA	S	GSSNRAT	V	LQLYNIPN	GFTFSSYAMS	W	NISSGSGSTYYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #7.9H4x7.12L2	RASQRFFYKYLA	S	GSSNRAT	V	LQLYNIPN	GFTFSSYAMS	W	AINAVGMKKFYADSVKG	GKGNTHKPYGYVRYFDV

MS-Roche #7.1H1	RASQSVSSSYLA	Y	GASSRAT	T	QQVYSPPH	GFTFSSYAMS	W	GINAAGFRTYYADSVKG	GKGNTHKPYGVRYFDV
MS-Roche #7.1L1	RASQRILRIYLA	Y	GASSRAT	T	QQVYSPPH	GFTFSSYAMS	W	AISSGGSTYYADSVKG	GKGNTHKPYGVRYFDV
Binder name	L-CDR1	pos.49	L-CDR2	pos. 85	L-CDR3	H-CDR1	pos.47	H-CDR2	H-CDR3
MS-Roche #7.1H1x7.1L1	RASQRILRIYLA	Y	GASSRAT	T	QQVYSPPH	GFTFSSYAMS	W	GINAAGFRTYYADSVKG	GKGNTHKPYGVRYFDV
MS-Roche #7.1H1	RASQSVSSSYLA	Y	GASSRAT	T	QQVYSPPH	GFTFSSYAMS	W	GINAAGFRTYYADSVKG	GKGNTHKPYGVRYFDV
MS-Roche #7.2L1	RASQVVDRTYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AISSGGSTYYADSVKG	GKGNTHKPYGVRYFDV
MS-Roche #7.1H1x7.2L1	RASQVVDRTYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	GINAAGFRTYYADSVKG	GKGNTHKPYGVRYFDV
MS-Roche #3.3H1	RASQSVSSSYLA	Y	GASSRAT	V	HQMSYPP	GFTFSSYAMS	W	VISEKSRFIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4L9	RASRRIHVYLA	Y	GASSRAT	T	QQTYDYPP	GFTFSSYAMS	W	AISSGGSTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.3H1x3.4L9	RASRRIHVYLA	Y	GASSRAT	T	QQTYDYPP	GFTFSSYAMS	W	VISEKSRFIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4H1	RASQSVSSSYLA	Y	GASSRAT	T	QQTYDYPP	GFTFSSYAMS	W	AISETSIKRYADSVKG	LTHYARYRYFDV
MS-Roche #3.4L9	RASRRIHVYLA	Y	GASSRAT	T	QQTYDYPP	GFTFSSYAMS	W	AISSGGSTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4H1x3.4L9	RASRRIHVYLA	Y	GASSRAT	T	QQTYDYPP	GFTFSSYAMS	W	AISETSIKRYADSVKG	LTHYARYRYFDV
MS-Roche #3.4H3	RASQSVSSSYLA	Y	GASSRAT	T	QQTYDYPP	GFTFSSYAMS	W	VISQIGRKIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4L7	RASQRLGRLYLA	Y	GASSRAT	T	QQTYDYPP	GFTFSSYAMS	W	AISSGGSTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4H3x3.4L7	RASQRLGRLYLA	Y	GASSRAT	T	QQTYDYPP	GFTFSSYAMS	W	VISQIGRKIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4H3	RASQSVSSSYLA	Y	GASSRAT	T	QQTYDYPP	GFTFSSYAMS	W	VISQIGRKIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4L9	RASRRIHVYLA	Y	GASSRAT	T	QQTYDYPP	GFTFSSYAMS	W	AISSGGSTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4H3x3.4L9	RASRRIHVYLA	Y	GASSRAT	T	QQTYDYPP	GFTFSSYAMS	W	VISQIGRKIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4H7	RASQSVSSSYLA	Y	GASSRAT	T	QQTYDYPP	GFTFSSYAMS	W	VISETGKNIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4L9	RASRRIHVYLA	Y	GASSRAT	T	QQTYDYPP	GFTFSSYAMS	W	AISSGGSTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4H7x3.4L9	RASRRIHVYLA	Y	GASSRAT	T	QQTYDYPP	GFTFSSYAMS	W	VISETGKNIYYADSVKG	LTHYARYRYFDV

MS-Roche #3.4H7	RASQSVSSSYLA	Y	GASSRAT	T	QQTYDYPP	GFTFSSYAMS	W	NISETGKNIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.4L7	RASQRLGRLYLA	Y	GASSRAT	T	QQTYDYPP	GFTFSSYAMS	W	AIISGSGSTYYADSVKG	LTHYARYRYFDV
Binder name	L-CDR1	pos.49	L-CDR2	pos. 85	L-CDR3	H-CDR1	pos.47	H-CDR2	H-CDR3
MS-Roche #3.4H7x3.4L7	RASQRLGRLYLA	Y	GASSRAT	T	QQTYDYPP	GFTFSSYAMS	W	NISETGKNIYYADSVKG	LTHYARYRYFDV
MS-Roche #3.6H5	RASQSVSSSYLA	Y	GASSRAT	V	QQIYNYP	GFTFSSYAMS	W	AIISGSKTKYYADSVKG	LTHYARYRYFDV
MS-Roche #3.6L1	RASQFIQRFYLA	Y	GASSRAT	V	QQIYNYP	GFTFSSYAMS	W	AIISGSGSTYYADSVKG	LTHYARYRYFDV
MS-Roche #3.6H5x3.6L1	RASQFIQRFYLA	Y	GASSRAT	V	QQIYNYP	GFTFSSYAMS	W	AIISGSKTKYYADSVKG	LTHYARYRYFDV
MS-Roche #7.2H2	RASQSVSSSYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AINGTGMKKYYADSVKG	GKGNTHKPYGVRYFDV
MS-Roche #7.2L1	RASQYVDRTYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AIISGSGSTYYADSVKG	GKGNTHKPYGVRYFDV
MS-Roche #7.2H2x7.2L1	RASQYVDRTYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AINGTGMKKYYADSVKG	GKGNTHKPYGVRYFDV
MS-Roche #7.4H2	RASQSVSSSYLA	Y	GASSRAT	V	QQIYNFPH	GFTFSSYAMS	W	AINYNGARIYYADSVKG	GKGNTHKPYGVRYFDV
MS-Roche #7.12L2	RASQRFYKYLA	S	GSSNRAT	V	LQLYNIPN	GFTFSSYAMS	W	NIISGSGSTYYADSVKG	GKGNTHKPYGVRYFDV
MS-Roche #7.4H2x7.12L2	RASQRFYKYLA	S	GSSNRAT	V	LQLYNIPN	GFTFSSYAMS	W	AINYNGARIYYADSVKG	GKGNTHKPYGVRYFDV
MS-Roche #7.9H2	RASQSVSSSYLA	Y	GASSRAT	T	LQIYNMIP	GFTFSSYAMS	W	AINADGNRKYADSVKG	GKGNTHKPYGVRYFDV
MS-Roche #7.2L1	RASQYVDRTYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AIISGSGSTYYADSVKG	GKGNTHKPYGVRYFDV
MS-Roche #7.9H2x7.2L1	RASQYVDRTYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AINADGNRKYADSVKG	GKGNTHKPYGVRYFDV
MS-Roche #7.11H2	RASQSVSSSYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AINANGYKYYADSVKG	GKGNTHKPYGVRYFDV
MS-Roche #7.2L1	RASQYVDRTYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AIISGSGSTYYADSVKG	GKGNTHKPYGVRYFDV
MS-Roche #7.11H2x7.2L1	RASQYVDRTYLA	Y	GASSRAT	T	QQIYSFPH	GFTFSSYAMS	W	AINANGYKYYADSVKG	GKGNTHKPYGVRYFDV
MS-Roche #7.9H2	RASQSVSSSYLA	Y	GASSRAT	T	LQIYNMIP	GFTFSSYAMS	W	AINADGNRKYADSVKG	GKGNTHKPYGVRYFDV

MS-Roche #7.12L1	RASQYVFRRYLA	S	GSSNRAT	V	LQLYNIPN	GFTFSSYGMS	W	NISGSGSSTYYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #7.9H2x7.12L1	RASQYVFRRYLA	S	GSSNRAT	V	LQLYNIPN	GFTFSSYAMS	W	AINADGNRKYADSVKG	GKGNTHKPYGYVRYFDV
Binder name	L-CDR1	pos.49	L-CDR2	pos. 85	L-CDR3	H-CDR1	pos.47	H-CDR2	H-CDR3
MS-Roche #7.11H2	RASQSVSSSYLA	Y	GASSRAT	T	QQVYSPPH	GFTFSSYAMS	W	AINANGYKKYYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #7.9L1	RASQRLSPRYLA	Y	GASSRAT	T	LQYNMPT	GFTFSSYAMS	W	AISGSGSSTYYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #7.11H2x7.9L1	RASQRLSPRYLA	Y	GASSRAT	T	LQYNMPT	GFTFSSYAMS	W	AINANGYKKYYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #8.1H1	RASQSVSSSYLA	Y	GASSRAT	T	QQLSNPP	GFTFSSYAMS	W	AISRSGSNYYADSVKG	LLSRGYNNGYTHKFDV
MS-Roche #8.2L1	RASQRVSGRYLA	Y	GASSRAT	T	QQLSSYP	GFTFSSYAMS	W	AISGSGSSTYYADSVKG	LLSRGYNNGYTHKFDV
MS-Roche #8.1H1x8.2L1	RASQRVSGRYLA	Y	GASSRAT	T	QQLSSYP	GFTFSSYAMS	W	AISRSGSNYYADSVKG	LLSRGYNNGYTHKFDV
MS-Roche #7.11H2	RASQSVSSSYLA	Y	GASSRAT	T	QQVYSPPH	GFTFSSYAMS	W	AINANGYKKYYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #7.12L1	RASQYVFRRYLA	S	GSSNRAT	V	LQLYNIPN	GFTFSSYGMS	W	NISGSGSSTYYADSVKG	GKGNTHKPYGYVRYFDV
MS-Roche #7.11H2x7.12L1	RASQYVFRRYLA	S	GSSNRAT	V	LQLYNIPN	GFTFSSYAMS	W	AINANGYKKYYADSVKG	GKGNTHKPYGYVRYFDV

Table 8 Arrows indicate the location of restriction enzyme sites used to digest corresponding plasmids

Table 9: K_D values for crosscloned MS-R Fab binding to A β 1-40 and A β 1-42 fibers as determined in the Biacore. The preparation of crosscloned Fabs is described in example 13. The K_D values were determined by kinetic curve fittings and corrected for the content of active Fab present in each sample as described in the text. Some of the Fabs were additionally purified by size exclusion chromatography or preparative ultracentrifugation to remove aggregated material. (L1), the H-CDR2-matured acceptor clone received only L-CDR1 from the L-CDR1 improved donor clone; (L1+2), the H-CDR2-matured acceptor clone received L-CDR1+2 from the L-CDR1 improved donor clone.

MS-R#	K_D A β 1-40 <i>nM</i>	K_D A β 1-42 <i>nM</i>
3.3H1x3.4L9	2.16	2.97
3.4H1x3.4L9	0.25	0.5
3.4H3x3.4L7	0.92	0.92
3.4H3x3.4L9	1.05	0.93
3.4H7x3.4L9	2.66	3.51
3.4H7x3.4L7	1.19	1.23
3.6H5x3.6L1	1.25	1.04
3.6H5x3.6L2	1.26	0.84
7.2H2x7.2L1	1.29	1.43
7.4H2x7.2L1	1.4	1.4
7.4H2x7.12L2	1.4	1.8
7.9H2x7.2L1(L1)	1.4	1.4
7.9H2x7.12L1	1.2	1.1
7.9H2x7.12L2(L1+2)	0.4	0.4
7.11H1x7.2L1	1.75	1.39
7.11H1x7.11L1	0.41	0.47
7.11H2x7.2L1(L1)	1	0.6
7.11H2x7.9L1 (L1)	0.1	1
8.1H1x8.2L1	1.3	1.6

Example 14: In vivo amyloid plaque decoration in a mouse model of Alzheimer's disease as revealed by confocal laser scanning microscopy and colocalization analysis.

[0130] Selected MS-R IgG1 antibodies were tested in APP/PS2 double transgenic mice (Reference: Richards et al., Soc. Neurosci. Abstr., Vol. 27, Program No. 5467, 2001) for amyloid plaque decoration in vivo. The antibodies (1 mg/mouse) were administered i.v. and after 3 days the brains were perfused with saline and prepared for cryosection. In another study the mice were exposed to higher concentrations of the antibodies, i.e. 2 mg injected i.v. at day 0, 3, and 6, and sacrificed at day nine. The presence of the antibodies bound to amyloid plaques was assessed on unfixed cryostat sections by double-labeled indirect immunofluorescence using goat anti-human IgG (H+L) conjugated to either Cy3 (#109-165-003, Jackson Immuno Research) followed by BAP-2-Alexa488 immunoconjugate. Imaging was done by confocal laser microscopy and image processing for quantitative detection of colocalizations by IMARIS and COLOCALIZATION software (Bitplane, Switzerland). Typical examples are shown in Figures 10-14. All of the MS-R antibodies tested were found positive in immunodecoration of amyloid plaques in vivo, although some variability was noted.

Example 15: Investigation of binding of different monoclonal antibodies to amyloid precursor protein (APP) on the surface of HEK293 cells:

[0131] APP is widely expressed in the central nervous system. Binding of antibody to cell surface APP may lead to complement activation and cell destruction in healthy brain areas. Therefore, it is mandatory for therapeutic A-beta antibodies to be devoid of reactivity towards APP. High affinity antibodies against the N-terminal domain of A-beta (e.g. BAP-1, BAP-2) recognize the respective epitope also in the framework of APP. In contrast, the antibodies against the middle epitope (e.g. 4G8), and the antibodies of the invention are surprisingly unable to recognize to cell surface APP. Thus, antibodies of the invention which decorate A-beta, but not APP in vivo, are superior to non-selective antibodies.

[0132] The method of flow cytometry is well known in the art. Relative units of fluorescence (FL1-H) measured by flow cytometry indicate cell surface binding of the respective antibody. A fluorescence shift on APP transfected HEK293

compared to untransfected HEK293 cells indicates the unwanted reaction with cell surface APP. As an example, antibodies BAP-1 and BAP-2 against the N-terminal domain show a significant shift of FL-1 signal in HEK293/APP (thick line) compared to untransfected HEK293 cells (dotted line). The 4G8 antibody (specific for the middle A-beta epitope) and all antibodies of the invention (specific for N-terminal and middle A-beta epitopes) show no significant shift in fluorescence. Differences in basal fluorescence between HEK293/APP and HEK293 cells are due to different cell size. A FACScan instrument was used in combination with the Cellquest Pro Software package (both Becton Dickinson).

Example 16: List of identified SEQ ID NOs relating to inventive antibody molecules

[0133] The appended table 10 relates to sequences as defined herein for some specific inventive antibody molecules.

Table 10: Identification of SEQ ID NOs for parental antibodies as well as optimized, matured and/or cross-cloned antibody molecules

Molecule #	VH prot	VL prot	VH DNA	VL DNA	HCDR3 prot	HCDR3 DNA	LCDR3 prot	LCDR3 DNA
3	4	10	3	9	22	21	16	15
7	6	12	5	11	24	23	18	17
8	8	14	7	13	26	25	20	19
3.6H5 x 3.6L2	33	47	32	46	61	60	75	74
3.6H8 x 3.6L2	35	49	34	48	63	62	77	76
7.4H2 x 7.2L1	37	51	36	50	65	64	79	78
7.9H2 x 7.12L2	39	53	38	52	67	66	81	80
7.9H4 x 7.12L2	41	55	40	54	69	68	83	82
7.11H1x7.11L1	43	57	42	56	71	70	85	84
7.11H1x7.2L1	45	59	44	58	73	72	87	86
7.9H7	89	91	88	90	93	92	95	94
3.3H1x3.4L9	295	325	294	324	355	354	385	384
3.4H1x3.4L9	297	327	296	326	357	356	387	386
3.4H3x3.4L7	299	329	298	328	359	358	389	388
3.4H3x3.4L9	301	331	300	330	361	360	391	390
3.4H7x3.4L9	303	333	302	332	363	362	393	392
3.4H7x3.4.7	305	335	304	334	365	364	395	394
3.6H5x3.6L1	307	337	306	336	367	366	397	396
7.2H2x7.2L1	309	339	308	338	369	368	399	398
7.4H2x7.12L2	311	341	310	340	371	370	401	400
7.9H2x7.2L1	313	343	312	342	373	372	403	402
7.9H2x7.12L1	315	345	314	344	375	374	405	404
7.11H2x7.2L1	317	347	316	346	377	376	407	406
7.11H2x7.9L1	319	349	318	348	379	378	409	408
7.11H2x7.12L1	321	351	320	350	381	380	411	410
8.1H1x8.2L1	323	353	322	352	383	382	413	412

[0134] Furthermore, the invention provides the following items:

1. An antibody molecule capable of specifically recognizing two regions of the β -A4 peptide/A β 4, wherein the first

region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof.

2. The antibody molecule of item 1, wherein said antibody molecule recognizes at least two consecutive amino acids within the two regions of β -A4.

3. The antibody molecule of item 1 or 2, wherein said antibody molecule recognizes in the first region an amino acid sequence comprising: AEFRHD, EF, EFR, FR, EFRHDSG, EFRHD or HDSG and in the second region an amino acid sequence comprising: HHQKL, LV, LVFFAE, VFFAED or VFFA, FFAEDV.

4. The antibody molecule of any one of items 1 to 3, wherein said antibody molecule comprises a variable V_H -region as encoded by a nucleic acid molecule as shown in a SEQ ID NO selected from the group consisting of SEQ ID NO: 3, 5 or 7 or a variable V_H -region as shown in a SEQ ID NO: selected from the group consisting of SEQ ID NOs: 4, 6 and 8.

5. The antibody molecule of any one of items 1 to 3, wherein said antibody molecule comprises a variable V_L -region as encoded by a nucleic acid molecule as shown in a SEQ ID NO selected from the group consisting of SEQ ID NO: 9, 11 and 13 or a variable V_L -region as shown in a SEQ ID NO selected from the group consisting of SEQ ID NOs: 10, 12 and 14.

6. The antibody molecule of any one of items 1 to 5, wherein said antibody molecule comprises at least one CDR3 of an V_L -region as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 15, 17 or 19 or at least one CDR3 amino acid sequence of an V_L -region as shown in SEQ ID NOs: 16, 18 or 20 and/or wherein said antibody molecule comprises at least one CDR3 of an V_H -region as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 21, 23 or 25 or at least one CDR3 amino acid sequence of an V_H -region as shown in SEQ ID NOs: 22, 24 or 26.

7. The antibody molecule of any one of items 1 to 6, wherein said antibody is selected from the group consisting of MSR-3, -7 and -8 or an affinity-matured version of MSR-3, -7 or -8.

8. The antibody molecule of any one of items 1 to 7, wherein said antibody molecule is a full antibody (immunoglobulin), a F(ab)-fragment, a F(ab)₂-fragment, a single-chain antibody, a chimeric antibody, a CDR-grafted antibody, a bivalent antibody-construct, a synthetic antibody or a cross-cloned antibody.

9. The antibody molecule of any one of items 1 to 8, wherein said at least two regions of β -A4 form a conformational epitope or a discontinuous epitope.

10. The antibody molecule of item 8 or 9, wherein said cross-cloned antibody is selected from the group consisting of

MS-R #3.3H1x3.4L9;
MS-R #3.6H5 x 3.6L2;
MS-R #3.6H8 x 3.6L2;
MS-R #7.4H2 x 7.2L1;
MS-R #7.9H2 x 7.12L2;
MS-R #7.9H4 x 7.12L2;
MS-R#7.11H1 x 7.11L1;
MS-R #7.11H1x 7.2L1;
MS-R #3.4H1 x 3.4L9;
MS-R #3.4H3 x 3.4L7;
MS-R #3.4H3 x 3.4L9;
MS-R #3.4H7 x 3.4L9;
MS-R #3.4H7 x 3.4L7;
MS-R #3.6H5 x 3.6L1;
MS-R #7.2H2 x 7.2L1;
MS-R #7.4H2 x 7.12L2;
MS-R #7.9H2 x 7.2L1;
MS-R #7.9H2 x 7.12L1;
MS-R #7.11H2 x 7.2L1;

MS-R #7.11H2 x 7.9L1;
MS-R #7.11H2 x 7.12L1 or
MS-R #8.1H1 x 8.2L1.

- 5 11. A nucleic acid molecule encoding an antibody molecule of any one of items 1 to 10.
12. A vector comprising the nucleic acid molecule of item 11.
- 10 13. A host cell comprising the vector of item 12.
14. A method for the preparation of an antibody molecule of any one of items 1 to 10 comprising culturing the host cell of item 13 under conditions that allow synthesis of said antibody molecule and recovering said antibody molecule from said culture.
- 15 15. A composition comprising an antibody molecule of any one of items 1 to 10 or an antibody molecule produced by the method of item 14.
16. The composition of item 15, which is a pharmaceutical or a diagnostic composition.
- 20 17. Use of an antibody molecule of any one of items 1 to 10 or an antibody molecule produced by the method of item 14, of a nucleic acid molecule of item 11, of a vector of item 12 or a host of item 13 for the preparation of a pharmaceutical composition for the prevention and/or treatment of a disease associated with amyloidogenesis and/or amyloid-plaque formation.
- 25 18. Use of an antibody molecule of any one of items 1 to 10 or an antibody molecule produced by the method of item 14 for the preparation of a diagnostic composition for the detection of a disease associated with amyloidogenesis and/or amyloid-plaque formation.
- 30 19. Use of an antibody molecule of any one of items 1 to 10 or an antibody molecule produced by the method of item 14 for the preparation of a pharmaceutical composition for the disintegration of β -amyloid plaques.
20. Use of an antibody molecule of any one of items 1 to 10 or an antibody molecule produced by the method of item 14 for the preparation of a pharmaceutical composition for passive immunization against β -amyloid plaque formation.
- 35 21. The use of items 17 or 18, wherein said disease is dementia, Alzheimer's disease, motor neuropathy, Down's syndrome, Creutzfeld Jacob disease, hereditary cerebral hemorrhage with amyloidosis Dutch type, Parkinson's disease, HIV-related dementia, ALS or neuronal disorders related to aging.
- 40 22. Kit comprising an antibody molecule of any one of items 1 to 10, a nucleic acid molecule of item 16, a vector of item 17 or a host cell of item 18.
23. A method for the optimization of an antibody molecule as defined in any one of items 1 to 10 comprising the steps of
- 45 (a) constructing a library of diversified Fab antibody fragments derived from an antibody comprising at least one CDR3 of an V_H -region as encoded by a nucleic acid molecule as shown in SEQ ID NOs: 21, 23 or 25 or at least one CDR3 amino acid sequence of an V_H -region as shown in SEQ ID NOs: 22, 24 or 26;
- (b) testing the resulting Fab optimization library by panning against $A\beta/A\beta_4$;
- (c) identifying optimized clones; and
- 50 (d) expressing of selected, optimized clones.
24. The method of item 23 further comprising a step (ca), whereby the optimized clones are further optimized by cassette mutagenesis
- 55 25. The method of item 23 or 24, wherein said $A\beta/A\beta_4$ in step (b) is aggregated $A\beta/A\beta_4$.
26. The method of any one of items 23 to 25, wherein said identification in step (c) is carried out by koff-ranking.

EP 2 368 907 B1

27. A method for the preparation of a pharmaceutical composition comprising the steps of

- (a) optimization of an antibody according to the method of any one of items 23 to 26; and
- (b) formulating the optimized antibody/antibody molecule with an physiologically acceptable carrier.

28. A pharmaceutical composition prepared by the method of item 27.

SEQUENCE LISTING

[0135]

<110> F. Hoffmann-La Roche AG
MorphoSys AG

<120> Anti A-beta antibodies and their use

<130> F 2842 EP/1 S3

<140> EP 02003844.4

<141> 2002-02-20

<150> EP 02003844.4

<151> 2002-02-20

<160> 414

<170> PatentIn version 3.1

<210> 1

<211> 9

<212> PRT

<213> artificial sequence

<220>

<223> synthetic construct; first region of beta-A4 peptide

<400> 1

Ala Glu Phe Arg His Asp Ser Gly Tyr
1 5

<210> 2

<211> 14

<212> PRT

<213> artificial sequence

<220>

<223> synthetic construct ; second region of beta-A4 peptide

<400> 2

Val His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly
1 5 10

<210> 3

<211> 368

EP 2 368 907 B1

<212> DNA

<213> artificial sequence

<220>

5 <223> synthetic construct; VH-region of MS-Roche#3

<400> 3

```

10      caggtgcaat tgggtggaaag cggcgggcggc ctggtgcaac cgggcgggcag cctgcgtctg      60
      agctgcgcgg cctccggatt tacctttagc agctatgcga tgagctgggt gcgccaagcc      120

15      cctgggaagg gtctcgagtg ggtgagcgcg attagcggtg gcggcggcag cacctattat      180
      gcggatagcg tgaaaggccg ttttaccatt tcacgtgata attcgaaaaa caccctgtat      240
      ctgcaaatga acagcctgcg tgcggaagat acggccgtgt attattgcgc gcgtcttact      300
20      cattatgctc gttattatcg ttattttgat gtttggggcc aaggcaccct ggtgacggtt      360
      agctcagc                                     368

```

<210> 4

25 <211> 122

<212> PRT

<213> artificial sequence

<220>

30 <223> synthetic construct; VH-region of MS-Roche#3

<400> 4

35

40

45

50

55

EP 2 368 907 B1

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

5 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

10 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

15 Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

20 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

25 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

30 Ala Arg Leu Thr His Tyr Ala Arg Tyr Tyr Arg Tyr Phe Asp Val Trp
100 105 110

35 Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 5
<211> 379
<212> DNA
<213> artificial sequence

40 cagggtgcaat tgggtggaag cggcggcggc ctgggtgcaac cgggcggcag cctgcgtctg 60
agctgcgcgg cctccggatt tacctttagc agctatgcga tgagctgggt gcgccaagcc 120
45 cctgggaagg gtctcgagtg ggtgagcgcg attagcggta gcggcggcag cacctattat 180
gcggatagcg tgaaaggccg ttaccattt cacgtgataa ttcgaaaaac accctgtatc 240
50 tgcaaatagaa cagcctgcgt gcggaagata cggccgtgta ttattgcgcg cgtggtaagg 300
gtaataactca taagccttat ggttatgttc gttattttga tgtttggggc caaggcaccc 360
tggtgacggt tagctcagc 379

55 <210> 6
<211> 126
<212> PRT
<213> artificial sequence

EP 2 368 907 B1

<220>

<223> synthetic construct; VH-region of MS-Roche#7

<400> 6

5

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

10

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

15

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

20

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

25

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

30

Ala Arg Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr
100 105 110

Phe Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125

35

<210> 7

<211> 374

<212> DNA

<213> artificial sequence

40

<220>

<223> synthetic construct; VH-region of MS-Roche#8

<400> 7

45

caggtgcaat tgggtgaaag cggcggcggc ctggtgcaac cgggcggcag cctgcgtctg 60

agctgcgcgg cctccggatt taccttttagc agctatgcga tgagctgggt gcgccaagcc 120

50

cctgggaagg gtctcgagtg ggtgagcgcg attagcggtg gcggcggcag cacctattat 180

gcggatagcg tgaaaggccg ttttaccatt tcacgtgata attcgaaaaa caccctgtat 240

55

ctgcaaatga acagcctgcg tgcggaagat acggccgtgt attattgcgc gcgtcttctt 300

tctcgtgggtt ataatgggtt ttatcataag ttgatgttt ggggccaagg caccctgggtg 360

acggtttagct cagc 374

EP 2 368 907 B1

<210> 8
 <211> 124
 <212> PRT
 <213> artificial sequence

5

<220>
 <223> synthetic construct; VH-region of MS-Roche#8

<400> 8

10

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

20

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
 35 40 45

25

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

30

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

35

Ala Arg Leu Leu Ser Arg Gly Tyr Asn Gly Tyr Tyr His Lys Phe Asp
 100 105 110

Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

40

<210> 9
 <211> 330
 <212> DNA
 <213> artificial sequence

45

<220>
 <223> synthetic construct; VL-region of MS-Roche#3

<400> 9

50

55

EP 2 368 907 B1

gatatcgtgc tgacccagag cccggcgacc ctgagcctgt ctccgggcga acgtgcgacc 60
 ctgagctgca gagcgagcca gagcgtgagc agcagctatc tggcgtggta ccagcagaaa 120
 5 ccaggtcaag caccgctctc attaatattat ggcgcgagca gccgtgcaac tgggggtcccg 180
 gcgcgtttta gcggtctctg atccggcacg gattttaccc tgaccattag cagcctggaa 240
 cctgaagact ttgcggttta ttattgccag caggtttata atcctcctgt tacctttggc 300
 10 caggggtacga aagttgaaat taaacgtacg 330

<210> 10

<211> 110

15 <212> PRT

<213> artificial sequence

<220>

20 <223> synthetic construct; VL-region of MS-Roche#3

<400> 10

25 Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
 20 25 30

30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45

35 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
 50 55 60

40 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
 65 70 75 80

Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Val Tyr Asn Pro Pro
 85 90 95

45 Val Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
 100 105 110

<210> 11

50 <211> 330

<212> DNA

<213> artificial sequence

<220>

55 <223> synthetic construct; VL-region of MS-Roche#7

<400> 11

EP 2 368 907 B1

gatatcgtgc tgacccagag cccggcgacc ctgagcctgt ctccgggcga acgtgcgacc 60
 ctgagctgca gagcgagcca gagcgtgagc agcagctatc tggcgtggta ccagcagaaa 120
 5 ccagggtcaag caccgcgtct attaatattat ggcgcgagca gccgtgcaac tgggggtcccg 180
 ggcgcgtttta gcggtctctgg atccggcacg gattttaccc tgaccattag cagcctggaa 240
 cctgaagact ttgcgactta ttattgcttt cagctttatt ctgacccctt tacctttggc 300
 10 cagggtacga aagttgaaat taaacgtacg 330

<210> 12

<211> 110

15 <212> PRT

<213> artificial sequence

<220>

20 <223> synthetic construct; VL-region of MS-Roche#7

<400> 12

25 Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
 20 25 30

30 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45

35 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
 50 55 60

40 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
 65 70 75 80

45 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Phe Gln Leu Tyr Ser Asp Pro
 85 90 95

50 Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
 100 105 110

<210> 13

<211> 330

<212> DNA

<213> artificial sequence

55 <220>

<223> synthetic construct; VL-region of MS-Roche#8

EP 2 368 907 B1

<400> 13

```

gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggcga acgtgcgacc      60
5  ctgagctgca gagcgagcca gagcgtgagc agcagctatc tggcgtggta ccagcagaaa      120
ccaggtcaag caccgctctc attaatttat ggcgcgagca gccgtgcaac tgggggtccc      180
10 ggcggtttta ggggctctgg atccggcacg gattttaccc tgaccattag cagcctggaa      240
cctgaagact ttgcgactta ttattgccag cagctttctt cttttcctcc tacctttggc      300
caggggtacga aagttgaaat taaacgtacg      330

```

15 <210> 14
 <211> 110
 <212> PRT
 <213> artificial sequence

20 <220>
 <223> synthetic construct; VL-region of MS-Roche#8

<400> 14

```

25 Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
   1             5             10             15

30 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
   20             25             30

35 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
   35             40             45

40 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
   50             55             60

45 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
   65             70             75             80

50 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Leu Ser Ser Phe Pro
   85             90             95

   Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
   100             105             110

```

55 <210> 15
 <211> 24
 <212> DNA
 <213> artificial sequence

<220>
 <223> synthetic construct; CDR3 of VL-region of MS-Roche#3

EP 2 368 907 B1

<400> 15
 cagcagggtt ataatcctcc tgtt 24

5
 <210> 16
 <211> 8
 <212> PRT
 <213> artificial sequence

10
 <220>
 <223> synthetic construct; CDR3 of VL-region of MS-Roche#3

<400> 16

15
 Gln Gln Val Tyr Asn Pro Pro Val
 1 5

20
 <210> 17
 <211> 24
 <212> DNA
 <213> artificial sequence

25
 <220>
 <223> synthetic construct; CDR3 of VL-region of MS-Roche#7

<400> 17
 ttccagcttt attctgatcc tttt 24

30
 <210> 18
 <211> 8
 <212> PRT
 <213> artificial sequence

35
 <220>
 <223> synthetic construct; CDR3 of VL-region of MS-Roche#7

<400> 18

40
 Phe Gln Leu Tyr Ser Asp Pro Phe
 1 5

45
 <210> 19
 <211> 24
 <212> DNA
 <213> artificial sequence

50
 <220>
 <223> synthetic construct; CDR3 of VL-region of MS-Roche#8

<400> 19
 cagcagcttt ctcttttcc tctt 24

55
 <210> 20
 <211> 8
 <212> PRT
 <213> artificial sequence

<220>

EP 2 368 907 B1

<223> synthetic construct; CDR3 of VL-region of MS-Roche#8

<400> 20

5
Gln Gln Leu Ser Ser Phe Pro Pro
1 5

<210> 21

10 <211> 39

<212> DNA

<213> artificial sequence

<220>

15 <223> synthetic construct; CDR3 of VH-region of MS-Roche#3

<400> 21

cttactcatt atgctcgta ttatcgatat ttgatgtt 39

20 <210> 22

<211> 13

<212> PRT

<213> artificial sequence

25 <220>

<223> synthetic construct; CDR3 of VH-region of MS-Roche#3

<400> 22

30
Leu Thr His Tyr Ala Arg Tyr Tyr Arg Tyr Phe Asp Val
1 5 10

<210> 23

35 <211> 51

<212> DNA

<213> artificial sequence

<220>

40 <223> synthetic construct; CDR3 of VH-region of MS-Roche#7

<400> 23

ggtaagggtg atactcataa gccttatggt tatgttcgtt atttgatgt t 51

45 <210> 24

<211> 17

<212> PRT

<213> artificial sequence

50 <220>

<223> synthetic construct; CDR3 of VH-region of MS-Roche#7

<400> 24

55

EP 2 368 907 B1

Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp
1 5 10 15

5 Val

<210> 25

<211> 45

<212> DNA

10 <213> artificial sequence

<220>

<223> synthetic construct; CDR3 of VH-region of MS-Roche#8

15 <400> 25

ctctttctc gtggtataa tgggtattat cataagttg atgtt 45

<210> 26

<211> 15

20 <212> PRT

<213> artificial sequence

<220>

<223> synthetic construct; CDR3 of VH-region of MS-Roche#8

25 <400> 26

Leu Leu Ser Arg Gly Tyr Asn Gly Tyr Tyr His Lys Phe Asp Val
1 5 10 15

30

<210> 27

<211> 42

<212> PRT

35 <213> artificial sequence

<220>

<223> synthetic construct; beta-A4 peptide

40 <400> 27

Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
1 5 10 15

45

Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
20 25 30

50 Gly Leu Met Val Gly Gly Val Val Ile Ala
35 40

<210> 28

<211> 17

55 <212> DNA

<213> artificial sequence

<220>

<223> synthetic construct; VL-primer for

<400> 28

gtggtggttc cgatatc 17

5

<210> 29

<211> 43

<212> DNA

<213> artificial sequence

10

<220>

<223> synthetic construct; VL-primer back

<400> 29

15

agcgtcacac tcggtgcggc ttccggctgg ccaagaacgg tta 43

<210> 30

<211> 17

<212> DNA

<213> artificial sequence

20

<220>

<223> synthetic construct; control primer for

25

<400> 30

caggaaacag ctatgac 17

<210> 31

<211> 19

<212> DNA

<213> artificial sequence

30

<220>

<223> synthetic construct; control primer back

35

<400> 31

taccgttgct cttcacccc 19

<210> 32

<211> 360

<212> DNA

<213> artificial sequence

40

<220>

<223> synthetic construct; VH MS-Roche#3.6H5 x 3.6L2

45

<400> 32

50

55

EP 2 368 907 B1

caattggtgg aaagcggcgg cggcctggtg caaccgggcg gcagcctgcg tctgagctgc 60
 gcggcctccg gatttacctt tagcagctat gcgatgagct gggcgcgcca agcccctggg 120
 5 aaggggtctcg agtgggtgag cgctatttct gagtctggta agactaagta ttatgctgat 180
 tctgttaagg gtcgtttttac catttcacgt gataattcga aaaacaccct gtatctgcaa 240
 atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtct tactcattat 300
 10 gctcgttatt atcgttattt tgatgtttgg ggccaaggca ccctggtgac ggtagctca 360

<210> 33

<211> 120

<212> PRT

<213> artificial sequence

<220>

<223> synthetic construct; VH MS-Roche#3.6H5 x 3.6L2

<400> 33

Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
 1 5 10 15
 Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
 20 25 30
 Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala
 35 40 45
 Ile Ser Glu Ser Gly Lys Thr Lys Tyr Tyr Ala Asp Ser Val Lys Gly
 50 55 60
 Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
 65 70 75 80
 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
 85 90 95
 Leu Thr His Tyr Ala Arg Tyr Tyr Arg Tyr Phe Asp Val Trp Gly Gln
 100 105 110
 Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> 34

<211> 360

<212> DNA

<213> artificial sequence

EP 2 368 907 B1

<220>

<223> synthetic construct; VH MS-Roche#3.6H8 x 3.6L2

<400> 34

```

5      caattggtgg aaagcggcgg cggcctggtg caaccgggcg gcagcctgcg tctgagctgc      60
      gcggcctccg gatttacctt tagcagctat gcgatgagct ggggtgcgcca agcccctggg      120
10     aagggtctcg agtgggtgag cgctatttct gagtattcta agtttaagta ttatgctgat      180
      tctgttaagg gtcgttttac catttcacgt gataattcga aaaacaccct gtatctgcaa      240
      atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtct tactcattat      300
15     gctcgttatt atcgttattt tgatgtttgg ggccaaggca ccttggtgac ggttagctca      360

```

<210> 35

<211> 120

<212> PRT

<213> artificial sequence

<220>

<223> synthetic construct; VH MS-Roche#3.6H8 x 3.6L2

<400> 35

```

30     Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
      1           5           10          15

      Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
      20          25          30

35     Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala
      35          40          45

40     Ile Ser Glu Tyr Ser Lys Phe Lys Tyr Tyr Ala Asp Ser Val Lys Gly
      50          55          60

45     Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
      65          70          75          80

      Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
      85          90          95

50     Leu Thr His Tyr Ala Arg Tyr Tyr Arg Tyr Phe Asp Val Trp Gly Gln
      100         105         110

55     Gly Thr Leu Val Thr Val Ser Ser
      115         120

```

<210> 36

EP 2 368 907 B1

<211> 372
 <212> DNA
 <213> artificial sequence

5 <220>
 <223> synthetic construct; VH MS-Roche#7.4H2 x 7.2L1

<400> 36

```

10      caattggtgg aaagcggcgg cggcctggtg caaccgggcg gcagcctgcg tctgagctgc      60
      gcggcctccg gatttacctt tagcagctat gcgatgagct gggtgcgcca agcccctggg      120
      aagggtctcg agtgggtgag cgctattaat tataatggtg ctcgtattta ttatgctgat      180
15      tctgttaagg gtcgttttac catttcacgt gataattcga aaaacaccct gtatctgcaa      240
      atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtgg taagggtaat      300
20      actcataagc cttatggtta tggtcgttat tttgatgttt ggggccaagg caccctgggtg      360
      acggttagct ca                                          372
    
```

25 <210> 37
 <211> 124
 <212> PRT
 <213> artificial sequence

30 <220>
 <223> synthetic construct; VH MS-Roche#7.4H2 x 7.2L1

<400> 37

```

35      Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
      1          5          10          15

      Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
      20          25          30

      Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala
    
```

45

50

55

EP 2 368 907 B1

	35	40	45
5	Ile Asn Tyr Asn Gly Ala Arg Ile Tyr Tyr Ala Asp Ser Val Lys Gly		
	50	55	60
10	Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln		
	65	70	75
	Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg		
	85	90	95
15	Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp		
	100	105	110
20	Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser		
	115	120	
25	<210> 38		
	<211> 372		
	<212> DNA		
	<213> artificial sequence		
30	<220>		
	<223> synthetic construct; VH MS-Roche#7.9H2 x 7.12L2		
	<400> 38		
35	caattggtgg aaagcggcgg cggcctggtg caaccgggcg gcagcctgcg tctgagctgc	60	
	gcggcctccg gatttacctt tagcagctat gcgatgagct gggcgcgcca agcccctggg	120	
	aagggtctcg agtgggtgag cgctattaat gctgatggta atcgtaagta ttatgctgat	180	
40	tctgttaagg gtcgttttac catttcacgt gataattcga aaaacaccct gtatctgcaa	240	
	atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtgg taagggtaat	300	
	actcataagc cttatgggta tgttcggttat tttgatgttt ggggccaagg caccctgggtg	360	
45	acgggttagct ca	372	
50	<210> 39		
	<211> 124		
	<212> PRT		
	<213> artificial sequence		
	<220>		
	<223> synthetic construct; VH MS-Roche#7.9H2 x 7.12L2		
55	<400> 39		

EP 2 368 907 B1

Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
1 5 10 15

5 Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
20 25 30

10 Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala
35 40 45

Ile Asn Ala Asp Gly Asn Arg Lys Tyr Tyr Ala Asp Ser Val Lys Gly
50 55 60

15 Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
65 70 75 80

20 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
85 90 95

25 Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp
100 105 110

30 Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 40
<211> 372
<212> DNA
<213> artificial sequence

35 <220>
<223> synthetic construct; VH MS-Roche#7.9H4 x 7.12L2

40 <400> 40

caattggtgg aaagcggcgg cggcctggtg caaccgggcg gcagcctgcg tctgagctgc 60
gcggcctccg gatttacctt tagcagctat gcgatgagct gggcgcgcca agcccctggg 120
45 aagggtctcg agtgggtgag cgctattaat gctgttggtg tgaagaagtt ttatgctgat 180
tctgttaagg gtcgttttac catttcacgt gataattcga aaaacaccct gtatctgcaa 240
atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtgg taagggtaat 300
50 actcataagc cttatgggta tgttcggttat tttgatgttt ggggccaagg caccctgggtg 360
acgggttagct ca 372

55 <210> 41
<211> 124
<212> PRT
<213> artificial sequence

EP 2 368 907 B1

<220>

<223> synthetic construct; VH MS-Roche#7.9H4 x 7.12L2

<400> 41

5

Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
1 5 10 15

10

Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
20 25 30

15

Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala
35 40 45

20

Ile Asn Ala Val Gly Met Lys Lys Phe Tyr Ala Asp Ser Val Lys Gly
50 55 60

25

Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
65 70 75 80

Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
85 90 95

30

Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp
100 105 110

35

Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 42

<211> 372

<212> DNA

40

<213> artificial sequence

<220>

<223> synthetic construct; VH MS-Roche#7.11H1 x 7.11L1

45

<400> 42

50

55

EP 2 368 907 B1

caattggtgg aaagcggcgg cggcctggtg caaccgggcg gcagcctgcg tctgagctgc 60
 gcggcctccg gatttacctt tagcagctat gcgatgagct gggcgcgcca agccctggg 120
 5 aagggctctcg agtgggtgag cggtattaat gctgctggtt ttcgtactta ttatgctgat 180
 tctgttaagg gtcgttttac catttcacgt gataattcga aaaacaccct gtatctgcaa 240
 atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtgg taagggtaat 300
 10 actcataagc cttatgggta tggtcggttat tttgatgttt ggggccaagg caccctggtg 360
 acgggtagct ca 372

15 <210> 43
 <211> 124
 <212> PRT
 <213> artificial sequence

20 <220>
 <223> synthetic construct; VH MS-Roche#7.11H1 x 7.11L1

<400> 43

25 Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
 1 5 10 15

30 Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
 20 25 30

35 Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Gly
 35 40 45

40 Ile Asn Ala Ala Gly Phe Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly
 50 55 60

Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
 65 70 75 80

45 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
 85 90 95

50 Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp
 100 105 110

Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

55 <210> 44
 <211> 372
 <212> DNA
 <213> artificial sequence

EP 2 368 907 B1

<220>

<223> synthetic construct; VH MS-Roche#7.11H1 x 7.2L1

<400> 44

5

caattggtgg aaagcggcgg cggcctggtg caaccgggcg gcagcctgcg tctgagctgc 60

gcggcctccg gatttacctt tagcagctat gcgatgagct gggcgcgcca agcccctggg 120

10

aagggtctcg agtgggtgag cgggtattaat gctgctggtt ttcgtactta ttatgctgat 180

tctgttaagg gtcgtttttac catttcacgt gataattcga aaaacaccct gtatctgcaa 240

15

atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtgg taagggtaat 300

actcataagc cttatgggta tggtcgttat tttgatgttt ggggccaagg caccctgggtg 360

acggtagct ca 372

20

<210> 45

<211> 124

<212> PRT

<213> artificial sequence

25

<220>

<223> synthetic construct; VH MS-Roche#7.11H1 x 7.2L1

<400> 45

30

35

40

45

50

55

EP 2 368 907 B1

	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	Ser	Leu	
	1				5				10						15		
5	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr	Ala	Met	
				20					25					30			
10	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	Ser	Gly	
			35					40					45				
15	Ile	Asn	Ala	Ala	Gly	Phe	Arg	Thr	Tyr	Tyr	Ala	Asp	Ser	Val	Lys	Gly	
	50						55					60					
20	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr	Leu	Gln	
	65					70					75					80	
25	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Ala	Arg	
					85					90					95		
30	Gly	Lys	Gly	Asn	Thr	His	Lys	Pro	Tyr	Gly	Tyr	Val	Arg	Tyr	Phe	Asp	
				100					105					110			
35	Val	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser					
			115				120										
40																	
	<210> 46																
	<211> 330																
	<212> DNA																
	<213> artificial sequence																
45																	
	<220>																
	<223> synthetic construct; VL MS-Roche#3.6H5 x 3.6L2																
50																	
	<400> 46																
55																	
	gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggcga acgtgcgacc 60																
	ctgagctgca gagcgagcca gtttctttct cgttattatc tggcgtggta ccagcagaaa 120																
	ccaggtcaag caccgcgtct attaatattat ggcgcgagca gccgtgcaac tgggggtcccg 180																
	gcgcgtttta gcggctctgg atccggcacg gattttaccc tgaccattag cagcctggaa 240																
	cctgaagact ttgcggttta ttattgccag cagacttata attatcctcc tacctttggc 300																
	cagggtagca aagttgaaat taaacgtacg 330																
60																	
	<210> 47																
	<211> 110																
	<212> PRT																
	<213> artificial sequence																
65																	
	<220>																

EP 2 368 907 B1

<223> synthetic construct; VL MS-Roche#3.6H5 x 3.6L2

<400> 47

```

5      Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
      1              5              10              15

10     Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Phe Leu Ser Arg Tyr
      20              25              30

15     Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
      35              40              45

20     Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
      50              55              60

25     Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
      65              70              75              80

30     Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Thr Tyr Asn Tyr Pro
      85              90              95

35     Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
      100             105             110

```

<210> 48

<211> 330

<212> DNA

<213> artificial sequence

35

<220>

<223> synthetic construct; VL MS-Roche#3.6H8 x 3.6L2

<400> 48

40

```

      gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggcga acgtgcgacc      60
      ctgagctgca gagcgagcca gtttctttct cggtattatc tggcgtggta ccagcagaaa      120
45     ccagggtcaag caccgctctt attaatttat ggcgcgagca gccgtgcaac tgggggtccc      180
      gcgcgtttta gcggctcttg atccggcacg gattttaccc tgaccattag cagcctggaa      240
      cctgaagact ttgcggttta ttattgccag cagacttata attatcctcc tacctttggc      300
50     cagggtacga aagttgaaat taaacgtacg                                     330

```

<210> 49

<211> 110

<212> PRT

<213> artificial sequence

55

<220>

EP 2 368 907 B1

<223> synthetic construct; VL MS-Roche#3.6H8 x 3.6L2

<400> 49

```

5      Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
      1              5              10              15

10     Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Phe Leu Ser Arg Tyr
      20              25              30

15     Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
      35              40              45

20     Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
      50              55              60

25     Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
      65              70              75              80

30     Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Thr Tyr Asn Tyr Pro
      85              90              95

35     Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
      100             105             110

```

<210> 50

<211> 330

<212> DNA

<213> artificial sequence

35

<220>

<223> synthetic construct; VL MS-Roche#7.4H2 x 7.2L1

<400> 50

40

```

      gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggcga acgtgcgacc      60
      ctgagctgca gagcgagcca gtatgttgat cgtacttata tggcgtggta ccagcagaaa      120
45     ccagggtcaag caccgcgtct attaatattat ggcgcgagca gccgtgcaac tgggggtcccg      180
      gcgcgtttta gcggctcttg atccggcacg gattttaccc tgaccattag cagcctggaa      240
      cctgaagact ttgcgactta ttattgccag cagatttatt cttttcctca tacctttggc      300
50     cagggtacga aagttgaaat taaacgtacg                                     330

```

55

<210> 51

<211> 110

<212> PRT

<213> artificial sequence

<220>

EP 2 368 907 B1

<223> synthetic construct; VL MS-Roche#7.4H2 x 7.2L1

<400> 51

```

5      Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
      1              5              10              15

      Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Tyr Val Asp Arg Thr
10      20              25              30

      Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
      35              40              45

15      Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
      50              55              60

20      Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
      65              70              75              80

25      Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ile Tyr Ser Phe Pro
      85              90              95

      His Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
30      100              105              110

```

<210> 52

<211> 330

<212> DNA

<213> artificial sequence

35

<220>

<223> synthetic construct; VL MS-Roche#7.9H2 x 7.12L2

<400> 52

40

```

      gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggcga acgtgcgacc      60
      ctgagctgca gagcgagcca gcgttttttt tataagtatc tggcgtggta ccagcagaaa      120
45      ccaggtcaag caccgcgtct attaatctct ggttcttcta accgtgcaac tgggggtccc      180
      gcgcgtttta gcggctcttg atccggcacg gattttaccc tgaccattag cagcctggaa      240
      cctgaagact ttgcggttta ttattgcctt cagctttata atattcctaa tacctttggc      300
50      cagggtacga aagttgaaat taaacgtacg                                330

```

<210> 53

<211> 110

<212> PRT

<213> artificial sequence

55

<220>

EP 2 368 907 B1

<223> synthetic construct; VL MS-Roche#7.9H2 x 7.12L2

<400> 53

```

5      Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
      1           5           10           15

10     Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Phe Phe Tyr Lys
      20           25           30

15     Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
      35           40           45

20     Ile Ser Gly Ser Ser Asn Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
      50           55           60

25     Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
      65           70           75           80

30     Pro Glu Asp Phe Ala Val Tyr Tyr Cys Leu Gln Leu Tyr Asn Ile Pro
      85           90           95

35     Asn Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
      100          105          110

```

<210> 54

<211> 330

<212> DNA

<213> artificial sequence

<220>

<223> synthetic construct; VL MS-Roche#7.9H4 x 7.12L2

<400> 54

```

40      gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggcga acgtgcgacc      60
      ctgagctgca gagcgagcca gcgttttttt tataagtatc tggcgtggta ccagcagaaa      120
45      ccaggtcaag caccgcgtct attaatcttct ggttcttcta accgtgcaac tgggggtccc      180
      gcgcgtttta gcggctcttg atccggcacg gattttaccc tgaccattag cagcctggaa      240
      cctgaagact ttgcggttta ttattgcctt cagctttata atattcctaa tacctttggc      300
50      cagggtacga aagttgaaat taaacgtacg                                     330

```

<210> 55

<211> 110

<212> PRT

<213> artificial sequence

<220>

EP 2 368 907 B1

<223> synthetic construct; VL MS-Roche#7.9H4 x 7.12L2

<400> 55

```

5      Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
      1             5             10             15

10     Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Phe Phe Tyr Lys
      20             25             30

15     Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
      35             40             45

20     Ile Ser Gly Ser Ser Asn Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
      50             55             60

25     Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
      65             70             75             80

30     Pro Glu Asp Phe Ala Val Tyr Tyr Cys Leu Gln Leu Tyr Asn Ile Pro
      85             90             95

35     Asn Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
      100            105            110

```

<210> 56

<211> 330

<212> DNA

<213> artificial sequence

35

<220>

<223> synthetic construct; VL MS-Roche#7.11H1 x 7.11L1

<400> 56

40

```

      gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggcga acgtgcgacc      60
      ctgagctgca gagcgagcca gcgtattctt cgtattttatc tggcgtggta ccagcagaaa      120
45     ccaggtcaag caccgcgtct attaatattat ggcgcgagca gccgtgcaac tgggggtccc      180
      gcgcgtttta gcggctcttg atccggcacg gattttaccc tgaccattag cagcctggaa      240
      cctgaagact ttgcgactta ttattgccag cagggtttatt ctctctctca tacctttggc      300
50     cagggtacga aagttgaaat taaacgtacg                                330

```

<210> 57

<211> 110

<212> PRT

<213> artificial sequence

55

<220>

EP 2 368 907 B1

<223> synthetic construct; VL MS-Roche#7.11H1 x 7.11L1

<400> 57

```

5      Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
      1              5              10              15

10     Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Ile Leu Arg Ile
      20              25              30

15     Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
      35              40              45

20     Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
      50              55              60

25     Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
      65              70              75              80

30     Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Val Tyr Ser Pro Pro
      85              90              95

35     His Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
      100             105             110

```

<210> 58

<211> 330

<212> DNA

<213> artificial sequence

35

<220>

<223> synthetic construct; VL MS-Roche#7.11H1 x 7.2L1

<400> 58

40

```

      gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccggggcga acgtgcgacc      60
      ctgagctgca gagcgagcca gtatgttgat cgtacttata tggcgtggta ccagcagaaa      120
45     ccagggtcaag caccgcgtct attaatattat ggcgcgagca gccgtgcaac tgggggtcccg      180
      gcgcgtttta gcggctcttg atccggcacg gattttaccc tgaccattag cagcctggaa      240
      cctgaagact ttgcgactta ttattgccag cagatttatt cttttcctca tacctttggc      300
50     cagggtacga aagttgaaat taaacgtacg                                330

```

<210> 59

<211> 110

<212> PRT

<213> artificial sequence

55

<220>

EP 2 368 907 B1

<223> synthetic construct; VL MS-Roche#7.11H1 x 7.2L1

<400> 59

```

5      Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
      1              5              10              15

10     Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Tyr Val Asp Arg Thr
      20              25              30

15     Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
      35              40              45

20     Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
      50              55              60

25     Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
      65              70              75              80

30     Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ile Tyr Ser Phe Pro
      85              90              95

35     His Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
      100             105             110

```

<210> 60

<211> 39

<212> DNA

<213> artificial sequence

<220>

<223> HCDR3 MS-Roche#3.6H5 x 3.6L2

<400> 60

cttactcatt atgctcgta ttatcggtat ttgatgtt 39

<210> 61

<211> 13

<212> PRT

<213> artificial sequence

<220>

<223> HCDR3 MS-Roche#3.6H5 x 3.6L2

<400> 61

```

      Leu Thr His Tyr Ala Arg Tyr Tyr Arg Tyr Phe Asp Val
      1              5              10

```

<210> 62

<211> 39

<212> DNA

EP 2 368 907 B1

<213> artificial sequence
 <220>
 <223> HCDR3 MS-Roche#3.6H8 x 3.6L2
 5
 <400> 62
 cttactcatt atgctcggtta ttatcggttat ttgatgtt 39
 <210> 63
 10 <211> 13
 <212> PRT
 <213> artificial sequence
 <220>
 15 <223> HCDR3 MS-Roche#3.6H8 x 3.6L2
 <400> 63
 20 Leu Thr His Tyr Ala Arg Tyr Tyr Arg Tyr Phe Asp Val
 1 5 10
 <210> 64
 <211> 51
 25 <212> DNA
 <213> artificial sequence
 <220>
 <223> HCDR3 MS-Roche#7.4H2x7.2L1
 30 <400> 64
 ggtaagggtta atactcataa gccttatggt tatgttcgtt atttgatgt t 51
 <210> 65
 35 <211> 17
 <212> PRT
 <213> artificial sequence
 <220>
 40 <223> HCDR3 MS-Roche#7.4H2x7.2L1
 <400> 65
 45 Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp
 1 5 10 15
 Val
 50 <210> 66
 <211> 51
 <212> DNA
 <213> artificial sequence
 55 <220>
 <223> HCDR3 MS-Roche#7.9H2x7.12L2
 <400> 66

EP 2 368 907 B1

ggtaagggtg atactcataa gccttatggt tatgttcgtt atttgatgt t 51

<210> 67

<211> 17

<212> PRT

<213> artificial sequence

<220>

<223> HCDR3 MS-Roche#7.9H2x7.12L2

<400> 67

Gly	Lys	Gly	Asn	Thr	His	Lys	Pro	Tyr	Gly	Tyr	Val	Arg	Tyr	Phe	Asp
1				5					10					15	

Val

<210> 68

<211> 51

<212> DNA

<213> artificial sequence

<220>

<223> HCDR3 MS-Roche#7.9H4x7.12L2

<400> 68

ggtaagggtg atactcataa gccttatggt tatgttcgtt atttgatgt t 51

<210> 69

<211> 17

<212> PRT

<213> artificial sequence

<220>

<223> HCDR3 MS-Roche#7.9H4x7.12L2

<400> 69

Gly	Lys	Gly	Asn	Thr	His	Lys	Pro	Tyr	Gly	Tyr	Val	Arg	Tyr	Phe	Asp
1				5					10					15	

Val

<210> 70

<211> 51

<212> DNA

<213> artificial sequence

<220>

<223> HCDR3 MS-Roche#7.11H1x7.11L1

<400> 70

ggtaagggtg atactcataa gccttatggt tatgttcgtt atttgatgt t 51

<210> 71

<211> 17

EP 2 368 907 B1

<212> PRT
<213> artificial sequence

<220>

5 <223> HCDR3 MS-Roche#7.11H1x7.11L1

<400> 71

10 Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp
1 5 10 15

Val

15 <210> 72
<211> 51
<212> DNA
<213> artificial sequence

20 <220>
<223> HCDR3 MS-Roche#7.11H1x7.2L1

<400> 72

25 ggtaaggga atactcataa gccttatggt tatgttcgtt atttgatgt t 51

<210> 73
<211> 17
<212> PRT
<213> artificial sequence

30 <220>
<223> HCDR3 MS-Roche#7.11H1x7.2L1

<400> 73

35 Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp
1 5 10 15

40 Val

<210> 74
<211> 24
<212> DNA
45 <213> artificial sequence

<220>
<223> LCDR3 MS-Roche#3.6H5 x 3.6L2

50 <400> 74
cagcagactt ataattatcc tcct 24

<210> 75
<211> 8
55 <212> PRT
<213> artificial sequence

<220>

EP 2 368 907 B1

<223> LCDR3 MS-Roche#3.6H5 x 3.6L2

<400> 75

5
Gln Gln Thr Tyr Asn Tyr Pro Pro
1 5

<210> 76

10 <211> 24

<212> DNA

<213> artificial sequence

<220>

15 <223> LCDR3 MS-Roche#3.6H8 x 3.6L2

<400> 76

cagcagactt ataattatcc tcct 24

20 <210> 77

<211> 8

<212> PRT

<213> artificial sequence

25 <220>

<223> LCDR3 MS-Roche#3.6H8 x 3.6L2

<400> 77

30
Gln Gln Thr Tyr Asn Tyr Pro Pro
1 5

<210> 78

35 <211> 24

<212> DNA

<213> artificial sequence

<220>

40 <223> LCDR3 MS-Roche#7.4H2x7.2L1

<400> 78

cagcagattt attcttttcc tcat 24

45 <210> 79

<211> 8

<212> PRT

<213> artificial sequence

50 <220>

<223> LCDR3 MS-Roche#7.4H2x7.2L1

<400> 79

55
Gln Gln Ile Tyr Ser Phe Pro His
1 5

<210> 80

EP 2 368 907 B1

<211> 24
 <212> DNA
 <213> artificial sequence

5

<220>
 <223> LCDR3 MS-Roche#7.9H2x7.12L2

<400> 80
 cttcagcttt ataattattcc taat 24

10

<210> 81
 <211> 8
 <212> PRT
 <213> artificial sequence

15

<220>
 <223> LCDR3 MS-Roche#7.9H2x7.12L2

<400> 81

20

Leu Gln Leu Tyr Asn Ile Pro Asn
 1 5

25

<210> 82
 <211> 24
 <212> DNA
 <213> artificial sequence

30

<220>
 <223> LCDR3 MS-Roche#7.9H4x7.12L2

<400> 82
 cttcagcttt ataattattcc taat 24

35

<210> 83
 <211> 8
 <212> PRT
 <213> artificial sequence

40

<220>
 <223> LCDR3 MS-Roche#7.9H4x7.12L2

<400> 83

45

Leu Gln Leu Tyr Asn Ile Pro Asn
 1 5

50

<210> 84
 <211> 24
 <212> DNA
 <213> artificial sequence

55

<220>
 <223> LCDR3 MS-Roche#7.11H1x7.11L1

<400> 84

EP 2 368 907 B1

cagcagggttt attctcctcc tcat 24

<210> 85

<211> 8

<212> PRT

<213> artificial sequence

<220>

<223> LCDR3 MS-Roche#7.11H1x7.11L1

<400> 85

Gln Gln Val Tyr Ser Pro Pro His

1

5

<210> 86

<211> 24

<212> DNA

<213> artificial sequence

<220>

<223> LCDR3 MS-Roche#7.11H1x7.2L1

<400> 86

cagcagattt attcttttcc tcat 24

<210> 87

<211> 8

<212> PRT

<213> artificial sequence

<220>

<223> LCDR3 MS-Roche#7.11H1x7.2L1

<400> 87

Gln Gln Ile Tyr Ser Phe Pro His

1

5

<210> 88

<211> 378

<212> DNA

<213> artificial sequence

<220>

<223> synthetic construct; VH MS-Roche#7.9H7

<400> 88

EP 2 368 907 B1

```

caggtgcaat tgggtgaaaag cggcgggcggc ctggtgcaac cgggcggcag cctgcgtctg      60
agctgcgcgg cctccggatt taccttttagc agctatgcga tgagctgggt ggcccaagcc      120
5  cctgggaagg gtctcgagtg ggtgagcgct attaatgctt ctggtactcg tacttattat      180
gctgattctg ttaagggctg ttttaccatt tcacgtgata attcgaaaaa caccctgtat      240
ctgcaaataga acagcctgcg tgcggaagat acggccgtgt attattgcgc gcgtggtaag      300
10 ggtaataactc ataagcctta tggttatggt cgttattttg atgtttgggg ccaaggcacc      360
ctggtgacgg ttagctca      378

```

```

15 <210> 89
    <211> 126
    <212> PRT
    <213> artificial sequence

```

```

20 <220>
    <223> synthetic construct; VH MS-Roche#7.9H7

```

```

    <400> 89

```

```

25      Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
      1              5              10              15

```

```

30      Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
      20              25              30

```

```

35      Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
      35              40              45

```

```

40      Ser Ala Ile Asn Ala Ser Gly Thr Arg Thr Tyr Tyr Ala Asp Ser Val
      50              55              60

```

```

45      Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
      65              70              75              80

```

```

50      Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
      85              90              95

```

```

55      Ala Arg Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr
      100              105              110

```

```

      Phe Asp Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
      115              120              125

```

```

55 <210> 90
    <211> 330
    <212> DNA
    <213> artificial sequence

```

EP 2 368 907 B1

<220>

<223> synthetic construct; VL MS-Roche#7.9H7

<400> 90

```

5      gatatcgtgc tgacccagag cccggcgacc ctgagcctgt ctccggggcga acgtgcgacc      60
      ctgagctgca gagcgagcca gagcgtgagc agcagctatc tggcgtggta ccagcagaaa      120
10     ccaggtcaag caccgcgtct attaatattat ggcgcgagca gccgtgcaac tgggggtcccg      180
      ggcgcgtttta gcggtctctg atccggcacg gattttaccc tgaccattag cagcctggaa      240
15     cctgaagact ttgcgactta ttattgcctt cagatttata atatgcctat tacctttggc      300
      cagggtacga aagttgaaat taaacgtacg      330

```

<210> 91

<211> 110

<212> PRT

<213> artificial sequence

<220>

<223> synthetic construct; VL MS-Roche#7.9H7

<400> 91

```

30     Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
      1      5      10      15
      Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
      20      25      30
35     Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
      35      40      45
40     Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
      50      55      60
45     Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
      65      70      75      80
      Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Ile Tyr Asn Met Pro
      85      90      95
50     Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
      100      105      110

```

<210> 92

<211> 51

<212> DNA

<213> artificial sequence

EP 2 368 907 B1

<220>
 <223> synthetic construct; HCDR3 MS-Roche#7.9H7

<400> 92
 5 ggtaagggtg atactcataa gccttatggt tatgttcgtt atttgatgt t 51

<210> 93
 <211> 17
 <212> PRT
 10 <213> artificial sequence

<220>
 <223> synthetic construct; HCDR3 MS-Roche#7.9H7

15 <400> 93

	Gly	Lys	Gly	Asn	Thr	His	Lys	Pro	Tyr	Gly	Tyr	Val	Arg	Tyr	Phe	Asp
	1				5					10					15	

20 Val

<210> 94
 <211> 24
 25 <212> DNA
 <213> artificial sequence

<220>
 <223> synthetic construct; LCDR3 MS-Roche#7.9H7

30 <400> 94
 cttcagattt ataatatgcc tatt 24

<210> 95
 35 <211> 8
 <212> PRT
 <213> artificial sequence

<220>
 40 <223> synthetic construct; LCDR3 MS-Roche#7.9H7

<400> 95

	Leu	Gln	Ile	Tyr	Asn	Met	Pro	Ile
	1				5			

45

<210> 96
 <211> 12
 50 <212> PRT
 <213> artificial sequence

<220>
 <223> synthetic construct; LCDR1 of MS-Roche#3

55 <400> 96

EP 2 368 907 B1

Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala
1 5 10

5 <210> 97
<211> 7
<212> PRT
<213> artificial sequence

10 <220>
<223> synthetic construct; LCDR2 of MS-Roche#3

<400> 97

15 Gly Ala Ser Ser Arg Ala Thr

1 5

20 <210> 98
<211> 8
<212> PRT
<213> artificial sequence

25 <220>
<223> synthetic construct; LCDR3 of MS-Roche#3

<400> 98

30 Gln Gln Val Tyr Asn Pro Pro Val
1 5

35 <210> 99
<211> 10
<212> PRT
<213> artificial sequence

40 <220>
<223> synthetic construct; HCDR1 of MS-Roche#3

<400> 99

45 Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser
1 5 10

50 <210> 100
<211> 17
<212> PRT
<213> artificial sequence

55 <220>
<223> synthetic construct; HCDR2 of MS-Roche#3

<400> 100

EP 2 368 907 B1

Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

5 Gly

<210> 101

<211> 13

10 <212> PRT

<213> artificial sequence

<220>

<223> synthetic construct; HCDR3 of MS-Roche#3

15

<400> 101

Leu Thr His Tyr Ala Arg Tyr Tyr Arg Tyr Phe Asp Val
1 5 10

20

<210> 102

<211> 8

<212> PRT

25 <213> artificial sequence

<220>

<223> synthetic construct; LCDR3 of MS-Roche#3.1

30

<400> 102

Gln Gln Val Tyr Ser Val Pro Pro
1 5

35

<210> 103

<211> 8

<212> PRT

<213> artificial sequence

40

<220>

<223> synthetic construct; LCDR3 of MS-Roche#3.2

<400> 103

45

Gln Gln Ile Tyr Ser Tyr Pro Pro
1 5

50

<210> 104

<211> 8

<212> PRT

<213> artificial sequence

55

<220>

<223> synthetic construct; LCDR3 of MS-Roche#3.3

<400> 104

EP 2 368 907 B1

His Gln Met Ser Ser Tyr Pro Pro
1 5

5
<210> 105
<211> 8
<212> PRT
<213> artificial sequence

10
<220>
<223> synthetic construct; LCDR3 of MS-Roche#3.4

<400> 105

15 Gln Gln Thr Tyr Asp Tyr Pro Pro
1 5

20
<210> 106
<211> 8
<212> PRT
<213> artificial sequence

25
<220>
<223> synthetic construct; LCDR3 of MS-Roche#3.5

<400> 106

30 Gln Gln Ile Tyr Asp Tyr Pro Pro
1 5

35
<210> 107
<211> 8
<212> PRT
<213> artificial sequence

40
<220>
<223> synthetic construct; LCDR3 of MS-Roche#3.6

<400> 107

45 Gln Gln Thr Tyr Asn Tyr Pro Pro
1 5

50
<210> 108
<211> 17
<212> PRT
<213> artificial sequence

55
<220>
<223> synthetic construct; HCDR2 of MS-Roche#3.2H1

<400> 108

EP 2 368 907 B1

Ala Ile Ser Glu His Gly Leu Asn Ile Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

5 Gly

<210> 109

<211> 17

10 <212> PRT

<213> artificial sequence

<220>

15 <223> synthetic construct; HCDR2 of MS-Roche#3.2H2

<400> 109

20 Ala Ile Ser Gln Arg Gly Gln Phe Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

25 <210> 110
<211> 17

<212> PRT

<213> artificial sequence

30 <220>

<223> synthetic construct; HCDR2 of MS-Roche#3.3H1

<400> 110

35 Val Ile Ser Glu Lys Ser Arg Phe Ile Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

40 Gly

<210> 111

<211> 17

<212> PRT

45 <213> artificial sequence

<220>

<223> synthetic construct; HCDR2 of MS-Roche#3.3H2

<400> 111

50 Val Ile Ser Gln Glu Ser Gln Tyr Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

55 Gly

<210> 112

EP 2 368 907 B1

<211> 17
 <212> PRT
 <213> artificial sequence

5 <220>
 <223> synthetic construct; HCDR2 of MS-Roche#3.3H3

<400> 112

10 Ala Ile Ser Gln Asn Gly Phe His Ile Tyr Tyr Ala Asp Ser Val Lys
 1 5 10 15

Gly

15 <210> 113
 <211> 17
 <212> PRT
 <213> artificial sequence

20 <220>
 <223> synthetic construct; HCDR2 of MS-Roche#3.4H1

<400> 113

25 Ala Ile Ser Glu Thr Ser Ile Arg Lys Tyr Tyr Ala Asp Ser Val Lys
 1 5 10 15

Gly

30 <210> 114
 <211> 16
 <212> PRT
 <213> artificial sequence

35 <220>
 <223> synthetic construct; HCDR2 of MS-Roche#3.4H2

<400> 114

40 Val Ile Asp Met Val Gly His Thr Tyr Tyr Ala Asp Ser Val Lys Gly
 45 1 5 10 15

<210> 115
 <211> 17
 <212> PRT
 <213> artificial sequence

50 <220>
 <223> synthetic construct; HCDR2 of MS-Roche#3.4H3

<400> 115

EP 2 368 907 B1

Val Ile Ser Gln Thr Gly Arg Lys Ile Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

5 Gly

<210> 116

<211> 17

10 <212> PRT

<213> artificial sequence

<220>

15 <223> synthetic construct; HCDR2 of MS-Roche#3.4H4

<400> 116

Ala Ile Ser Glu Thr Gly Met His Ile Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

20 Gly

<210> 117

25 <211> 17

<212> PRT

<213> artificial sequence

<220>

30 <223> synthetic construct; HCDR2 of MS-Roche#3.4H5

<400> 117

Val Ile Ser Gln Val Gly Ala His Ile Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

35 Gly

<210> 118

<211> 17

<212> PRT

<213> artificial sequence

45 <220>

<223> synthetic construct; HCDR2 of MS-Roche#3.4H6

<400> 118

Ala Ile Ser Glu Ser Gly Trp Ser Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

55 Gly

<210> 119

<211> 17

EP 2 368 907 B1

<212> PRT
<213> artificial sequence

<220>

5 <223> synthetic construct; HCDR2 of MS-Roche#3.4H7

<400> 119

10 Val Ile Ser Glu Thr Gly Lys Asn Ile Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

15 Gly

<210> 120

<211> 17

<212> PRT

20 <213> artificial sequence

<220>

<223> synthetic construct; HCDR2 of MS-Roche#3.4H8

25 <400> 120

30 Ala Ile Ser Glu His Gly Arg Phe Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

<210> 121

35 <211> 17

<212> PRT

<213> artificial sequence

<220>

40 <223> synthetic construct; HCDR2 of MS-Roche#3.4H9

<400> 121

45 Ala Ile Ser Glu Ser Ser Lys Asn Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

50 <210> 122

<211> 17

<212> PRT

<213> artificial sequence

55 <220>

<223> synthetic construct; HCDR2 of MS-Roche#3.4H10

<400> 122

EP 2 368 907 B1

Ala Ile Ser Glu Ser Gly Arg Gly Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

5 Gly

<210> 123

<211> 17

10 <212> PRT

<213> artificial sequence

<220>

15 <223> synthetic construct; HCDR2 of MS-Roche#3.4H11

<400> 123

Ala Ile Ser Glu Phe Gly Lys Asn Ile Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

20 Gly

<210> 124

25 <211> 17

<212> PRT

<213> artificial sequence

<220>

30 <223> synthetic construct; HCDR2 of MS-Roche#3.4H12

<400> 124

Val Ile Ser Gln Thr Gly Gln Asn Ile Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

35 Gly

<210> 125

<211> 17

<212> PRT

<213> artificial sequence

45 <220>

<223> synthetic construct; HCDR2 of MS-Roche#3.4H13

<400> 125

Ala Ile Ser Glu Gln Gly Arg Asn Ile Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

55 Gly

<210> 126

EP 2 368 907 B1

<211> 17
 <212> PRT
 <213> artificial sequence

5 <220>
 <223> synthetic construct; HCDR2 of MS-Roche#3.4H14

<400> 126

10 Ala Ile Ser Glu Ser Gly Gln Tyr Lys Tyr Tyr Ala Asp Ser Val Lys
 1 5 10 15

Gly

15 <210> 127
 <211> 17
 <212> PRT
 <213> artificial sequence

20 <220>
 <223> synthetic construct; HCDR2 of MS-Roche#3.4H16

<400> 127

25 Ala Ile Ser Glu Ser Gly Val Asn Ile Tyr Tyr Ala Asp Ser Val Lys
 1 5 10 15

Gly

30 <210> 128
 <211> 17
 <212> PRT
 <213> artificial sequence

35 <220>
 <223> synthetic construct; HCDR2 of MS-Roche#3.4H17

<400> 128

40 Ala Ile Ser Glu Phe Gly Gln Phe Ile Tyr Tyr Ala Asp Ser Val Lys
 45 1 5 10 15

Gly

50 <210> 129
 <211> 17
 <212> PRT
 <213> artificial sequence

55 <220>
 <223> synthetic construct; HCDR2 of MS-Roche#3.4H18

<400> 129

EP 2 368 907 B1

Ala Ile Ser Gln Gln Ser Asn Phe Ile Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

5 Gly

<210> 130

<211> 12

10 <212> PRT

<213> artificial sequence

<220>

<223> synthetic construct; LCDR1 of MS-Roche#3.4L7

15

<400> 130

20 Arg Ala Ser Gln Arg Leu Gly Arg Leu Tyr Leu Ala
1 5 10

<210> 131

<211> 12

<212> PRT

25 <213> artificial sequence

<220>

<223> synthetic construct; LCDR1 of MS-Roche#3.4L8

30 <400> 131

Arg Ala Ser Gln Trp Ile Thr Lys Ser Tyr Leu Ala
1 5 10

35

<210> 132

<211> 12

<212> PRT

<213> artificial sequence

40

<220>

<223> synthetic construct; LCDR1 of MS-Roche#3.4L9

<400> 132

45

Arg Ala Ser Arg Arg Ile His Val Tyr Tyr Leu Ala
1 5 10

50

<210> 133

<211> 12

<212> PRT

<213> artificial sequence

55

<220>

<223> synthetic construct; LCDR1 of MS-Roche#3.4L11

<400> 133

EP 2 368 907 B1

Arg Ala Ser Gln Leu Val Gly Arg Ala Tyr Leu Ala
1 5 10

5 <210> 134
<211> 17
<212> PRT
<213> artificial sequence

10 <220>
<223> synthetic construct; HCDR2 of MS-Roche#3.6H1

<400> 134

15 Val Ile Ser Glu Ser Gly Gln Tyr Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

20 Gly

<210> 135
<211> 17
<212> PRT
25 <213> artificial sequence

<220>
<223> synthetic construct; HCDR2 of MS-Roche#3.6H2

30 <400> 135

Val Ile Ser Glu Arg Gly Ile Asn Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

35 Gly

<210> 136
<211> 17
40 <212> PRT
<213> artificial sequence

<220>
<223> synthetic construct; HCDR2 of MS-Roche#3.6H3

45 <400> 136

50 Val Ile Ser Glu Thr Gly Lys Phe Ile Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

55 <210> 137
<211> 17
<212> PRT
<213> artificial sequence

EP 2 368 907 B1

<220>

<223> synthetic construct; HCDR2 of MS-Roche#3.6H4

<400> 137

5

Ala Ile Ser Glu Arg Gly Arg His Ile Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

10

Gly

<210> 138

<211> 17

15

<212> PRT

<213> artificial sequence

<220>

<223> synthetic construct; HCDR2 of MS-Roche#3.6H5

20

<400> 138

Ala Ile Ser Glu Ser Gly Lys Thr Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

25

Gly

<210> 139

30

<211> 17

<212> PRT

<213> artificial sequence

<220>

35

<223> synthetic construct; HCDR2 of MS-Roche#3.6H6

<400> 139

Ala Ile Ser Glu His Gly Thr Asn Ile Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

40

Gly

45

<210> 140

<211> 17

<212> PRT

<213> artificial sequence

50

<220>

<223> synthetic construct; HCDR2 of MS-Roche#3.6H8

<400> 140

55

EP 2 368 907 B1

Ala Ile Ser Glu Tyr Ser Lys Phe Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

5 Gly

<210> 141

<211> 12

<212> PRT

10 <213> artificial sequence

<220>

<223> synthetic construct; LCDR1 of MS-Roche#3.6L1

15 <400> 141

Arg Ala Ser Gln Phe Ile Gln Arg Phe Tyr Leu Ala
1 5 10

20

<210> 142

<211> 12

<212> PRT

<213> artificial sequence

25

<220>

<223> synthetic construct; LCDR1 of MS-Roche#3.6L2

<400> 142

30

Arg Ala Ser Gln Phe Leu Ser Arg Tyr Tyr Leu Ala
1 5 10

35

<210> 143

<211> 12

<212> PRT

<213> artificial sequence

40

<220>

<223> synthetic construct; LCDR1 of MS-Roche#7

<400> 143

45

Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala
1 5 10

50

<210> 144

<211> 7

<212> PRT

<213> artificial sequence

55

<220>

<223> synthetic construct; LCDR2 of MS-Roche#7

<400> 144

EP 2 368 907 B1

Gly Ala Ser Ser Arg Ala Thr
1 5

5 <210> 145
<211> 8
<212> PRT
<213> artificial sequence

10 <220>
<223> synthetic construct; LCDR3 of MS-Roche#7

<400> 145

15 Phe Gln Leu Tyr Ser Asp Pro Phe
1 5

20 <210> 146
<211> 10
<212> PRT
<213> artificial sequence

<220>
25 <223> synthetic construct; HCDR1 of MS-Roche#7

<400> 146

30 Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser
1 5 10

<210> 147
<211> 17
35 <212> PRT
<213> artificial sequence

<220>
40 <223> synthetic construct; HCDR2 of MS-Roche#7

<400> 147

45 Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

50 <210> 148
<211> 17
<212> PRT
<213> artificial sequence

<220>
55 <223> synthetic construct; HCDR3 of MS-Roche#7

<400> 148

EP 2 368 907 B1

Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp
1 5 10 15

5 Val

<210> 149

<211> 8

<212> PRT

10 <213> artificial sequence

<220>

<223> synthetic construct; LCDR3 of MS-Roche#7.1

15 <400> 149

His Gln Leu Tyr Ser Ser Pro Tyr
1 5

20

<210> 150

<211> 8

<212> PRT

<213> artificial sequence

25

<220>

<223> synthetic construct; LCDR3of MS-Roche#7.2

<400> 150

30

Gln Gln Ile Tyr Ser Phe Pro His
1 5

35

<210> 151

<211> 8

<212> PRT

<213> artificial sequence

40

<220>

<223> synthetic construct; LCDR3 of MS-Roche#7.3

<400> 151

45

His Gln Val Tyr Ser His Pro Phe
1 5

50

<210> 152

<211> 8

<212> PRT

<213> artificial sequence

55

<220>

<223> synthetic construct; LCDR3 of MS-Roche#7.4

<400> 152

EP 2 368 907 B1

Gln Gln Ile Tyr Asn Phe Pro His
1 5

5 <210> 153
<211> 8
<212> PRT
<213> artificial sequence

10 <220>
<223> synthetic construct; LCDR3 of MS-Roche#7.5

<400> 153

15 His Gln Val Tyr Ser Ser Pro Phe
1 5

20 <210> 154
<211> 8
<212> PRT
<213> artificial sequence

<220>
25 <223> synthetic construct; LCDR3 of MS-Roche#7.6

<400> 154

30 His Gln Leu Tyr Ser Pro Pro Tyr
1 5

<210> 155
<211> 8
<212> PRT
35 <213> artificial sequence

<220>
<223> synthetic construct; LCDR3 of MS-Roche#7.7

40 <400> 155

45 His Gln Val Tyr Ser Ala Pro Phe
1 5

<210> 156
<211> 8
<212> PRT
<213> artificial sequence

50 <220>
<223> synthetic construct; LCDR3 of MS-Roche#7.8

<400> 156

55 His Gln Val Tyr Ser Phe Pro Ile
1 5

EP 2 368 907 B1

<210> 157
 <211> 8
 <212> PRT
 <213> artificial sequence
 5
 <220>
 <223> synthetic construct; LCDR3 of MS-Roche#7.9
 <400> 157
 10
 Leu Gln Ile Tyr Asn Met Pro Ile
 1 5
 <210> 158
 <211> 8
 <212> PRT
 <213> artificial sequence
 15
 <220>
 <223> synthetic construct; LCDR3 of MS-Roche#7.10
 <400> 158
 20
 Gln Gln Val Tyr Asn Pro Pro His
 1 5
 <210> 159
 <211> 8
 <212> PRT
 <213> artificial sequence
 25
 <220>
 <223> synthetic construct; LCDR3 of MS-Roche#7.11
 <400> 159
 30
 Gln Gln Val Tyr Ser Pro Pro His
 1 5
 <210> 160
 <211> 12
 <212> PRT
 <213> artificial sequence
 35
 <220>
 <223> synthetic construct; LCDR1 of MS-Roche#7.12
 <400> > 160
 40
 Arg Ala Ser Gln Tyr Val Ser Ser Pro Tyr Leu Ala
 1 5 10
 <210> 161
 <211> 7

EP 2 368 907 B1

<212> PRT
 <213> artificial sequence

 <220>
 5 <223> synthetic construct; LCDR2 of MS-Roche#7.12

 <400> 161

 10 Gly Ser Ser Asn Arg Ala Thr
 1 5

 <210> 162
 <211> 8
 <212> PRT
 15 <213> artificial sequence

 <220>
 <223> synthetic construct; LCDR3 of MS-Roche#7.12

 20 <400> 162

 Leu Gln Leu Tyr Asn Ile Pro Asn
 1 5

 25 <210> 163
 <211> 10
 <212> PRT
 <213> artificial sequence

 30 <220>
 <223> synthetic construct; HCDR1 of MS-Roche#7.12

 <400> 163

 35 Gly Phe Thr Phe Ser Ser Tyr Gly Met Ser
 1 5 10

 40 <210> 164
 <211> 17
 <212> PRT
 <213> artificial sequence

 <220>
 45 <223> synthetic construct; HCDR2 of MS-Roche#7.12

 <400> 164

 50 Asn Ile Ser Gly Ser Gly Ser Ser Thr Tyr Tyr Ala Asp Ser Val Lys

 1 5 10 15

 55 Gly

 <210> 165

EP 2 368 907 B1

<211> 17
 <212> PRT
 <213> artificial sequence

 5 <220>
 <223> synthetic construct; HCDR3 of MS-Roche#7.12

 <400> 165

 10 Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp
 1 5 10 15

 Val
 15
 <210> 166
 <211> 8
 <212> PRT
 <213> artificial sequence
 20
 <220>
 <223> synthetic construct; LCDR3 of MS-Roche#7.13

 <400> 166
 25
 His Gln Val Tyr Ser Pro Pro Phe
 1 5

 30 <210> 167
 <211> 17
 <212> PRT
 <213> artificial sequence

 35 <220>
 <223> synthetic construct; HCDR2 of MS-Roche#7.2H1

 <400> 167

 40 Ala Ile Asn Ala Asn Gly Leu Lys Lys Tyr Tyr Ala Asp Ser Val Lys
 1 5 10 15

 45 Gly

 <210> 168
 <211> 17
 <212> PRT
 50 <213> artificial sequence

 <220>
 <223> synthetic construct; HCDR2 of MS-Roche#7.2H2

 55 <400> 168

EP 2 368 907 B1

Ala Ile Asn Gly Thr Gly Met Lys Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

5 Gly

<210> 169

<211> 17

<212> PRT

10 <213> artificial sequence

<220>

<223> synthetic construct; HCDR2 of MS-Roche#7.2H3

15 <400> 169

Ala Ile Asn Ala Asn Gly Tyr Lys Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

20 Gly

<210> 170

25 <211> 17

<212> PRT

<213> artificial sequence

<220>

30 <223> synthetic construct; HCDR2 of MS-Roche#7.2H4

<400> 170

35 Ala Ile Asn Ser Lys Gly Ser Arg Ile Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

40 Gly

<210> 171

<211> 17

<212> PRT

<213> artificial sequence

45 <220>

<223> synthetic construct; HCDR2 of MS-Roche#7.2H5

<400> 171

50 Ala Ile Asn Ala Thr Gly Arg Ser Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

55 Gly

<210> 172

EP 2 368 907 B1

<211> 17
<212> PRT
<213> artificial sequence

5 <220>
<223> synthetic construct; HCDR2 of MS-Roche#7.2H6

<400> 172

10 Ala Ile Asn Ala Arg Gly Asn Arg Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

15 Gly

<210> 173
<211> 17
<212> PRT
20 <213> artificial sequence

<220>
<223> synthetic construct; HCDR2 of MS-Roche#7.2H7

25 <400> 173

Ala Ile Asn Ser Arg Gly Ser Asp Thr His Tyr Ala Asp Ser Val Lys
1 5 10 15

30 Gly

<210> 174
<211> 17
35 <212> PRT
<213> artificial sequence

<220>
<223> synthetic construct; HCDR2 of MS-Roche#7.2H8

40 <400> 174

Ala Ile Asn Ala Ser Gly His Lys Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

45 Gly

50 <210> 175
<211> 12
<212> PRT
<213> artificial sequence

55 <220>
<223> synthetic construct; LCDR1 of MS-Roche#7.2L1

EP 2 368 907 B1

<400> 175

	Arg	Ala	Ser	Gln	Tyr	Val	Asp	Arg	Thr	Tyr	Leu	Ala
5	1				5					10		

<210> 176

<211> 12

<212> PRT

10 <213> artificial sequence

<220>

<223> synthetic construct; LCDR1 of MS-Roche#7.2L2

15 <400> 176

	Arg	Ala	Ser	Gln	Tyr	Ile	Ser	Phe	Arg	Tyr	Leu	Ala
20	1				5					10		

<210> 177

<211> 12

<212> PRT

25 <213> artificial sequence

<220>

<223> synthetic construct; LCDR1 of MS-Roche#7.2L4

30 <400> 177

	Arg	Ala	Ser	Gln	Phe	Ile	Arg	Arg	Ser	Tyr	Leu	Ala
	1				5					10		

35 <210> 178

<211> 8

<212> PRT

<213> artificial sequence

40 <220>

<223> synthetic construct; LCDR3 of MS-Roche#7.3H1

<400> 178

45				His	Gln	Val	Tyr	Ser	His	Pro	Phe
----	--	--	--	-----	-----	-----	-----	-----	-----	-----	-----

				1						5
--	--	--	--	---	--	--	--	--	--	---

50 <210> 179

<211> 17

<212> PRT

55 <213> artificial sequence

<220>

<223> synthetic construct; HCDR2 of MS-Roche#7.3H1

EP 2 368 907 B1

<400> 179

5 Ala Ile Ser Ala Ile Ser Asn Lys Thr Tyr Tyr Ala Asp Ser Val Lys
 1 5 10 15

Gly

10 <210> 180
 <211> 12
 <212> PRT
 <213> artificial sequence

15 <220>
 <223> synthetic construct; LCDR1 of MS-Roche#7.3L1

<400> 180

20 Arg Ala Ser Gln Tyr Leu His Tyr Gly Tyr Leu Ala
 1 5 10

25 <210> 181
 <211> 17
 <212> PRT
 <213> artificial sequence

30 <220>
 <223> synthetic construct; HCDR2 of MS-Roche#7.4H1

<400> 181

35 Ala Ile Asn Ala Thr Gly Tyr Arg Thr Tyr Tyr Ala Asp Ser Val Lys
 1 5 10 15

Gly

40 <210> 182
 <211> 17
 <212> PRT
 <213> artificial sequence

45 <220>
 <223> synthetic construct; HCDR2 of MS-Roche#7.4H2

<400> 182

50 Ala Ile Asn Tyr Asn Gly Ala Arg Ile Tyr Tyr Ala Asp Ser Val Lys
 1 5 10 15

55 Gly

<210> 183
<211> 8

EP 2 368 907 B1

<212> PRT

<213> artificial sequence

<220>

<223> synthetic construct; LCDR3 of MS-Roche#7.9H1

<400> 183

Leu Gln Ile Tyr Asn Met Pro Ile
1 5

<210> 184

<211> 17

<212> PRT

<213> artificial sequence

<220>

<223> synthetic construct; HCDR2 of MS-Roche#7.9H1

<400> 184

Ala Ile Asn Ala Asn Gly Gln Arg Lys Phe Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

<210> 185

<211> 17

<212> PRT

<213> artificial sequence

 $\langle 220 \rangle$

<223> synthetic construct; HCDR2 of MS-Roche#7.9H2

<400> 185

Ala Ile Asn Ala Asp Gly Asn Arg Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

<210> 186

<211> 17

<212> PRT

<213> artificial sequence

<220>

<223> synthetic construct; HCDR2 of MS-Roche#7.9H3

<400> 186

EP 2 368 907 B1

Ala Ile Asn Tyr Gln Gly Asn Arg Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

5 Gly

<210> 187

<211> 17

<212> PRT

10 <213> artificial sequence

<220>

<223> synthetic construct; HCDR2 of MS-Roche#7.9H4

15 <400> 187

Ala Ile Asn Ala Val Gly Met Lys Lys Phe Tyr Ala Asp Ser Val Lys
1 5 10 15

20 Gly

<210> 188

<211> 17

25 <212> PRT

<213> artificial sequence

<220>

<223> synthetic construct; HCDR2 of MS-Roche#7.9H5

30 <400> 188

Ala Ile Asn His Ala Gly Asn Lys Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

35 Gly

<210> 189

40 <211> 12

<212> PRT

<213> artificial sequence

<220>

45 <223> synthetic construct; LCDR1 of MS-Roche#7.9L1

<400> 189

50 Arg Ala Ser Gln Arg Leu Ser Pro Arg Tyr Leu Ala
1 5 10

<210> 190

<211> 12

55 <212> PRT

<213> artificial sequence

<220>

EP 2 368 907 B1

<223> synthetic construct; LCDR1 of MS-Roche#7.9L2

<400> 190

5 Arg Ala Ser Gln Tyr Leu His Lys Arg Tyr Leu Ala
1 5 10

<210> 191

10 <211> 17

<212> PRT

<213> artificial sequence

<220>

15 <223> synthetic construct; HCDR2 of MS-Roche#7.9H6

<400> 191

20 Ala Ile Asn Ala Ser Gly Arg Leu Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

25

<210> 192

<211> 17

<212> PRT

<213> artificial sequence

30

<220>

<223> synthetic construct; HCDR2 of MS-Roche#7.9H7

<400> 192

35

Ala Ile Asn Ala Ser Gly Thr Arg Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

40

<210> 193

<211> 17

45 <212> PRT

<213> artificial sequence

<220>

<223> synthetic construct; HCDR2 of MS-Roche#7.9H8

50

<400> 193

Ala Ile Asn Ala Ser Gly Ser Lys Ile Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

55

Gly

EP 2 368 907 B1

<210> 194
 <211> 17
 <212> PRT
 <213> artificial sequence
 5
 <220>
 <223> synthetic construct; HCDR2 of MS-Roche#7.9H9
 <400> 194
 10
 Ala Ile Asn Gly Lys Gly Asn Lys Lys Tyr Tyr Ala Asp Ser Val Lys
 1 5 10 15
 15 Gly
 <210> 195
 <211> 17
 <212> PRT
 20 <213> artificial sequence
 <220>
 <223> synthetic construct; HCDR2 of MS-Roche#7.11H1
 25 <400> 195
 Gly Ile Asn Ala Ala Gly Phe Arg Thr Tyr Tyr Ala Asp Ser Val Lys
 1 5 10 15
 30 Gly
 <210> 196
 <211> 17
 35 <212> PRT
 <213> artificial sequence
 <220>
 <223> synthetic construct; HCDR2 of MS-Roche#7.11H2
 40 <400> 196
 Ala Ile Asn Ala Asn Gly Tyr Lys Lys Tyr Tyr Ala Asp Ser Val Lys
 45 1 5 10 15
 Gly
 50 <210> 197
 <211> 17
 <212> PRT
 <213> artificial sequence
 55 <220>
 <223> synthetic construct; HCDR2 of MS-Roche#7.11H3
 <400> 197

EP 2 368 907 B1

Gly Ile Asn Ala Asn Gly Asn Arg Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

5 Gly

<210> 198

<211> 17

<212> PRT

10 <213> artificial sequence

<220>

<223> synthetic construct; HCDR2 of MS-Roche#7.11H4

15 <400> 198

Ala Ile Asn Ala Asn Gly Tyr Lys Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

20

Gly

<210> 199

25 <211> 17

<212> PRT

<213> artificial sequence

<220>

30 <223> synthetic construct; HCDR2 of MS-Roche#7.11H5

<400> 199

Ala Ile Asn Ala His Gly Gln Arg Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

35

Gly

40 <210> 200

<211> 12

<212> PRT

<213> artificial sequence

45 <220>

<223> synthetic construct; LCDR1 of MS-Roche#7.11L1

<400> 200

Arg Ala Ser Gln Arg Ile Leu Arg Ile Tyr Leu Ala
1 5 10

50

<210> 201

<211> 12

55 <212> PRT

<213> artificial sequence

<220>

EP 2 368 907 B1

<223> synthetic construct; LCDR1 of MS-Roche#7.12H1

<400> 201

5 Arg Ala Ser Gln Tyr Val Phe Arg Arg Tyr Leu Ala
1 5 10

<210> 202

<211> 8

10 <212> PRT

<213> artificial sequence

<220>

15 <223> synthetic construct; LCDR3 of MS-Roche#7.12H1

<400> 202

20 Leu Gln Leu Tyr Asn Ile Pro Asn
1 5

<210> 203

<211> 10

<212> PRT

<213> artificial sequence

25

<220>

<223> synthetic construct; HCDR1 of MS-Roche#7.12H1

<400> 203

30

Gly Phe Thr Phe Ser Ser Tyr Gly Met Ser
1 5 10

35 <210> 204

<211> 17

<212> PRT

<213> artificial sequence

40

<220>

<223> synthetic construct; HCDR2 of MS-Roche#7.12H1

<400> 204

45

Asn Ile Asn Gly Asn Gly Asn Arg Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

50

Gly

<210> 205

<211> 17

<212> PRT

55

<213> artificial sequence

<220>

<223> synthetic construct; HCDR2 of MS-Roche#7.12L1

EP 2 368 907 B1

<400> 205

5 Asn Ile Ser Gly Ser Gly Ser Ser Thr Tyr Tyr Ala Asp Ser Val Lys
 1 5 10 15

Gly

<210> 206

10 <211> 12

<212> PRT

<213> artificial sequence

<220>

15 <223> synthetic construct; LCDR1 of MS-Roche#7.12L2

<400> 206

20 Arg Ala Ser Gln Arg Phe Phe Tyr Lys Tyr Leu Ala
 1 5 10

<210> 207

25 <211> 12

<212> PRT

<213> artificial sequence

<220>

30 <223> synthetic construct; LCDR1 of MS-Roche#7.12L3

<400> 207

35 Arg Ala Ser Gln Phe Val Arg Arg Gly Phe Leu Ala
 1 5 10

<210> 208

40 <211> 12

<212> PRT

<213> artificial sequence

<220>

45 <223> synthetic construct; LCDR1 of MS-Roche#7.12L4

<400> 208

50 Arg Ala Ser Gln Arg Leu Lys Arg Ser Tyr Leu Ala
 1 5 10

<210> 209

55 <211> 12

<212> PRT

<213> artificial sequence

<220>

<223> synthetic construct; LCDR1 of MS-Roche#7.12L6

EP 2 368 907 B1

<400> 209

5 Arg Ala Ser Gln Tyr Leu Trp Tyr Arg Tyr Leu Ala
1 5 10

<210> 210

<211> 12

<212> PRT

10 <213> artificial sequence

<220>

<223> synthetic construct; LCDR1 of MS-Roche#7.12L7

15 <400> 210

20 Arg Ala Ser Gln Trp Ile Arg Lys Thr Tyr Leu Ala
1 5 10

<210> 211

<211> 12

<212> PRT

25 <213> artificial sequence

<220>

<223> synthetic construct; LCDR1 of MS-Roche#8

30 <400> 211

35 Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala
1 5 10

<210> 212

<211> 7

<212> PRT

<213> artificial sequence

40 <220>

<223> synthetic construct; LCDR2 of MS-Roche#8

<400> 212

45 Gly Ala Ser Ser Arg Ala Thr
1 5

<210> 213

50 <211> 8

<212> PRT

<213> artificial sequence

<220>

55 <223> synthetic construct; LCDR3 of MS-Roche#8

<400> 213

EP 2 368 907 B1

Gln Gln Leu Ser Ser Phe Pro Pro
1 5

5 <210> 214
<211> 10
<212> PRT
<213> artificial sequence

10 <220>
<223> synthetic construct; HCDR1 of MS-Roche#8

<400> 214

15 Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser
1 5 10

20 <210> 215
<211> 17
<212> PRT
<213> artificial sequence

<220>
25 <223> synthetic construct; HCDR2 of MS-Roche#8

<400> 215

30 Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

35 <210> 216
<211> 15
<212> PRT
<213> artificial sequence

40 <220>
<223> synthetic construct; HCDR3 of MS-Roche#8

<400> 216

45 Leu Leu Ser Arg Gly Tyr Asn Gly Tyr Tyr His Lys Phe Asp Val
1 5 10 15

50 <210> 217
<211> 8
<212> PRT
<213> artificial sequence

<220>
55 <223> synthetic construct; LCDR3 of MS-Roche#8.1

<400> 217

EP 2 368 907 B1

Gln Gln Leu Ser Asn Tyr Pro Pro
1 5

5 <210> 218
<211> 8
<212> PRT
<213> artificial sequence

<220>
10 <223> synthetic construct; LCDR3 of MS-Roche#8.2

<400> 218

15 Gln Gln Leu Ser Ser Tyr Pro Pro
1 5

<210> 219
<211> 17
20 <212> PRT
<213> artificial sequence

<220>
25 <223> synthetic construct; HCDR2 of MS-Roche#8.1H1

<400> 219

30 Ala Ile Ser Arg Ser Gly Ser Asn Ile Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

35 <210> 220
<211> 8
<212> PRT
<213> artificial sequence

<220>
40 <223> synthetic construct; LCDR3 of MS-Roche#8.2H1

<400> 220

45 Gln Gln Leu Ser Ser Tyr Pro Pro
1 5

<210> 221
<211> 17
50 <212> PRT
<213> artificial sequence

<220>
55 <223> synthetic construct; HCDR2 of MS-Roche#8.2H1

<400> 221

EP 2 368 907 B1

Ala Ile Ser Ile Thr Gly Arg Arg Lys Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

5 Gly

<210> 222

<211> 17

<212> PRT

10 <213> artificial sequence

<220>

<223> synthetic construct; HCDR2 of MS-Roche#8.2H2

15 <400> 222

Ala Ile Ser Arg Thr Gly Ser Lys Thr Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

20

Gly

<210> 223

25 <211> 16

<212> PRT

<213> artificial sequence

<220>

30 <223> synthetic construct; HCDR2 of MS-Roche#8.2H4

<400> 223

35 Ala Thr Ser Val Lys Gly Lys Thr Tyr Tyr Ala Asp Ser Val Lys Gly
1 5 10 15

<210> 224

40 <211> 12

<212> PRT

<213> artificial sequence

<220>

45 <223> synthetic construct; LCDR1 of MS-Roche#8.2L1

<400> 224

50 Arg Ala Ser Gln Arg Val Ser Gly Arg Tyr Leu Ala
1 5 10

<210> 225

<211> 109

<212> PRT

55 <213> artificial sequence

<220>

<223> synthetic construct; VL kappa1

5 <220>
 <221> MISC_FEATURE
 <222> (96)..(96)
 <223> Xaa = any amino acid of a mixture of Ala, Asp, Glu, Phe, Gly, His
 , Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, or
 Tyr

 10 <220>
 <221> MISC_FEATURE
 <222> (93)..(93)
 <223> Xaa = any amino acid of a mixture of Ala, Asp, Gly, His, Leu, Asn
 or Ser

 15 <220>
 <221> MISC_FEATURE
 <222> (92)..(92)
 <223> Xaa = any amino acid of a mixture of Asp, Gly, Asn, Ser or Tyr

 20 <220>
 <221> MISC_FEATURE
 <222> (91)..(91)
 <223> Xaa = any amino acid of a mixture of Ala, Asp, Glu, Phe, Gly, His
 , Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp or Tyr

 25 <220>
 <221> MISC_FEATURE
 <222> (89)..(89)
 <223> Xaa = any amino acid of a mixture of Phe, His, Ile, Leu, Met or G
 In,
 30 <220>
 <221> MISC_FEATURE
 <222> (85)..(85)
 <223> Xaa = can be Thr or Val

 35 <220>
 <221> MISC_FEATURE
 <222> (94)..(94)
 <223> Xaa = any amino acid of a mixture of Ala, Asp, Glu, Phe, Gly, His
 , Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, or
 Tyr

 40 <220>
 <221> MISC_FEATURE
 <222> (95)..(95)
 <223> Xaa = any amino acid of a mixture of Leu, Pro or Ser

 45 <400> 225

 50

 55

EP 2 368 907 B1

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

5 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Ser Tyr
 20 25 30

10 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

15 Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

20 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
 65 70 75 80

25 Glu Asp Phe Ala Xaa Tyr Tyr Cys Xaa Gln Xaa Xaa Xaa Xaa Xaa Xaa
 85 90 95

30 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
 100 105

35 <210> 226
 <211> 114
 <212> PRT
 <213> artificial sequence

40 <220>
 <223> synthetic construct; VL kappa2

45 <220>
 <221> misc_feature
 <222> (101)..(101)
 <223> Xaa = any amino acid of a mixture of Ala, Asp, Glu, Phe, Gly, His
 , Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, or
 Tyr

50 <220>
 <221> misc_feature
 <222> (94)..(94)
 <223> Xaa = any amino acid of a mixture of Phe, His, Ile, Leu, Met or G
 In,

55 <220>
 <221> misc_feature
 <222> (96)..(96)
 <223> Xaa = any amino acid of a mixture of Ala, Asp, Glu, Phe, Gly, His
 , Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp or Tyr

60 <220>
 <221> misc_feature
 <222> (97)..(97)
 <223> Xaa = any amino acid of a mixture of Asp, Gly, Asn, Ser or Tyr

EP 2 368 907 B1

<220>
 <221> misc_feature
 <222> (98)..(98)
 <223> Xaa = any amino acid of a mixture of Ala, Asp, Gly, His, Leu, Asn
 5 or Ser

 <220>
 <221> misc_feature
 <222> (99)..(99)
 10 <223> Xaa = any amino acid of a mixture of Ala, Asp, Glu, Phe, Gly, His
 , Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, or
 Tyr

 <220>
 15 <221> misc_feature
 <222> (100)..(100)
 <223> Xaa = any amino acid of a mixture of Leu, Pro or Ser

 <400> 226
 20
 Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15

 25 Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Leu His Ser
 20 25 30

 30 Asn Gly Tyr Asn Tyr Leu Asp Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45

 Pro Gln Leu Leu Ile Tyr Leu Gly Ser Asn Arg Ala Ser Gly Val Pro
 50 55 60
 35
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80

 40 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Xaa Gln Xaa
 85 90 95

 45 Xaa Xaa Xaa Xaa Xaa Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105 110

 Arg Thr
 50
 <210> 227
 <211> 110
 <212> PRT
 <213> artificial sequence

 55 <220>
 <223> synthetic construct; VL kappa3

 <220>

EP 2 368 907 B1

<221> misc_feature
 <222> (97)..(97)
 <223> Xaa = any amino acid of a mixture of Ala, Asp, Glu, Phe, Gly, His , Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, or Tyr

5

<220>
 <221> misc_feature
 <222> (90)..(90)
 <223> Xaa = any amino acid of a mixture of Phe, His, Ile, Leu, Met or G In,

10

<220>
 <221> misc_feature
 <222> (86)..(86)
 <223> Xaa = Thr or Val

15

<220>
 <221> misc_feature
 <222> (92)..(92)
 <223> Xaa = any amino acid of a mixture of Ala, Asp, Glu, Phe, Gly, His , Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp or Tyr

20

<220>
 <221> misc_feature
 <222> (93)..(93)
 <223> Xaa = any amino acid of a mixture of Asp, Gly, Asn, Ser or Tyr

25

<220>
 <221> misc_feature
 <222> (94)..(94)
 <223> Xaa = any amino acid of a mixture of Ala, Asp, Gly, His, Leu, Asn or Ser

30

<220>
 <221> misc_feature
 <222> (95)..(95)
 <223> Xaa = any amino acid of a mixture of Ala, Asp, Glu, Phe, Gly, His , Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, or Tyr

35

<220>
 <221> misc_feature
 <222> (96)..(96)
 <223> Xaa = any amino acid of a mixture of Leu, Pro or Ser

40

<400> 227

45

50

55

EP 2 368 907 B1

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15

5 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser
 20 25 30

10 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45

15 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
 50 55 60

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
 65 70 75 80

20 Pro Glu Asp Phe Ala Xaa Tyr Tyr Cys Xaa Gln Xaa Xaa Xaa Xaa Xaa
 85 90 95

25 Xaa Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
 100 105 110

30 <210> 228
 <211> 115
 <212> PRT
 <213> artificial sequence

35 <220>
 <221> MISC_FEATURE
 <222> (102)..(102)
 <223> Xaa = any amino acid of a mixture of Ala, Asp, Glu, Phe, Gly, His
 , Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, or
 40 Tyr

45 <220>
 <221> MISC_FEATURE
 <222> (95)..(95)
 <223> Xaa = any amino acid of a mixture of Phe, His, Ile, Leu, Met or G
 In,

50 <220>
 <221> MISC_FEATURE
 <222> (97)..(97)
 <223> Xaa = any amino acid of a mixture of Ala, Asp, Glu, Phe, Gly, His
 , Ile, Lys, Leu, Met, Asn, Gln, Arg, Ser, Thr, Val, Trp or Tyr

55 <220>
 <221> MISC_FEATURE
 <222> (98)..(98)
 <223> Xaa = any amino acid of a mixture of Asp, Gly, Asn, Ser or Tyr

EP 2 368 907 B1

<220>
 <221> MISC_FEATURE
 <222> (99)..(99)
 <223> Xaa = any amino acid of a mixture of Ala, Asp, Gly, His, Leu, Asn
 5 or Ser

 <220>
 <221> MISC_FEATURE
 <222> (100)..(100)
 10 <223> Xaa = any amino acid of a mixture of Ala, Asp, Glu, Phe, Gly, His
 , Ile, Lys, Leu, Met, Asn, Pro, Gln, Arg, Ser, Thr, Val, Trp, or
 Tyr

 <220>
 15 <221> MISC_FEATURE
 <222> (101)..(101)
 <223> Xaa = any amino acid of a mixture of Leu, Pro or Ser

 <400> 228
 20
 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
 1 5 10 15

 25 Glu Arg Ala Thr Ile Asn Cys Arg Ser Ser Gln Ser Val Leu Tyr Ser
 20 25 30

 30 Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
 35 40 45

 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
 50 55 60
 35
 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
 65 70 75 80

 40 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Xaa Gln
 85 90 95

 45 Xaa Xaa Xaa Xaa Xaa Xaa Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
 100 105 110

 Lys Arg Thr
 115
 50
 <210> 229
 <211> 111
 <212> PRT
 <213> artificial sequence
 55
 <220>
 <223> synthetic construct; VL lambdal

<220>
 <221> MISC_FEATURE
 <222> (99)..(99)
 <223> Xaa = any amino acid

5

<220>
 <221> MISC_FEATURE
 <222> (97)..(98)
 <223> Xaa = any amino acid except a Cys or a deletion

10

<220>
 <221> MISC_FEATURE
 <222> (94)..(96)
 <223> Xaa = any amino acid except a Cys

15

<220>
 <221> MISC_FEATURE
 <222> (92)..(92)
 <223> Xaa = any amino acid of Cys, Phe, His, Arg, Trp or Tyr

20

<400> 229

Asp Ile Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
 1 5 10 15

25

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
 20 25 30

30

Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
 35 40 45

35

Ile Tyr Asp Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
 50 55 60

40

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln
 65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Xaa Asp Xaa Xaa Xaa
 85 90 95

45

Xaa Xaa Xaa Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
 100 105 110

50

<210> 230
 <211> 112
 <212> PRT
 <213> artificial sequence

55

<220>
 <223> synthetic construct; VL lambda2

<220>
 <221> MISC_FEATURE

EP 2 368 907 B1

<222> (100)..(100)

<223> Xaa = any amino acid

<220>

5 <221> MISC_FEATURE

<222> (93)..(93)

<223> Xaa = any amino acid of Cys, Phe, His, Arg, Trp or Tyr

<220>

10 <221> MISC_FEATURE

<222> (95)..(97)

<223> Xaa = any amino acid except a Cys

<220>

15 <221> MISC_FEATURE

<222> (98)..(99)

<223> Xaa = any amino acid except a Cys or a deletion

<400> 230

20

Asp	Ile	Ala	Leu	Thr	Gln	Pro	Ala	Ser	Val	Ser	Gly	Ser	Pro	Gly	Gln
1				5					10					15	

25

Ser	Ile	Thr	Ile	Ser	Cys	Thr	Gly	Thr	Ser	Ser	Asp	Val	Gly	Gly	Tyr
			20					25					30		

30

Asn	Tyr	Val	Ser	Trp	Tyr	Gln	Gln	His	Pro	Gly	Lys	Ala	Pro	Lys	Leu
		35					40					45			

35

Met	Ile	Tyr	Asp	Val	Ser	Asn	Arg	Pro	Ser	Gly	Val	Ser	Asn	Arg	Phe
	50					55					60				

40

Gln	Ala	Glu	Asp	Glu	Ala	Asp	Tyr	Tyr	Cys	Gln	Ser	Xaa	Asp	Xaa	Xaa
				85					90					95	

45

Xaa	Xaa	Xaa	Xaa	Val	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Thr	Val	Leu	Gly
			100					105					110		

<210> 231

<211> 109

<212> PRT

50 <213> artificial sequence

<220>

<223> synthetic construct; VL lambda3

55

<220>

<221> MISC_FEATURE

<222> (97) .. (97)

<223> Xaa = any amino acid

<220>

<221> MISC_FEATURE

<222> (90) .. (90)

<223> Xaa = any amino acid of Cys, Phe, His, Arg, Trp or Tyr

5

<220>

<221> MISC_FEATURE

<222> (92) .. (94)

<223> Xaa = any amino acid except a Cys

10

<220>

<221> MISC_FEATURE

<222> (95)..(96)

<223> Xaa = any amino acid except a Cys or a deletion

15

<400> 231

Asp	Ile	Glu	Leu	Thr	Gln	Pro	Pro	Ser	Val	Ser	Val	Ala	Pro	Gly	Gln
1				5					10					15	

20

Thr	Ala	Arg	Ile	Ser	Cys	Ser	Gly	Asp	Ala	Leu	Gly	Asp	Lys	Tyr	Ala
			20					25					30		

25

Ser	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Val	Leu	Val	Ile	Tyr
		35					40					45			

30

Asp	Asp	Ser	Asp	Arg	Pro	Ser	Gly	Ile	Pro	Glu	Arg	Phe	Ser	Gly	Ser
	50					55					60				

35

Asn	Ser	Gly	Asn	Thr	Ala	Thr	Leu	Thr	Ile	Ser	Gly	Thr	Gln	Ala	Glu
65					70					75					80

Asp	Glu	Ala	Asp	Tyr	Tyr	Cys	Gln	Ser	Xaa	Asp	Xaa	Xaa	Xaa	Xaa	Xaa
			85						90					95	

40

Xaa	Val	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Thr	Val	Leu	Gly
			100					105				

<210> 232

<211> 127

<212> PRT

<213> artificial sequence

45

<220>

<223> synthetic construct; VH1A

50

<220>

<221> MISC_FEATURE

<222> (99) .. (112)

<223> Xaa = any amino acid or a deletion

55

<220>

<221> MISC_FEATURE

EP 2 368 907 B1

<222> (116)..(116)

<223> Xaa = any amino acid out of a mixture of Phe, His, Ile, Leu, Asn, Pro, Ser, Val, Trp or Tyr

5

<220>

<221> MISC_FEATURE

<222> (114)..(114)

<223> Xaa = any amino acid out of a mixture of Ala, Asp, Glu, Phe, Gly, Ile, Leu, Met, Pro, Gln, Ser, Thr, Val or Tyr

10

<220>

<221> MISC_FEATURE

<222> (113)..(113)

<223> Xaa = any amino acid

15

<400> 232

20

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ser
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser Ser Tyr
20 25 30

25

Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

30

Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln Lys Phe
50 55 60

35

Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

40

Ala Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
100 105 110

45

Xaa Xaa Asp Xaa Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125

<210> 233

<211> 127

50

<212> PRT

<213> artificial sequence

<220>

<223> synthetic construct; VH1B

55

<220>

<221> MISC_FEATURE

<222> (99)..(112)

EP 2 368 907 B1

<223> Xaa = any amino acid or a deletion

<220>

<221> MISC_FEATURE

5 <222> (113)..(113)

<223> Xaa = any amino acid

<220>

<221> MISC_FEATURE

10 <222> (114)..(114)

<223> Xaa = any amino acid out of a mixture of Ala, Asp, Glu, Phe, Gly, Ile, Leu, Met, Pro, Gln, Ser, Thr, Val or Tyr

<220>

15 <221> MISC_FEATURE

<222> (116)..(116)

<223> Xaa = any amino acid out of a mixture of Phe, His, Ile, Leu, Asn, Pro, Ser, Val, Trp or Tyr

20 <400> 233

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

25 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30

30 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

35 Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe
50 55 60

40 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

45 Ala Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
100 105 110

50 Xaa Xaa Asp Xaa Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125

<210> 234

<211> 128

<212> PRT

55 <213> artificial sequence

<220>

<223> synthetic construct; VH2

EP 2 368 907 B1

<220>
 <221> MISC_FEATURE
 <222> (100)..(113)
 <223> Xaa = any amino acid or a deletion

5

<220>
 <221> MISC_FEATURE
 <222> (114)..(114)
 <223> Xaa = any amino acid

10

<220>
 <221> MISC_FEATURE
 <222> (117)..(117)
 <223> Xaa = any amino acid out of a mixture of Phe, His, Ile, Leu, Asn, Pro, Ser, Val, Trp or Tyr

15

<220>
 <221> MISC_FEATURE
 <222> (115)..(115)
 <223> Xaa = any amino acid out of a mixture of Ala, Asp, Glu, Phe, Gly, Ile, Leu, Met, Pro, Gln, Ser, Thr, Val or Tyr

20

<400> 234

25

Gln Val Gln Leu Lys Glu Ser Gly Pro Ala Leu Val Lys Pro Thr Gln
 1 5 10 15

30

Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Ser Thr Ser
 20 25 30

35

Gly Val Gly Val Gly Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu
 35 40 45

Trp Leu Ala Leu Ile Asp Trp Asp Asp Asp Lys Tyr Tyr Ser Thr Ser
 50 55 60

40

Leu Lys Thr Arg Leu Thr Ile Ser Lys Asp Thr Ser Lys Asn Gln Val
 65 70 75 80

45

Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr
 85 90 95

50

Cys Ala Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
 100 105 110

Xaa Xaa Xaa Asp Xaa Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120 125

55

<210> 235
 <211> 127
 <212> PRT
 <213> artificial sequence

EP 2 368 907 B1

<220>

<223> synthetic construct; VH3

<220>

5 <221> MISC_FEATURE

<222> (99)..(112)

<223> Xaa = any amino acid or a deletion

<220>

10 <221> MISC_FEATURE

<222> (113)..(113)

<223> Xaa = any amino acid

<220>

15 <221> MISC_FEATURE

<222> (116)..(116)

<223> Xaa = any amino acid out of a mixture of Phe, His, Ile, Leu, Asn, Pro, Ser, Val, Trp or Tyr

<220>

20 <221> MISC_FEATURE

<222> (114)..(114)

<223> Xaa = any amino acid out of a mixture of Ala, Asp, Glu, Phe, Gly, Ile, Leu, Met, Pro, Gln, Ser, Thr, Val or Tyr

<400> 235

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
100 105 110

Xaa Xaa Asp Xaa Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125

<210> 236
 <211> 126
 <212> PRT
 <213> artificial sequence
 5
 <220>
 <223> synthetic construct; VH4
 <220>
 10 <221> MISC_FEATURE
 <222> (98)..(111)
 <223> Xaa = any amino acid or a deletion
 <220>
 15 <221> MISC_FEATURE
 <222> (112)..(112)
 <223> Xaa = any amino acid
 <220>
 20 <221> MISC_FEATURE
 <222> (113)..(113)
 <223> Xaa = any amino acid out of a mixture of Ala, Asp, Glu, Phe, Gly,
 Ile, Leu, Met, Pro, Gln, Ser, Thr, Val or Tyr
 <220>
 25 <221> MISC_FEATURE
 <222> (115)..(115)
 <223> Xaa = any amino acid out of a mixture of Phe, His, Ile, Leu, Asn,
 Pro, Ser, Val, Trp or Tyr
 30
 <400> 236
 35
 40
 45
 50
 55

EP 2 368 907 B1

[illegible]

EP 2 368 907 B1

Ile, Leu, Met, Pro, Gln, Ser, Thr, Val or Tyr

<400> 237

```

5      Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
      1          5          10          15

10     Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Thr Ser Tyr
      20          25          30

15     Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
      35          40          45

20     Gly Ile Ile Tyr Pro Gly Asp Ser Asp Thr Arg Tyr Ser Pro Ser Phe
      50          55          60

25     Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
      65          70          75          80

30     Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
      85          90          95

35     Ala Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
      100          105          110

40     Xaa Xaa Asp Xaa Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
      115          120          125

35     <210> 238
      <211> 130
      <212> PRT
      <213> artificial sequence

40     <220>
      <223> synthetic construct; VH6

      <220>
      <221> MISC_FEATURE
45     <222> (102)..(115)
      <223> Xaa = any amino acid or a deletion

      <220>
      <221> MISC_FEATURE
50     <222> (116)..(116)
      <223> Xaa = any amino acid

      <220>
      <221> MISC_FEATURE
55     <222> (119)..(119)
      <223> Xaa = any amino acid out of a mixture of Phe, His, Ile, Leu, Asn,
      Pro, Ser, Val, Trp or Tyr

```

EP 2 368 907 B1

<220>

<221> MISC_FEATURE

<222> (117)..(117)

<223> Xaa = any amino acid out of a mixture of Ala, Asp, Glu, Phe, Gly, Ile, Leu, Met, Pro, Gln, Ser, Thr, Val or Tyr

<400> 238

```

10      Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
      1              5              10              15

      Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn
      20              25              30

      Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Gly Arg Gly Leu Glu
      35              40              45

20      Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala
      50              55              60

      Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn
25      65              70              75              80

      Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val
30      85              90              95

      Tyr Tyr Cys Ala Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
      100              105              110

35      Xaa Xaa Xaa Xaa Xaa Asp Xaa Trp Gly Gln Gly Thr Leu Val Thr Val
      115              120              125

40      Ser Ser

```

130

<210> 239

<211> 327

<212> DNA

<213> artificial sequence

<220>

<223> synthetic construct; VL kappa1

<220>

<221> misc_feature

<222> (286)..(288)

<223> nnn = GCT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CCT, CAG, CGT, TCT, ACT, GTT, TGG or TAT

EP 2 368 907 B1

<220>
 <221> misc_feature
 <222> (271)..(273)
 <223> nnn = GCT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CAG,
 5 CGT, TCT, ACT, GTT, TGG or TAT

 <220>
 <221> misc_feature
 <222> (265)..(267)
 10 <223> nnn = TTT, CAT, CTT, ATG or CAG

 <220>
 <221> misc_feature
 <222> (253)..(256)
 15 <223> nnn = can be ACT or GTT

 <220>
 <221> misc_feature
 <222> (283)..(285)
 20 <223> nnn = CTT, CCT or TCT

 <220>
 <221> misc_feature
 <222> (280)..(282)
 25 <223> nnn = GCT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CCT,
 CAG, CGT, TCT, ACT, GTT, TGG or TAT

 <220>
 <221> misc feature
 <222> (277)..(279)
 30 <223> nnn = GCT, GAT, GGT, CAT, CTT, AAT or TCT

 <220>
 <221> misc_feature
 <222> (274)..(276)
 35 <223> nnn = GAT, GGT, AAT, TCT or TAT

 <400> 239

 40 gatatccaga tgacccagag cccgtctagc ctgagcgcga gcgtgggtga tcgtgtgacc 60
 attacctgca gagcgagcca gggcattagc agctatctgg cgtgggtacca gcagaaacca 120
 ggtaaagcac cgaaactatt aatttatgca gccagcagct tgcaaagcgg ggtcccgtcc 180
 45 cgttttagcg gctctggatc cggcactgat ttaccctga ccattagcag cctgcaacct 240
 gaagactttg cgnnntatta ttgcnnncag nnnnnnnnnn nnnnnnnnac ctttgccag 300
 50 ggtacgaaag ttgaaattaa acgtacg 327

 <210> 240
 <211> 328
 55 <212> DNA
 <213> artificial sequence

 <220>

EP 2 368 907 B1

<223> synthetic construct; VL kappa2

<220>

<221> misc_feature

5 <222> (289)..(289)

<223> n = GCT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CCT, CAG, CGT, TCT, ACT, GTT, TGG or TAT

<220>

10 <221> misc_feature

<222> (280)..(280)

<223> n = TTT, CAT, CTT, ATG or CAG

<220>

15 <221> misc_feature

<222> (284)..(284)

<223> n = GCT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CAG, CGT, TCT, ACT, GTT, TGG or TAT

<220>

20 <221> misc_feature

<222> (285)..(285)

<223> n = GAT, GGT, AAT, TCT or TAT

<220>

25 <221> misc_feature

<222> (286)..(289)

<223> n = GCT, GAT, GGT, CAT, CTT, AAT or TCT

<220>

30 <221> misc_feature

<222> (287)..(287)

<223> n = GCT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CCT, CAG, CGT, TCT, ACT, GTT, TGG or TAT

<220>

35 <221> misc_feature

<222> (288)..(288)

<223> n = CTT, CCT or TCT

<400> 240

	gatatcgtga tgaccagag ccactgagc ctgccagtga ctccgggcga gcctgcgagc	60
45	attagctgca gaagcagcca aagcctgctg catagcaacg gctataacta tctggattgg	120
	taccttcaaa aaccaggtca aagccgcgag ctattaattt atctgggcag caaccgtgcc	180
50	agtggggtcc cggatcggtt tagcggctct ggatccggca ccgattttac cctgaaaatt	240
	agccgtgtgg aagctgaaga cgtgggcgtg tattattgcn cagnnnnnna cctttggcca	300
	gggtacgaaa gttgaaatta aacgtacg	328

<210> 241

<211> 330

<212> DNA

<213> artificial sequence

<220>

<223> synthetic construct; VL kappa3

<220>

5 <221> misc_feature

<222> (289)..(291)

<223> nnn = GCT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CCT, CAG, CGT, TCT, ACT, GTT, TGG or TAT

10 <220>

<221> misc_feature

<222> (256)..(258)

<223> nnn = can be ACT or GTT

15 <220>

<221> misc_feature

<222> (265)..(276)

<223> nnn = TTT, CAT, CTT, ATG or CAG

20 <220>

<221> misc_feature

<222> (274)..(276)

<223> nnn = GCT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CAG, CGT, TCT, ACT, GTT, TGG or TAT

25 <220>

<221> misc_feature

<222> (277)..(279)

<223> nnn = GAT, GGT, AAT, TCT or TAT

30 <220>

<221> misc_feature

<222> (280)..(282)

<223> nnn = GCT, GAT, GGT, CAT, CTT, AAT or TCT

35 <220>

<221> misc_feature

<222> (283)..(285)

<223> nnn = GCT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CCT, CAG, CGT, TCT, ACT, GTT, TGG or TAT

40 <220>

<221> misc_feature

<222> (286)..(288)

<223> nnn = CTT, CCT or TCT

<400> 241

50 <220>

55 <220>

EP 2 368 907 B1

gatatcgtgc tgacccagag cccggcgacc ctgagcctgt ctccggggcga acgtgcgacc 60
 ctgagctgca gagcgagcca gagcgtgagc agcagctatc tggcgtggta ccagcagaaa 120
 5 ccaggtcaag caccgctctc attaatattat ggcgcgagca gccgtgcaac tgggggtcccg 180
 gcgcgtttta gcggtctctgg atccggcacg gattttaccc tgaccattag cagcctggaa 240
 cctgaagact ttgcgnnnta ttattgcnnn cagnnnnnnnn nnnnnnnnnn nacctttggc 300
 10 caggggtacga aagttgaaat taaacgtacg 330

<210> 242

<211> 345

15 <212> DNA

<213> artificial sequence

<220>

<223> synthetic construct; VL kappa4

20

<220>

<221> misc_feature

<222> (304)..(306)

<223> nnn = GCT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CCT,
 25 CAG, CGT, TCT, ACT, GTT, TGG or TAT

<220>

<221> misc_feature

<222> (283)..(285)

30 <223> nnn = TTT, CAT, CTT, ATG or CAG

<220>

<221> misc_feature

<222> (289)..(291)

35 <223> nnn = GCT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CAG,
 CGT, TCT, ACT, GTT, TGG or TAT

<220>

<221> misc_feature

40 <222> (292)..(294)

<223> nnn = GAT, GGT, AAT, TCT or TAT

<220>

<221> misc_feature

45 <222> (295)..(297)

<223> nnn = GCT, GAT, GGT, CAT, CTT, AAT or TCT

<220>

<221> misc_feature

50 <222> (298)..(300)

<223> nnn = GCT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CCT,
 CAG, CGT, TCT, ACT, GTT, TGG or TAT

<220>

<221> misc_feature

55 <222> (301)..(303)

<223> nnn = CTT, CCT or TCT

EP 2 368 907 B1

<400> 242

	gatatcgtga tgacccagag cccggatagc ctggcggtga gcctgggcca acgtgcgacc	60
5	attaactgca gaagcagcca gagcgtgctg tatagcagca acaacaaaaa ctatctggcg	120
	tgggtaccagc agaaaccagg tcagccgccg aaactattaa tttattgggc atccacccgt	180
10	gaaagcgggg tcccggatcg ttttagcggc tctggatccg gcaactgattt taccctgacc	240
	atttcgtccc tgcaagctga agacgtggcg gtgtattatt gcnnncagnn nnnnnnnnnn	300
	nnnnnnacct ttggccaggg tacgaaagtt gaaattaaac gtacg	345

15 <210> 243

<211> 322

<212> DNA

<213> artificial sequence

20 <220>

<223> synthetic construct; VL lambda1

<220>

<221> misc_feature

25 <222> (274)..(274)

<223> n = TGT, TTT, CAT, CGT, TGG or TAT

<220>

<221> misc_feature

30 <222> (278)..(280)

<223> n = GCT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CCT, C AG, CGT, TCT, ACT, GTT, TGG or TAT

<220>

35 <221> misc_feature

<222> (281)..(282)

<223> n = GCT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CCT, C AG, CGT, TCT, ACT, GTT, TGG or TAT or a deletion

40 <220>

<221> misc_feature

<222> (283)..(283)

<223> n = GCT, TGT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, C CT, CAG, CGT, TCT, ACT, GTT, TGG or TAT

45 <400> 243

	gatatcgtgc tgacccagcc gccttcagtg agtggcgcac caggtcagcg tgtgaccatc	60
50	tcgtgtagcg gcagcagcag caacattggc agcaactatg tgagctggta ccagcagttg	120
	cccgggacgg cgccgaaact gctgatttat gataacaacc agcgtccctc aggcgtgccg	180
55	gacggtttta gcggatccaa aagcggcacc agcgcgagcc ttgcgattac gggcctgcaa	240
	agcgaagacg aagcggatta ttattgccag tctngatnnn nnngtgtttg gcggcgccac	300
	gaagttaacc gttcttgccc ag	322

<210> 244
 <211> 336
 <212> DNA
 <213> artificial sequence

5

<220>
 <223> synthetic construct; VL lambda2

10

<220>
 <221> misc_feature
 <222> (274)..(276)
 <223> nnn = TGT, TTT, CAT, CGT, TGG or TAT

15

<220>
 <221> misc_feature
 <222> (290)..(295)
 <223> nnn = GCT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CCT, CAG, CGT, TCT, ACT, GTT, TGG or TAT or a deletion

20

<220>
 <221> misc_feature
 <222> (296)..(298)
 <223> nnn = GCT, TGT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CCT, CAG, CGT, TCT, ACT, GTT, TGG or TAT

25

<220>
 <221> misc_feature
 <222> (280)..(289)
 <223> nnn = GCT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CCT, CAG, CGT, TCT, ACT, GTT, TGG or TAT

30

<400> 244

35

gatatcgcac	tgaccagcc	agcttcagtg	agcggctcac	caggtcagag	cattaccatc	60
tcgtgtacgg	gtactagcag	cgatgtgggc	ggctataact	atgtgagctg	gtaccagcag	120
catcccgga	aggcgccgaa	actgatgatt	tatgatgtga	gcaaccgtcc	ctcaggcggtg	180
agcaaccgtt	ttagcggatc	caaaagcggc	aacaccgcga	gcctgaccat	tagcggcctg	240
caagcggaag	acgaagcgga	ttattattgc	cagnnngatn	nnnnnnnnnn	nnnnnnngtg	300
tttggcggcg	gcacgaagtt	aaccgttctt	ggccag			336

45

<210> 245
 <211> 327
 <212> DNA
 <213> artificial sequence

50

<220>
 <223> synthetic construct; VL lambda3

55

<220>
 <221> misc_feature
 <222> (265)..(267)
 <223> nnn = TGT, TTT, CAT, CGT, TGG or TAT

<220>
 <221> misc_feature
 <222> (286)..(288)
 <223> nnn = GCT, TGT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT,
 5 CCT, CAG, CGT, TCT, ACT, GTT, TGG or TAT

<220>
 <221> misc_feature
 <222> (280)..(285)
 10 <223> nnn = GCT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CCT,
 CAG, CGT, TCT, ACT, GTT, TGG or TAT or a deletion

<220>
 <221> misc_feature
 15 <222> (271)..(279)
 <223> nnn = GCT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CCT, CAG, CGT, TCT, ACT, GTT,
 TGG or TAT

<400> 245
 20

gatatacgaac	tgaccacagcc	gccttcagtg	agcgttgccac	caggtcagac	cgcgcgatc	60
tcgtgtagcg	gcgatgcgct	gggcgataaa	tacgcgagct	ggtaccagca	gaaacccggg	120
caggcgccag	ttctggtgat	ttatgatgat	tctgaccgtc	cctcaggcat	cccggaacgc	180
tttagcggat	ccaacagcgg	caacaccgcg	accctgacca	ttagcggcac	tcaggcgga	240
gacgaagcgg	attattattg	ccagnnngat	nnnnnnnnnn	nnnnnnnnngt	gtttggcggc	300
ggcacgaagt	taaccgttct	tggccag				327

<210> 246
 <211> 382
 35 <212> DNA
 <213> artificial sequence

<220>
 <223> synthetic construct; VH1A
 40

<220>
 <221> misc_feature
 <222> (345)..(347)
 <223> nnn = TTT, CAT, ATT, CTT, AAT, CCT, TCT, GTT, TGG or TAT
 45

<220>
 <221> misc_feature
 <222> (339)..(341)
 <223> nnn = GCT, GAT, GAG, TTT, GGT, ATT, CTT, ATG, CCT, CAG, TCT, ACT,
 50 GTT or TAT

<220>
 <221> misc_feature
 <222> (336)..(338)
 55 <223> nnn = GCT, TGT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT,
 CCT, CAG, CGT, TCT, ACT, GTT, TGG or TAT

<220>

EP 2 368 907 B1

<221> misc_feature
 <222> (295)..(335)
 <223> nnn = GCT, TGT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT,
 CCT, CAG, CGT, TCT, ACT, GTT, TGG or TAT or a deletion
 5
 <400> 246

 cagggtgcaat tggttcagtc tggcgcgga gtagaaaaaac cgggcagcag cgtgaaagtg 60
 10 agctgcaaag cctccggagg cacttttagc agctatgcga ttagctgggt gcgccaagcc 120
 cctgggcagg gtctcgagt gatgggcggc attattccga tttttggcac ggcgaactac 180
 15
 gcgcagaagt ttcagggccg ggtgaccatt accgcggatg aaagcaccag caccgcgtat 240
 atggaactga gcagcctgcg tagcgaagat acggccgtgt attattgcgc gcgtnnnnnn 300
 20 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn ngatnnntgg ggccaaggca 360
 ccctgggtgac ggtagctca gc 382
 25
 <210> 247
 <211> 383
 <212> DNA
 <213> artificial sequence
 30
 <220>
 <223> synthetic construct; VH1B
 <220>
 <221> misc_feature
 <222> (346)..(348)
 35 <223> nnn = TTT, CAT, ATT, CTT, AAT, CCT, TCT, GTT, TGG or TAT
 <220>
 <221> misc_feature
 <222> (295)..(336)
 40 <223> nnn = GCT, TGT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT,
 CCT, CAG, CGT, TCT, ACT, GTT, TGG or TAT or a deletion
 <220>
 <221> misc_feature
 45 <222> (337)..(339)
 <223> nnn = GCT, TGT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT,
 CCT, CAG, CGT, TCT, ACT, GTT, TGG or TAT
 50
 <220>
 <221> misc_feature
 <222> (340)..(342)
 <223> nnn = GCT, GAT, GAG, TTT, GGT, ATT, CTT, ATG, CCT, CAG, TCT, ACT,
 GTT or TAT
 55
 <400> 247

EP 2 368 907 B1

cagggtgcaat tgggttcagag cggcgcgga gtgaaaaaac cgggcgcgag cgtgaaagtg 60

agctgcaaag cctccggata tacctttacc agctattata tgcactgggt ccgccaagcc 120

5 cctggggcagg gctctcgagtg gatgggctgg attaaccga atagcggcgg cacgaactac 180

gcgcagaagt ttcagggccg ggtgaccatg acccgtgata ccagcattag caccgcgtat 240

atggaactga gcagcctgcg tagcgaagat acggccgtgt attattgcgc gcgtnnnnnn 300

10 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nngatnnntg gggccaaggc 360

accctgggtga cggtttagctc agc 383

15 <210> 248
<211> 386
<212> DNA
<213> artificial sequence

20 <220>
<223> synthetic construct; VH2

<220>
<221> misc_feature
25 <222> (349)..(351)
<223> nnn = TTT, CAT, ATT, CTT, AAT, CCT, TCT, GTT, TGG or TAT

<220>
<221> misc_feature
30 <222> (298)..(339)
<223> nnn = GCT, TGT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CCT, CAG, CGT, TCT, ACT, GTT, TGG or TAT or a deletion

<220>
35 <221> misc_feature
<222> (340)..(342)
<223> nnn = GCT, TGT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, CCT, CAG, CGT, TCT, ACT, GTT, TGG or TAT

<220>
40 <221> misc_feature
<222> (343)..(345)
<223> nnn = GCT, GAT, GAG, TTT, GGT, ATT, CTT, ATG, CCT, CAG, TCT, ACT, GTT or TAT

45 <400> 248

50

55

EP 2 368 907 B1

cagggtgcaat tgaagaaag cggcccgcc ctggtgaaac cgacccaaac cctgaccctg 60
acctgtacct tttccggatt tagcctgtcc acgtctggcg ttggcgtggg ctggattcgc 120
5 cagccgcctg ggaaagccct cgagtggctg gctctgattg attgggatga tgataagtat 180
tatagcacca gcctgaaaac gcgtctgacc attagcaaag atacttcgaa aaatcagggtg 240
gtgctgacta tgaccaacat ggaccgggtg gatacggcca cctattattg cgcgcgtnnn 300
10 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnngatnn ntggggccaa 360
ggcaccctgg tgacggtag ctacgc 386

15 <210> 249
<211> 349
<212> DNA
<213> artificial sequence

20 <220>
<223> synthetic construct; VH3
<220>
<221> misc_feature
25 <222> (314)..(314)
<223> n = TTT, CAT, ATT, CTT, AAT, CCT, TCT, GTT, TGG or TAT

<220>
<221> misc_feature
30 <222> (295)..(308)
<223> n = GCT, TGT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, C
CT, CAG, CGT, TCT, ACT, GTT, TGG or TAT or a deletion

<220>
<221> misc_feature
35 <222> (309)..(309)
<223> n = GCT, TGT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, C
CT, CAG, CGT, TCT, ACT, GTT, TGG or TAT

40 <220>
<221> misc_feature
<222> (310)..(310)
<223> n = GCT, GAT, GAG, TTT, GGT, ATT, CTT, ATG, CCT, CAG, TCT, ACT, G
TT or TAT

45 <400> 249

cagggtgcaat tgggtgaaag cggcgccggc ctggtgcaac cggcgccgag cctgcgtctg 60
50 agctgcgcgg cctccggatt taccttttagc agctatgcga tgagctgggt gcgccaagcc 120
cctgggaagg gtctcgagtg ggtgagcgcg attagcggta gcggcgccag cacctattat 180
gcggatagcg tgaagggccg ttttaccatt tcacgtgata attcgaaaaa caccctgtat 240
55 ctgcaaatga acagcctgcg tgcggaagat acggccgtgt attattgcgc gcgtnnnnnn 300
nnnnnnnnnn gatntggggc caaggcacc tggtgacggt tagctcagc 349

<210> 250
 <211> 346
 <212> DNA
 <213> artificial sequence

5

<220>
 <223> synthetic construct; VH4

10

<220>
 <221> misc_feature
 <222> (311)..(311)
 <223> n = TTT, CAT, ATT, CTT, AAT, CCT, TCT, GTT, TGG or TAT

15

<220>
 <221> misc_feature
 <222> (292)..(305)
 <223> n = GCT, TGT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, C
 CT, CAG, CGT, TCT, ACT, GTT, TGG or TAT or a deletion

20

<220>
 <221> misc_feature
 <222> (306)..(306)
 <223> n = GCT, TGT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, C

25

CT, CAG, CGT, TCT, ACT, GTT, TGG or TAT

<220>
 <221> misc_feature
 <222> (307)..(307)
 <223> n = GCT, GAT, GAG, TTT, GGT, ATT, CTT, ATG, CCT, CAG, TCT, ACT, G
 TT or TAT

30

<400> 250

35

caggtgcaat	tgcaagaaag	tggtccgggc	ctggtgaaac	cgagcgaaac	cctgagcctg	60
acctgcaccg	tttccggagg	cagcattagc	agctattatt	ggagctggat	tcgccagccg	120
cctgggaagg	gtctcgagt	gattggctat	atttattata	gcggcagcac	caactataat	180
ccgagcctga	aaagccgggt	gaccattagc	gttgatactt	cgaaaaacca	gtttagcctg	240
aaactgagca	gcgtgacggc	ggcggatacg	gccgtgtatt	attgcgcgcg	tnnnnnnnnn	300
nnnnnnngat	ntggggccaa	ggcacccctg	tgacgggtag	ctcagc		346

<210> 251
 <211> 349
 <212> DNA
 <213> artificial sequence

50

<220>
 <223> synthetic construct; VH5

55

<220>
 <221> misc_feature
 <222> (314)..(314)
 <223> n = TTT, CAT, ATT, CTT, AAT, CCT, TCT, GTT, TGG or TAT

<220>
 <221> misc_feature
 <222> (295)..(304)
 <223> n = GCT, TGT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, C
 5 CT, CAG, CGT, TCT, ACT, GTT, TGG or TAT or a deletion

<220>
 <221> misc_feature
 <222> (305)..(307)
 10 <223> n = GCT, TGT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT, C
 CT, CAG, CGT, TCT, ACT, GTT, TGG or TAT

<220>
 <221> misc_feature
 15 <222> (308)..(310)
 <223> n = GCT, GAT, GAG, TTT, GGT, ATT, CTT, ATG, CCT, CAG, TCT, ACT, G
 TT or TAT

<400> 251
 20

caggtgcaat	tggttcagag	cggcgcggaa	gtgaaaaaac	cgggcgaaag	cctgaaaatt	60
agctgcaaag	gttccggata	ttcctttacg	agctattgga	ttggctgggt	gcgccagatg	120
cctgggaagg	gtctcgagt	gatgggcatt	atztatccgg	gcgatagcga	taccgcgttat	180
tctccgagct	ttcagggcca	ggtgaccatt	agcgcggata	aaagcattag	caccgcgtat	240
cttcaatgga	gcagcctgaa	agcgagcgat	acggccatgt	attattgcgc	gcgtnnnnnn	300
nnnnnnnnnn	gatntggggc	caaggcaccc	tggtgacggt	tagctcagc		349

<210> 252
 <211> 392
 35 <212> DNA
 <213> artificial sequence

<220>
 <223> synthetic construct; VH6
 40

<220>
 <221> misc_feature
 <222> (355)..(357)
 <223> nnn = TTT, CAT, ATT, CTT, AAT, CCT, TCT, GTT, TGG or TAT
 45

<220>
 <221> misc_feature
 <222> (304)..(345)
 <223> nnn = GCT, TGT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT,
 50 CCT, CAG, CGT, TCT, ACT, GTT, TGG or TAT or a deletion

<220>
 <221> misc_feature
 <222> (346)..(348)
 55 <223> nnn = GCT, TGT, GAT, GAG, TTT, GGT, CAT, ATT, AAG, CTT, ATG, AAT,
 CCT, CAG, CGT, TCT, ACT, GTT, TGG or TAT

<220>

EP 2 368 907 B1

<221> misc_feature

<222> (349)..(351)

<223> nnn = GCT, GAT, GAG, TTT, GGT, ATT, CTT, ATG, CCT, CAG, TCT, ACT, GTT or TAT

<400> 252

```

caggtgcaat tgcaacagtc tgggtccgggc ctggtgaaac cgagccaaac cctgagcctg      60
acctgtgcga tttccggaga tagcgtgagc agcaacagcg cggcgtggaa ctggattcgc      120
cagtctcctg ggcgtggcct cgagtggctg ggccgtacct attatcgtag caaatgggtat      180
aacgattatg cggtgagcgt gaaaagccgg attaccatca acccggatac ttcgaaaaaac      240
cagtttagcc tgcaactgaa cagcgtgacc ccggaagata cggccgtgta ttattgcgcg      300
cgtnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn ngatnnntgg      360
ggccaaggca ccctggtgac ggtagctca gc                                     392

```

<210> 253

<211> 4151

<212> DNA

<213> artificial sequence

<220>

<223> synthetic construct; pMORPH 18 Fab_5'

<400> 253

EP 2 368 907 B1

	tctagataac gagggcaaaa aatgaaaaaag acagctatcg cgattgcagt ggccactggct	60
	ggtttcgcta ccgtagcgca ggccgatatc gtgctgaccc agagcccggc gaccctgagc	120
5	ctgtctccgg gcgaacgtgc gaccctgagc tgcagagcga gccagagcgt gagcagcagc	180
	tatctggcgt ggtaccagca gaaaccaggt caagcaccgc gtctattaat ttatggcgcg	240
	agcagccgtg caactggggg cccggcgcgt tttagcggct ctggatccgg cacggatttt	300
10	accctgacca ttagcagcct ggaacctgaa gactttgcgg tgtattattg ccagcagcat	360
	tataccaccc cgccgacctt tggccagggt acgaaagttg aaattaaacg tacggtggct	420
15	gtcccgagcg tgtttatttt tccgccgagc gatgaacaac tgaaaagcgg cacggcgagc	480
	gtggtgtgcc tgctgaacaa cttttatccg cgtgaagcga aagttcagtg gaaagtagac	540
	aacgcgctgc aaagcggcaa cagccaggaa agcgtgaccg aacaggatag caaagatagc	600
20	acctattctc tgagcagcac cctgaccctg agcaaagcgg attatgaaaa acataaagtg	660
	tatgcgtgcg aagtgaccca tcaaggctctg agcagcccgg tgactaaatc ttttaatcgt	720
25	ggcgaggcct gataagcatg cgtaggagaa aataaaatga aacaaagcac tattgcactg	780
	gcactcttac cgttgctctt caccctgtt accaaagccg aagtgcaatt ggtggaaagc	840
	ggcggcggcc tgggtgaacc gggcggcagc ctgcgtctga gctgcgcggc ctccggattt	900
30	accttttagca gctatgcgat gagctgggtg cgccaagccc ctgggaaggg tctcgagtgg	960
	gtgagcgcga ttagcggtag cggcggcagc acctattatg cggatagcgt gaaaggccgt	1020
35	tttaccatth cacgtgataa ttcgaaaaac accctgtatc tgcaaatgaa cagcctgcgt	1080
40		
45		
50		
55		

EP 2 368 907 B1

	gcggaagata cggccgtgta ttattgcgcg cgttggggcg gcgatggctt ttatgcgatg	1140
	gattattggg gccaaaggcac cctgggtgacg gttagctcag cgtcgaccaa aggtccaagc	1200
5	gtgtttccgc tggctccgag cagcaaaagc accagcggcg gcacggctgc cctgggctgc	1260
	ctgggttaaag attatttccc ggaaccagtc accgtgagct ggaacagcgg ggcgctgacc	1320
	agcggcgtgc atacctttcc ggcggtgctg caaagcagcg gcctgtatag cctgagcagc	1380
10	gttgtgaccg tgccgagcag cagcttaggc actcagacct atatttgcaa cgtgaaccat	1440
	aaaccgagca acaccaaagt ggataaaaaa gtggaaccga aaagcgaatt cgggggaggg	1500
	agcgggagcg gtgattttga ttatgaaaag atggcaaacg ctaataaggg ggctatgacc	1560
15	gaaaatgccg atgaaaacgc gctacagtct gacgctaaag gcaaacttga ttctgtcgct	1620
	actgattacg gtgctgctat cgatggtttc attgggtgacg tttccggcct tgctaattgg	1680
20	aatggtgcta ctggtgattt tgctggctct aattcccaaa tggctcaagt cggtgacgg	1740
	gataattcac ctttaatgaa taatttccgt caatatttac cttccctccc tcaatcgggt	1800
	gaatgtcgcc cttttgtctt tggcgctggg aaaccatatg aattttctat tgattgtgac	1860
25	aaaataaaact tattccgtgg tgtctttgcg tttcttttat atgttgccac ctttatgtat	1920
	gtattttcta cgtttgctaa catactgcgt aataaggagt cttgataagc ttgacctgtg	1980
30	aagtgaaaaa tggcgcagat tgtgcgacat tttttttgtc tgccgtttta tgaaattgta	2040
	aacgttaata ttttgttaaa attcgcgtta aatttttgtt aaatcagctc attttttaac	2100
	caataggccg aaatcggcaa aatcccttat aaatcaaaaag aatagaccga gatagggttg	2160
35	agtgttgttc cagtttgga caagagtcca ctattaaaga acgtggactc caacgtcaaa	2220
	gggcgaaaaa ccgtctatca gggcgatggc ccactacgag aaccatcacc ctaatcaagt	2280
40	tttttggggg cgaggtgccg taaagcacta aatcggaacc cttaaaggag ccccgatatt	2340
	agagcttgac ggggaaagcc ggcgaacgtg gcgagaaagg aagggaagaa agcgaaagga	2400
	gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac cacaccgcgc	2460
45	gcgcttaatg cgcgctaca gggcgcgctg tagccatgtg agcaaaaaggc cagcaaaagg	2520
	ccaggaaccg taaaaaggcc gcgttgctgg cgtttttcca taggctccgc cccctgacg	2580
	agcatcacia aaatcgacgc tcaagtcaga ggtggcgaaa cccgacagga ctataaagat	2640
50	accaggcggt tccccctgga agctccctcg tgcgctctcc tgttccgacc ctgcgcgtta	2700
	ccggatacct gtccgccttt ctcccttcgg gaagcgtggc gctttctcat agctcacgct	2760
55	gtaggtatct cagttcgggt taggtcgctt gctccaagct gggctgtgtg cacgaacccc	2820
	ccgttcagtc cgaccgctgc gccttatccg gtaactatcg tcttgagtcc aaccgggtaa	2880

EP 2 368 907 B1

gacacgactt atcgccactg gcagcagcca ctggtaacag gattagcaga gcgaggatatg 2940
 taggcggtgc tacagagttc ttgaagtggg ggcctaacta cggctacact agaagaacag 3000
 5 tatttggtat ctgcgctctg ctgtagccag ttaccttcgg aaaaagagtt ggtagctctt 3060
 gatccggcaa acaaaccacc gctggtagcg gtgggtttttt tgtttgcaag cagcagatta 3120
 10 cgcgcagaaa aaaaggatct caagaagatc ctttgatctt ttctacgggg tctgacgctc 3180
 agtggaaacga aaactcacgt taagggattht tggtcagatc tagcaccagg cgtttaaggg 3240
 caccaataac tgccttaaaa aaattacgcc ccgccctgcc actcatcgca gtactgttgt 3300
 15 aattcattaa gcattctgcc gacatggaag ccatcacaaa cggcatgatg aacctgaatc 3360
 gccagcggca tcagcacctt gtcgccttgc gtataatatt tgcccatagt gaaaacgggg 3420
 gcgaagaagt tgtccatatt ggctacgttt aaatcaaaac tggtgaaaact caccagggga 3480
 20 ttggctgaga cgaaaaacat attctcaata aacccttttag ggaaataggc cagggttttca 3540
 ccgtaacacg ccacatcttg cgaatatatg tgtagaaact gccggaaatc gtcgtggtat 3600
 25 tcactccaga gcgatgaaaa cgtttcagtt tgctcatgga aaacggtgta acaaggggtga 3660
 acactatccc atatcaccag ctcaccgtct ttcatthgcca tacggaaactc cgggtgagca 3720
 ttcatcaggc gggcaagaat gtgaataaaag gccggataaa acttgtgctt atttttcttt 3780
 30 acggtcttta aaaaggccgt aatatccagc tgaacggtct ggttataggc acattgagca 3840
 actgactgaa atgcctcaaa atgttcttta cgatgccatt gggatatatc aacggtggta 3900
 35 tatccagtga tttttttctc catthttagct tccttagctc ctgaaaaatct cgataactca 3960
 aaaaatacgc ccggtagtga tcttattttca ttatggtgaa agttggaacc tcacccgacg 4020
 tctaattgta gttagctcac tcattaggca cccaggctt tacactttat gcttccggct 4080
 40 cgtatgttgt gtggaattgt gagcggataa caatttcaca caggaaacag ctatgaccat 4140
 gattacgaat t 4151

45 <210> 254
 <211> 638
 <212> PRT
 <213> artificial sequence

50 <220>
 <223> synthetic construct; pMORPH18_Fab protein

<400> 254

55 Met Lys Lys Thr Ala Ile Ala Ile Ala Val Ala Leu Ala Gly Phe Ala
 1 5 10 15

EP 2 368 907 B1

	Thr Val Ala Gln Ala Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu	
	20	25 30
5	Ser Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln	
	35	40 45
10	Ser Val Ser Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln	
	50	55 60
15	Ala Pro Arg Leu Leu Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val	
	65	70 75 80
20	Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr	
	85	90 95
25	Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln	
	100	105 110
30	His Tyr Thr Thr Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile	
	115	120 125
35	Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp	
	130	135 140
40	Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn	
	145	150 155 160
45	Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu	
	165	170 175
50	Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp	
	180	185 190
55	Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr	
	195	200 205
60	Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser	
	210	215 220
65	Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Ala Met Lys Gln Ser	
	225	230 235 240
70	Thr Ile Ala Leu Ala Leu Leu Pro Leu Leu Phe Thr Pro Val Thr Lys	
	245	250 255

EP 2 368 907 B1

	Ala	Gln	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	
				260					265					270			
5	Gly	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	
			275					280					285				
10	Tyr	Ala	Met	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	
		290					295					300					
15	Val	Ser	Ala	Ile	Ser	Gly	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	
	305					310					315					320	
20	Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	
				325						330					335		
25	Tyr	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	
				340					345					350			
30	Cys	Ala	Arg	Trp	Gly	Gly	Asp	Gly	Phe	Tyr	Ala	Met	Asp	Tyr	Trp	Gly	
			355					360					365				
35	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser	Ala	Ser	Thr	Lys	Gly	Pro	Ser	
		370					375						380				
40	Val	Phe	Pro	Leu	Ala	Pro	Ser	Ser	Lys	Ser	Thr	Ser	Gly	Gly	Thr	Ala	
	385					390					395					400	
45	Ala	Leu	Gly	Cys	Leu	Val	Lys	Asp	Tyr	Phe	Pro	Glu	Pro	Val	Thr	Val	
					405					410					415		
50	Ser	Trp	Asn	Ser	Gly	Ala	Leu	Thr	Ser	Gly	Val	His	Thr	Phe	Pro	Ala	
			420						425					430			
55	Val	Leu	Gln	Ser	Ser	Gly	Leu	Tyr	Ser	Leu	Ser	Ser	Val	Val	Thr	Val	
		435					440						445				
60	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys	Asn	Val	Asn	His	
		450				455						460					
65	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Glu	
	465					470					475					480	
70	Phe	Gly	Gly	Gly	Ser	Gly	Ser	Gly	Asp	Phe	Asp	Tyr	Glu	Lys	Met	Ala	

EP 2 368 907 B1

485

490

495

5 Asn Ala Asn Lys Gly Ala Met Thr Glu Asn Ala Asp Glu Asn Ala Leu
500 505 510

10 Gln Ser Asp Ala Lys Gly Lys Leu Asp Ser Val Ala Thr Asp Tyr Gly
515 520 525

15 Ala Ala Ile Asp Gly Phe Ile Gly Asp Val Ser Gly Leu Ala Asn Gly
530 535 540

20 Asn Gly Ala Thr Gly Asp Phe Ala Gly Ser Asn Ser Gln Met Ala Gln
545 550 555 560

25 Val Gly Asp Gly Asp Asn Ser Pro Leu Met Asn Asn Phe Arg Gln Tyr
565 570 575

30 Leu Pro Ser Leu Pro Gln Ser Val Glu Cys Arg Pro Phe Val Phe Gly
580 585 590

35 Ala Gly Lys Pro Tyr Glu Phe Ser Ile Asp Cys Asp Lys Ile Asn Leu
595 600 605

40 Phe Arg Gly Val Phe Ala Phe Leu Leu Tyr Val Ala Thr Phe Met Tyr
610 615 620

45 Val Phe Ser Thr Phe Ala Asn Ile Leu Arg Asn Lys Glu Ser
625 630 635

<210> 255

<211> 5020

40 <212> DNA

<213> artificial sequence

<220>

<223> synthetic construct; pMORPH x9

45

<400> 255

atcgtgctga cccagccgcc ttcagtgagt ggcgcaccag gtcagcgtgt gaccatctcg 60
50 tgtagcggca gcagcagcaa cattggcagc aactatgtga gctggtacca gcagttgccc 120
gggacggcgc cgaaactgct gatttatgat aacaaccagc gtccctcagg cgtgccggat 180
cgttttagcg gatccaaaag cggcaccagc gcgagccttg cgattacggg cctgcaaagc 240
55 gaagacgaag cggattatta ttgccagagc tatgacatgc ctcaggctgt gtttggcggc 300
ggcacgaagt ttaaccgttc ttggccagcc gaaagccgca ccgagtgtga cgctgtttcc 360

EP 2 368 907 B1

	gccgagcagc gaagaattgc aggcgaacaa agcgaccctg gtgtgcctga ttagcgactt	420
	ttatccggga gccgtgacag tggcctggaa ggcagatagc agccccgtca aggcgggagt	480
5	ggagaccacc acaccctcca aacaaagcaa caacaagtac gcggccagca gctatctgag	540
	cctgacgcct gagcagtgga agtcccacag aagctacagc tgccagggtca cgcattgaggg	600
10	gagcaccgtg gaaaaaacccg ttgcgccgac tgaggcctga taagcatgcg taggagaaaa	660
	taaaatgaaa caaagcacta ttgcaactggc actcttaccg ttgctcttca cccctgttac	720
	caaagcccag gtgcaattga aagaaagcgg cccggccctg gtgaaaccga cccaaaccct	780
15	gaccctgacc tgtacctttt ccggatttag cctgtccacg tctggcggtg gcgtgggctg	840
	gattcgccag ccgcctggga aagccctcga gtggctggct ctgattgatt gggatgatga	900
	taagtattat agcaccagcc tgaaaacgcg tctgaccatt agcaaagata cttcgaaaaa	960
20	tcagggtggtg ctgactatga ccaacatgga cccggtggat acggccacct attattgcgc	1020
	gcgttctcct cgttatcgtg gtgcttttga ttattggggc caaggcaccg tggtagcgg	1080
25	tagctcagcg tcgaccaaag gtccaagcgt gtttccgctg gctccgagca gcaaaagcac	1140
	cagcggcggc acggctgccc tgggctgcct ggttaaagat tatttcccgg aaccagtcac	1200
	cgtgagctgg aacagcgggg cgctgaccag cggcgtgcat acctttccgg cggtagctgca	1260
30	aagcagcggc ctgtatagcc tgagcagcgt tgtgaccgtg ccgagcagca gcttaggcac	1320
	tcagacctat atttgcaacg tgaaccataa accgagcaac accaaaagtg ataaaaaagt	1380
35	ggaaccgaaa agcgaattcg actataaaga tgacgatgac aaaggcgcgc cgtggagcca	1440
	cccgagttt gaaaaatgat aagcttgacc tgtgaagtga aaaatggcgc agattgtgcg	1500
	acattttttt tgtctgccgt ttaattaaag gggggggggg gccggcctgg ggggggggtg	1560
40	acatgaaatt gtaaacgtta atattttgtt aaaattcgcg ttaaattttt gttaaatacag	1620
	ctcatttttt aaccaatagg ccgaaatcgg caaaatccct tataaatcaa aagaatagac	1680
	cgagataggg ttgagtgttg ttccagtttg gaacaagagt ccactattaa agaacgtgga	1740
45	ctccaacgtc aaagggcgaa aaaccgtcta tcagggcgat ggcccactac gagaaccatc	1800
	accctaataca agtttttttg ggtcgaggtg ccgtaaagca ctaaatcgga accctaaagg	1860
50	gagccccga tttagagctt gacggggaaa gccggcgaac gtggcgagaa aggaaggga	1920
	gaaagcgaaa ggagcgggcg ctagggcgct ggcaagtgtg gcggtcacgc tgcgcgtaac	1980
	caccacaccc gccgcgctta atgcgcgcgt acagggcgcg tgctagacta gtgtttaaac	2040
55	cggaccgggg gggggcttaa gtgggctgca aaacaaaacg gcctcctgtc aggaagccgc	2100

EP 2 368 907 B1

	ttttatcggg tagcctcact gcccgctttc cagtcgggaa acctgtcgtg ccagctgcat	2160
	cagtgaatcg gccaacgcgc ggggagaggg ggtttgcgta ttgggagcca gggtaggtttt	2220
5	tcttttcacc agtgagacgg gcaacagctg attgcccttc accgcctggc cctgagagag	2280
	ttgcagcaag cgggtccacgc tggtttgccc cagcaggcga aaatcctgtt tgatgggtgg	2340
	cagcggcggg atataacatg agctgtcctc ggtatcgtcg tatccacta ccgagatgtc	2400
10	cgcaccaacg cgcagcccgg actcggtaat ggcacgcatt gcgccagcg ccatctgato	2460
	gttggcaacc agcatcgcag tgggaacgat gccctcatte agcatttgca tggtttggtg	2520
15	aaaaccggac atggcactcc agtcgccttc ccgttcgct atcggctgaa tttgattgag	2580
	agtgagatat ttatgccagc cagccagacg cagacgcgcc gagacagaac ttaatggggc	2640
	agctaacagc gcgatttgct ggtggcccaa tgcgaccaga tgcctcacgc ccagtcgcgt	2700
20	accgtcctca tgggagaaaa taatactgtt gatgggtgtc tggtcagaga catcaagaaa	2760
	taacgccgga acattagtgc aggagcttc cacagcaata gcacctggt catccagcgg	2820
	atagtttaata atcagcccac tgacacgttg cgcgagaaga ttgtgcaccg ccgctttaca	2880
25	ggcttcgacg ccgcttcgtt ctaccatcga cagcaccacg ctggcaccga gttgatcggc	2940
	gcgagattta atcgcgcgca caatttgca cgccgcgtgc agggccagac tggaggtggc	3000
30	aacgccaatc agcaacgact gtttgccgc cagttgtgt gccacgcggt taggaatgta	3060
	attcagctcc gccatcgccg ctccacttt ttccgcgtt ttgcagaaa cgtggctggc	3120
	ctggttcacc acgcgggaaa cggctgata agagacaccg gcatactctg cgacatcgta	3180
35	taacgttact ggtttcacat tcaccaccct gaattgactc tcttcggggc gctatcatgc	3240
	cataccgga aaggttttgc gccattcgat gctagccatg tgagcaaaag gccagcaaaa	3300
	ggccaggaac cgtaaaaagg ccgcgttgct ggcgtttttc cataggotcc gccccctga	3360
40	cgagcatcac aaaaatcgac gctcaagtca gaggtggcga aaccgcagag gactataaag	3420
	ataccaggcg tttccccctg gaagctccct cgtgcgctct cctgttccga cctgcccgt	3480
45	taccggatac ctgtccgctt ttctcccttc ggggaagcgtg gcgctttctc atagctcacg	3540
	ctgtaggtat ctgattcgg ttaggtcgt tcgctccaag ctgggctgtg tgcacgaacc	3600
	ccccgttcag cccgaccgct gcgccttatc cggtaactat cgtottgagt ccaaccgggt	3660
50	aagacacgac ttatcgccac tggcagcagc cactggtaac aggattagca gagcgaggta	3720
	tgtaggcggg gctacagagt tcttgaagtg gtggcctaac tacggctaca ctagaagaac	3780
	agtatttggt atctgcgtc tgctgtagcc agttaccttc ggaaaaagag ttggtagctc	3840
55	ttgatccggc aaacaaacca ccgctggtag cggtaggtttt tttgtttgca agcagcagat	3900

EP 2 368 907 B1

	tacgcgcaga	aaaaaaggat	ctcaagaaga	tcctttgatc	ttttctacgg	ggtctgacgc	3960
	tcagtggaac	gaaaactcac	gttaagggat	tttggtcaga	tctagcacca	ggcgtttaag	4020
5	ggcaccaata	actgccttaa	aaaaattacg	ccccgccctg	ccactcatcg	cagtactggt	4080
	gtaattcatt	aagcattctg	ccgacatgga	agccatcaca	aacggcatga	tgaacctgaa	4140
	tcgccagcgg	catcagcacc	ttgtcgcctt	gcgtataata	tttgcccata	gtgaaaacgg	4200
10	gggcgaagaa	gttgtccata	ttggctacgt	ttaaatacaa	actggtgaaa	ctcaccacgg	4260
	gattggctga	gacgaaaaac	atatttctca	taaacccttt	agggaaatag	gccagggtttt	4320
15	caccgtaaca	cgccacatct	tgcgaatata	tgtgtagaaa	ctgccgaaa	tcgtcgtggt	4380
	attcactcca	gagcgatgaa	aacgtttcag	tttgctcatg	gaaaacggtg	taacaagggt	4440
	gaacactatc	ccatatcacc	agctcaccgt	ctttcattgc	catacggaac	tccgggtgag	4500
20	cattcatcag	gcgggcaaga	atgtgaataa	aggccggata	aaacttgtgc	ttatttttct	4560
	ttacgggtctt	taaaaaggcc	gtaatatcca	gctgaacggt	ctgggttatag	gtacattgag	4620
	caactgactg	aaatgcctca	aaatgttctt	tacgatgcc	ttgggatata	tcaacggtgg	4680
25	tatatccagt	gatttttttc	tccatttttag	cttccttagc	tcctgaaaat	ctcgataact	4740
	caaaaaatac	gcccggtagt	gatcttattt	cattatgggt	aaagttggaa	cctcacccca	4800
30	cgtctaattgt	gagttagctc	actcattagg	caccccaggc	tttacacttt	atgcttccgg	4860
	ctcgtatggt	gtgtggaatt	gtgagcggat	aacaatttca	cacaggaaac	agctatgacc	4920
	atgattacga	atttctagat	aacgagggca	aaaaatgaaa	aagacagcta	tcgcgattgc	4980
35	agtggcactg	gctggttttcg	ctaccgtagc	gcaggccgat			5020

<210> 256

<211> 7

<212> PRT

<213> artificial sequence

 $\langle 220 \rangle$

<223> synthetic construct

<400> 256

Ala Glu Phe Arg His Asp Cys
1 5

<210> 257

<211> 7

<212> PRT

<213> artificial sequence

$\langle 220 \rangle$

<223> synthetic construct

EP 2 368 907 B1

<400> 257

Glu Phe Arg His Asp Ser Cys
1 5

<210> 258

$\langle 211 \rangle$ 7

<212> PRT

10 <213> artificial sequence

$\langle 220 \rangle$

<223> synthetic construct

15 <400> 258

Phe Arg His Asp Ser Gly Cys
1 5

20

<210> 259

 $\langle 211 \rangle$ 7

<212> PRT

<213> artificial sequence

25

<220>

<223> sy

<400> 259

30

Arg His Asp Ser Gly Tyr Cys
1 . 5

35 <210> 260

$\langle 211 \rangle$ 7

<212> PRT

<213> artificial sequence

40 $\langle 220 \rangle$

<223> synthetic construct

<400> 260

45 His Asp Ser Gly Tyr Glu Cys
1 5

<210> 261

 $\langle 211 \rangle$ 7

<212> PRT

<213> artificial sequence

<220>

55 <223> synthetic construct

<900> 261

EP 2 368 907 B1

Asp Ser Gly Tyr Glu Val Cys
1 5

5 <210> 262
<211> 7
<212> PRT
<213> artificial sequence

10 <220>
<223> synthetic construct

<400> 262

15 Ser Gly Tyr Glu Val His Cys
1 5

20 <210> 263
<211> 7
<212> PRT
<213> artificial sequence

25 <220>
<223> synthetic construct

<400> 263

30 Tyr Glu Val His His Gln Cys
1 5

<210> 264
<211> 7
<212> PRT
<213> artificial sequence

35 <220>
<223> synthetic construct

<400> 264

40 Glu Val His His Gln Lys Cys
1 5

45 <210> 265
<211> 7
<212> PRT
<213> artificial sequence

50 <220>
<223> synthetic construct

<400> 265

55 Val His His Gln Lys Leu Cys

EP 2 368 907 B1

1

5

5
<210> 266
<211> 7
<212> PRT
<213> artificial sequence

10
<220>
<223> synthetic construct

<400> 266

15
His His Gln Lys Leu Val Cys
1 5

20
<210> 267
<211> 7
<212> PRT
<213> artificial sequence

25
<220>
<223> synthetic construct

<400> 267

30
His Gln Lys Leu Val Phe Cys
1 5

35
<210> 268
<211> 7
<212> PRT
<213> artificial sequence

40
<220>
<223> synthetic construct

<400> 268

45
Gln Lys Leu Val Phe Phe Cys
1 5

50
<210> 269
<211> 7
<212> PRT
<213> artificial sequence

55
<220>
<223> synthetic construct

<400> 269

Lys Leu Val Phe Phe Ala Cys
1 5

EP 2 368 907 B1

	<210> 270	
	<211> 7	
	<212> PRT	
	<213> artificial sequence	
5		
	<220>	
	<223> synthetic construct	
10	<400> 270	
		Leu Val Phe Phe Ala Glu Cys
		1 5
15	<210> 271	
	<211> 7	
	<212> PRT	
	<213> artificial sequence	
20	<220>	
	<223> synthetic construct	
	<400> 271	
25		
		Val Phe Phe Ala Glu Asp Cys
		1 5
30	<210> 272	
	<211> 7	
	<212> PRT	
	<213> artificial sequence	
	<220>	
35	<223> synthetic construct	
	<400> 272	
40		
		Phe Phe Ala Glu Asp Val Cys
		1 5
45	<210> 273	
	<211> 7	
	<212> PRT	
	<213> artificial sequence	
	<220>	
	<223> synthetic construct	
50		
	<400> 273	
55		
		Phe Ala Glu Asp Val Gly Cys
		1 5
	<210> 274	
	<211> 7	

EP 2 368 907 B1

<212> PRT
 <213> artificial sequence

 <220>
 5 <223> synthetic construct

 <400> 274

 10 Ala Glu Asp Val Gly Ser Cys
 1 5

 <210> 275
 <211> 7
 15 <212> PRT
 <213> artificial sequence

 <220>
 <223> synthetic construct
 20
 <400> 275

 Glu Asp Val Gly Ser Asn Cys
 25 1 5

 <210> 276
 <211> 7
 <212> PRT
 30 <213> artificial sequence

 <220>
 <223> synthetic construct
 35 <400> 276

 Asp Val Gly Ser Asn Lys Cys
 40 1 5

 <210> 277
 <211> 7
 <212> PRT
 <213> artificial sequence
 45
 <220>
 <223> synthetic construct

 <400> 277
 50

 Val Gly Ser Asn Lys Gly Cys
 55 1 5

 <210> 278
 <211> 7
 <212> PRT
 <213> artificial sequence

EP 2 368 907 B1

<220>
 <223> synthetic construct

 <400> 278
 5

 Gly Ser Asn Lys Gly Ala Cys
 1 5

 10 <210> 279
 <211> 7
 <212> PRT
 <213> artificial sequence

 15 <220>
 <223> synthetic construct

 <400> 279

 20

 Cys Ser Asn Lys Gly Ala Ile
 1 5

 25 <210> 280
 <211> 7
 <212> PRT
 <213> artificial sequence

 30 <220>
 <223> synthetic construct

 <400> 280

 35

 Cys Asn Lys Gly Ala Ile Ile
 1 5

 40 <210> 281
 <211> 7
 <212> PRT
 <213> artificial sequence

 45 <220>
 <223> synthetic construct

 <400> 281

 50

 Cys Lys Gly Ala Ile Ile Gly
 1 5

 55 <210> 282
 <211> 7
 <212> PRT
 <213> artificial sequence

 <220>
 <223> synthetic construct

EP 2 368 907 B1

<400> 282

5 Cys Gly Leu Met Val Gly Gly
1 5

<210> 283

<211> 7

<212> PRT

10 <213> artificial sequence

<220>

<223> synthetic construct

15 <400> 283

20 Cys Met Val Gly Gly Val Val
1 5

<210> 284

<211> 7

<212> PRT

25 <213> artificial sequence

<220>

<223> synthetic construct

30 <400> 284

Cys Gly Gly Val Val Ile Ala
1 5

35 <210> 285

<211> 6

<212> PRT

<213> artificial sequence

40 <220>

<223> synthetic construct; peptide 1 A beta

<400> 285

45 Ala Glu Phe Arg His Asp
1 5

<210> 286

<211> 7

50 <212> PRT

<213> artificial sequence

<220>

<223> synthetic construct; peptide 2 A beta

55 <400> 286

EP 2 368 907 B1

Glu Phe Arg His Asp Ser Gly
1 5

5 <210> 287
<211> 5
<212> PRT
<213> artificial sequence

10 <220>
<223> synthetic construct; peptide 3 A beta

<400> 287

15 Glu Phe Arg His Asp
1 5

<210> 288
20 <211> 4
<212> PRT
<213> artificial sequence

<220>
25 <223> synthetic construct; peptide 4 A beta

<400> 288

30 His Asp Ser Gly
1

<210> 289
35 <211> 5
<212> PRT
<213> artificial sequence

<220>
<223> synthetic construct; peptide 5 A beta
40 <400> 289

45 His His Gln Lys Leu
1 5

<210> 290
<211> 6
<212> PRT
<213> artificial sequence
50 <220>
<223> synthetic construct; peptide 6 A beta

<400> 290
55

Leu Val Phe Phe Ala Glu
1 5

EP 2 368 907 B1

<210> 291
 <211> 6
 <212> PRT
 <213> artificial sequence
 5
 <220>
 <223> synthetic construct; peptide 7 A beta
 <400> 291
 10
 Val Phe Phe Ala Glu Asp
 1 5
 15
 <210> 292
 <211> 4
 <212> PRT
 <213> artificial sequence
 20
 <220>
 <223> synthetic construct; peptide 8 A beta
 <400> 292
 25
 Val Phe Phe Ala
 1
 30
 <210> 293
 <211> 6
 <212> PRT
 <213> artificial sequence
 35
 <220>
 <223> synthetic construct; peptide 9 A beta
 <400> 293
 40
 Phe Phe Ala Glu Asp Val
 1 5
 45
 <210> 294
 <211> 360
 <212> DNA
 <213> artificial sequence
 <220>
 <223> synthetic construct
 50
 <400> 294
 55

EP 2 368 907 B1

caattggtgg aaagcggcgg cggcctggtg caaccgggcg gcagcctgcg tctgagctgc 60
 gcggcctccg gatttacctt tagcagctat gcgatgagct gggcgcgcca agcccctggg 120
 5 aagggtctcg agtgggtgag cgttatttct gagaagtctc gttttattta ttatgctgat 180
 tctgttaagg gtcgtttttac catttcacgt gataattcga aaaacaccct gtatctgcaa 240
 atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtct tactcattat 300
 10 gctcgttatt atcgttattt tgatgtttgg ggccaaggca ccctggtgac gggttagctca 360

<210> 295
 <211> 120
 <212> PRT
 <213> artificial sequence

<220>
 <223> synthetic construct

<400> 295

Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
 1 5 10 15

Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
 20 25 30

Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val
 35 40 45

Ile Ser Glu Lys Ser Arg Phe Ile Tyr Tyr Ala Asp Ser Val Lys Gly
 50 55 60

Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
 65 70 75 80

Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
 85 90 95

Leu Thr His Tyr Ala Arg Tyr Tyr Arg Tyr Phe Asp Val Trp Gly Gln
 100 105 110

Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> 296
 <211> 360
 <212> DNA
 <213> artificial sequence

EP 2 368 907 B1

<220>

<223> synthetic construct

<400> 296

5
caattggtgg aaagcggcgg cggcctggtg caaccgggcg gcagcctgcg totgagctgc 60
gcggcctccg gatttacctt tagcagctat gcgatgagct gggcgcgcca agccctggg 120
10
aagggtctcg agtgggtgag cgctatttct gagacttcta ttcgtaagta ttatgctgat 180
tctgttaagg gtcgttttac catttcacgt gataattcga aaaacaccct gtatctgcaa 240
15
atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtct tactcattat 300
gctcgttatt atcgttattt tgatgtttgg ggccaaggca ccctggtgac ggtagctca 360

<210> 297

20 <211> 120

<212> PRT

<213> artificial sequence

<220>

25 <223> synthetic construct

<400> 297

30 Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
1 5 10 15
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
20 25 30
35 Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala
35 40 45
40 Ile Ser Glu Thr Ser Ile Arg Lys Tyr Tyr Ala Asp Ser Val Lys Gly
50 55 60
45 Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
65 70 75 80
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
50 85 90 95
Leu Thr His Tyr Ala Arg Tyr Tyr Arg Tyr Phe Asp Val Trp Gly Gln
100 105 110
55 Gly Thr Leu Val Thr Val Ser Ser
115 120

EP 2 368 907 B1

<210> 298
 <211> 360
 <212> DNA
 <213> artificial sequence

5

<220>
 <223> synthetic construct

10

<400> 298

15

20

```

caattggtgg aaagcggcgg cggcctggtg caaccgggcg gcagcctgcg tctgagctgc      60
gcggcctccg gatttacctt tagcagctat gcgatgagct gggcgcgcca agcccctggg      120
aagggtctcg agtgggtgag cgttatttct cagactggtc gtaagattta ttatgctgat      180
tctgttaagg gtcgtttttac catttcacgt gataattcga aaaacaccct gtatctgcaa      240
atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtct tactcattat      300
gctcgttatt atcgttattt tgatgtttgg ggccaaggca ccctggtgac ggtagctca      360
  
```

25

<210> 299
 <211> 120
 <212> PRT
 <213> artificial sequence

30

<220>
 <223> synthetic construct

<400> 299

35

40

45

50

55

EP 2 368 907 B1

	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	Ser	Leu	
	1				5				10						15		
5	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr	Ala	Met	
				20					25					30			
10	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	Ser	Val	
			35					40					45				
15	Ile	Ser	Gln	Thr	Gly	Arg	Lys	Ile	Tyr	Tyr	Ala	Asp	Ser	Val	Lys	Gly	
	50						55					60					
20	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr	Leu	Gln	
	65					70					75					80	
25	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Ala	Arg	
					85					90					95		
30	Leu	Thr	His	Tyr	Ala	Arg	Tyr	Tyr	Arg	Tyr	Phe	Asp	Val	Trp	Gly	Gln	
			100						105					110			
35	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser									
			115					120									
40																	
	<210> 300																
	<211> 360																
	<212> DNA																
	<213> artificial sequence																
45																	
	<220>																
	<223> synthetic construct																
50																	
	<400> 300																
55																	
	caattggtgg	aaagcggcgg	cggcctggtg	caaccgggcg	gcagcctgcg	tctgagctgc											60
	gcggcctccg	gatttacctt	tagcagctat	gcgatgagct	gggtgcgcca	agccccctggg											120
	aaggggtctcg	agtgggtgag	cgttatttct	cagactggtc	gtaagattta	ttatgctgat											180
	tctgttaagg	gtcgttttac	catttcacgt	gataattcga	aaaacaccct	gtatctgcaa											240
	atgaacagcc	tgcgtgcgga	agatacggcc	gtgtattatt	gcgcgcgtct	tactcattat											300
	gctcgttatt	atcgttattt	tgatgttttg	ggccaaggca	ccctggtgac	ggttagctca											360
60																	
	<210> 301																
	<211> 120																
	<212> PRT																
	<213> artificial sequence																
65																	
	<220>																

EP 2 368 907 B1

<223> synthetic construct

<400> 301

```

5      Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
      1              5              10              15

10     Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
      20              25              30

15     Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val
      35              40              45

20     Ile Ser Gln Thr Gly Arg Lys Ile Tyr Tyr Ala Asp Ser Val Lys Gly
      50              55              60

25     Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
      65              70              75              80

30     Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
      85              90              95

35     Leu Thr His Tyr Ala Arg Tyr Tyr Arg Tyr Phe Asp Val Trp Gly Gln
      100             105             110

40     Gly Thr Leu Val Thr Val Ser Ser
      115             120

```

35 <210> 302
 <211> 360
 <212> DNA
 <213> artificial sequence

40 <220>
 <223> synthetic construct

<400> 302

```

45     caattggtgg aaagcggcgg cggcctggtg caaccggggc gcagcctgcg tctgagctgc      60
      gcggcctccg gatttacctt tagcagctat gcgatgagct gggcgcgcca agcccctggg      120
      aagggtctcg agtgggtgag cgttatttct gagactggta agaatatatta ttatgctgat      180
50     totgttaagg gtcgttttac catttcacgt gataattcga aaaacaccct gtatctgcaa      240
      atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtct tactcattat      300
55     gtcggttatt atcggtattt tgatggttgg ggccaaggca ccttggtgac ggtagctca      360

```

<210> 303
 <211> 120

EP 2 368 907 B1

<212> PRT
<213> artificial sequence

<220>
<223> synthetic construct

<400> 303

10 Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
1 5 10 15

15 Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
20 25 30

20 Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val
35 40 45

Ile Ser Glu Thr Gly Lys Asn Ile Tyr Tyr Ala Asp Ser Val Lys Gly
50 55 60

25 Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
65 70 75 80

30 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
85 90 95

Leu Thr His Tyr Ala Arg Tyr Tyr Arg Tyr Phe Asp Val Trp Gly Gln

35 100 105 110

Gly Thr Leu Val Thr Val Ser Ser
115 120

40
<210> 304
<211> 360
<212> DNA
<213> artificial sequence

<220>
<223> synthetic construct

<400> 304

EP 2 368 907 B1

caattggtgg aaagcggcgg cggcctggtg caaccgggcg gcagcctgcg tctgagctgc 60
 gcggcctccg gatttacctt tagcagctat gcgatgagct gggcgcgcca agcccctggg 120
 5 aagggtctcg agtgggtgag cggtatttct gagactggta agaataattta ttatgctgat 180
 tctgttaagg gtcgtttttac catttcacgt gataattcga aaaacaccct gtatctgcaa 240
 atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtct tactcattat 300
 10 gctcgttatt atcgttattt tgatgttttg ggccaaggca ccctggtgac ggtagctca 360

<210> 305
 <211> 120
 15 <212> PRT
 <213> artificial sequence

<220>
 <223> synthetic construct
 20
 <400> 305

Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
 1 5 10 15
 25 Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
 20 25 30
 30 Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Val
 35 40 45
 35 Ile Ser Glu Thr Gly Lys Asn Ile Tyr Tyr Ala Asp Ser Val Lys Gly
 50 55 60
 40 Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
 65 70 75 80
 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
 85 90 95
 45 Leu Thr His Tyr Ala Arg Tyr Tyr Arg Tyr Phe Asp Val Trp Gly Gln
 100 105 110
 50 Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> 306
 <211> 360
 55 <212> DNA
 <213> artificial sequence

<220>

EP 2 368 907 B1

<223> synthetic construct

<400> 306

```

5      caattggtgg aaagcggcgg cggcctgggtg caaccggggcg gcagcctgcg tctgagctgc      60
      gcggcctccg gatttacctt tagcagctat gcgatgagct ggggtgcgcca agcccctggg      120
10     aaggggtctcg agtgggtgag cgctattttct gagtctggta agactaagta ttatgctgat      180
      tctgttaagg gtcgtttttac catttcacgt gataattcga aaaacaccct gtatctgcaa      240
      atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtct tactcattat      300
15     gctcgttatt atcgttattt tgatgttttg ggccaaggca ccctggtgac ggtagctca      360

```

<210> 307

<211> 120

<212> PRT

20 <213> artificial sequence

<220>

<223> synthetic construct

25 <400> 307

```

      Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
      1              5              10              15
30     Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
      20              25              30
35     Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala
      35              40              45
40     Ile Ser Glu Ser Gly Lys Thr Lys Tyr Tyr Ala Asp Ser Val Lys Gly
      50              55              60
      Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
      65              70              75              80
45     Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
      85              90              95
50     Leu Thr His Tyr Ala Arg Tyr Tyr Arg Tyr Phe Asp Val Trp Gly Gln
      100             105             110
      Gly Thr Leu Val Thr Val Ser Ser
55     115              120

```

<210> 308

<211> 372

EP 2 368 907 B1

<212> DNA
<213> artificial sequence

<220>
<223> synthetic construct

<400> 308

```

10      caattggtgg aaagcggcgg cggcctggtg caaccgggcg gcagcctgcg tctgagctgc      60
      gcggcctccg gatttacctt tagcagctat gcgatgagct gggcgcgcca agcccctggg      120
      aaggggtctcg agtgggtgag cgctattaat ggtactggta tgaagaagta ttatgctgat      180
15      tctgttaagg gtcgttttac catttcacgt gataattcga aaaacaccct gtatctgcaa      240
      atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtgg taagggtaat      300
      actcataagc cttatgggta tgttcgttat tttgatgttt ggggccaagg caccotgggtg      360
20      acggtttagct ca                                          372

```

<210> 309
<211> 124
<212> PRT
<213> artificial sequence

<220>
<223> synthetic construct

<400> 309

```

35      Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
      1              5              10              15

      Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
              20              25              30

```

EP 2 368 907 B1

	Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala	
	35 40 45	
5	Ile Asn Gly Thr Gly Met Lys Lys Tyr Tyr Ala Asp Ser Val Lys Gly	
	50 55 60	
10	Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln	
	65 70 75 80	
15	Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg	
	85 90 95	
20	Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp	
	100 105 110	
25	Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser	
	115 120	
	<210> 310	
	<211> 372	
	<212> DNA	
	<213> artificial sequence	
30	<220>	
	<223> synthetic construct	
	<400> 310	
35	caattggtgg aaagcggcgg cggcctggtg caaccgggcg gcagcctgcg tctgagctgc	60
	gcggcctccg gatttacctt tagcagctat gcgatgagct gggcgcgcca agcccctggg	120
	aagggtctcg agtgggtgag cgctattaat tataatggtg ctcgtattta ttatgctgat	180
40	tctgttaagg gtcgttttac catttcacgt gataattcga aaaacaccct gtatctgcaa	240
	atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtgg taagggtaat	300
	actcataagc cttatgggta tggtcggttat tttgatgttt ggggccaagg caccctggtg	360
45	acgggttagct ca	372
	<210> 311	
	<211> 124	
50	<212> PRT	
	<213> artificial sequence	
	<220>	
	<223> synthetic construct	
55	<400> 311	

EP 2 368 907 B1

Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu

5 1 5 10 15

Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
20 25 30

10 Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala
35 40 45

15 Ile Asn Tyr Asn Gly Ala Arg Ile Tyr Tyr Ala Asp Ser Val Lys Gly
50 55 60

20 Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
65 70 75 80

25 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
85 90 95

30 Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp
100 105 110

35 Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 312

<211> 372

35 <212> DNA

<213> artificial sequence

<220>

<223> synthetic construct

40

<400> 312

caattggtgg aaagcggcgg cggcctggtg caaccgggcg gcagcctgcg tctgagctgc 60
45 gcggcctccg gatttacctt tagcagctat gcgatgagct gggcgcgcca agcccctggg 120
aagggtctcg agtgggtgag cgctattaat gctgatggta atcgtaagta ttatgctgat 180
tctgttaagg gtcgttttac catttcacgt gataattcga aaaacaccct gtatctgcaa 240
50 atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtgg taagggtaat 300
actcataagc cttatgggta tggtcggtat tttgatgttt ggggccaagg caccctggtg 360
55 acggttagct ca 372

<210> 313

<211> 124

EP 2 368 907 B1

<212> PRT

<213> artificial sequence

<220>

5 <223> synthetic construct

<400> 313

10 Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
1 5 10 15

Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
20 25 30

Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala
35 40 45

20 Ile Asn Ala Asp Gly Asn Arg Lys Tyr Tyr Ala Asp Ser Val Lys Gly
50 55 60

25 Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
65 70 75 80

Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
85 90 95

Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp
100 105 110

35 Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 314

40 <211> 372

<212> DNA

<213> artificial sequence

<220>

45 <223> synthetic construct

<400> 314

50

55

EP 2 368 907 B1

caattggtgg aaagcggcgg cggcctggtg caaccgggcg gcagcctgcg tctgagctgc 60
 gcggcctccg gatttacctt tagcagctat gcgatgagct gggcgcgcca agcccctggg 120
 5 aagggtctcg agtgggtgag cgctattaat gctgatggta atcgtaagta ttatgctgat 180
 totgttaagg gtcgttttac catttcacgt gataattcga aaaacaccct gtatctgcaa 240
 atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtgg taagggtaat 300
 10 actcataagc cttatgggta tggtcgttat tttgatgttt ggggccaagg caccctggtg 360
 acggtttagct ca 372

15
 <210> 315
 <211> 124
 <212> PRT
 <213> artificial sequence

20
 <220>
 <223> synthetic construct

25
 <400> 315

Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
 1 5 10 15

30 Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
 20 25 30

35 Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala
 35 40 45

40 Ile Asn Ala Asp Gly Asn Arg Lys Tyr Tyr Ala Asp Ser Val Lys Gly
 50 55 60

Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
 65 70 75 80

45 Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
 85 90 95

50 Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp
 100 105 110

Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

55
 <210> 316
 <211> 372
 <212> DNA

EP 2 368 907 B1

<213> artificial sequence

<220>

<223> synthetic construct

5

<400> 316

10	caattggtgg aaagcggcgg cggcctggtg caaccgggcg gcagcctgcg tctgagctgc	60
	gcggcctccg gatttacctt tagcagctat gcgatgagct gggcgcgcca agcccctggg	120
	aagggtctcg agtgggtgag cgctattaat gctaattggtt ataagaagta ttatgctgat	180
15	tctgttaagg gtcgtttttac catttcacgt gataattcga aaaacaccct gtatctgcaa	240
	atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtgg taagggtaat	300
20	actcataagc cttatgggta tggtcgttat ttgatgttt ggggccaagg caccctgggtg	360
	acggtttagct ca	372

<210> 317

<211> 124

25

<212> PRT

<213> artificial sequence

<220>

<223> synthetic construct

30

<400> 317

35

40

45

50

55

EP 2 368 907 B1

	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Leu	Val	Gln	Pro	Gly	Gly	Ser	Leu	
	1				5					10					15		
5	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr	Ala	Met	
				20					25					30			
10	Ser	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	Val	Ser	Ala	
			35					40					45				
15	Ile	Asn	Ala	Asn	Gly	Tyr	Lys	Lys	Tyr	Tyr	Ala	Asp	Ser	Val	Lys	Gly	
	50						55					60					
20	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	Tyr	Leu	Gln	
	65					70					75					80	
25	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	Cys	Ala	Arg	
					85					90					95		
30	Gly	Lys	Gly	Asn	Thr	His	Lys	Pro	Tyr	Gly	Tyr	Val	Arg	Tyr	Phe	Asp	
				100					105					110			
35	Val	Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser					
			115					120									
40	<210> 318																
	<211> 372																
	<212> DNA																
	<213> artificial sequence																
45	<220>																
	<223> synthetic construct																
50	<400> 318																
	caattggtgg	aaagcggcgg	cggcctggtg	caaccgggcg	gcagcctgcg	tctgagctgc										60	
	gcggcctccg	gatttacctt	tagcagctat	gcgatgagct	gggtgcgcca	agcccctggg										120	
55	aagggtctcg	agtgggtgag	cgctattaat	gctaattggtt	ataagaagta	ttatgctgat										180	
	tctgttaagg	gtcgtttttac	catttcacgt	gataattcga	aaaacaccct	gtatctgcaa										240	
	atgaacagcc	tgcgtgcgga	agatacggcc	gtgtattatt	gcgcgcgtgg	taagggtaat										300	
60	actcataagc	cttatgggta	tggttcgttat	tttgatgttt	ggggccaagg	caccctgggtg										360	
	acggttagct	ca														372	
55	<210> 319																
	<211> 124																
	<212> PRT																
	<213> artificial sequence																

EP 2 368 907 B1

<220>

<223> synthetic construct

<400> 319

5

Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
1 5 10 15

10

Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
20 25 30

15

Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala
35 40 45

20

Ile Asn Ala Asn Gly Tyr Lys Lys Tyr Tyr Ala Asp Ser Val Lys Gly
50 55 60

Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
65 70 75 80

25

Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
85 90 95

30

Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp
100 105 110

Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

35

<210> 320

<211> 372

<212> DNA

<213> artificial sequence

40

<220>

<223> synthetic construct

<400> 320

45

50

55

EP 2 368 907 B1

```

caattggtgg aaagcggcgg cggcctggtg caaccgggcg gcagcctgcg tctgagctgc      60
gcggcctccg gatttacctt tagcagctat gcgatgagct ggggtgcgcca agcccctggg      120
5  aaggggtctcg agtgggtgag cgctattaat gctaattggtt ataagaagta ttatgctgat      180
tctgttaagg gtcgttttac catttcacgt gataattcga aaaacaccct gtatctgcaa      240
atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtgg taagggtaat      300
10 actcataagc cttatggtta tgttcgttat tttgatgttt ggggcccaagg caccctgggtg      360
acggtttagct ca                                                                372

```

```

15  <210> 321
    <211> 124
    <212> PRT
    <213> artificial sequence

```

```

20  <220>
    <223> synthetic construct

```

```

25  <400> 321

```

```

    Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
    1          5          10          15

```

```

30  Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
    20          25          30

```

```

35  Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala
    35          40          45

```

```

    Ile Asn Ala Asn Gly Tyr Lys Lys Tyr Tyr Ala Asp Ser Val Lys Gly
    50          55          60

```

```

    Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
    65          70          75          80

```

```

45  Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
    85          90          95

```

```

50  Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp
    100          105          110

```

```

55  Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
    115          120

```

```

<210> 322

```

EP 2 368 907 B1

<211> 366
<212> DNA
<213> artificial sequence

5 <220>
<223> synthetic construct

<400> 322

```

10      caattggtgg aaagcggcgg cggcctggtg caaccgggcg gcagcctgcg tctgagctgc      60
      gcggcctccg gatttacctt tagcagctat gcgatgagct gggtgcgcca agcccctggg      120
15      aagggctctg agtgggtgag cgctatttct cgttctgggt ctaatattta ttatgctgat      180
      tctgttaagg gtcgttttac catttcacgt gataattcga aaaacaccct gtatctgcaa      240
      atgaacagcc tgcgtgcgga agatacggcc gtgtattatt gcgcgcgtct tctttctcgt      300
20      ggttataatg gttattatca taagtgtgat gtttggggcc aaggcaccct ggtgacgggt      360
      agctca                                          366

```

25 <210> 323
<211> 122
<212> PRT
<213> artificial sequence

30 <220>
<223> synthetic construct

<400> 323

```

35      Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser Leu
      1          5          10          15

      Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met
40      20          25          30

      Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala
      35          40          45

45      Ile Ser Arg Ser Gly Ser Asn Ile Tyr Tyr Ala Asp Ser Val Lys Gly
      50          55          60

50      Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Gln
      65          70          75          80

```

55

EP 2 368 907 B1

Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
85 90 95

5 Leu Leu Ser Arg Gly Tyr Asn Gly Tyr Tyr His Lys Phe Asp Val Trp
100 105 110

10 Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 324

<211> 330

<212> DNA

15 <213> artificial sequence

<220>

<223> synthetic construct

20 <400> 324

gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggcca acgtgcgacc 60
ctgagctgca gagcgagccg gcgtattcat gtttattatc tggcgtggta ccagcagaaa 120
25 ccagggtcaag caccgcgtct attaatattat ggcgcgagca gccgtgcaac tgggggtcccg 180
gcgcgtttta gcggctctgg atccggcacg gattttaccc tgaccattag cagcctggaa 240
30 cctgaagact ttgcgactta ttattgccag cagacttatg attatcctcc tacctttggc 300
cagggtacga aagttgaaat taaacgtacg 330

<210> 325

35 <211> 110

<212> PRT

<213> artificial sequence

<220>

40 <223> synthetic construct

<400> 325

45 Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

50 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Arg Arg Ile His Val Tyr
20 25 30

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45

55 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser

EP 2 368 907 B1

50

55

60

5 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
65 70 75 80

10 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Asp Tyr Pro
85 90 95

Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
100 105 110

15 <210> 326
<211> 330
<212> DNA
<213> artificial sequence

20 <220>
<223> synthetic construct

<400> 326

25 gatatacgtgc tgacccagag cccggcgacc ctgagcctgt ctccggggcga acgtgcgacc 60
ctgagctgca gagcgagccg gcgtattcat gtttattatc tggcgtggta ccagcagaaa 120
30 ccagggtcaag caccgcgtct attaatattat ggcgcgagca gccgtgcaac tgggggtcccg 180
gcgcgtttta gcggctctgg atccggcacg gattttaccc tgaccattag cagcctggaa 240
cctgaagact ttgcgactta ttattgccag cagacttatg attatcctcc tacctttggc 300
35 cagggtacga aagttgaaat taaacgtacg 330

<210> 327
<211> 110
<212> PRT
40 <213> artificial sequence

<220>
<223> synthetic construct

45 <400> 327

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

50 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Arg Arg Ile His Val Tyr
20 25 30

55 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45

EP 2 368 907 B1

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
50 55 60

5 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
65 70 75 80

10 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Asp Tyr Pro
85 90 95

15 Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
100 105 110

<210> 328
<211> 330
<212> DNA
<213> artificial sequence

20 <220>
<223> synthetic construct

25 <400> 328

gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggcga acgtgcgacc 60
ctgagctgca gagcgagcca gcgtcttggc cgtctttatc tggcgtggta ccagcagaaa 120
30 ccagggtcaag caccgcgtct attaatattat ggcgcgagca gccgtgcaac tgggggtcccg 180
gcgcgcttcta gcggctctgg atccggcacg gattttaccc tgaccattag cagcctggaa 240
cctgaagact ttgcgactta ttattgccag cagacttatg attatcctcc tacctttggc 300
35 cagggtacga aagttgaaat taaacgtacg 330

<210> 329
<211> 110
40 <212> PRT
<213> artificial sequence

<220>
<223> synthetic construct

45 <400> 329

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
50 1 5 10 15

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Leu Gly Arg Leu
20 25 30

55 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45

EP 2 368 907 B1

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
50 55 60

5 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
65 70 75 80

10 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Asp Tyr Pro
85 90 95

15 Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
100 105 110

<210> 330
<211> 330
<212> DNA
<213> artificial sequence

20 <220>
<223> synthetic construct

25 <400> 330

gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggcca acgtgcgacc 60
ctgagctgca gagcgagccg gcgtattcat gtttattatc tggcgtggta ccagcagaaa 120
30 ccagggtcaag caccgcgtct attaatattat ggcgcgagca gccgtgcaac tgggggtcccg 180
gcgcggtttta gcggctctgg atccggcacg gattttaccc tgaccattag cagcctggaa 240
cctgaagact ttgcgactta ttattgccag cagacttatg attatcctcc tacctttggc 300
35 cagggtacga aagttgaaat taaacgtacg 330

<210> 331
<211> 110
40 <212> PRT
<213> artificial sequence

<220>
<223> synthetic construct

45 <400> 331

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

50 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Arg Arg Ile His Val Tyr
20 25 30

55 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45

EP 2 368 907 B1

Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
50 55 60

5 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
65 70 75 80

10 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Asp Tyr Pro
85 90 95

15 Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
100 105 110

<210> 332
<211> 330
<212> DNA
<213> artificial sequence

20 <220>
<223> synthetic construct

25 <400> 332

gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggcga acgtgcgacc 60
ctgagctgca gagcgagccg gcgtattcat gtttattatc tggcgtggta ccagcagaaa 120
30 ccagggtcaag caccgcgtct attaatattat ggcgcgagca gccgtgcaac tgggggtcccg 180
gcgcggtttta gcggctctgg atccggcacg gattttaccc tgaccattag cagcctggaa 240
cctgaagact ttgcgactta ttattgccag cagacttatg attatcctcc tacctttggc 300
35 cagggtacga aagttgaaat taaacgtacg 330

<210> 333
<211> 110
40 <212> PRT
<213> artificial sequence

<220>
<223> synthetic construct

45 <400> 333

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

50 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Arg Arg Ile His Val Tyr
20 25 30

55 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu

EP 2 368 907 B1

35 40 45

5 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
50 55 60

10 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
65 70 75 80

15 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Asp Tyr Pro
85 90 95

20 Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
100 105 110

<210> 334
<211> 330
<212> DNA
<213> artificial sequence

25 <220>
<223> synthetic construct

<400> 334

30 gataatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggcca acgtgcgacc 60
ctgagctgca gagcgagcca gcgtcttggc cgtctttatc tggcgtggta ccagcagaaa 120
ccagggtcaag caccgcgtct attaatattat ggcgcgagca gccgtgcaac tgggggtcccg 180
35 gcgcgtttta gcggctctgg atccggcagc gattttaccc tgaccattag cagcctggaa 240
cctgaagact ttgcgactta ttattgccag cagacttatg attatcctcc tacctttggc 300
cagggtacga aagttgaaat taaacgtacg 330

40 <210> 335
<211> 110
<212> PRT
<213> artificial sequence

45 <220>
<223> synthetic construct

50 <400> 335

55 Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Leu Gly Arg Leu
20 25 30

EP 2 368 907 B1

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45

5 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
 50 55 60

10 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
 65 70 75 80

15 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Thr Tyr Asp Tyr Pro
 85 90 95

Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
 100 105 110

20 <210> 336
 <211> 330
 <212> DNA
 <213> artificial sequence

25 <220>
 <223> synthetic construct

<400> 336

30 gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggcca acgtgcgacc 60
 ctgagctgca gagcgagcca gtttattcag cgtttttatc tggcgtggta ccagcagaaa 120
 ccagggtcaag caccgctctt attaatattat ggcgcgagca gccgtgcaac tgggggtcccg 180
 35 gcgcgtttta gcggctcttg atccggcacg gattttaccc tgaccattag cagcctggaa 240
 cctgaagact ttgcggttta ttattgccag cagacttata attatcctcc tacctttggc 300
 40 cagggtacga aagttgaaat taaacgtacg 330

<210> 337
 <211> 110
 <212> PRT
 45 <213> artificial sequence

<220>
 <223> synthetic construct

50 <400> 337

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15

55 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Phe Ile Gln Arg Phe
 20 25 30

EP 2 368 907 B1

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45

5 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
 50 55 60

10 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
 65 70 75 80

15 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Thr Tyr Asn Tyr Pro
 85 90 95

Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
 100 105 110

20 <210> 338
 <211> 330
 <212> DNA
 <213> artificial sequence

25 <220>
 <223> synthetic construct

<400> 338

30 gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggcga acgtgcgacc 60
 ctgagctgca gagcgagcca gtatgttgat cgtacttatac tggcgtggta ccagcagaaa 120
 ccagggtcaag caccgcgtct attaatattat ggcgcgagca gccgtgcaac tgggggtcccg 180
 35 gcgcgtttta gcggctctgg atccggcagc gattttaccc tgaccattag cagcctggaa 240
 cctgaagact ttgcgactta ttattgccag cagatttatt cttttcctca tacctttggc 300
 40 cagggtacga aagttgaaat taaacgtacg 330

<210> 339
 <211> 110
 <212> PRT
 45 <213> artificial sequence

<220>
 <223> synthetic construct

50 <400> 339

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15

55 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Tyr Val Asp Arg Thr
 20 25 30

EP 2 368 907 B1

Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45

5 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
 50 55 60

10 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
 65 70 75 80

15 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ile Tyr Ser Phe Pro
 85 90 95

His Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
 100 105 110

20 <210> 340
 <211> 330
 <212> DNA
 <213> artificial sequence

25 <220>
 <223> synthetic construct

<400> 340

30 gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggcca acgtgcgacc 60
 ctgagctgca gagcgagcca gcgttttttt tataagtatc tggcgtggta ccagcagaaa 120
 ccagggtcaag caccgctctt attaatcttct gggtcttcta accgtgcaac tgggggtcccg 180
 35 gcgcgtttta gcggctcttg atccggcacg gattttaccc tgaccattag cagcctggaa 240
 cctgaagact ttgcggttta ttattgcctt cagctttata atattcctaa tacctttggc 300
 40 cagggtacga aagttgaaat taaacgtacg 330

<210> 341
 <211> 110
 <212> PRT
 45 <213> artificial sequence

<220>
 <223> synthetic construct

50 <400> 341

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15

55 Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Phe Phe Tyr Lys

EP 2 368 907 B1

20 25 30

5 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45

10 Ile Ser Gly Ser Ser Asn Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
50 55 60

15 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
65 70 75 80

20 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Leu Gln Leu Tyr Asn Ile Pro
85 90 95

25 Asn Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
100 105 110

<210> 342
<211> 330
<212> DNA
<213> artificial sequence

30 <220>
<223> synthetic construct

35 gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggcca acgtgcgacc 60

ctgagctgca gagcgagcca gtatgttgat cgtacttatac tggcgtggta ccagcagaaa 120

ccagggtcaag caccgcgtct attaatattat ggcgcgagca gccgtgcaac tgggggtcccg 180

gcgcgtttta gcggctctgg atccggcacg gattttaccc tgaccattag cagcctggaa 240

40 cctgaagact ttgcgactta ttattgccag cagatttatt cttttcctca tacctttggc 300

cagggtacga aagttgaaat taaacgtacg 330

45 <210> 343
<211> 110
<212> PRT
<213> artificial sequence

50 <220>
<223> synthetic construct

55 <400> 343

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

EP 2 368 907 B1

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Tyr Val Asp Arg Thr
20 25 30

5 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
35 40 45

10 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
50 55 60

15 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
65 70 75 80

20 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ile Tyr Ser Phe Pro
85 90 95

25 His Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
100 105 110

<210> 344
<211> 330
<212> DNA
<213> artificial sequence

30 <220>
<223> synthetic construct

<400> 344

35 gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggcca acgtgcgacc 60
ctgagctgca gagcgagcca gtatgttttt cgtcgttattc tggcgtggta ccagcagaaa 120
ccagggtcaag caccgcgtct attaatcttct gggtcttcta accgtgcaac tgggggtcccg 180
40 gcgcgtttta gcggctcttg atccggcacg gattttaccc tgaccattag cagcctggaa 240
cctgaagact ttgcggttta ttattgcctt cagctttata atattcctaa tacctttggc 300
cagggtagca aagttgaaat taaacgtacg 330

45 <210> 345
<211> 110
<212> PRT
<213> artificial sequence

50 <220>
<223> synthetic construct

55 <400> 345

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

EP 2 368 907 B1

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Tyr Val Phe Arg Arg
 20 25 30
 5 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45
 10 Ile Ser Gly Ser Ser Asn Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
 50 55 60
 15 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
 65 70 75 80
 Pro Glu Asp Phe Ala Val Tyr Tyr Cys Leu Gln Leu Tyr Asn Ile Pro
 85 90 95
 20 Asn Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
 100 105 110

<210> 346
 <211> 330
 <212> DNA
 <213> artificial sequence

<220>
 <223> synthetic construct

<400> 346

gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggcca acgtgcgacc 60
 ctgagctgca gagcgagcca gtatgttgat cgtacttatac tggcgtggta ccagcagaaa 120
 ccagggtcaag caccgcgtct attaatattat ggcgcgagca gccgtgcaac tgggggtccc 180
 40 ggcgcgtttta ggcgcgtctgg atccggcacg gattttaccc tgaccattag cagcctggaa 240
 cctgaagact ttgcgactta ttattgccag cagatttatt cttttcctca tacctttggc 300
 cagggtacga aagttgaaat taaacgtacg 330

<210> 347
 <211> 110
 <212> PRT
 <213> artificial sequence

<220>
 <223> synthetic construct

<400> 347

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
 1 5 10 15

EP 2 368 907 B1

Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Tyr Val Asp Arg Thr
 20 25 30
 5 Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
 35 40 45
 10 Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
 50 55 60
 15 Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu
 65 70 75 80
 20 Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Ile Tyr Ser Phe Pro
 85 90 95
 25 His Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
 100 105 110

25 <210> 348
 <211> 330
 <212> DNA
 <213> artificial sequence

30 <220>
 <223> synthetic construct

<400> 348

35 gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggcca acgtgcgacc 60
 ctgagctgca gagcgagcca gcgtctttct cctcggtatc tggcgtggta ccagcagaaa 120
 ccagggtcaag caccgctctt attaatattat ggcgcgagca gccgtgcaac tgggggtccc 180
 40 gcgcgtttta gcggtctctg atccggcacg gattttaccc tgaccattag cagcctggaa 240
 cctgaagact ttgcgactta ttattgcctt cagatttata atatgcctat tacctttggc 300
 cagggtacga aagttgaaat taaacgtacg 330

45 <210> 349
 <211> 110
 <212> PRT
 50 <213> artificial sequence

<220>
 <223> synthetic construct

55 <400> 349

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly

EP 2 368 907 B1

	1	5	10	15
5	Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Arg Leu Ser Pro Arg	20	25	30
10	Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu	35	40	45
15	Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Val Pro Ala Arg Phe Ser	50	55	60
20	Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu	65	70	75
25	Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln Ile Tyr Asn Met Pro	85	90	95
30	Ile Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr	100	105	110
35	<210> 350 <211> 330 <212> DNA <213> artificial sequence <220> <223> synthetic construct <400> 350			
40	gatatcgtgc tgaccagag cccggcgacc ctgagcctgt ctccgggga acgtgcgacc 60 ctgagctgca gagcgagcca gtatgttttt cgtcgtttatc tggcgtggta ccagcagaaa 120 ccagggtcaag caccgcgtct attaatcttct gggtcttcta accgtgcaac tgggggtccc 180 gcgcgtttta ggggctctgg atccggcacg gattttaccc tgaccattag cagcctggaa 240 cctgaagact ttgcggttta ttattgcctt cagctttata atattcctaa tacctttggc 300 cagggtacga aagttgaaat taaacgtacg 330			
50	<210> 351 <211> 110 <212> PRT <213> artificial sequence <220> <223> synthetic construct <400> 351			

EP 2 368 907 B1

	Asp	Ile	Val	Leu	Thr	Gln	Ser	Pro	Ala	Thr	Leu	Ser	Leu	Ser	Pro	Gly
	1				5					10					15	
5	Glu	Arg	Ala	Thr	Leu	Ser	Cys	Arg	Ala	Ser	Gln	Tyr	Val	Phe	Arg	Arg
				20					25					30		
10	Tyr	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Arg	Leu	Leu
			35					40					45			
15	Ile	Ser	Gly	Ser	Ser	Asn	Arg	Ala	Thr	Gly	Val	Pro	Ala	Arg	Phe	Ser
		50					55					60				
20	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Glu
	65					70					75				80	
25	Pro	Glu	Asp	Phe	Ala	Val	Tyr	Tyr	Cys	Leu	Gln	Leu	Tyr	Asn	Ile	Pro
					85					90					95	
30	Asn	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Arg	Thr		
				100					105					110		

<210> 352
 <211> 330
 <212> DNA
 <213> artificial sequence

<220>
 <223> synthetic construct

<400> 352

	gatatcgtgc	tgaccagag	cccggcgacc	ctgagcctgt	ctccgggcga	acgtgcgacc	60
40	ctgagctgca	gagcgagcca	gcgtgtttct	ggtcgttatt	tggcgtggta	ccagcagaaa	120
	ccagggtcaag	caccgcgtct	attaatttat	ggcgcgagca	gccgtgcaac	tgggggtccc	180
45	gcgcgtttta	gcggctctgg	atccggcacg	gattttaccc	tgaccattag	cagcctggaa	240
	cctgaagact	ttgcgactta	ttattgccag	cagctttctt	cttatcctcc	tacctttggc	300
	cagggtacga	aagttgaaat	taaacgtacg				330

<210> 353
 <211> 110
 <212> PRT
 <213> artificial sequence

<220>
 <223> synthetic construct

<400> 353

EP 2 368 907 B1

	Asp	Ile	Val	Leu	Thr	Gln	Ser	Pro	Ala	Thr	Leu	Ser	Leu	Ser	Pro	Gly	
	1				5					10					15		
5	Glu	Arg	Ala	Thr	Leu	Ser	Cys	Arg	Ala	Ser	Gln	Arg	Val	Ser	Gly	Arg	
				20					25					30			
	Tyr	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ala	Pro	Arg	Leu	Leu	
10			35					40					45				
	Ile	Tyr	Gly	Ala	Ser	Ser	Arg	Ala	Thr	Gly	Val	Pro	Ala	Arg	Phe	Ser	
		50					55					60					
15	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Glu	
	65					70					75					80	
	Pro	Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Leu	Ser	Ser	Tyr	Pro	
20				85					90						95		
	Pro	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Arg	Thr			
25				100					105					110			

	<210> 354	
	<211> 39	
	<212> DNA	
30	<213> artificial sequence	
	<220>	
	<223> synthetic construct	
35	<400> 354	
	cttactcatt atgctcggtta ttatcggttat ttgatgtt	39
	<210> 355	
	<211> 13	
40	<212> PRT	
	<213> artificial sequence	
	<220>	
	<223> synthetic construct	
45	<400> 355	

	Leu	Thr	His	Tyr	Ala	Arg	Tyr	Tyr	Arg	Tyr	Phe	Asp	Val	
50	1				5					10				
	<210> 356													
	<211> 39													
	<212> DNA													
55	<213> artificial sequence													
	<220>													
	<223> synthetic construct													

EP 2 368 907 B1

<400> 356
 cttactcatt atgctcgta ttatcggtat ttgatgtt 39

5
 <210> 357
 <211> 13
 <212> PRT
 <213> artificial sequence

10
 <220>
 <223> synthetic construct

<400> 357

15

Leu	Thr	His	Tyr	Ala	Arg	Tyr	Tyr	Arg	Tyr	Phe	Asp	Val
1				5					10			

20
 <210> 358
 <211> 39
 <212> DNA
 <213> artificial sequence

25
 <220>
 <223> synthetic construct

<400> 358
 cttactcatt atgctcgta ttatcggtat ttgatgtt 39

30
 <210> 359
 <211> 13
 <212> PRT
 <213> artificial sequence

35
 <220>
 <223> synthetic construct

<400> 359

40

Leu	Thr	His	Tyr	Ala	Arg	Tyr	Tyr	Arg	Tyr	Phe	Asp	Val
1				5					10			

45
 <210> 360
 <211> 39
 <212> DNA
 <213> artificial sequence

50
 <220>
 <223> synthetic construct

<400> 360
 cttactcatt atgctcgta ttatcggtat ttgatgtt 39

55
 <210> 361
 <211> 13
 <212> PRT
 <213> artificial sequence

EP 2 368 907 B1

<220>

<223> synthetic construct

<400> 361

5

Leu	Thr	His	Tyr	Ala	Arg	Tyr	Tyr	Arg	Tyr	Phe	Asp	Val
1				5					10			

10

<210> 362

<211> 39

<212> DNA

<213> artificial sequence

15

<220>

<223> synthetic construct

<400> 362

cttactcatt atgctcgta ttatcggtat ttgatgtt 39

20

<210> 363

<211> 13

<212> PRT

<213> artificial sequence

25

<220>

<223> synthetic construct

<400> 363

30

Leu	Thr	His	Tyr	Ala	Arg	Tyr	Tyr	Arg	Tyr	Phe	Asp	Val
1				5					10			

35

<210> 364

<211> 39

<212> DNA

<213> artificial sequence

40

<220>

<223> synthetic construct

<400> 364

cttactcatt atgctcgta ttatcggtat ttgatgtt 39

45

<210> 365

<211> 13

<212> PRT

<213> artificial sequence

50

<220>

<223> synthetic construct

<400> 365

55

Leu	Thr	His	Tyr	Ala	Arg	Tyr	Tyr	Arg	Tyr	Phe	Asp	Val
1				5					10			

EP 2 368 907 B1

<210> 366
 <211> 39
 <212> DNA
 <213> artificial sequence
 5
 <220>
 <223> synthetic construct
 <400> 366
 10 cttactcatt atgctcggtta ttatcggtat ttgatgtt 39
 <210> 367
 <211> 13
 <212> PRT
 15 <213> artificial sequence
 <220>
 <223> synthetic construct
 20 <400> 367
 Leu Thr His Tyr Ala Arg Tyr Tyr Arg Tyr Phe Asp Val
 1 5 10
 25 <210> 368
 <211> 51
 <212> DNA
 <213> artificial sequence
 30 <220>
 <223> synthetic construct
 <400> 368
 35 ggtaagggtta atactcataa gccttatggt tatgttcgtt atttgatgt t 51
 <210> 369
 <211> 17
 <212> PRT
 40 <213> artificial sequence
 <220>
 <223> synthetic construct
 45 <400> 369
 Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp
 1 5 10 15
 50 Val
 <210> 370
 55 <211> 51
 <212> DNA
 <213> artificial sequence

<220>

<223> synthetic construct

<400> 370

5 ggtaaggga atactcataa gccttatggt tatgttcgtt atttgatgt t 51

<210> 371

<211> 17

<212> PRT

10 <213> artificial sequence

<220>

<223> synthetic construct

15 <400> 371

Gly	Lys	Gly	Asn	Thr	His	Lys	Pro	Tyr	Gly	Tyr	Val	Arg	Tyr	Phe	Asp
1				5					10					15	

20

Val

<210> 372

<211> 51

25 <212> DNA

<213> artificial sequence

<220>

<223> synthetic construct

30

<400> 372

ggtaaggga atactcataa gccttatggt tatgttcgtt atttgatgt t 51

<210> 373

35 <211> 17

<212> PRT

<213> artificial sequence

<220>

40 <223> synthetic construct

<400> 373

Gly	Lys	Gly	Asn	Thr	His	Lys	Pro	Tyr	Gly	Tyr	Val	Arg	Tyr	Phe	Asp
1				5					10					15	

50

Val

<210> 374

<211> 51

55 <212> DNA

<213> artificial sequence

<220>

EP 2 368 907 B1

<223> synthetic construct

<400> 374

ggtaagggtatactcataa gccttatggt tatgttcgtt atttgatgt t 51

<210> 375

<211> 17

<212> PRT

<213> artificial sequence

<220>

<223> synthetic construct

<400> 375

Gly	Lys	Gly	Asn	Thr	His	Lys	Pro	Tyr	Gly	Tyr	Val	Arg	Tyr	Phe	Asp
1				5				10						15	

Val

<210> 376

<211> 51

<212> DNA

<213> artificial sequence

<220>

<223> synthetic construct

<400> 376

ggtaagggtatactcataa gccttatggt tatgttcgtt atttgatgt t 51

<210> 377

<211> 17

<212> PRT

<213> artificial sequence

<220>

<223> synthetic construct

<400> 377

Gly	Lys	Gly	Asn	Thr	His	Lys	Pro	Tyr	Gly	Tyr	Val	Arg	Tyr	Phe	Asp
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

1

5

10

15

Val

<210> 378

<211> 51

<212> DNA

<213> artificial sequence

<220>

<223> synthetic construct

EP 2 368 907 B1

<400> 378
ggtaagggtg atactcataa gccttatggt tatgttcgtt atttgatgt t 51

5
<210> 379
<211> 17
<212> PRT
<213> artificial sequence

10
<220>
<223> synthetic construct

<400> 379

15
Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp
1 5 10 15

Val

20
<210> 380
<211> 51
<212> DNA
<213> artificial sequence

25
<220>
<223> synthetic construct

<400> 380
ggtaagggtg atactcataa gccttatggt tatgttcgtt atttgatgt t 51

30
<210> 381
<211> 17
<212> PRT
<213> artificial sequence

35
<220>
<223> synthetic construct

<400> 381

40
Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp
1 5 10 15

45
Val

<210> 382
<211> 45
<212> DNA
50
<213> artificial sequence

<220>
<223> synthetic construct

55
<400> 382
cttcttctc gtggtataa tgggtattat cataagtttg atgtt 45

<210> 383

EP 2 368 907 B1

<211> 15
 <212> PRT
 <213> artificial sequence

5

<220>
 <223> synthetic construct

<400> 383

10

Leu	Leu	Ser	Arg	Gly	Tyr	Asn	Gly	Tyr	Tyr	His	Lys	Phe	Asp	Val
1				5					10					15

<210> 384
 <211> 24
 <212> DNA
 <213> artificial sequence

15

<220>
 <223> synthetic construct

20

<400> 384
 cagcagactt atgattatcc tcct 24

25

<210> 385
 <211> 8
 <212> PRT
 <213> artificial sequence

30

<220>
 <223> synthetic construct

<400> 385

35

Gln	Gln	Thr	Tyr	Asp	Tyr	Pro	Pro
1				5			

<210> 386
 <211> 24
 <212> DNA
 <213> artificial sequence

40

<220>
 <223> synthetic construct

45

<400> 386
 cagcagactt atgattatcc tcct 24

50

<210> 387
 <211> 8
 <212> PRT
 <213> artificial sequence

55

<220>
 <223> synthetic construct

<400> 387

EP 2 368 907 B1

Gln Gln Thr Tyr Asp Tyr Pro Pro
1 5

5
<210> 388
<211> 24
<212> DNA
<213> artificial sequence

10
<220>
<223> synthetic construct

<400> 388
cagcagactt atgattatcc tcct 24

15
<210> 389
<211> 8
<212> PRT
<213> artificial sequence

20
<220>
<223> synthetic construct

<400> 389

25
Gln Gln Thr Tyr Asp Tyr Pro Pro
1 5

30
<210> 390
<211> 24
<212> DNA
<213> artificial sequence

35
<220>
<223> synthetic construct

<400> 390
cagcagactt atgattatcc tcct 24

40
<210> 391
<211> 8
<212> PRT
<213> artificial sequence

45
<220>
<223> synthetic construct

<400> 391

50
Gln Gln Thr Tyr Asp Tyr Pro Pro
1 5

55
<210> 392
<211> 24
<212> DNA
<213> artificial sequence

<220>
<223> synthetic construct

EP 2 368 907 B1

	<400> 392	
	cagcagactt atgattatcc tcct	24
5	<210> 393	
	<211> 8	
	<212> PRT	
	<213> artificial sequence	
10	<220>	
	<223> synthetic construct	
	<400> 393	
15	Gln Gln Thr Tyr Asp Tyr Pro Pro	
	1 5	
20	<210> 394	
	<211> 24	
	<212> DNA	
	<213> artificial sequence	
25	<220>	
	<223> synthetic construct	
	<400> 394	
	cagcagactt atgattatcc tcct	24
30	<210> 395	
	<211> 8	
	<212> PRT	
	<213> artificial sequence	
35	<220>	
	<223> synthetic construct	
	<400> 395	
40	Gln Gln Thr Tyr Asp Tyr Pro Pro	
	1 5	
45	<210> 396	
	<211> 24	
	<212> DNA	
	<213> artificial sequence	
50	<220>	
	<223> synthetic construct	
	<400> 396	
	cagcagactt ataattatcc tcct	24
55	<210> 397	
	<211> 8	
	<212> PRT	
	<213> artificial sequence	
	<220>	

EP 2 368 907 B1

<223> synthetic construct

<400> 397

5 Gln Gln Thr Tyr Asn Tyr Pro Pro
1 5

<210> 398

<211> 24

10 <212> DNA

<213> artificial sequence

<220>

<223> synthetic construct

15

<400> 398

cagcagattt attctttcc tcat 24

<210> 399

20 <211> 8

<212> PRT

<213> artificial sequence

<220>

25 <223> synthetic construct

<400> 399

30 Gln Gln Ile Tyr Ser Phe Pro His
1 5

<210> 400

<211> 24

35 <212> DNA

<213> artificial sequence

<220>

<223> synthetic construct

40

<400> 400

cttcagcttt ataattcc taat 24

<210> 401

45 <211> 8

<212> PRT

<213> artificial sequence

<220>

50 <223> synthetic construct

<400> 401

55 Leu Gln Leu Tyr Asn Ile Pro Asn
1 5

<210> 402

<211> 24

EP 2 368 907 B1

<212> DNA
 <213> artificial sequence

 <220>
 5 <223> synthetic construct

 <400> 402
 cagcagattt attcttttcc tcat 24

 10 <210> 403
 <211> 8
 <212> PRT
 <213> artificial sequence

 15 <220>
 <223> synthetic construct

 <400> 403

 20 Gln Gln Ile Tyr Ser Phe Pro His
 1 5

 <210> 404
 25 <211> 24
 <212> DNA
 <213> artificial sequence

 <220>
 30 <223> synthetic construct

 <400> 404
 cttcagcttt ataatttcc taat 24

 35 <210> 405
 <211> 8
 <212> PRT
 <213> artificial sequence

 40 <220>
 <223> synthetic construct

 <400> 405

 45 Leu Gln Leu Tyr Asn Ile Pro Asn
 1 5

 <210> 406
 50 <211> 24
 <212> DNA
 <213> artificial sequence

 <220>
 55 <223> synthetic construct

 <400> 406
 cagcagattt attcttttcc tcat 24

<210> 407
 <211> 8
 <212> PRT
 <213> artificial sequence
 5
 <220>
 <223> synthetic construct
 10
 <400> 407
 Gln Gln Ile Tyr Ser Phe Pro His
 1 5
 15
 <210> 408
 <211> 24
 <212> DNA
 <213> artificial sequence
 20
 <220>
 <223> synthetic construct
 <400> 408
 cagcagattt attctttcc tcat 24
 25
 <210> 409
 <211> 8
 <212> PRT
 <213> artificial sequence
 30
 <220>
 <223> synthetic construct
 <400> 409
 35
 Leu Gln Ile Tyr Asn Met Pro Ile
 1 5
 40
 <210> 410
 <211> 24
 <212> DNA
 <213> artificial sequence
 <220>
 45
 <223> synthetic construct
 <400> 410
 cttcagcttt ataattcc taat 24
 50
 <210> 411
 <211> 8
 <212> PRT
 <213> artificial sequence
 55
 <220>
 <223> synthetic construct
 <400> 411

EP 2 368 907 B1

Leu Gln Leu Tyr Asn Ile Pro Asn
1 5

5 <210> 412
<211> 24
<212> DNA
<213> artificial sequence

10 <220>
<223> synthetic construct

<400> 412
cagcagcttt cttcttatcc tcct 24

15 <210> 413
<211> 8
<212> PRT
<213> artificial sequence

20 <220>
<223> synthetic construct

<400> 413

25 Gln Gln Leu Ser Ser Tyr Pro Pro
1 5

30 <210> 414
<211> 52
<212> PRT
<213> artificial sequence

<220>
<223> synthetic construct

35 <400> 414

40 Ile Ser Glu Val Lys Met Asp Ala Glu Phe Arg His Asp Ser Gly Tyr
1 5 10 15

Glu Val His His Gln Lys Leu Val Phe Phe Ala Glu Asp Val Gly Ser
20 25 30

45 Asn Lys Gly Ala Ile Ile Gly Leu Met Val Gly Gly Val Val Ile Ala
35 40 45

50 Thr Val Ile Val
50

Claims

55 1. An anti-beta-A4 peptide antibody molecule comprising

(a) a variable VL-Region comprising complementary determining regions, L-CDR1, L-CDR2 and L-CDR3, where-

in:

- (1) L-CDR1 comprises SEQ ID No: 143: Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala;
- (2) L-CDR2 comprises SEQ ID No: 144: Gly Ala Ser Ser Arg Ala Thr; and
- (3) L-CDR3 comprises SEQ ID No: 95: Leu Gln Ile Tyr Asn Met Pro Ile; and

(b) a variable VH-Region comprising complementary determining regions, H-CDR1, H-CDR2 and H-CDR3, wherein:

- (1) H-CDR1 comprises SEQ ID No: 146: Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser;
- (2) H-CDR2 comprises SEQ ID Nos.: 192: Ala Ile Asn Ala Ser Gly Thr Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly; and
- (3) H-CDR3 comprises SEQ ID Nos.: 93: Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp Val.

2. The antibody molecule of claim 1, wherein said antibody molecule comprises a variable VH-region as shown in a SEQ ID NO: 89 and a variable VL-region as shown in a SEQ ID NO: 91.
3. The antibody molecule of claim 1 or 2, wherein said antibody molecule comprises a variable VH-region as encoded by a nucleic acid molecule as shown in a SEQ ID No:88 a variable VL-region as encoded by a nucleic acid molecule as shown in a SEQ ID NO:90.
4. The antibody molecule of any one of claims 1 to 3, wherein said antibody molecule is a full antibody (immunoglobulin), a F(ab)-fragment, a F(ab)₂-fragment, a single-chain antibody, a chimeric antibody, a CDR-grafted antibody, a bivalent antibody-construct, a synthetic antibody or a cross-cloned antibody.
5. A nucleic acid molecule encoding an antibody molecule of any one of claims 1 to 4.
6. A vector comprising the nucleic acid molecule of claim 5.
7. A host cell comprising the vector of claim 6.
8. A method for the preparation of an antibody molecule of any one of claims 1 to 4 comprising culturing the host cell of claim 7 under conditions that allow synthesis of said antibody molecule and recovering said antibody molecule from said culture.
9. A composition comprising an antibody molecule of any one of claims 1 to 4 or an antibody molecule produced by the method of claim 8.
10. The composition of claim 9, which is a pharmaceutical or a diagnostic composition.
11. Use of an antibody molecule of any one of claims 1 to 4 or an antibody molecule produced by the method of claim 8, of a nucleic acid molecule of claim 5, of a vector of claim 6 or a host of claim 7 for the preparation of a pharmaceutical composition for the prevention and/or treatment of a disease associated with amyloidogenesis and/or amyloid-plaque formation.
12. A pharmaceutical composition comprising an antibody molecule of any one of claims 1 to 4 or an antibody molecule produced by the method of claim 8, of a nucleic acid molecule of claim 5, of a vector of claim 6 or a host of claim 7 for use in the prevention and/or treatment of a disease associated with amyloidogenesis and/or amyloid-plaque formation.
13. Use of an antibody molecule of any one of claims 1 to 4 or an antibody molecule produced by the method of claim 8 for the preparation of a diagnostic composition for the detection of a disease associated with amyloidogenesis and/or amyloid-plaque formation.
14. A diagnostic composition comprising an antibody molecule of any one of claims 1 to 4 or an antibody molecule produced by the method of claim 8 for use in the detection of a disease associated with amyloidogenesis and/or amyloid-plaque formation.

15. Use of an antibody molecule of any one of claims 1 to 4 or an antibody molecule produced by the method of claim 8 for the preparation of a pharmaceutical composition for the disintegration of β -amyloid plaques.
16. A pharmaceutical composition comprising an antibody molecule of any one of claims 1 to 4 or an antibody molecule produced by the method of claim 8 for use in the disintegration of β -amyloid plaques.
17. Use of an antibody molecule of any one of claims 1 to 4 or an antibody molecule produced by the method of claim 8 for the preparation of a pharmaceutical composition for passive immunization against β -amyloid plaque formation.
18. A pharmaceutical composition comprising an antibody molecule of any one of claims 1 to 4 or an antibody molecule produced by the method of claim 8 for use in passive immunization against β -amyloid plaque formation.
19. The use of any one of claims 11, 13, 15 or 17, or the pharmaceutical composition for the use of claim 12, or the diagnostic composition for the use of claim 14, wherein said disease is dementia, Alzheimer's disease, motor neuropathy, Down's syndrome, Creutzfeld Jacob disease, hereditary cerebral hemorrhage with amyloidosis Dutch type, Parkinson's disease, HIV-related dementia, ALS or neuronal disorders related to aging.

Patentansprüche

1. Anti-beta-A4-Peptid Antikörpermolekül, umfassend

(a) eine variable VL-Region, die komplementaritätsbestimmende Regionen L-CDR1, L-CDR2 und L-CDR3 umfasst, wobei:

- (1) L-CDR1 SEQ ID NO:143: Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala umfasst;
- (2) L-CDR2 SEQ ID NO:144: Gly Ala Ser Ser Arg Ala Thr umfasst; und
- (3) L-CDR3 SEQ ID NO:95: Leu Gln Ile Tyr Asn Met Pro Ile umfasst; und

(b) eine variable VH-Region, die komplementaritätsbestimmende Regionen H-CDR1, H-CDR2 und H-CDR3 umfasst, wobei:

- (1) H-CDR1 SEQ ID NO:146: Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser umfasst;
- (2) H-CDR2 SEQ ID NO:192: Ala Ile Asn Ala Ser Gly Thr Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly umfasst; und
- (3) H-CDR3 SEQ ID NO:93: Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp Val umfasst.

2. Antikörpermolekül nach Anspruch 1, wobei das Antikörpermolekül eine wie in SEQ ID NO:89 gezeigte variable VH-Region und eine wie in SEQ ID NO:91 gezeigte variable VL-Region umfasst.

3. Antikörpermolekül nach Anspruch 1 oder 2, wobei das Antikörpermolekül eine variable VH-Region, die durch ein in SEQ ID NO:88 gezeigtes Nucleinsäuremolekül codiert ist und eine variable VL-Region, die durch ein in SEQ ID NO:90 gezeigtes Nucleinsäuremolekül codiert ist, umfasst.

4. Antikörpermolekül nach einem der Ansprüche 1 bis 3, wobei das Antikörpermolekül ein vollständiger Antikörper (Immunoglobulin), ein F(ab)-Fragment, ein F(ab)₂-Fragment, ein Einzelkettenantikörper (single chain antibody), ein chimärer Antikörper, ein CDR-grafted Antikörper, ein bivalentes Antikörperkonstrukt, ein synthetischer Antikörper oder ein kreuzklonierter Antikörper ist.

5. Nucleinsäuremolekül, das ein Antikörpermolekül nach einem der Ansprüche 1 bis 4 codiert.

6. Vektor, der das Nucleinsäuremolekül nach Anspruch 5 umfasst.

7. Wirtszelle, die den Vektor nach Anspruch 6 umfasst.

8. Verfahren zur Herstellung eines Antikörpermoleküls nach einem der Ansprüche 1 bis 4, das das Züchten der Wirtszelle nach Anspruch 7 unter Bedingungen, die die Synthese des Antikörpermoleküls ermöglichen und das Gewinnen des Antikörpermoleküls aus der Kultur umfasst.

9. Zusammensetzung, die ein Antikörpermolekül nach einem der Ansprüche 1 bis 4 oder ein Antikörpermolekül, das hergestellt ist durch das Verfahren nach Anspruch 8 umfasst.
10. Zusammensetzung nach Anspruch 9, die eine pharmazeutische oder diagnostische Zusammensetzung ist.
11. Verwendung eines Antikörpermoleküls nach einem der Ansprüche 1 bis 4 oder eines Antikörpermoleküls hergestellt durch das Verfahren nach Anspruch 8, eines Nucleinsäuremoleküls nach Anspruch 5, eines Vektors nach Anspruch 6 oder eines Wirts nach Anspruch 7 zur Herstellung eines Arzneimittels zur Vorbeugung und/oder Behandlung einer Erkrankung, die mit Amyloidgenese und/oder der Bildung von amyloiden Plaques in Zusammenhang steht.
12. Arzneimittel, das ein Antikörpermolekül nach einem der Ansprüche 1 bis 4 oder ein Antikörpermolekül, das hergestellt ist durch das Verfahren nach Anspruch 8, ein Nucleinsäuremolekül nach Anspruch 5, einen Vektor nach Anspruch 6 oder eine Wirtszelle nach Anspruch 7 umfasst, zur Verwendung bei der Vorbeugung und/oder Behandlung einer Erkrankung, die mit Amyloidgenese und/oder der Bildung von amyloiden Plaques in Zusammenhang steht.
13. Verwendung eines Antikörpermoleküls nach einem der Ansprüche 1 bis 4 oder eines Antikörpermoleküls, das hergestellt ist durch das Verfahren nach Anspruch 8 zur Herstellung einer diagnostischen Zusammensetzung zum Nachweis einer Erkrankung, die mit Amyloidgenese und/oder der Bildung von amyloiden Plaques in Zusammenhang steht.
14. Diagnostische Zusammensetzung, die ein Antikörpermolekül nach einem der Ansprüche 1 bis 4 oder ein Antikörpermolekül, das hergestellt ist durch das Verfahren nach Anspruch 8 umfasst, zur Verwendung bei dem Nachweis einer Erkrankung, die mit Amyloidgenese und/oder der Bildung von amyloiden Plaques verbunden ist.
15. Verwendung eines Antikörpermoleküls nach einem der Ansprüche 1 bis 4 oder eines Antikörpermoleküls, das hergestellt ist durch das Verfahren nach Anspruch 8 zur Herstellung eines Arzneimittels zum Auflösen von β -Amyloid-Plaques.
16. Arzneimittel, das ein Antikörpermolekül nach einem der Ansprüche 1 bis 4 oder ein Antikörpermolekül, das hergestellt ist durch das Verfahren nach Anspruch 8 umfasst, zur Verwendung bei dem Auflösen von β -Amyloid-Plaques.
17. Verwendung eines Antikörpermoleküls nach einem der Ansprüche 1 bis 4 oder eines Antikörpermoleküls, das hergestellt ist durch das Verfahren nach Anspruch 8 zur Herstellung eines Arzneimittels zur passiven Immunisierung gegen die Bildung von β -Amyloid-Plaques.
18. Arzneimittel, das ein Antikörpermolekül nach einem der Ansprüche 1 bis 4 oder ein Antikörpermolekül, das hergestellt ist durch das Verfahren nach Anspruch 8 umfasst, zur Verwendung bei der passiven Immunisierung gegen die Bildung von β -Amyloid-Plaques.
19. Verwendung nach einem der Ansprüche 11, 13, 15 oder 17, oder Arzneimittel zur Verwendung nach Anspruch 12 oder diagnostische Zusammensetzung zur Verwendung nach Anspruch 14, wobei die Erkrankung Demenz, Alzheimer-Krankheit, motorische Neuropathie, Down-Syndrom, Creutzfeld-Jakob-Krankheit, erbliche Hirnblutung mit Amyloidose vom Dutch-Typ (hereditary cerebral hemorrhage with amyloidosis Dutch type), Parkinson-Krankheit, mit HIV-verbundene Demenz, ALS oder mit Alterung verbundene neuronale Störungen ist.

Revendications

1. Molécule d'anticorps du peptide anti-bêta-A4 comprenant

(a) une région variable VL comprenant les régions déterminant la complémentarité, L-CDR1, L-CDR2 et L-CDR3, où :

- (1) la L-CDR1 comprend SEQ ID NO : 143 : Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala ;
- (2) la L-CDR2 comprend SEQ ID NO : 144 : Gly Ala Ser Ser Arg Ala Thr ; et
- (3) la L-CDR3 comprend SEQ ID NO : 95 : Leu Gln Ile Tyr Asn Met Pro Ile ; et

(b) une région variable VH comprenant les régions déterminant la complémentarité, H-CDR1, H-CDR2 et H-

CDR3, où :

- (1) la H-CDR1 comprend SEQ ID NO : 146 : Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser ;
- (2) la H-CDR2 comprend SEQ ID NO : 192 : Ala Ile Asn Ala Ser Gly Thr Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly ; et
- (3) la H-CDR3 comprend SEQ ID NO : 93 : Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp Val.

2. Molécule d'anticorps selon la revendication 1, ladite molécule d'anticorps comprenant une région variable VH telle que représentée par SEQ ID NO : 89 et une région variable VL telle que représentée par SEQ ID NO : 91.
3. Molécule d'anticorps selon la revendication 1 ou 2, ladite molécule d'anticorps comprenant une région variable VH telle que codée par une molécule d'acide nucléique telle que représentée par SEQ ID NO : 88 et une région variable VL telle que codée par une molécule d'acide nucléique telle que représentée par SEQ ID NO : 90.
4. Molécule d'anticorps selon l'une quelconque des revendications 1 à 3, ladite molécule d'anticorps étant un anticorps entier (immunoglobuline), un fragment F(ab), un fragment F(ab)₂, un anticorps à chaîne unique, un anticorps chimérique, un anticorps à CDR greffées, une construction d'anticorps bivalent, un anticorps de synthèse ou un anticorps issu de clones croisés.
5. Molécule d'acide nucléique codant pour une molécule d'anticorps selon l'une quelconque des revendications 1 à 4.
6. Vecteur comprenant la molécule d'acide nucléique selon la revendication 5.
7. Cellule hôte comprenant le vecteur selon la revendication 6.
8. Procédé de préparation d'une molécule d'anticorps selon l'une quelconque des revendications 1 à 4, comprenant la culture de la cellule hôte selon la revendication 7 dans des conditions qui permettent la synthèse de ladite molécule d'anticorps et la récupération de ladite molécule d'anticorps à partir de ladite culture.
9. Composition comprenant une molécule d'anticorps selon l'une quelconque des revendications 1 à 4 ou une molécule d'anticorps produite par le procédé selon la revendication 8.
10. Composition selon la revendication 9, qui est une composition pharmaceutique ou de diagnostic.
11. Utilisation d'une molécule d'anticorps selon l'une quelconque des revendications 1 à 4 ou d'une molécule d'anticorps produite par le procédé selon la revendication 8, d'une molécule d'acide nucléique selon la revendication 5, d'un vecteur selon la revendication 6 ou d'un hôte selon la revendication 7 pour la préparation d'une composition pharmaceutique destinée à la prévention et/ou au traitement d'une maladie associée à l'amyloïdogenèse et/ou à la formation de plaques amyloïdes.
12. Composition pharmaceutique comprenant une molécule d'anticorps selon l'une quelconque des revendications 1 à 4 ou une molécule d'anticorps produite par le procédé selon la revendication 8, une molécule d'acide nucléique selon la revendication 5, un vecteur selon la revendication 6 ou un hôte selon la revendication 7 pour une utilisation dans la prévention et/ou le traitement d'une maladie associée à l'amyloïdogenèse et/ou à la formation de plaques amyloïdes.
13. Utilisation d'une molécule d'anticorps selon l'une quelconque des revendications 1 à 4 ou d'une molécule d'anticorps produite par le procédé selon la revendication 8 pour la préparation d'une composition de diagnostic pour la détection d'une maladie associée à l'amyloïdogenèse et/ou à la formation de plaques amyloïdes.
14. Composition de diagnostic comprenant une molécule d'anticorps selon l'une quelconque des revendications 1 à 4 ou une molécule d'anticorps produite par le procédé selon la revendication 8 pour une utilisation dans la détection d'une maladie associée à l'amyloïdogenèse et/ou à la formation de plaques amyloïdes.
15. Utilisation d'une molécule d'anticorps selon l'une quelconque des revendications 1 à 4 ou d'une molécule d'anticorps produite par le procédé selon la revendication 8 pour la préparation d'une composition pharmaceutique destinée à la désintégration des plaques de β -amyloïde.

16. Composition pharmaceutique comprenant une molécule d'anticorps selon l'une quelconque des revendications 1 à 4 ou une molécule d'anticorps produite par le procédé selon la revendication 8 pour une utilisation dans la désintégration des plaques de β -amyloïde.

5 **17.** Utilisation d'une molécule d'anticorps selon l'une quelconque des revendications 1 à 4 ou d'une molécule d'anticorps produite par le procédé selon la revendication 8 pour la préparation d'une composition pharmaceutique destinée à une immunisation passive contre la formation de plaques de β -amyloïde.

10 **18.** Composition pharmaceutique comprenant une molécule d'anticorps selon l'une quelconque des revendications 1 à 4 ou une molécule d'anticorps produite par le procédé selon la revendication 8 pour une utilisation dans l'immunisation passive contre la formation de plaques de β -amyloïde.

15 **19.** Utilisation selon l'une quelconque des revendications 11, 13, 15 ou 17, ou composition pharmaceutique pour l'utilisation selon la revendication 12, ou composition de diagnostic pour l'utilisation selon la revendication 14, où ladite maladie est la démence, la maladie d'Alzheimer, la neuropathie motrice, le syndrome de Down, la maladie de Creutzfeld-Jacob, l'hémorragie cérébrale héréditaire avec amylose de type hollandais, la maladie de Parkinson, la démence associée au VIH, la SLA ou les troubles neuronaux associés au vieillissement.

20

25

30

35

40

45

50

55

Sequence Summary of HuCAL-Fab1 Library

7

[illegible]

IN

Fig. 1a

Position	Framework 1										CDR 1										Framework 2										CDR 2									
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	
1	2	3	4	5	6	7	8	9	0	1	2	3	4																											

Fig. 1a cont.

Framework 3										CDR 3										Framework 4																	
7										9										10																	
6	5	4	3	2	1	0	8	7	6	5	4	3	2	1	0	9	8	7	6	5	4	3	2	1	0	10	9	8	7	6	5	4	3	2	1	0	
BamHI										BbsI										BsaBI																	
S	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	X	Q	X	X	X	X	X	X	X
D	R	F	S	G	S	G	S	G	T	D	F	T	L	K	I	S	R	V	E	A	E	D	V	G	V	Y	Y	C	X	Q	X	X	X	X	X	X	X
A	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	S	L	E	P	E	D	F	A	T	Y	Y	C	X	Q	X	X	X	X	X	X	X
D	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	S	L	Q	A	E	D	V	A	V	Y	Y	C	X	Q	X	X	X	X	X	X	X
BamHI										BbsI										BsaBI																	
D	R	F	S	G	S	K	S	G	T	S	A	S	L	A	I	T	G	L	Q	S	E	D	E	A	D	Y	Y	C	Q	S	X	D	X	X	X	X	X
N	R	F	S	G	S	K	S	G	N	T	A	S	L	T	I	S	G	L	Q	A	E	D	E	A	D	Y	Y	C	Q	S	X	D	X	X	X	X	X
E	R	F	S	G	S	N	S	G	N	T	A	T	L	T	I	S	G	T	Q	A	E	D	E	A	D	Y	Y	C	Q	S	X	D	X	X	X	X	X
BamHI										BbsI										HpaI																	
																				L T V L G																	
																				L T V L G																	
																				L T V L G																	
																				L T V L G																	
																				MscI																	

[illegible]

Sequence Summary of HuCAL-Fab1 Library

[illegible]


HV

Position	Framework 1																CDR 1																F1															
	1																2																	3														
	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	a	b	2	3	4	5	6	7	8	9	0	1	4														
	MfeI																BspEI																															
VH1A	CAG	GTG	CAA	TTG	GTG	CAG	TCT	GGC	GC	G	GAA	GTG	AAA	AAA	CCG	GGC	AGC	AGC	GTG	AAA	GTG	AGC	TGC	AAA	GCC	TCC	GGG	GGC	ACT	TTT	AGC	AGC	-	TAT	GCG	ATT	AGC	TGG	GTG	CAC	CMA	GCC	CCT					
VH1B	CAG	GTG	CAA	TTG	GTG	CAG	AGC	GGC	CG	G	GAA	GTG	AAA	AAA	CCG	GGC	GC	AGC	GTG	AAA	GTG	AGC	TGC	AAA	GCC	TCC	GGG	TAT	ACC	TTT	ACC	AGC	-	-	TAT	TAT	ATG	CAC	TGG	GTG	CAC	CMA	GCC	CCT				
VH2	CAG	GTG	CAA	TTG	AAA	GAA	AGC	GGC	CG	G	GTG	GTG	AAA	AAA	CCG	ACC	CMA	ACC	CTG	ACC	CTG	ACC	TGT	ACC	TTT	TCC	GGG	TTT	AGC	CTG	TCC	AGC	TCT	GGC	GTT	GGC	GTG	AGC	TGG	ATT	CAC	CAG	CGC	CCT				
VH3	CAG	GTG	CAA	TTG	GTG	GAA	AGC	GGC	GCC	G	GGC	GTG	AAA	AAA	CCG	GGC	AGC	CTG	CGT	CGT	CGT	TGC	GCG	GCC	TCC	GGG	TTT	AGC	CTG	TTT	AGC	AGC	-	TAT	GCG	ATG	AGC	TGG	GTG	CAC	CMA	GCC	CCT					
VH4	CAG	GTG	CAA	TTG	CAA	GAA	AGT	GCT	CG	G	GGC	CTG	GTG	AAA	CCG	AGC	GAA	ACC	CTG	AGC	CTG	ACC	TGC	ACC	GTT	TCC	GGG	GGC	AGC	ATT	AGC	AGC	-	-	TAT	TAT	TGG	AGC	TGG	ATT	CAC	CAG	ATG	CCT				
VH5	CAG	GTG	CAA	TTG	GTG	CAG	AGC	GGC	GC	G	GAA	GTG	AAA	AAA	CCG	GGC	GAA	AGC	CTG	AAA	ATT	AGC	TGC	AAA	GCT	TCC	GGG	TAT	TCC	TTT	AGC	AGC	-	-	TAT	TGG	ATT	GCG	TGG	GTG	CAC	CAG	ATG	CCT				
VH6	CAG	GTG	CAA	TTG	CAA	CAG	TCT	GCT	CG	G	GGC	CTG	GTG	AAA	CCG	AGC	CMA	ACC	CTG	AGC	CTG	ACC	TGT	GCG	ATT	TCC	GGG	GAT	AGC	GTG	AGC	AGC	AAC	AGC	GCG	GCG	TGG	AAC	TGG	ATT	CAC	CAG	TCT	CCT				

234

235

Fig. 2



```

lacZ'      SD      ompA
~~~      ~~~~      ~~~~~~
XbaI
~~~~~

          M K K T A I A I A V .
1  TCTAGATAAC GAGGGCAAAA AATGAAAAAG ACAGCTATCG CGATTGCAGT
   AGATCIATTG CTCCCGTTTT TTACTTTTTC TGTCGATAGC GCTAACGTCA
                                   Vk3
                                   ~~~~~~

          ompA
          ~~~~~~

                                   EcoRV
                                   ~~~~~~

. A L A G F A T V A Q A D I V L T Q .
51 GGCAGTGGCT GGTTCGCTA CCGTAGCGCA GGCCGATATC GTGCTGACCC

```

Fig. 2 cont.

```

CCGTGACCGA CCAAAGCGAT GGCATCGCGT CCGGCTATAG CACGACTGGG
Vk3
-----
  S P A T L S L S P G E R A T L S
101 AGAGCCCGGC GACCCTGAGC CTGTCTCCGG GCGAACGTGC GACCCTGAGC
TCTCGGGCCG CTGGGACTCG GACAGAGGCC CGCTTGACAG CTGGGACTCG
Vk3
-----
  C R A S Q S V S S S Y L A W Y Q Q
151 TGCAGAGCGA GCCAGAGCGT GAGCAGCAGC TATCTGGCGT GGTACCAGCA
ACGTCTCGCT CGGTCTCGCA CTCGTCTCG ATAGACCGCA CCATGGTCGT
Vk3
-----
  K P G Q A P R L L I Y G A S S R A
201 GAAACCAGGT CAAGCACCGC GTCTATTAAT TTATGGCGCG AGCAGCCGTG
CTTTGGTCCA GTTCGTGGCG CAGATAATTA AATACCGCGC TCGTCGGCAC
Vk3
-----
  T G V P A R F S G S G S G T D F
251 CAACTGGGGT CCGGCGCGCT TTTAGCGGCT CTGGATCCGG CACGGATTTT
GTTGACCCCA GGGCCGCGCA AAATCGCCGA GACCTAGGCC GTGCCTAAAA
Vk3
-----
BbsI
-----
  T L T I S S L E P E D F A V Y Y C
301 ACCCTGACCA TTAGCAGCCT GGAACCTGAA GACTTTGCGG TGTATTATTG
TGGGACTGGT AATCGTCGGA CCTTGGACTT CTGAAACGCC ACATAATAAC
Vk3
-----
MscI
-----
  Q Q H Y T T P P T F G Q G T K V E
351 CCAGCAGCAT TATACCACCC CGCCGACCTT TGGCCAGGGT ACGAAAGTTG
GGTCGTCGTA ATATGGTGGG GCGGCTGGAA ACCGGTCCCA TGCTTTCAAC
CL kappa
-----
Vk3
-----
BsiWI
-----
  I K R T V A A P S V F I F P P S
401 AAATTAAACG TACGGTGGCT GCTCCGAGCG TGTTTATTTT TCCGCCGAGC
TTTAATTTGC ATGCCACCGA CGAGGCTCGC ACAAATAAAA AGGCGGCTCG
CL kappa
-----
  D E Q L K S G T A S V V C L L N N
451 GATGAACAAC TGAAAAGCGG CACGGCGAGC GTGGTGTGCC TGCTGAACAA
CTACTTGTG ACTTTTCGCC GTGCCGCTCG CACCACACGG ACGACTTGTT
CL kappa
-----
  F Y P R E A K V Q W K V D N A L Q
501 CTTTTATCCG CGTGAAGCGA AAGTTCAGTG GAAAGTAGAC AACCGCTGTC
GAAAATAGGC GCACTTCGCT TTCAAGTCAC CTTTCATCTG TTGCGCGACG
CL kappa
-----
  S G N S Q E S V T E Q D S K D S
551 AAAGCGGCAA CAGCCAGGAA AGCGTGACCG AACAGGATAG CAAAGATAGC
TTTCGCCGTT GTCGGTCCTT TCGCACTGGC TTGTCCTATC GTTTCATCG
CL kappa
-----

```

Fig. 2 cont.

```

      T Y S L S S T L T L S K A D Y E K .
601 ACCTATTCTC TGAGCAGCAC CCTGACCCTG AGCAAAGCGG ATTATGAAAA
      TGGATAAGAG ACTCGTCGTG GGAAGGGGAC TCGTTTCGCC TAATACTTTT
      CL kappa
      -----
      H K V Y A C E V T H Q G L S S P V .
651 ACATAAAGTG TATGCGTGCG AAGTGACCCA TCAAGGTCTG AGCAGCCCCG
      TGTATTTTAC ATACGCACGC TTCCTGGGT AGTTCAGAC TCGTCGGGCC
      CL kappa
      -----
      StuI          SphI
      -----
      T K S F N R G E A
701 TGAATAATC TTTTAATCGT GGCAGGCCT GATAAGCATG CGTAGGAGAA
      ACTGATTTAG AAAATTAGCA CCGCTCCGGA CTATTCGTAC GCATCCTCTT
      phoA
      -----
      SapI
      -----
      M K Q S T I A L A L L P L L F .
751 AATAAATGA AACAAAGCAC TATTGCACTG GCACTCTTAC CGTTGCTCTT
      TTATTTTACT TTGTTTCGTG ATAACGTGAC CGTGAGAATG GCAACGAGAA
      VH3
      -----
      phoA
      -----
      SapI          MfeI
      -----
      T P V T K A Q V Q L V E S G G G L .
801 CACCCCTGTT ACCAAAGCCG AAGTGCAATT GGTGGAAAGC GGCGGCGGCC
      GTGGGGACAA TGGTTTCGGC TTCACGTAA CCACCTTTCG CCGCCGCCGG
      VH3
      -----
      V Q P G G S L R L S C A A S G F
851 TGGTGCAACC GGGCGGCAGC CTGCGTCTGA GCTGCGCGGC CTCCGGATTT
      ACCACGTTGG CCGCGCGTCG GACGCAGACT CGACGCGCCG GAGGCCTAAA
      VH3
      -----
      T F S S Y A M S W V R Q A P G K G .
901 ACCTTTAGCA GCTATGCGAT GAGCTGGGTG CGCCAAGCCC CTGGGAAGGG
      TGGAAATCGT CGATACGCTA CTCGACCCAC GCGGTTCCGG GACCTTCCC
      VH3
      -----
      L E W V S A I S G S G G S T Y Y A .
951 TCTCGAGTGG GTGAGCGCGA TTAGCGGTAG CGGCGGCAGC ACCTATTATG
      AGAGCTCACC CACTCGCGCT AATCGCCATC GCCGCCGTCG TGGATAATAC
      VH3
      -----
      PmlI
      -----
      D S V K G R F T I S R D N S K N
1001 CGGATAGCGT GAAAGGCCGT TTTACCATTT CACGTGATAA TTCGAAAAAC
      GCCTATCGCA CTTTCCGGCA AAATGGTAAA GTGCACTATT AAGCTTTTGG
      VH3
      -----
      T L Y L Q M N S L R A E D T A V Y .
1051 ACCCTGTATC TGCAAATGAA CAGCCTGCGT GCGGAAGATA CGGCCGTGTA
      TGGGACATAG ACGTTTACTT GTCGGACGCA CGCCTTCTAT GCCCGCACAT
      VH3
      -----
      BssHII

```

Fig. 2 cont.

```

-----
      . Y C A R W G G D G F Y A M D Y W G .
1101 TTATTGCGCG CGTTGGGGCG GCGATGGCTT TTATGCGATG GATTATTGGG
      AATAACGCGC GCAACCCCGC CGCTACCGAA AATACGCTAC CTAATAACCC
                               CH1
-----
                               VH3
-----
                               SalI
-----
      StyI                               BlnI
-----
      . Q G T L V T V S S A S T K G P S
1151 GCCAAGGCAC CCTGGTGACG GTTAGCTCAG CGTCGACCAA AGGTCCAAGC
      CGGTTCCGTG GGACCACTGC CAATCGAGTC GCAGCTGGTT TCCAGGTTCC
                               CH1
-----
      V F P L A P S S K S T S G G T A A .
1201 GTGTTTCCGC TGGCTCCGAG CAGCAAAAGC ACCAGCGGCG GCACGGCTGC
      CACAAAGGCG ACCGAGGCTC GTCGTTTTTC TGGTCGCCGC CGTGCCGACG
                               CH1
-----
      . L G C L V K D Y F P E P V T V S W .
1251 CCTGGGCTGC CTGGTTAAAG ATTATTTCCC GGAACCAAGTC ACCGTGAGCT
      GGACCCGACG GACCAATTTT TAATAAAGG CTTGGTCAG TGGCACTCGA
                               CH1
-----
      . N S G A L T S G V H T F P A V L
1301 GGAACAGCGG GGCCTGACC AGCGGCGTGC ATACCTTTCC GGCGGTGCTG
      CCTTGTCGCC CCGCGACTGG TCGCCGACG TATGGAAGG CCGCCACGAC
                               CH1
-----
      Q S S G L Y S L S S V V T V P S S .
1351 CAAAGCAGCG GCCTGTATAG CCTGAGCAGC GTTGTGACCG TGCCGAGCAG
      GTTTCGTGCG CGGACATATC GGAATCGTCG CAACACTGGC ACGGCTCGTC
                               CH1
-----
      . S L G T Q T Y I C N V N H K P S N .
1401 CAGCTTAGGC ACTCAGACCT ATATTTGCAA CGTGAACCAT AAACCGAGCA
      GTCGAATCCG TGAGTCTGGA TATAAACGTT GCACTTGGTA TTTGGCTCGT
                               CH1                               CTgIII
-----
                               EcoRI
-----
      . T K V D K K V E P K S E F G G G
1451 ACACCAAAGT GGATAAAAAA GTGGAACCGA AAAGCGAATT CGGGGGAGGG
      TGTGGTTTCA CCTATTTTTT CACCTTGGCT TTTGCTTAA GCCCCCTCCC
                               CTgIII
-----
      S G S G D F D Y E K M A N A N K G .
1501 AGCGGGAGCG GTGATTTTGA TTATGAAAAG ATGGCAAACG CTAATAAGGG
      TCGCCCTCGC CACTAAACT AATACTTTT TACCGTTTGC GATTATTCCC
                               CTgIII
-----
      . A M T E N A D E N A L Q S D A K G .
1551 GGCTATGACC GAAAATGCCG ATGAAAACGC GCTACAGTCT GACGCTAAAG
      CCGATACTGG CTTTTACGGC TACTTTTTCG CGATGTCAGA CTGCGATTTC
                               CTgIII
-----
      . K L D S V A T D Y G A A I D G F
1601 GCAAACCTGA TTCTGTCGCT ACTGATTACG GTGCTGCTAT CGATGGTTTC

```

Fig. 2 cont.

```

CGTTTGAAC T AAGACAGCGA T GACTAATGC CACGACGATA GCTACCAAAG
CTgIII
-----
I G D V S G L A N G N G A T G D F .
1651 ATTGGTGACG TTTCCGGCCT TGCTAATGGT AATGGTGCTA CTGGTGATTT
TAACCACTGC AAAGGCCGGA ACGATTACCA TTACCACGAT GACCACTAAA
CTgIII
-----
A G S N S Q M A Q V G D G D N S P .
1701 TGCTGGCTCT AATTCCCAA TGGCTCAAGT CGGTGACGGT GATAATTCAC
ACGACCGAGA TTAAGGGTTT ACCGAGTTCA GCCACTGCCA CTATTAAGTG
CTgIII
-----
L M N N F R Q Y L P S L P Q S V
1751 CTTTAATGAA TAATTTCCGT CAATATTTAC CTTCCCTCCC TCAATCGGTT
GAAATTACTT ATTAAAGGCA GTTATAAATG GAAGGGAGGG AGTTAGCCAA
CTgIII
-----
E C R P F V F G A G K P Y E F S I .
1801 GAATGTCGCC CTTTTGTCTT TGGCGCTGGT AAACCATATG AATTTTCTAT
CTTACAGCGG GAAAACAGAA ACCGCGACCA TTTGGTATAC TTAAAAGATA
CTgIII
-----
D C D K I N L F R G V F A F L L Y .
1851 TGATTGTGAC AAAATAAACT TATTCCGTGG TGTCTTGGCG TTTCTTTTAT
ACTAACA CTG TTTTATTTGA ATAAGGCACC ACAGAAACGC AAAGAAAATA
CTgIII
-----
V A T F M Y V F S T F A N I L R
1901 ATGTTGCCAC CTTTATGTAT GTATTTTCTA CGTTTGCTAA CATACTGCGT
TACAACGGTG GAAATACATA CATAAAAGAT GCAAACGATT GTATGACGCA
CTgIII
-----
Stop lpp terminator
-----
HindIII
-----
N K E S
1951 AATAAGGAGT CTTGATAAGC TTGACCTGTG AAGTGAAAAA TGGCGCAGAT
TTATCCTCA GAACTATTCG AACTGGACAC TTCACTTTTT ACCGCGTCTA
lpp terminator
-----
2001 TGTGCGACAT TTTTTTTGTC TGCCGTTTAA TGAAATTGTA AACGTTAATA
ACACGCTGTA AAAAAACAG ACGGCAAATT ACTTTAACAT TTGCAATTAT
-----
f1 origin
2051 TTTTGTTAAA ATTCGCGTTA AATTTTGTG AAATCAGCTC ATTTTAAAC
AAAACAATTT TAAGCGCAAT TTAAAAACAA TTTAGTCGAG TAAAAAATTG
-----
f1 origin
2101 CAATAGGCCG AAATCGGCAA AATCCCTTAT AAATCAAAAG AATAGACCGA
GTTATCCGGC TTTAGCCGTT TTAGGGAATA TTTAGTTTTC TTATCTGGCT
-----
f1 origin
2151 GATAGGETTG AGTGTGTGTC CAGTTTGGAA CAAGAGTCCA CTATTAAAGA
CTATCCCAAC TCACAACAAG GTCAAACCTT GTTCTCAGGT GATAATTCT
-----
f1 origin
2201 ACGTGGACTC CAACGTCAAA GGGCGAAAAA CCGTCTATCA GGGCGATGGC
TGCACCTGAG GTTGCAAGTTT CCCGCTTTTT GGCAGATAGT CCCGCTACCG
-----

```

Fig. 2 cont.

```

                                fl origin
                                T->A
2251  CCACTACGAG AACCATCACC CTAATCAAGT TTTTGGGGT CGAGGTGCCG
      GGTGATGCTC TTGGTAGTGG GATTAGTTCA AAAAACCCCA GCTCCACGGC
      ~~~~~
                                fl origin
2301  TAAAGCACTA AATCGGAACC CTAAAGGGAG CCCCCGATTT AGAGCTTGAC
      ATTCGTGAT  TTAGCCTTGG GATTCCCTC GGGGGCTAAA TCTCGAACTG
      ~~~~~
                                fl origin
2351  GGGGAAAGCC GCGGAACGTG GCGAGAAAGG AAGGGAAGAA AGCGAAAGGA
      CCCCTTTCGG CCGCTTGAC  CGCTCTTCC TTCCCTTCTT TCGCTTTCCT
      ~~~~~
                                fl origin
2401  GCGGGCGCTA GGGCGCTGGC AAGTGTAGCG GTCACGCTGC GCGTAACCAC
      CGCCCGCGAT CCCGCGACCG TTCACATCGC CAGTGCGACG CGCATTGGTG
      ~~~~~
                                fl origin
                                NheI
2451  CACACCCGCC GCGCTTAATG CGCCGCTACA GGGCGCGTGC TAGCCATGTG
      GTGTGGGCGG CGCGAATTAC GCGGCGATGT CCCGCGCACG ATCGGTACAC
      ~~~~~
                                fl origin
                                ColEI
2501  AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAGGCC GCGTTGCTGG
      TCGTTTTCCG GTCGTTTTCC GGTCTTGGC  ATTTTCCGG  CGCAACGACC
      ~~~~~
                                ColEI
                                ORI
2551  CGTTTTTCCA TAGGCTCCGC CCCCCTGACG AGCATCACAA AAATCGACGC
      GCAAAAAGGT ATCCGAGGCG GGGGGACTGC TCGTAGTGTT TTAGCTGCG
      ~~~~~
                                ColEI
2601  TCAAGTCAGA GGTGGCGAAA CCCGACAGGA CTATAAAGAT ACCAGGCGTT
      AGTTCAGTCT CCACCGCTTT GGGCTGTCTT GATATTCTA TGGTCCGCAA
      ~~~~~
                                ColEI
2651  TCCCCCTGGA AGCTCCCTCG TCGCTCTTCC TGTTCGACC CTGCCGCTTA
      AGGGGGACCT TCGAGGGAGC ACGCGAGAGG ACAAGGCTGG GACGGCGAAT
      ~~~~~
                                ColEI
                                mutation
2701  CCGGATACCT GTCCGCCTTT CTCCCTTCGG GAAGCGTGGC GCTTTCTCAT
      GGCCTATGGA CAGGCGGAAA GAGGGAAGCC CTTCGCACCG CGAAAGAGTA
      ~~~~~
                                ColEI
                                mutation
2751  AGCTCACGCT GTAGGTATCT CAGTTCGGTG TAGGTCGTTC GCTCCAAGCT
      TCGAGTGCGA CATCCATAGA GTCAAGCCAC ATCCAGCAAG CGAGGTTCGA
      ~~~~~
                                ColEI
                                mutation
2801  GGGCTGTGTG CACGAACCCC CCGTTCAGTC CGACCGCTGC GCCTTATCCG
      CCCGACACAC GTGCTTGGGG GGCAAGTCAG GCTGGCGACG CGGAATAGGC
      ~~~~~
                                ColEI

```

Fig. 2 cont.

```

2851  GTAAGTATCG TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG
      CATTGATAGC AGAACTCAGG TTGGGCCATT CTGTGCTGAA TAGCGGTGAC
      ~~~~~
                        ColEI
2901  GCAGCAGCCA CTGGTAACAG GATTAGCAGA GCGAGGTATG TAGGCGGTGC
      CGTCGTCGGT GACCATTGTC CTAATCGTCT CGCTCCATAC ATCCGCCACG
      ~~~~~
                        ColEI
                                          mutation
2951  TACAGAGTTC TTGAAGTGGT GGCCTAACTA CGGCTACACT AGAAGAACAG
      ATGTCTCAAG AACTTCACCA CCGGATTGAT GCCGATGTGA TCTTCTTGTC
      ~~~~~
                        ColEI
                        mutation
3001  TATTGGTAT CTGCGCTCTG CTGTAGCCAG TTACCTTCGG AAAAAGAGTT
      ATAAACCATA GACGCGAGAC GACATCGGTC AATGGAAGCC TTTTCTCAA
      ~~~~~
                        ColEI
3051  GGTAGCTCTT GATCCGGCAA ACAAACCACC GCTGGTAGCG GTGGTTTTTT
      CCATCGAGAA CTAGGCCGTT TGTTTGGTGG CGACCATCGC CACCAAAAAA
      ~~~~~
                        ColEI
3101  TGTTTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT CAAGAAGATC
      ACAAACGTTT GTCGTCTAAT GCGCGTCTTT TTTTCCTAGA GTTCTTCTAG
      ~~~~~
                        ColEI
3151  CTTTGATCTT TTCTACGGGG TCTGACGCTC AGTGGAACGA AAATCAGCT
      GAAACTAGAA AAGATGCCCC AGACTGCGAG TCACCTTGCT TTTGAGTGCA
      ~~~~~
                        ColEI
                                          cat terminator
                                          ~~~~~
                        BglII
                        ~~~~~
3201  TAAGGGATTT TGGTCAGATC TAGCACCAGG CGTTTAAGGG CACCAATAAC
      ATTCCCTAAA ACCAGTCTAG ATCGTGGTCC GCAAATGCC GTGGTTATTG
      ~~~~~
                        ColEI
                        cat terminator
                        ~~~~~
3251  TGCCTTAAAA AAATTACGCC CCGCCCTGCC ACTCATCGCA GTACTGTTGT
      ACGGAATTTT TTTAATGCGG GCGGGGACGG TGAGTAGCGT CATGACAACA
      ~~~~~
                        CM(R)
3301  AATTCATTAA GCATTCTGCC GACATGGAAG CCATCACAAA CGGCATGATG
      TTAAGTAATT CGTAAGACGG CTGTACCTTC GGTAGTGTTT GCCGTACTAC
      ~~~~~
                        CM(R)
3351  AACCTGAATC GCCAGCGGCA TCAGCACCTT GTCGCCTTGC GTATAATATT
      TTGGACTTAG CGGTCGCCGT AGTCGTGGAA CAGCGGAACG CATATTATAA
      ~~~~~
                        CM(R)
3401  TGCCCATAGT GAAAACGGGG GCGAAGAAGT TGTCCATATT GGCTACGTTT
      ACGGGTATCA CTTTGGCCCC CGCTTCTTCA ACAGGTATAA CCGATGCAAA
      ~~~~~
                        CM(R)
3451  AAATCAAAAC TGGTGAAACT CACCCAGGGA TTGGCTGAGA CGAAAAACAT
      TTTAGTTTTG ACCACTTTGA GTGGGTCCCT AACCGACTCT GCTTTTGTGA
      ~~~~~

```

Fig. 2 cont.

```

                                CM(R)
3501  ATTCTCAATA AACCCCTTTAG GGAAATAGGC CAGGTTTTCA CCGTAACACG
      TAAGAGTTAT TTGGGAAATC CCTTTATCCG GTCCAAAAGT GGCATTGTGC
      ~~~~~
                                CM(R)
3551  CCACATCTTG CGAATATATG TGTAGAAACT GCCGGAAATC GTCGTGGTAT
      GGTGTAGAAC GCTTATATAC ACATCTTTGA CGGCCTTTAG CAGCACCATA
      ~~~~~
                                CM(R)
3601  TCACTCCAGA GCGATGAAAA CGTTTCAGTT TGCTCATGGA AAACGGTGTA
      AGTGAGGTCT CGCTACTTTT GCAAAGTCAA ACGAGTACCT TTTGCCACAT
      ~~~~~
                                CM(R)
3651  ACAAGGGTGA ACACTATCCC ATATCACCAG CTCACCGTCT TTCATTGCCA
      TGTTCCTTCT TGTGATAGGG TATAGTGGTC GAGTGGCAGA AAGTAACGGT
      ~~~~~
                                CM(R)
3701  TACGGAAGTC CGGGTGAGCA TTCATCAGGC GGGCAAGAAT GTGAATAAAG
      ATGCCTTGAG GCCCACTCGT AAGTAGTCCG CCCGTTCTTA CACTTATTTT
      ~~~~~
                                CM(R)
3751  GCCGGATAAA ACTTGTGCTT ATTTTCTTTT ACGGTCTTTA AAAAGGCCGT
      CGGCCTATTT TGAACACGAA TAAAAAGAAA TGCCAGAAAT TTTTCCGGCA
      ~~~~~
                                CM(R)
3801  AATATCCAGC TGAACGGTCT GGTATAGGT ACATTGAGCA ACTGACTGAA
      TTATAGGTCTG ACTTGCCAGA CCAATATCCA TGTAAGTCTG TGACTGACTT
      ~~~~~
                                CM(R)
3851  ATGCCTCAAA ATGTTCTTTA CGATGCCATT GGGATATATC AACGGTGCTA
      TACGGAGTTT TACAAGAAAT GCTACGGTAA CCCTATATAG TTGCCACCAT
      ~~~~~
                                CM(R)
3901  TATCCAGTGA TTTTTTCTC CATTTTAGCT TCCTTAGCTC CTGAAAATCT
      ATAGGTCACT AAAAAAGAG GTAAAATCGA AGGAATCGAG GACTTTTAGA
      ~~~~~
                                CM(R)                                SD
      ~~~~~
                                cat promoter
3951  CGATAACTCA AAAAATACGC CCGGTAGTGA TCTTATTTCA TTATGGTGAA
      GCTATTGAGT TTTTATGCG GGCCATCACT AGAATAAAGT AATACCACTT
      ~~~~~
                                cat promoter
                                CRP site
                                ~~~~~
4001  AGTTGGAACC TCACCCGACG TCTAATGTGA GTTAGCTCAC TCATTAGGCA
      TCAACCTTGG AGTGGGCTGC AGATTACACT CAATCGAGTG AGTAATCCGT
      ~~~~~
      cat promoter
                                lac mRNA
      start
                                ~
                                lac operator
                                ~~~~~
                                -35 region                                -10 region
                                ~~~~~                                ~~~~~
4051  CCCCAGGCTT TACACTTTAT GCTTCCGGCT CGTATGTTGT GTGGAATTGT
      GGGGTCCGAA ATGTGAAATA CGAAGGCCGA GCATACAACA CACCTTAACA
      lac operator                                SD                                lacZ'
      ~~~~~                                ~~~~~                                ~~~~~
4101  GAGCGGATAA CAATTTTACA CAGGAAACAG CTATGACCAT GATTACGAAT

```

Fig. 2 cont.

```
CTCGCCTATT GTTAAAGTGT GTCCTTTGTC GATACTGGTA CTAATGCTTA  
lacZ'  
~  
4151 T  
A
```

Fig. 3




Fig. 3 cont.

	EcoRV				SexAI
	----				-----
1	ATCGTGCTGA	CCCAGCCGCC	TTCAGTGAGT	GGCGCACCAG	GTCAGCGTGT
	TAGCACGACT	GGGTCGGCGG	AAGTCACTCA	CCGCGTGGTC	CAGTCGCACA
51	GACCATCTCG	TGTAGCGGCA	GCAGCAGCAA	CATTGGCAGC	AACTATGTGA
	CTGGTAGAGC	ACATCGCCGT	CGTCGTCGTT	GTAACCGTCG	TTGATACACT
		XmaI			

	KpnI	SmaI			
	-----	-----			
	Acc65I	AvaI			
	-----	-----			
101	GCTGGTACCA	GCAGTTGCCC	GGGACGGCGC	CGAAACTGCT	GATTTATGAT
	CGACCATGGT	CGTCAACGGG	CCCTGCCGCG	GCTTTGACGA	CTAAATACTA
		Bsu36I		BamHI	
		-----		-----	
151	AACAACCAGC	GTCCCTCAGG	CGTGCCGGAT	CGTTTTAGCG	GATCCAAAAG
	TTGTTGGTCG	CAGGGAGTCC	GCACGGCCTA	GCAAAATCGC	CTAGGTTTTC
				BpuAI	

				BbsI	

201	CGGCACCAGC	GCGAGCCTTG	CGATTACGGG	CCTGCAAAGC	GAAGACGAAG
	GGCGTGGTCG	CGCTCGGAAC	GCTAATGCCC	GGACGTTTCG	CTTCTGCTTC
		Bsu36I			

251	CGGATTATTA	TTGCCAGAGC	TATGACATGC	CTCAGGCTGT	GTTTGGCGGC
	GCCTAATAAT	AACGGTCTCG	ATACTGTACG	GAGTCCGACA	CAAACCGCCC
		MscI		DraIII	
		-----		-----	
301	GGCACGAAGT	TTAACCGTTC	TTGGCCAGCC	GAAAGCCGCA	CCGAGTGTGA
	CCGTGCTTCA	AATTGGCAAG	AACCGGTCGG	CTTTCGGCGT	GGCTCACACT
351	CGCTGTTTCC	GCCGAGCAGC	GAAGAATTGC	AGGCGAACAA	AGCGACCCTG
	GCGACAAAGG	CGGCTCGTCG	CTTCTTAACG	TCCGCTTGTT	TCGCTGGGAC
401	GTGTGCCTGA	TTAGCGACTT	TTATCCGGGA	GCCGTGACAG	TGGCCTGGAA
	CACACGGACT	AATCGCTGAA	AATAGGCCCT	CGGCACTGTC	ACCGGACCTT
451	GGCAGATAGC	AGCCCCGTCA	AGGCGGGAGT	GGAGACCACC	ACACCCCTCCA
	CCGTCTATCG	TCGGGGCAGT	TCCGCCCTCA	CCTCTGGTGG	TGTGGGAGGT
501	AACAAAGCAA	CAACAAGTAC	GCGGCCAGCA	GCTATCTGAG	CCTGACGCCT
	TTGTTTCGTT	GTTGTTTCATG	CGCCGGTCGT	CGATAGACTC	GGACTCGGGA
551	GAGCAGTGGA	AGTCCCACAG	AAGCTACAGC	TGCCAGGTCA	CGCATGAGGG
	CTCGTCACCT	TCAGGGTGTC	TTCGATGTCG	ACGGTCCAGT	GCGTACTCCC

Fig. 3 cont.

				StuI	SphI
				~~~~~	~~~~~
601	GAGCACCGTG	GAAAAAACCG	TTGCGCCGAC	TGAGGCCTGA	TAAGCATGCG
	CTCGTGGCAC	CTTTTTTGGC	AACGCGGCTG	ACTCCGGACT	ATTCTGTACGC
651	TAGGAGAAAA	TAAAATGAAA	CAAAGCACTA	TTGCACTGGC	ACTCTTACCG
	ATCCTCTTTT	ATTTTACTTT	GTTTCGTGAT	AACGTGACCG	TGAGAATGGC
			MfeI		
			~~~~~		
701	TTGCTCTTCA	CCCCTGTTAC	CAAAGCCCAG	GTGCAATTGA	AAGAAAGCGG
	AACGAGAAGT	GGGGACAATG	GTTTCGGGTC	CACGTTAACT	TTCTTTTCGCC
				BspEI	
				~	
751	CCCGGCCCTG	GTGAAACCGA	CCCAAACCTT	GACCCTGACC	TGTACCTTTT
	GGGCCGGGAC	CACTTTGGCT	GGGTTTGGGA	CTGGGACTGG	ACATGGAAAA
	BspEI				
	~~~~~				
801	CCGGATTTAG	CCTGTCCACG	TCTGGCGTTG	GCGTGGGCTG	GATTGCGCCAG
	GGCCTAAATC	GGACAGGTGC	AGACCGCAAC	CGCACCCGAC	CTAAGCGGTC
		XhoI			
		~~~~~			
		AvaI			
		~~~~~			
851	CCGCCTGGGA	AAGCCCTCGA	GTGGCTGGCT	CTGATTGATT	GGGATGATGA
	GGCGGACCCT	TTCGGGAGCT	CACCGACCGA	GACTAACTAA	CCCTACTACT
901	TAAGTATTAT	AGCACCAGCC	TGAAAACGCG	TCTGACCATT	AGCAAAGATA
	ATTCATAATA	TCGTGGTCGG	ACTTTTGCGC	AGACTGGTAA	TCGTTTCTAT
	BstBI				
	~~~~~				
	SfuI				
	~~~~~				
	NspV				
	~~~~~				
951	CTTCGAAAAA	TCAGGTGGTG	CTGACTATGA	CCAACATGGA	CCCGGTGGAT
	GAAGCTTTTT	AGTCCACCAC	GACTGATACT	GGTTGTACCT	GGGCCACCTA
		BssHII			
		~~~~~			
1001	ACGGCCACCT	ATTATTGCGC	GCGTTCTCCT	CGTTATCGTG	GTGCTTTTGA
	TGCCGGTGGA	TAATAACGCG	CGCAAGAGGA	GCAATAGCAC	CACGAAAACT
			BlpI		
			~~~~~		
	StyI		~~~~~	CellI	
	~~~~~		~~~~~		
1051	TTATTGGGGC	CAAGGCACCC	TGGTGACGGT	TAGCTCAGCG	TCGACCAAAG
	AATAACCCCG	GTTCCGTGGG	ACCACTGCCA	ATCGAGTCGC	AGCTGGTTTC

Fig. 3 cont.

```

1101  GTCCAAGCGT  GTTTC CGCTG  GCTCCGAGCA  GCAAAAGCAC  CAGCGGCGGC
      CAGGTTTCGA  CAAAGGCGAC  CGAGGCTCGT  CGTTTTTCGTG  GTCGCCGCCG

1151  ACGGCTGCCC  TGGGCTGCCT  GGTAAAGAT  TATTTCCCGG  AACCAGTCAC
      TGCCGACGGG  ACCCGACGGA  CCAATTTCTA  ATAAAGGGCC  TTGGTCAGTG

1201  CGTGAGCTGG  AACAGCGGGG  CGCTGACCAG  CGGCGTG CAT  ACCTTTCCGG
      GCACTCGACC  TTGTCGCCCC  GCGACTGGTC  GCCGCACGTA  TGGAAAGGCC

1251  CGGTGCTGCA  AAGCAGCGGC  CTGTATAGCC  TGAGCAGCGT  TGTGACCGTG
      GCCACGACGT  TTCGTCGCCG  GACATATCGG  ACTCGTCGCA  AACTTGGCAC

1301  CCGAGCAGCA  GCTTAGGCAC  TCAGACCTAT  ATTTGCAACG  TGAACCATAA
      GGCTCGTCGT  CGAATCCGTG  AGTCTGGATA  TAAACGTTGC  ACTTGGTATT

                                           EcoRI
                                           ~~~~~~
1351 ACCGAGCAAC ACCAAAGTGG ATAAAAAAGT GGAACCGAAA AGCGAATTCC
 TGGCTCGTTG TGGTTTCACC TATTTTTTCA CCTTGGCTTT TCGCTTAAGC

 BssHII
                                           ~~~~~~
1401  ACTATAAAGA  TGACGATGAC  AAAGGCGCGC  CGTGGAGCCA  CCCGCAGTTT
      TGATATTTCT  ACTGCTACTG  TTTCCGCGCG  GCACCTCGGT  GGGCGTCAAA

                                           HindIII
                                           ~~~~~~
1451 GAAAAATGAT AAGCTTGACC TGTGAAGTGA AAAATGGCGC AGATTGTGCG
 CTTTTTACTA TTCGAACTGG ACACTTCACT TTTTACCGCG TCTAACACGC

 OGIII3 100.0%
 =====
1501 ACATTTTTTT TGTCTGCCGT TTAATTAAAG GGGGGGGGGG GCCGGCCTGG
 TGTAAAAAAA ACAGACGGCA AATTAATTTT CCCCCCCCCC CGGCCGGACC

1551 GGGGGGGTGT ACATGAAATT GTAAACGTTA ATATTTTGTT AAAATTCGCG
 CCCCCCACA TGTACTTTAA CATTTGCAAT TATAAAACAA TTTTAAGCGC

1601 TTAAATTTTT GTTAAATCAG CTCATTTTTT AACCAATAGG CCGAAATCGG
 AATTTAAAAA CAATTTAGTC GAGTAAAAAA TTGGTTATCC GGCTTTAGCC

1651 CAAAATCCCT TATAAATCAA AAGAATAGAC CGAGATAGGG TTGAGTGTTG
 GTTTTAGGGA ATATTTAGTT TTCTTATCTG GCTCTATCCC AACTCACAAC

1701 TTCCAGTTTG GAACAAGAGT CCACTATTAA AGAACGTGGA CTCCAACGTC
 AAGGTCAAAC CTTGTTCTCA GGTGATAATT TCTTGACCT GAGGTTGCAG

1751 AAAGGGCGAA AAACCGTCTA TCAGGGCGAT GGCCCACTAC GAGAACCATC
 TTTCCCGCTT TTTGGCAGAT AGTCCCGCTA CCGGGTGATG CTCTTGGTAG

1801 ACCCTAATCA AGTTTTTTTG GGTGAGGTG CCGTAAAGCA CTAAATCGGA
 TGGGATTAGT TCAAAAAACC CCAGCTCCAC GGCATTTCTG GATTTAGCCT

```

Fig. 3 cont.

1851	ACCCTAAAGG	GAGCCCCCGA	TTTAGAGCTT	GACGGGGAAA	GCCGGCGAAC
	TGGGATTTC	CTCGGGGGCT	AAATCTCGAA	CTGCCCCTTT	CGGCCGCTTG
1901	GTGGCGAGAA	AGGAAGGGAA	GAAAGCGAAA	GGAGCGGGCG	CTAGGGCGCT
	CACCGCTCTT	TCCTTCCCTT	CTTTCGCTTT	CCTCGCCCGC	GATCCCGCGA
1951	GGCAAGTGTA	GCGGTCACGC	TGCGCGTAAC	CACCACACCC	GCCGCGCTTA
	CCGTTACAT	CGCCAGTGCG	ACGCGCATTG	GTGGTGTTGG	CGGCGCGAAT
2001	ATGCGCCGCT	ACAGGGCGCG	TGCTAGACTA	GTGTTTAAAC	CGGACCGGGG
	TACGCGGCGA	TGTCCCGCGC	ACGATCTGAT	CACAAATTTG	GCCTGGCCCC
2051	GGGGGCTTAA	GTGGGCTGCA	AAACAAAACG	GCCTCCTGTC	AGGAAGCCGC
	CCCCCGAATT	CACCCGACGT	TTTGTTTTGC	CGGAGGACAG	TCCTTCGGCG
2101	TTTTATCGGG	TAGCCTCACT	GCCCGCTTTC	CAGTCGGGAA	ACCTGTCGTG
	AAAATAGCCC	ATCGGAGTGA	CGGGCGAAAG	GTCAGCCCTT	TGGACAGCAC
2151	CCAGCTGCAT	CAGTGAATCG	GCCAACGCGC	GGGGAGAGGC	GGTTTGCGTA
	GGTCGACGTA	GTCACCTAGC	CGGTTGCGCG	CCCCTCTCCG	CCAAACGCAT
2201	TTGGGAGCCA	GGGTGGTTTT	TCTTTTCACC	AGTGAGACGG	GCAACAGCTG
	AACCCTCGGT	CCCACCAAAA	AGAAAAGTGG	TCACTCTGCC	CGTTGTGCGAC
2251	ATTGCCCTTC	ACCGCCTGGC	CCTGAGAGAG	TTGCAGCAAG	CGGTCCACGC
	TAACGGGAAG	TGGCGGACCG	GGACTCTCTC	AACGTCGTTC	GCCAGGTGCG
2301	TGGTTTGCCC	CAGCAGGCGA	AAATCCTGTT	TGATGGTGGT	CAGCGGCGGG
	ACCAAACGGG	GTCGTCCGCT	TTTAGGACAA	ACTACCACCA	GTCGCCGCC
2351	ATATAACATG	AGCTGTCCTC	GGTATCGTCG	TATCCCACTA	CCGAGATGTC
	TATATTGTAC	TCGACAGGAG	CCATAGCAGC	ATAGGGTGAT	GGCTCTACAG
2401	CGCACCAACG	CGCAGCCCGG	ACTCGGTAAT	GGCACGCATT	GCGCCCAGCG
	GCGTGGTTGC	GCGTCGGGCC	TGAGCCATTA	CCGTGCGTAA	CGCGGGTTCG
2451	CCATCTGATC	GTTGGCAACC	AGCATCGCAG	TGGGAACGAT	GCCCTCATTC
	GGTAGACTAG	CAACCGTTGG	TCGTAGCGTC	ACCCTTGCTA	CGGGAGTAAG
2501	AGCATTTGCA	TGGTTTGTTG	AAAACCGGAC	ATGGCACTCC	AGTCGCCTTC
	TCGTAAACGT	ACCAAACAAC	TTTTGGCCTG	TACCGTGAGG	TCAGCGGAAG
2551	CCGTTCCGCT	ATCGGCTGAA	TTTGATTGCG	AGTGAGATAT	TTATGCCAGC
	GGCAAGGCGA	TAGCCGACTT	AAACTAACGC	TCACTCTATA	AATACGGTCG
2601	CAGCCAGACG	CAGACCGGCC	GAGACAGAAC	TTAATGGGCC	AGCTAACAGC
	GTCGGTCTGC	GTCTGCGCGG	CTCTGTCTTG	AATTACCCCG	TCGATTGTCTG
2651	GCGATTTGCT	GGTGGCCCAA	TGCGACCAGA	TGCTCCACGC	CCAGTCGCGT
	CGCTAAACGA	CCACCGGGTT	ACGCTGGTCT	ACGAGGTGCG	GGTCAGCGCA
2701	ACCGTCCTCA	TGGGAGAAAA	TAATACTGTT	GATGGGTGTC	TGGTCAGAGA
	TGGCAGGAGT	ACCCTCTTTT	ATTATGACAA	CTACCCACAG	ACCAGTCTCT

Fig. 3 cont.

2751	CATCAAGAAA	TAACGCCGGA	ACATTAGTGC	AGGCAGCTTC	CACAGCAATA
	GTAGTTCTTT	ATTGCGGCCT	TGTAATCACG	TCCGTCGAAG	GTGTCGTTAT
2801	GCATCCTGGT	CATCCAGCGG	ATAGTTAATA	ATCAGCCCAC	TGACACGTTG
	CGTAGGACCA	GTAGGTCGCC	TATCAATTAT	TAGTCGGGTG	ACTGTGCAAC
	ApaLI ~~~~~				
2851	CGCGAGAAGA	TTGTGCACCG	CCGCTTTACA	GGCTTCGACG	CCGCTTCGTT
	GCGCTCTTCT	AACACGTGGC	GGCGAAATGT	CCGAAGCTGC	GGCGAAGCAA
2901	CTACCATCGA	CACGACCACG	CTGGCACCCA	GTTGATCGGC	GCGAGATTTA
	GATGGTAGCT	GTGCTGGTGC	GACCGTGGGT	CAACTAGCCG	CGCTCTAAAT
2951	ATCGCCGCGA	CAATTTGCGA	CGGCGCGTGC	AGGGCCAGAC	TGGAGGTGGC
	TAGCGGCGCT	GTTAAACGCT	GCCGCGCACG	TCCCGGTCTG	ACCTCCACCG
3001	AACGCCAATC	AGCAACGACT	GTTTGCCCGC	CAGTTGTTGT	GCCACGCGGT
	TTGCGGTTAG	TCGTTGCTGA	CAAACGGGCG	GTCAACAACA	CGGTGCGCCA
3051	TAGGAATGTA	ATTCAGCTCC	GCCATCGCCG	CTTCCACTTT	TTCCCGCGTT
	ATCCTTACAT	TAAGTCGAGG	CGGTAGCGGC	GAAGGTGAAA	AAGGGCGCAA
3101	TTCGCAGAAA	CGTGGCTGGC	CTGGTTCACC	ACGCGGGAAA	CGGTCTGATA
	AAGCGTCTTT	GCACCGACCG	GACCAAGTGG	TGCGCCCTTT	GCCAGACTAT
3151	AGAGACACCG	GCATACTCTG	CGACATCGTA	TAACGTTACT	GGTTTCACAT
	TCTCTGTGGC	CGTATGAGAC	GCTGTAGCAT	ATTGCAATGA	CCAAAGTGTA
3201	TCACCACCOCT	GAATTGACTC	TCTTCCGGGC	GCTATCATGC	CATACCGCGA
	AGTGGTGCGA	CTTAAGTGA	AGAAGGCCCC	CGATAGTACG	GTATGCGCGT
3251	AAGGTTTTGC	GCCATTCGAT	GCTAGCCATG	TGAGCAAAAG	GCCAGCAAAA
	TTCCAAAACG	CGGTAAGCTA	CGATCGGTAC	ACTCGTTTTT	CGGTGTTTTT
3301	GGCCAGGAAC	CGTAAAAAGG	CCGCGTTGCT	GGCGTTTTTC	CATAGGCTCC
	CCGGTCCTTG	GCATTTTTCC	GGCGCAACGA	CCGCAAAAAG	GTATCCGAGG
3351	GCCCCCCTGA	CGAGCATCAC	AAAAATCGAC	GCTCAAGTCA	GAGGTGGCGA
	CGGGGGGACT	GCTCGTAGTG	TTTTTAGCTG	CGAGTTCAGT	CTCCACCGCT
3401	AACCCGACAG	GACTATAAAG	ATACCAGGCG	TTTCCCCCTG	GAAGCTCCCT
	TTGGGCTGTC	CTGATATTTT	TATGGTCCGC	AAAGGGGGAC	CTTCGAGGGA
3451	CGTGCGCTCT	CCTGTTCCGA	CCCTGCCGCT	TACCGGATAC	CTGTCCGCCT
	GCACGCGAGA	GGACAAGGCT	GGGACGGCGA	ATGGCCTATG	GACAGGCGGA
3501	TTCTCCCTTC	GGGAAGCGTG	GCGCTTTCTC	ATAGCTCACG	CTGTAGGTAT
	AAGAGGGAAG	CCCTTCGCAC	CGCGAAAGAG	TATCGAGTGC	GACATCCATA
	ApaLI ~~~~~				
3551	CTCAGTTCGG	TGTAGGTCGT	TCGCTCCAAG	CTGGGCTGTG	TGCACGAACC
	GAGTCAAGCC	ACATCCAGCA	AGCGAGGTTT	GACCCGACAC	ACGTGCTTGG

Fig. 3 cont.

3601	CCCCGTTTCAG	CCCGACCGCT	GCGCCTTATC	CGGTAACTAT	CGTCTTGAGT
	GGGGCAAGTC	GGGCTGGCGA	CGCGGAATAG	GCCATTGATA	GCAGAACTCA
3651	CCAACCCGGT	AAGACACGAC	TTATCGCCAC	TGGCAGCAGC	CACTGGTAAC
	GGTTGGGCCA	TTCTGTGCTG	AATAGCGGTG	ACCGTCGTCG	GTGACCATTG
3701	AGGATTAGCA	GAGCGAGGTA	TGTAGGCGGT	GCTACAGAGT	TCTTGAAGTG
	TCCTAATCGT	CTCGCTCCAT	ACATCCGCCA	CGATGTCTCA	AGAACTTCAC
3751	GTGGCCTAAC	TACGGCTACA	CTAGAAGAAC	AGTATTTGGT	ATCTGCGCTC
	CACCGGATTG	ATGCCGATGT	GATCTTCTTG	TCATAAACCA	TAGACGCGAG
3801	TGCTGTAGCC	AGTTACCTTC	GGAAAAAGAG	TTGGTAGCTC	TTGATCCGGC
	ACGACATCGG	TCAATGGAAG	CCTTTTTTCTC	AACCATCGAG	AACTAGGCCG
3851	AAACAAACCA	CCGCTGGTAG	CGGTGGTTTT	TTTGTTTGCA	AGCAGCAGAT
	TTTGTTTGGT	GGCGACCATC	GCCACCAAAA	AAACAAACGT	TCGTCGTCTA
3901	TACGCGCAGA	AAAAAAGGAT	CTCAAGAAGA	TCCTTTGATC	TTTTCTACGG
	ATGCGCGTCT	TTTTTTCCTA	GAGTTCTTCT	AGGAAACTAG	AAAAGATGCC
3951	GGTCTGACGC	TCAGTGGAAC	GAAAACTCAC	GTTAAGGGAT	TTTGGTCAGA
	CCAGACTGCG	AGTCACCTTG	CTTTTGAGTG	CAATTCCCTA	AAACCAGTCT
4001	TCTAGCACCA	GGCGTTTAAAG	GGCACCAATA	ACTGCCTTAA	AAAAATTACG
	AGATCGTGGT	CCGCAAATTC	CCGTGGTTAT	TGACGGAATT	TTTTTAATGC
4051	CCCCGCCCTG	CCACTCATCG	CAGTACTGTT	GTAATTCATT	AAGCATTCTG
	GGGGCGGGAC	GGTGAGTAGC	GTCATGACAA	CATTAAGTAA	TTCGTAAGAC
4101	CCGACATGGA	AGCCATCACA	AACGGCATGA	TGAACCTGAA	TCGCCAGCGG
	GGCTGTACCT	TCGGTAGTGT	TTGCCGTACT	ACTTGGAATT	AGCGGTCGCC
4151	CATCAGCACC	TTGTGCGCTT	GCGTATAATA	TTTGCCCAT	GTGAAAACGG
	GTAGTCGTGG	AACAGCGGAA	CGCATATTAT	AAACGGGTAT	CACTTTTGCC
4201	GGGCGAAGAA	GTTGTCCATA	TTGGCTACGT	TTAAATCAAA	ACTGGTGAAA
	CCCGCTTCTT	CAACAGGTAT	AACCGATGCA	AATTTAGTTT	TGACCACTTT
4251	CTCACCAGG	GATTGGCTGA	GACGAAAAAC	ATATTCTCAA	TAAACCCTTT
	GAGTGGGTCC	CTAACCGACT	CTGCTTTTTG	TATAAGAGTT	ATTTGGGAAA
4301	AGGGAAATAG	GCCAGSTTTT	CACCGTAACA	CGCCACATCT	TGCGAATATA
	TCCCTTTATC	CGGTCCAAAA	GTGGCATTGT	GCGGTGTAGA	ACGCTTATAT
4351	TGTGTAGAAA	CTGCCGGAAA	TCGTCGTGGT	ATTCACTCCA	GAGCGATGAA
	ACACATCTTT	GACGGCCTTT	AGCAGCACCA	TAAGTGAGGT	CTCGCTACTT
4401	AACGTTTCAG	TTTGCTCATG	GAAAAACGGT	TAACAAGGGT	GAACACTATC
	TTGCAAAGTC	AAACGAGTAC	CTTTTGCCAC	ATTGTTCCCA	CTTGTGATAG
4451	CCATATCACC	AGCTCACCGT	CTTTCATTGC	CATACGGAAC	TCCGGGTGAG
	GGTATAGTGG	TCGAGTGCGA	GAAAGTAACG	GTATGCCTTG	AGGCCCACTC

## Fig. 3 cont.

```

4501 CATTTCATCAG GCGGGCAAGA ATGTGAATAA AGGCCGGATA AAAC TTGTGC
 GTAAGTAGTC CGCCCGTTCT TACACTTATT TCCGGCCTAT TTTGAACACG

4551 TTATTTTTCT TTACGGTCTT TAAAAAGGCC GTAATATCCA GCTGAACGGT
 AATAAAAAGA AATGCCAGAA ATTTTCCGG CATTATAGGT CGACTTGCCA

4601 CTGGTTATAG GTACATTGAG CAACTGACTG AAATGCCTCA AAATGTTCTT
 GACCAATATC CATGTAATC GTTGACTGAC TTTACGGAGT TTTACAAGAA

4651 TACGATGCCA TTGGGATATA TCAACGGTGG TATATCCAGT GATTTTTTTC
 ATGCTACGGT AACCTATAT AGTTGCCACC ATATAGGTCA CTAAAAAAG

4701 TCCATTTTAG CTTCTTAGC TCCTGAAAAT CTCGATAACT CAAAAAATAC
 AGGTAAAATC GAAGGAATCG AGGACTTTTA GAGCTATTGA GTTTTTTATG

4751 GCCCGGTAGT GATCTTATTT CATTATGGTG AAAGTTGGAA CCTCACCCGA
 CGGGCCATCA CTAGAATAAA GTAATACCAC TTTCAACCTT GGAGTGGGCT

4801 CGTCTAATGT GAGTTAGCTC ACTCATTAGG CACCCAGGC TTTACTTTT
 GCAGATTACA CTCAATCGAG TGAGTAATCC GTGGGGTCCG AAATGTGAAA

4851 ATGCTTCCGG CTCGTATGTT GTGTGGAATT GTGAGCGGAT AACAAATTTCA
 TACGAAGGCC GAGCATACAA CACACCTTAA CACTCGCCTA TTGTAAAGT

 M13 Reverse primer 100.0% XbaI
 ===== ~~~~~~
4901 CACAGGAAAC AGCTATGACC ATGATTACGA ATTTCTAGAT AACGAGGGCA
 GTGTCCTTTG TCGATACTGG TACTAATGCT TAAAGATCTA TTGCTCCCGT

4951 AAAAATGAAA AAGACAGCTA TCGCGATTGC AGTGGCACTG GCTGGTTTCG
 TTTTACTTTT TTCTGTCGAT AGCGCTAACG TCACCGTGAC CGACCAAAGC

 EcoRV
      ~~~
5001  CTACCGTAGC GCAGGCCGAT
      GATGGCATCG CGTCCGGCTA

```



Fig. 4a cont.

Framework 3										CDR 3										Framework 4									
6										9										10									
8										9										10									
7										8										9									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI										MscI									
8										9										10									
9										8										9									
10										9										10									
BamHI										BbsI																			

Fig. 4b

Sequence of MS-Roche#3, #7 and #8

VL

Framework 1																				CDR 1												
1										2										3												
EcoRV										PstI										KpnI												
Position	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6						
MS-Roche #3	GAT	ATC	GTG	CTG	ACC	CAG	AGC	CGG	GCG	ACC	CTG	AGC	CTG	AGC	TGC	ACA	GCG	AGC	CAG	AGC	GTG	AGC	AGC	---	---	---	AGC	TAT	CTG	GCG	TGG	TAC
	BamII																															
MS-Roche #7	GAT	ATC	GTG	CTG	ACC	CAG	AGC	CGG	GCG	ACC	CTG	AGC	CTG	AGC	TGC	ACA	GCG	AGC	CAG	AGC	GTG	AGC	AGC	---	---	---	AGC	TAT	CTG	GCG	TGG	TAC
	BamII																															
MS-Roche #8	GAT	ATC	GTG	CTG	ACC	CAG	AGC	CGG	GCG	ACC	CTG	AGC	CTG	AGC	TGC	ACA	GCG	AGC	CAG	AGC	GTG	AGC	AGC	---	---	---	AGC	TAT	CTG	GCG	TGG	TAC
	BamII																															

VH

Position	Framework 1															CDR 1																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																	
	1															2															3																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																		
	1	2	3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	0	1	a	b	2	3	4	5	6	7	8	9	0																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																	

[illegible]

Fig. 4b cont.

CDR 3										Framework 4										
9										10										
3	4	5	6	7	8	9	0	1	2	3	4	5	6	7	8	9	BsaWI			
TTT	GCG	GTT	TAT	TAT	TGC	CAG	CAG	GTT	TAT	AAT	CCT	CCT								
TTT	GCG	ACT	TAT	TAT	TGC	TTT	CAG	CTT	TAT	TCT	GAT	CCT	GTT	ACT	AAA	CGT		ACG		
TTT	GCG	ACT	TAT	TAT	TGC	CAG	CAG	CTT	TCT	TCT	TTT	CCT	CTT	ACT	AAA	CGT		ACG		

Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9A




Fig. 9B




Fig. 9C




Fig. 9D






Fig. 10


A



B



C



D






Fig. 11


A



B



C




D




Fig. 12


A



B



C



D






Fig. 13


A



B



C



D






Fig. 14


A



B



C



D




Fig. 15 - 1




Fig. 15 - 2




Fig. 15 - 3






Fig. 15 - 4



## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

## Patent documents cited in the description

- US 4666829 A [0004]
- WO 0072880 A [0004] [0018]
- WO 0187337 A [0032]
- WO 0187338 A [0032]
- US 6300064 B [0032]
- EP 96929278 A [0032]
- WO 9429469 A [0050]
- WO 9700957 A [0050]
- US 5580859 A [0050]
- US 5589466 A [0050]
- US 4394448 A [0050]
- US 5741957 A [0056]
- US 5304489 A [0056]
- US 5849992 A [0056]
- WO 9708320 A [0091] [0092]
- EP 02003844 A [0135]

## Non-patent literature cited in the description

- SELKOE. *Ann. Rev. Cell Biol.*, 1994, vol. 10, 373-403 [0004]
- KOO. *PNAS*, 1999, vol. 96, 9989-9990 [0004]
- GLENNER. *BBRC*, 1984, vol. 12, 1131 [0004]
- SINHA. *PNAS*, 1999, vol. 96, 11094-1053 [0004]
- PRICE. *Science*, 1998, vol. 282, 1078-1083 [0004]
- HARDY. *TINS*, 1997, vol. 20, 154 [0004]
- HARPER. *Ann. Rev. Biochem.*, 1997, vol. 66, 385-407 [0006]
- WAGNER. *J. Clin. Invest.*, 1999, vol. 104, 1239-1332 [0006]
- JARRETT. *Cell*, 1993, vol. 93, 1055-1058 [0006]
- GEYSEN. *Mol. Immunol.*, 1986, vol. 23, 709-715 [0013]
- SELA. *Science*, 1969, vol. 166, 1365 [0016]
- LAVER. *Cell*, 1990, vol. 61, 553-6 [0016]
- IDA et al. *J. Biol. Chem.*, 1996, vol. 271, 22908-22914 [0017]
- JOHNSON-WOOD et al. *Proc. Natl. Acad. Sci. USA*, 1997, vol. 1994, 1550-1555 [0017]
- SUZUKI et al. *Science*, 1994, vol. 264, 1336-1340 [0017]
- BROCKHAUS. *Neuro Rep.*, 1998, vol. 9, 1481-1486 [0017]
- BROCKHAUS. *Neuroreport*, 1998, vol. 9, 1481-1486 [0017] [0117]
- SCHENK et al. *Nature*, 1999, vol. 400, 173-177 [0018]
- JANUS et al. *Nature*, 2000, vol. 408, 979-982 [0018]
- MORGAN et al. *Nature*, 2000, vol. 408, 982-985 [0018]
- BARD et al. *Nat. Med.*, 2000, vol. 6, 916-919 [0018]
- KIM. *Neuroscience Research Communications*, 1988, vol. 2, 121-130 [0018]
- BACSKAI. *Abstract Society for Neuroscience 31st Annual Meeting*, 10 November 2001 [0021]
- SOLOMON. *Proc. Natl. Acad. Sci. USA*, 1997, vol. 94, 4109-4112 [0022]
- SOLOMON. *Proc. Natl. Acad. Sci. USA*, 1996, vol. 93, 452-455 [0022] [0121]
- LAVER. *Cell*, 1990, vol. 61, 553-556 [0024]
- GHOSHAL. *J. Neurochem.*, 2001, vol. 77, 1372-1385 [0027]
- HOCHLEITNER. *J. Imm.*, 2000, vol. 164, 4156-4161 [0027]
- JONES. *Nature*, 1986, vol. 321, 522-515 [0030]
- RIECHMANN. *Nature*, 1988, vol. 332, 323-327 [0030]
- KNAPPIK. *J. Mol. Biol.*, 2000, vol. 296, 55 [0032]
- KREBS. *J. Imm. Meth.*, 2000, vol. 254, 67-84 [0032]
- BENTLEY. *Hybridoma*, 1998, vol. 17, 559-567 [0039]
- RACHER. *Appl. Microbiol. Biotechnol.*, 1994, vol. 40, 851-856 [0039]
- SAMUELSSON. *Eur. J. Immunol.*, 1996, vol. 26, 3029-3034 [0039]
- MALMQUIST. *Biochem. Soc. Trans.*, 1999, vol. 27, 335-340 [0041]
- GOSSEN ; BUJARD. *Proc. Natl. Acad. Sci. USA*, 1992, vol. 89, 5547-5551 [0045]
- GOSSEN et al. *Trends Biotech.*, 1994, vol. 12, 58-62 [0045]
- CROOK. *EMBO J.*, 1989, vol. 8, 513-519 [0045]
- CHARRON. *J. Biol. Chem.*, 1995, vol. 270, 25739-25745 [0049]
- PAGANO. *Science*, 1992, vol. 255, 1144-1147 [0049]
- GYURIS. *Cell*, 1995, vol. 75, 791-803 [0049]
- CAPSONI. *Proc. Natl. Acad. Sci. USA*, 2000, vol. 97, 6826-6831 [0050]
- BIOCCA. *Embo J.*, 1990, vol. 9, 101-108 [0050]
- GIORDANO. *Nature Medicine*, 1996, vol. 2, 534-539 [0050]

- **SCHAPER.** *Circ. Res.*, 1996, vol. 79, 911-919 [0050]
- **ANDERSON.** *Science*, 1992, vol. 256, 808-813 [0050]
- **ISNER.** *Lancet*, 1996, vol. 348, 370-374 [0050]
- **MUHLHAUSER.** *Circ. Res.*, 1995, vol. 77, 1077-1086 [0050]
- **ONODUA.** *Blood*, 1998, vol. 91, 30-36 [0050]
- **VERZELETTI.** *Hum. Gene Ther.*, 1998, vol. 9, 2243-2251 [0050]
- **VERMA.** *Nature*, 1997, vol. 389, 239-242 [0050]
- **ANDERSON.** *Nature*, 1998, vol. 392, 25-30 [0050]
- **WANG.** *Gene Therapy*, 1997, vol. 4, 393-400 [0050]
- **WANG.** *Nature Medicine*, 1996, vol. 2, 714-716 [0050]
- **SCHAPER.** *Current Opinion in Biotechnology*, 1996, vol. 7, 635-640 [0050]
- **BLÖMER.** *J. Virology*, 1997, vol. 71, 6641-6649 [0050]
- **GEDDES.** *Front Neuroendocrinol.*, 1999, vol. 20, 296-316 [0050]
- **GEDDES.** *Nat. Med.*, 1997, vol. 3, 1402-1404 [0050]
- **MEIER.** *J. Neuropathol. Exp. Neurol.*, 1999, vol. 58, 1099-1110 [0050]
- **BARD.** *Nature Med.*, 2000, vol. 6, 916-919 [0061]
- **TIJSSEN.** Practice and theory of enzyme immunoassays. 1985, vol. 15 [0067]
- **DAVIS LG ; DIBMER MD.** Basic methods in molecular biology. Battey Elsevier, 1990 [0067]
- Immunochemical methods in cell and molecular biology. Academic Press, 1987 [0067]
- Methods in Enzymology. Academic Press, Inc, [0067]
- **YANG.** *J. Mol. Biol.*, 1995, vol. 25, 392-403 [0077]
- **SCHIER.** *J. Mol. Biol.*, 1996, vol. 263, 551-567 [0077]
- **BARBAS.** *Trends. Biotech*, 1996, vol. 14, 230-34 [0077]
- **WU.** *PNAS*, 1998, vol. 95, 6037-6042 [0077]
- **SCHIER.** *Human Antibodies Hybridomas*, 1996, vol. 7, 97 [0077]
- **MOORE.** *J. Mol. Biol.*, 1997, vol. 272, 336 [0077]
- **KAY.** *Gene*, 1993, vol. 128, 59-65 [0078]
- **BORREBAECK.** Antibody Engineering. Oxford University, 1995, 229-266 [0078]
- **MCCAFFERTY.** Antibody Engineering. Oxford University Press, 1996 [0078]
- **KAY.** A Laboratory Manual. Academic Press, 1996 [0078]
- **SCHIER.** *J. Mol. Biol.*, 1996, vol. 255, 28-43 [0081]
- **DUENAS.** *Mol. Immunol.*, 1996, vol. 33, 279-286 [0081]
- **KNAPPIK.** *J. Mol. Biol.*, 2000, vol. 296, 57-86 [0090]
- **AUSUBEL.** Current protocols in molecular biology. John Wiley & Sons, Inc, 1998 [0096]
- **JOHNSON.** *Anal. Biochem.*, 1991, vol. 198, 268-277 [0112]
- **RICHALET-SÉCORDEL.** *Anal. Biochem.*, 1997, vol. 249, 165-173 [0112]
- **CHRISTENSEN.** *Analytical Biochemistry*, 1997, vol. 249, 153-164 [0112]
- **BOHRMANN et al.** *J. Biol. Chem.*, 1999, vol. 274, 15990-15995 [0115]
- **KIM.** *Neuroscience Research Communication*, 1988, vol. 2, 121-130 [0117]
- **BOHRMANN.** *J Biol Chem*, 1999, vol. 274 (23), 15990-5 [0117]
- **YANG et al.** *J.Mol.Biol.*, 1995, vol. 254, 392-403 [0126]
- **SCHIER et al.** *J.Mol.Biol.*, 1996, vol. 263, 551-567 [0126]
- **CHEN et al.** *J.Mol.Biol.*, 1999, vol. 293, 865-881 [0126]
- **RICHARDS et al.** *Soc. Neurosci. Abstr.*, 2001, vol. 27 [0130]

**Az EP 2 368 907 lajstromszámú európai szabadalom igénypontjainak magyar fordítása:**

1. Anti-béta-A4-peptid antitestmolekula, amely tartalmaz
  - (a) variábilis VL-régiót, amely L-CDR1, L-CDR2 és L-CDR3 komplementer determináló régiókat tartalmaz, ahol:
    - (1) L-CDR1 tartalmaz SEQ ID NO: 143-at: Arg Ala Ser Gln Ser Val Ser Ser Ser Tyr Leu Ala;
    - (2) L-CDR2 tartalmaz SEQ ID NO: 144-et: Gly Ala Ser Ser Arg Ala Thr; és
    - (3) L-CDR3 tartalmaz SEQ ID NO: 95-öt: Leu Gln Ile Tyr Asn Met Pro Ile; és
  - (b) variábilis VH-régiót, amely H-CDR1, H-CDR2 és H-CDR3 komplementer determináló régiókat tartalmaz, ahol:
    - (1) H-CDR1 tartalmaz SEQ ID NO: 146-ot: Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser;
    - (2) H-CDR2 tartalmaz SEQ ID NO: 192-t: Ala Ile Asn Ala Ser Gly Thr Arg Thr Tyr Tyr Ala Asp Ser Val Lys Gly; és
    - (3) H-CDR3 comprises SEQ ID NO: 93-at: Gly Lys Gly Asn Thr His Lys Pro Tyr Gly Tyr Val Arg Tyr Phe Asp Val.
2. Az 1. igénypont szerinti antitestmolekula, ahol az említett antitestmolekula SEQ ID NO: 89 szerinti variábilis VH-régiót és SEQ ID NO: 91 szerinti variábilis VL-régiót tartalmaz.
3. Az 1. vagy 2. igénypont szerinti antitestmolekula, ahol az említett antitestmolekula SEQ ID NO: 88 szerinti nukleinsav-molekula által kódolt variábilis VH-régiót és SEQ ID NO: 90 szerinti nukleinsav-molekula által kódolt variábilis VL-régiót tartalmaz.
4. Az 1–3. igénypontok bármelyike szerinti antitestmolekula, ahol az említett antitestmolekula teljes antitest (immunglobulin), F(ab)-fragmens, F(ab)₂-fragmens, egyszálú antitest, kiméra antitest, CDR-oltott antitest, bivalens antitest-konstrukció, szintetikus antitest vagy kereszt-klónozott antitest.
5. Nukleinsav-molekula, amely az 1–4. igénypontok bármelyike szerinti antitestmolekulát kódol.
6. Vektor, amely tartalmazza az 5. igénypont szerinti nukleinsav-molekulát.
7. Gazdasejt, amely tartalmazza a 6. igénypont szerinti vektort.

8. Eljárás az 1–4. igénypontok bármelyike szerinti antitestmolekula előállítására, amelynek során a 7. igénypont szerinti gazdasejtet olyan körülmények között növesztjük, amelyek lehetővé teszik az említett antitestmolekula szintézisét, és kinyerjük az említett antitestmolekulát az említett tenyészetből.
9. Kompozíció, amely tartalmaz az 1–4. igénypontok bármelyike szerinti antitestmolekulát vagy a 8. igénypont szerinti eljárással előállított antitestmolekulát.
10. A 9. igénypont szerinti kompozíció, amely gyógyszerkészítmény vagy diagnosztikai kompozíció.
11. Az 1–4. igénypontok bármelyike szerinti antitestmolekula vagy a 8. igénypont szerinti eljárással előállított antitestmolekula, az 5. igénypont szerinti nukleinsavmolekula, a 6. igénypont szerinti vektor vagy a 7. igénypont szerinti gazdaszervezet alkalmazása amiloidogenezissel és/vagy amiloid-plakk-képződéssel társuló betegség megelőzésére és/vagy kezelésére szolgáló gyógyszerkészítmény előállítására.
12. Gyógyszerkészítmény, amely tartalmaz az 1–4. igénypontok bármelyike szerinti antitestmolekulát vagy a 8. igénypont szerinti eljárással előállított antitestmolekulát, az 5. igénypont szerinti nukleinsavmolekulát, a 6. igénypont szerinti vektort vagy a 7. igénypont szerinti gazdaszervezetet, amiloidgenézissel és/vagy amiloid-plakk-képződéssel társuló betegség megelőzésében és/vagy kezelésében történő alkalmazásra.
13. Az 1–4. igénypontok bármelyike szerinti antitestmolekula vagy a 8. igénypont szerinti eljárással előállított antitestmolekula alkalmazása amiloidgenézissel és/vagy amiloid-plakk-képződéssel társuló betegség detektálására szolgáló diagnosztikai kompozíció előállítására.
14. Az 1–4. igénypontok bármelyike szerinti antitestmolekulát vagy a 8. igénypont szerinti eljárással előállított antitestmolekulát tartalmazó diagnosztikai kompozíció amiloidgenézissel és/vagy amiloid-plakk-képződéssel társuló betegség detektálásában történő alkalmazásra.
15. Az 1–4. igénypontok bármelyike szerinti antitestmolekula vagy a 8. igénypont szerinti eljárással előállított antitestmolekula alkalmazása  $\beta$ -amiloid plakkok dezintegrálására szolgáló gyógyszerkészítmény előállítására.

16. Gyógyszerkészítmény, amely tartalmaz az 1–4. igénypontok bármelyike szerinti antitestmolekulát vagy a 8. igénypont szerinti eljárással előállított antitestmolekulát,  $\beta$ -amiloid plakkok dezintegrálásában való alkalmazásra.
17. Az 1–4. igénypontok bármelyike szerinti antitestmolekula vagy a 8. igénypont szerinti eljárással előállított antitestmolekula alkalmazása  $\beta$ -amiloid plakkok képződése elleni passzív immunizálásra szolgáló gyógyszerkészítmény előállítására.
18. Gyógyszerkészítmény, amely tartalmaz az 1–4. igénypontok bármelyike szerinti antitestmolekulát vagy a 8. igénypont szerinti eljárással előállított antitestmolekulát,  $\beta$ -amiloid plakkok képződése elleni passzív immunizálásban való alkalmazásra.
19. A 11., 13., 15. vagy 17. igénypontok bármelyike szerinti alkalmazás, vagy alkalmazásra szolgáló gyógyszerkészítmény a 12. igénypont szerint, vagy alkalmazásra szolgáló diagnosztikai kompozíció a 14. igénypont szerint, ahol az említett betegség demencia, Alzheimer-kór, motoros neuropátia, Down-kór, Creutzfeld-Jacob-kór, holland típusú örökletes agyi vérzés amiloidózissal, Parkinson-kór, HIV-vel kapcsolatos demencia, ALS vagy öregedéssel kapcsolatos idegi rendellenességek.

160/18

Meghatalmazott:



Dr. Miskolczy Zsuzsanna

 111 Budapest, Egyetem utca 40.  
 Tel: 215-4740 Fax: 215-4335